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Abstract 
Unlike most cancer types, melanoma incidence has been increasing over the past 
30 years in the United States. The unique characteristics of melanoma argue for research 
that captures the specific issues faced by melanoma survivors. Studies of long-term 
melanoma survivors are lacking, and the survivorship research to date has been limited 
by the inability to make comparisons with a population control group.  The goal of this 
dissertation was to document the long-term effects of a melanoma diagnosis and 
treatment on survivors and compare their quality of life and health behaviors with 
population controls.  First, a series of focus groups were conducted to describe the 
breadth of experiences among melanoma survivors, focusing on the experience at 
diagnosis, ongoing physical, emotional and social concerns, and behavioral changes since 
diagnosis (Manuscript 1).  Based on these data, a comprehensive questionnaire to address 
the quality of life issues faced by melanoma survivors was designed and tested.  Finally a 
cross-sectional study of melanoma survivors and population controls was conducted.  The 
goal was to collect data to evaluate the impact of melanoma on long-term survivorship 
focusing on quality of life (Manuscript 2) and sun exposure and protection behaviors 
(Manuscript 3).  A total of 592 melanoma survivors and 518 controls completed the 
survey.  Results indicate that long-term survivors of melanoma reported similar general 
physical and emotional quality of life as controls.  In addition, while they generally 
reported greater use of sun protection behaviors than controls, a significant subgroup 
experienced sunburn in the past year, putting them at elevated risk for future melanomas.  
The data presented in this dissertation suggest that long-term melanoma survivors 
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reported similar quality of life as controls, though opportunities exist to improve their sun 
exposure and protection behaviors. 
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1 Background and Purpose 
1.1 Introduction 
 As of January 1, 2014, an estimated 14.5 million cancer survivors were living in 
the United States.1  The American Cancer Society defines a cancer survivor as “any 
person who has been diagnosed with cancer, from the time of diagnosis through the 
balance of life.”  In practice, however, survivorship is generally considered as the period 
following treatment.  Improvements in cancer detection, treatments, follow-up care, and 
screening have increased cancer survival rates.  This has led, however, to more survivors 
living long enough to experience long-term and late effects of cancer and cancer therapy 
and development of secondary malignancies.2  
 The impact of cancer on an individual depends on many factors – age, 
comorbidities, diagnosis (disease, stage, location), and type and intensity of treatment.3  
Unfortunately, few cancer treatments are considered benign; surgery, chemotherapy, 
and/or radiation are often the mainstay and are known to cause numerous short- and long-
term physical and psychological side effects.2  For this reason, many clinical trials of new 
treatments include measures of treatment side effects and quality of life in addition to the 
primary outcomes of overall and disease-free survival.   
 In the past decade a number of studies were conducted to ascertain information on 
cancer survivors.4  Results to date indicate that most cancer survivors describe good 
general health, however some face long-term physical, social, and emotional concerns, 
including anxiety related to fear of recurrence.5,6  Given the large population and research 
funding, most studies in adults have been conducted among female breast cancer 
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survivors.  Cancer survivors, however, represent a heterogeneous group with more than 
100 distinct diseases, with a wide range of treatments, social and demographic 
characteristics, and other comorbid health conditions.7  For this reason, the Office of 
Cancer Survivorship has called for research on survivorship issues facing adults with 
understudied cancers.8   
 Melanoma is one such understudied cancer.9   The unique characteristics of 
melanoma -- its occurrence among males and females, the young age at diagnosis for 
some, and the range of treatment therapies -- argue for research that captures the specific 
issues faced by melanoma survivors.  A better understanding of the long-term effects of a 
melanoma diagnosis is needed as clinicians and researchers develop appropriate follow-
up care guidelines and create educational and other interventions as needed to improve 
the duration and quality of life of melanoma survivors. 
1.2 Melanoma 
 Melanoma is a malignant tumor of melanocytes and mostly occurs in the skin. 
The lifetime risk of developing melanoma of the skin is approximately 2.1% percent.  Of 
the seven most common cancers in the United States, melanoma is the only one for which 
incidence has been increasing and the “melanoma epidemic”10 has shown little signs of 
trend reversal.11,12  It is diagnosed primarily among non-Hispanic whites, however ethnic 
minorities with melanoma are known to have worse prognosis.13 The incidence of 
melanoma is higher among males than females, particularly those at older ages, though 
both sexes are well-represented. While the median age at diagnosis is 62, many young 
adults are diagnosed with the disease.14 Melanoma is the most common form of cancer 
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for young adults 25-29 and the second most common form of cancer for young adults 15-
29 years old behind lymphoma.15 
 Melanoma is considered one of the most preventable types of cancer, with 
excessive ultraviolet radiation (UVR) exposure being one of the strongest factors.16,17  
Additional risk factors include increased number of moles and/or freckles, fair skin, light 
hair, eye color, family history of melanoma, and immune suppression.18  Even when 
diagnosed at an early stage, melanoma can be aggressive, and resistant to treatment.19 
Unfortunately melanoma also has high rates of recurrence, even if diagnosed at an early 
stage, with excess risk of recurrence remaining 20 years or more after the initial 
diagnosis.20,21 
 The treatment strategies used in melanoma are diverse and treatment-related 
morbidity can be significant.  Most individuals have surgery for their melanoma and a 
proportion of these have either sentinel lymph node biopsy or lymphadenectomy.22 
Lymphedema, a late-effect of surgical management of melanoma, has not been well 
characterized in survivors and could vary from 2-19% in the upper limbs and 18-64% in 
the lower limbs.23-32  Patients with stage III and selected stage IIB melanomas may be 
offered interferon α-2b adjuvant therapy, which is thought to delay recurrence though 
improvement in survival has not been consistently shown.33,34  This treatment is 
associated with significant toxicities resulting in (% of patients): severe fatigue (21-24%), 
severe cytopenias (10%), depression (40-72%), suicidal ideation (up to 10%), and grade 
3-4 hepatotoxicity (27-29%). Frequent follow-up and blood tests are necessary while 
patients are receiving therapy, representing both financial costs and further alterations in 
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quality of life.35-37 For those with metastatic disease, therapy can include immunotherapy 
with agents such as interleukin-2 and ipilimumab, targeted therapy with BRAF inhibitors, 
or chemotherapy using dacarbazine, temozolomide or platinum and paclitaxel 
combinations.38,39  Toxicities include hypotension, fluid overload, pulmonary edema, 
renal insufficiency, nausea, vomiting, and hallucinations. Some treatment options can 
cause chronic toxicity such as acute auto-immune diarrhea, skin rashes, or deficiency in 
hormone secretions related to auto-immune destruction of hormonal glands (pituitary, 
adrenal, and thyroid). In addition, the long lasting side effects of therapy with platinum 
and paclitaxel regimens can include neuropathy, auto-toxicity, and renal insufficiency.   
 The young age at melanoma diagnosis for some and high risk of recurrence leads 
to an estimated 15-20 years of potential life-lost.40-42 Melanoma ranks seventh in number 
of years lost among all cancers,43 lower than childhood cancers but similar to Hodgkin’s 
lymphoma and breast cancer.  This raises questions regarding the effect of the diagnosis 
on quality of life, issues of parenting, employment, health insurance and access to health 
care, lifestyle, and continued surveillance.   
1.3 Quality of Life 
 Quality of life (QOL) is a multi-dimensional concept that incorporates three 
overlapping domains of function: physical, psychological, and social, as they relate to 
health status.44 Change in QOL is a recognized major health outcome of cancer diagnosis 
and treatment, which may impact a patient’s prognosis, including survival.45-47 
Individuals’ overall life satisfaction, perceptions of their health status, and ability to take 
part in valued activities are components of QOL.44 QOL can be significantly affected by 
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pain, fatigue and other symptoms of cancer and treatment side effects.   It has been shown 
to differ by cancer diagnosis, stage of disease, and time from diagnosis.48-50  
 Melanoma survivors are a unique population to evaluate in terms of alteration of 
QOL related to their diagnosis or treatment, as they are younger than other cancer 
populations and have a significant risk for tumor recurrence or for a second primary.  
Despite this and the rising incidence of melanoma, few studies have explored this 
population. Data on QOL are available on those with advanced stage melanoma 
undergoing experimental treatments,51-67 however little is known about specific 
survivorship issues faced by those with early stage disease or who have survived many 
years.68  This is further complicated by the lack of control groups within studies, making 
it hard to conclude whether any differences in QOL are attributable to the melanoma 
diagnosis. 
1.3.1 Physical Domains 
 Changes in the physical functioning of persons living with cancer affect their 
ability to perform physical activities and carry out social roles (e.g. employment, 
household chores).  Issues can include fatigue, pain, and functional limitations leading to 
difficulties with returning to work and maintaining previous physical activity levels.2  
Physical performance has been shown to be lower in cancer survivors compared to 
healthy controls.69   Among melanoma survivors in particular, treatment-specific physical 
symptoms include fatigue and nausea associated with adjuvant therapy,51,58,59 and altered 
sensation and pain at surgery site.70  Importantly, a recent study found that physical role 
functioning is associated with time to recurrence and survival among patients with 
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melanoma receiving interferon treatment.71  It is unknown, however, what proportion of 
melanoma survivors experience these issues, compared to healthy controls, and if they 
remain long-term.   
1.3.2 Psychological Domains 
 Because most cancers are life-threatening, disruptions in emotional health are 
expected.  Research to date suggests anxiety is more prevalent than depression in long-
term cancer survivors compared to controls, generally due to fear of cancer progression 
or recurrence.72   
 As most melanoma survivors are treated with surgery only, particularly those with 
early stage disease, it has been postulated that QOL issues in this population are likely 
psychological in nature.68  Studies among melanoma survivors have found that 
approximately 30% have clinically significant levels of distress,73 which is similar to 
other cancers.68  This is worst around time of diagnosis and is believed to decrease over 
time.  Adjuvant therapy for melanoma, in particular interferon, is associated with 
increased depression and emotional issues.56,58,59,67  In addition to treatments received, 
known risk factors for emotional distress in melanoma survivors include being female, 
younger and less educated and those lacking social support.73  As with physical concerns, 
psychological issues have been found to be associated with survival among those with 
both early and advanced stage melanoma.74,75  For this reason, it is important to 
understand whether melanoma survivors are at increased risk of poor emotional QOL 
compared to controls and what characteristics are associated with these outcomes.   
1.3.3 Social Domains 
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 Social support is associated with good psychological adjustment and better coping 
strategies among cancer survivors.73,76,77  The relationship between social support and 
cancer progression has been extensively explored among breast cancer survivors, though 
the data are less convincing for other cancers.78  In addition to social support potentially 
affecting cancer outcomes, a cancer diagnosis can also affect social relationships.  For 
example, a recent study found that young adult cancer survivors face higher risk of 
divorce.79 
 Among patients with metastatic melanoma, low levels of social support were 
associated with distress and lower emotional QOL.80  In contrast, another study did not 
find an association between melanoma-related distress and perceived social support.81  
This may represent a dichotomy in experiences; some melanoma survivors report their 
diagnosis had a positive impact on their life because it strengthened family relationships82 
whereas others have stated they feel socially isolated when others want to spend time in 
the sun.83  Understanding social concerns among melanoma survivors is necessary, 
particularly as many are young at the time of diagnosis.    
1.4 Risk Factors among Cancer Survivors 
 It is anticipated that physical, emotional, and social QOL concerns among 
melanoma survivors may differ by demographic and clinical characteristics.  A key factor 
is sex.  Sex is an independent prognostic factor for surviving melanoma, with females 
surviving longer than males.84-88  Females with melanoma, however, also appear to have 
higher levels of distress, anxiety, and emotional stress than males.81,89-93  Another study 
suggested females may experience more pain, itchiness, and numbness at their melanoma 
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surgical site than males.91  Finally, in a study among females with early stage melanoma, 
the majority reported poorer self-image and concern about recurrence.94  Interestingly, a 
large study of melanoma survivors found males were more likely to believe cancer had 
affected their overall health than females.82  A potential complicating issue to the 
relationship between QOL and sex among melanoma survivors may be age.  Studies 
exploring the relationship between age and distress have found conflicting results.82,95  It 
may be that the effect of age is not linear; younger survivors may be more likely to 
experience emotional issues, particularly females, and older adults may experience more 
physical issues, which may be similar by sex. 
 Cancer stage and treatments are also associated with QOL though this has not 
been consistently found in melanoma.  One study found an association between 
melanoma stage and physical and emotional QOL.91  Two studies, however, found no 
association between disease stage and emotional QOL.81,96  Melanoma survivors 
receiving combination therapy report lower QOL compared to those receiving surgery 
alone.82  An interesting association between social support and treatment was observed in 
one study, with those with advanced stage undergoing adjuvant therapy reporting higher 
social support, in part due to the additional support received by health professionals.95 
 A few other characteristics have been considered, including education, family 
history of melanoma, and number of co-morbidities.89-91,97  Exploring potential predictors 
of QOL in this population is important so those at risk for lower QOL can be identified 
and intervened upon. 
1.5 Sun Protection 
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 UVR exposure, from the sun or indoor tanning, is an established risk factor for 
melanoma 98,99 and indoor tanning has been associated with the development of 
melanoma.100 For melanomas that develop as a consequence of UVR exposure, the 
damage done to the skin by UVR exposure behavior prior to the first melanoma cannot 
be ameliorated and this damage may increase risk of a subsequent melanoma.  However, 
it is thought that UVR exposure following a melanoma diagnosis can be modified to 
reduce risk of a new melanoma diagnosis.101   
 It has been suggested that cancer may be a “teachable moment” for health 
behavior change.102 Unfortunately, while some survivors initiate positive health 
behaviors, others do not.103  In the case of melanoma, reduction of sun exposure is 
paramount.  Individuals are advised to limit time in the sun during peak hours, seek 
shade, wear protecting clothing, use sunscreen, and avoid indoor tanning devices.14  
Surprisingly little research has documented UVR exposure among melanoma survivors.  
Studies to date on sun exposure and protection behaviors among melanoma survivors 
have been mixed.   A recent qualitative study found that melanoma survivors reported 
being more conscious of sun exposure and protection.83  Another study found that 56.6% 
of melanoma survivors reported not sunbathing because it is harmful, compared to 16.6% 
of a control group.104  A large online survey found that despite a melanoma diagnosis, 
38% of melanoma survivors reported intentional tanning in the past year 105 and 27% 
reported at least one severe sunburn in past year.106  Another population-based study 
found similar use of indoor tanning among melanoma survivors and non-cancer 
controls.107  The timing of these surveys in relation to diagnosis may explain differences 
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in results, however.  A small prospective study of melanoma survivors found that initially 
UVR exposure was lower among survivors the first year after diagnosis compared to a 
control group but then it converged over the three year study.108,109 
 A few studies have found increases in sun-protection behaviors among melanoma 
patients following diagnosis.110-112 Barriers to sun protection in the general population 
have been identified as “inconvenience, forgetting to use sun safety measures, desire to 
be tanned, and protective clothing being too hot to wear.”113  In comparison to non-cancer 
controls, two studies found that melanoma survivors use sunscreen and seek shade more 
frequently than non-cancer controls,106,107 whereas another study found sun protection 
behaviors were comparable but not greater than general population estimates.114   
 These studies suggest that if an improvement in sun behaviors among melanoma 
survivors is present, it is moderate. Further clarification of these behaviors in long-term 
melanoma survivors is needed, particularly in comparison with an appropriately matched 
control group.  In addition, characteristics of those who do and do not improve sun 
protection are not well understood.  A population-based study of melanoma survivors in 
Europe reported that females adjust their sun protection behaviors more than males;91 sex 
differences have been found in other studies.114-117  Bowen et al. found females were 
more likely to use sunscreen and males were more likely to wear protective clothing, 
particularly hats.116  Another study found that females reported fewer sunburns and were 
more likely to stay in shade or use sunscreen whereas males were less likely to indoor tan 
and more likely to wear protective clothing.117  Additional factors that may be important 
include age, skin type, and family history of melanoma, though these have not been 
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extensively studied.  A better understanding of these factors is necessary to know where 
to direct intervention efforts. 
1.6 Limitations of Existing Research 
Research to date on cancer survivors has not focused on those diagnosed with 
melanoma. In particular, studies on long-term survivors of melanoma are lacking.  QOL 
is now recognized as an important outcome for patients with advanced and metastatic 
melanoma undergoing adjuvant therapy, but few researchers have focused on these 
outcomes among those with early stage disease.  Studies that have been reported included 
either small sample sizes or did not have a control group with measured confounders.  
Because of these limitations, reported study results have been mixed and generally 
inconclusive.   
1.7 Assessment of QOL among Melanoma Survivors 
 Although numerous instruments exist for the measurement of psychosocial 
factors, overall QOL, and health behaviors in relation to cancer, they are considered too 
general and inadequate for addressing the wide range of concerns among those surviving 
melanoma.9,82,118,119  To date, a limited number of studies examining QOL issues have 
been carried out in long-term melanoma survivors.  The majority of these studies relied 
on currently available generic and cancer-specific instruments to assess a narrow range of 
issues, primarily related to emotional distress, anxiety, depression and psychosocial 
adjustment, or overall QOL.45,54,58,65,82,92,114,118,120-129   
 Few instruments have been developed specifically for melanoma survivors and 
those that have focused on the time just after diagnosis and treatment.  Two instruments 
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exist to date: the Functional Assessment of Cancer Therapy – Melanoma (FACT-M)130,131 
and the recently pilot tested Melanoma Module for the European Organization for 
Research and Treatment of Cancer (EORTC), which was designed for use in international 
clinical trials of melanoma treatment.132  The unique characteristics of melanoma 
underscore the need to develop a questionnaire that captures the specific issues faced by 
melanoma survivors as they move beyond the diagnosis and treatment period.  
1.8 Dissertation Purpose 
With incidence of melanoma increasing, the number of long-term melanoma 
survivors is increasing; therefore it is important to understand the long-term effects of the 
diagnosis on QOL and health behaviors.  The purpose of the work outlined in this 
dissertation was to 1) document the breadth of long-term effects of a melanoma diagnosis 
and treatment on survivors via focus groups; 2) create a comprehensive questionnaire for 
assessing these effects; and 3) conduct a cross-sectional study of long-term melanoma 
survivors and population controls to assess and compare QOL and sun exposure and 
protection behaviors.   
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2 Part I: Qualitative Assessment of Melanoma Survivors and Questionnaire 
Creation 
The overarching goal of this dissertation was to document the long-term effects of 
a melanoma diagnosis and treatment on survivors and compare their QOL and health 
behaviors with population controls.  Since existing instruments for assessing QOL in this 
population focused primarily on immediate concerns following treatment, the first step in 
accomplishing this goal was to develop a more inclusive and comprehensive 
questionnaire.  The next two chapters describe the work performed to create a 
questionnaire for long-term survivors, with appropriate items for population controls.  
First, a series of focus groups were conducted to describe the breadth of 
experiences among melanoma survivors, focusing on the experience at diagnosis, 
ongoing physical, emotional and social concerns, and behavioral changes since diagnosis. 
(Chapter 3; Manuscript 1).  Then a questionnaire was developed to address the concerns 
identified during the focus groups using currently available standardized instruments 
when possible and pilot tested in melanoma survivors (Chapter 4).   
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3 Part I: Paper 1 - A qualitative study of quality of life concerns following a 
melanoma diagnosis 
3.1 Introduction 
 Melanoma, one of the most serious types of skin cancers, is unlike most common 
cancer types in that the incidence has been increasing over the past 30 years.11,12,133  With 
a 5-year survival rate of 91%, currently over one million melanoma survivors are living 
in the United States.1  Even when diagnosed at an early stage, however, melanoma can be 
aggressive, resistant to treatment, and has the ability to metastasize even at the earliest 
stages.19 These factors, and the young age at diagnosis for some, lead to an estimated 15-
20 years of potential life-lost,40-42 ranking melanoma seventh in number of years lost 
among all cancers in the United States.43  Melanoma also has high rates of recurrence, 
even if diagnosed at an early stage, with excess risk of recurrence remaining even 20 
years after the initial diagnosis.20,21  A better understanding of the long-term and late 
effects of a melanoma diagnosis is needed as clinicians and researchers develop 
appropriate follow-up care guidelines and create educational and other interventions 
aimed to improve the lifespan and QOL of melanoma survivors. 
 QOL is a multidimensional concept that incorporates physical, psychological and 
social functioning and an individuals’ overall life satisfaction, perceptions of their health 
status, and ability to take part in valued activities are important components.  Although 
numerous instruments exist for the measurement of psychosocial factors and overall QOL 
in relation to cancer, they are considered inadequate for addressing the wide range of 
concerns among those surviving melanoma.9,82,118,119  To date, a limited number of 
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studies examining QOL issues have been carried out in long-term melanoma survivors.  
The majority of these studies relied on currently available generic and cancer-specific 
instruments to assess a narrow range of issues, primarily related to emotional distress, 
anxiety, depression and psychosocial adjustment, or overall QOL. 45,54,58,65,82,92,114,118,120-
129  Few instruments have been developed specifically for melanoma survivors and they 
focus on the time just after diagnosis and treatment: the Functional Assessment of Cancer 
Therapy – Melanoma (FACT-M)130,131 and the recently pilot tested Melanoma Module 
for the European Organization for Research and Treatment of Cancer (EORTC), which is 
designed for use in international clinical trials of melanoma treatment.132  The unique 
characteristics of melanoma -- its occurrence among males and females, their 
comparatively younger age, and range of treatment therapies used – underscore the need 
to develop a questionnaire that captures the specific issues faced by melanoma survivors 
as they move beyond the diagnosis and treatment period.  
 The objective of the research reported here was to conduct focus groups to identify 
a relevant and inclusive list of QOL issues among melanoma survivors to form the basis 
of a questionnaire.  Instead of focusing solely on the period of time immediately 
surrounding melanoma diagnosis and treatment, as others have done, we were interested 
in studying the issues survivors face as they live beyond their treatment.   
3.2 Methods 
3.2.1 Study Participants and Recruitment 
 The study was approved by the University of Minnesota Institutional Review Board 
(1201M09423).  A convenience sample of patients treated by dermatologists and 
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oncologists at the University of Minnesota were identified for participation in this study.  
English speaking individuals diagnosed with stage I-III cutaneous melanoma in 
Minnesota since 2008, ages 18-65 years old at diagnosis, were eligible for this study.  
The age limits were imposed to match the eligibility criteria of a previous study 
conducted by the Principal Investigator (PI, D. Lazovich).100  Eligible individuals were 
sent an invitation letter, co-signed by their dermatologist, oncologist or surgeon, and the 
PI.  Potential participants were then called to see if they were willing to participate in a 
focus group. For those who agreed, a reminder letter was sent including a consent form to 
review prior to arrival. 
3.2.2 Focus Groups 
 Focus groups were conducted to identify survivorship issues faced by people 
diagnosed with stage I-III melanoma.  Groups were conducted separately for those with 
early stage disease (I and II) and advanced stage disease (III) due to the differences in 
treatments received.  Due to previous reports of differences in psychological adjustment 
after a diagnosis of melanoma between sexes,92  focus groups were also held separately 
for males and females when possible.  Five groups were formed from 33 participants, 
consisting of two all-male early stage melanoma groups (n=6 and 7), two all-female early 
stage melanoma groups (n=8 and 7) and one mixed-sex advanced stage melanoma group 
(n=5).     
 The focus groups lasted approximately 90 minutes each and were held on the 
University of Minnesota Minneapolis campus.  Participants provided written informed 
consent immediately prior to the start of the discussion.  Each session was digitally 
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audio-recorded and participants received $75 for their participation.  All groups had the 
same moderator (DL) and co-moderator (RIV) and followed established methods for 
conduct of focus groups.134 
  The question guide for the focus groups was developed iteratively.  First, an 
extensive review was conducted of the literature that included published reports of QOL 
in melanoma survivors as well as existing QOL questionnaires.  The data from these 
studies were used to generate a list of topics thought to be important among persons 
diagnosed with melanoma.  These topics were reviewed by all investigators and then 
refined into broad questions to serve as the focus group moderator guide.135  The final 
questions included are presented in Table 1 and related to experience at diagnosis, 
physical, emotional and social concerns since diagnosis, and behavioral changes since 
diagnosis.   
 At the end of each session, the moderator summarized key points discussed during 
the focus group and requested feedback from the group regarding the accuracy of the 
summary. After each session, the moderator and co-moderator discussed their 
observations and impressions of the content and process of the focus group session.  All 
recordings from the focus groups were transcribed.   
3.2.3 Analysis 
 We used standard procedures of qualitative thematic text analysis to analyze the 
focus group transcripts.135  Two researchers (DL and RIV) independently read the 
transcripts and agreed to broad themes from the focus group discussions.  Each researcher 
then conducted an analysis using descriptive coding techniques.134  Results were 
 18 
 
compared for consistency and thoroughness and overarching themes and sub-topics were 
agreed upon.  A preliminary summary was mailed to all participants.  Notes taken during 
the interviews were used to complement the conclusions.  Exemplary quotes from 
participants are provided as appropriate and presented verbatim; therefore they were not 
corrected for grammar or word choice. 
3.3 Results 
 We identified 105 eligible melanoma patients, of whom 72 (68.6%) indicated they 
were willing to participate; 33 ultimately participated (31.4%).  Among those who 
expressed initial interest but did not participate, the most common reason given was 
scheduling conflicts.  Those who participated were similar to those who did not 
participate in sex and age.  Participants were evenly distributed by sex (54.5% female), 
and most had a history of Stage I disease (63.6%) with 18.2% each with a history of 
either Stage II or Stage III disease; the mean age was 49 ± 13 years.  About one-third had 
family history of melanoma or a personal history of other skin cancers.   
3.3.1 Experience at diagnosis 
 Following introductions, each focus group started with a discussion of what 
participants experienced at the time of the melanoma diagnosis.  The large majority of 
participants reported feeling shock, fear and disbelief of the severity of the diagnosis. 
“Fear, screaming.  It’s a word [cancer] you don’t ever want to hear.  That 
was my initial reaction.” 
  A few said they had noticed changes in their mole but that their concerns were 
assessed as normal by healthcare providers.  They expressed anger when they finally 
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received the diagnosis of melanoma.   
“I was angry […] I had been questioning this spot for a year and had been 
told it was nothing and not to worry about it.  So learning that it was 
melanoma, I was angry.” 
 Once diagnosed, most reported having surgery within a few days.  Participants said 
the rapid pace of treatment was overwhelming as they tried to process the diagnosis, learn 
about melanoma, and undergo surgery.  Many admitted they had little knowledge about 
melanoma before their diagnosis, which made the process more difficult.  Those with 
early stage disease reported being thankful their disease was caught early, however those 
with stage II and III disease described difficulty making decisions regarding additional 
therapy.   
“[My doctor] really just gave me all the options of why I should do it, and 
reasons why I may not want to do it.  Really let me make that decision on my 
own and talk to my family about what I wanted to do.  Whether I thought it 
would help, whether I should do it, whether I shouldn’t.” 
 As with many cancers, some described their melanoma diagnosis as a devastating 
and traumatic experience.  In particular, those with younger children reported having 
concerns about their families and family members would process the information.   
“I was sure that, at the time, this is it, I’m dying, this is it.  I was absolutely 
petrified and absolutely scared to death.” 
 In contrast, while not the majority, a few reported their diagnosis was not 
particularly concerning, neither at the time of diagnosis nor in survivorship. 
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 “I feel like I’m in the wrong group because mine was no big deal.” 
“I would never say necessarily I had cancer, I had a mole with cancer.” 
 Finally, a few reported feeling guilty and angry at themselves about the time they 
spent in the sun early in their life as they attributed that to leading to their melanoma.  
3.3.2 Physical Concerns 
 Next we asked about physical concerns, both at the time of diagnosis and in the 
survivorship period.  Some participants reported lingering physical concerns, including 
pain, numbness, and lymphedema.  A few noted some restrictions and limited motion 
during recovery that resolved with time and/or physical therapy.  The few participants 
who received adjuvant therapy reported additional side effects, with fatigue described as 
the most troublesome and pervasive.   
“My melanoma was on the side of my face.  So they went in to the neck 
resection and they went so deep that I was in a lot of pain… I still have neck 
pain on that side of my neck.” 
“I wear compression garments on usually a daily basis to keep all that fluid 
from moving everywhere.” 
 A few with stage I disease and small tumors reported minor surgeries and no 
physical changes of note.   
“I didn’t have any problem.  I walked out of the doctor’s office and went back 
to work.  That’s it.” 
 Lastly, some reported requiring extra vitamin D supplementation and a few noted 
still struggling with low levels and the resulting fatigue that they attributed to sun 
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avoidance.   
3.3.3 Emotional Concerns 
 The majority of participants reported longer-term concerns that were emotional in 
nature, with most experiencing some form of anxiety.  A few reported general anxiety, 
whereas others were worried about follow-up checks and tests, their general health, and 
were fearful of other cancers and melanoma for themselves and their children.  Some 
reported their anxiety improved with time, while for others the anxiety remained years 
after their diagnosis. 
“You listen to every one of us, the anxiety is the one thing that really got us.  
It’s the anxiety, and the anxiety continues.” 
“…you get really uptight just before that scan.  I don’t even realize but my 
husband says, ‘you’re so bad the week before you scan’.” 
“When I start feeling icky from other things, that’s one of the first things that 
pops into my head.  I wonder if I have cancer.” 
 A number of participants said they were surprised by the size of their scar and were 
self-conscious about it and the changes to their self-image.   
“It was just a teeny, tiny spot and they cut all the way down to the muscle and 
took all the tissue just for preventive.” 
 “When they ended up taking that piece out of my cheek, I remember looking 
in the mirror, and I still do it, but I have learned to control the hysteria.  I 
look in the mirror and I don’t see my normal face.” 
“I get asked about my scar all the time.  Drives me nuts, because it’s 
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something I hate.” 
 Many reported relying on their family for emotional support, whereas a few 
participants reported their faith and spirituality was important for maintaining their 
emotional health.  Some participants, however, reported difficulty discussing melanoma 
with their family.   
“I think if I didn’t have the support that I had at the time, it would have been a 
completely different story.” 
“I wish I could talk more about it because, I tell you, it’s almost a taboo 
subject in my family.  They just don’t want to hear about it.  It’s fear or 
something.” 
 Several participants also noted feeling lonely and isolated despite family support.  
Interestingly, this issue came up not during the discussion of emotional health, but at the 
end of the focus groups when we asked subjects their motivation for participating in our 
study.  We consistently heard how appreciative they were of the opportunity to 
participate in the discussion group as an opportunity to meet with others diagnosed with 
melanoma.  
“…it was kind of nice to be able to leave here today and not feel alone.  
Because that was my biggest thing, I constantly felt alone.  Like I was the only 
person who had it…” 
3.3.4 Social Concerns 
 When asked about any social changes, participants noted a number of social 
concerns, including altering social activities to avoid sun exposure and wanting to 
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educate others about melanoma.  Most expressed a desire to not let their diagnosis affect 
their interactions; however some were careful to limit activities in the sun.   
“…once or twice in the summer we go camping now instead of almost every 
weekend.” 
 Some reported feeling the need to educate others about melanoma and prevention 
strategies.  In particular, many reported being frustrated by the lack of appreciation by 
others of the seriousness of melanoma.   
“I was amazed by the number of people who hear melanoma, and they’re like, 
oh that’s skin cancer, not a big deal.” 
“My big thing is getting other people to understand how serious this is.” 
 A few reported not having insurance or having a high deductible plan and therefore 
faced difficulties with financial uncertainty and receiving optimal care.  Quite a few also 
stated trouble obtaining life insurance after the diagnosis. 
“The reason I never got the mole taken off [earlier] was because I didn’t have 
insurance initially.”   
“I had a high deductible insurance, so I kind of choose what my aftercare is, 
because budget-wise I don’t necessarily do everything the doctor is asking me, 
every test.” 
3.3.5 Behavioral Changes 
 When asked about any changes in health behaviors since diagnosis, many 
participants reported behavior changes.  Some were limiting their time in the sun and 
increasing the use of protective clothing and sunscreen when in the sun, particularly those 
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with higher stage disease.   
“I don’t see the sun.” 
“I have a lot of those long-sleeve shirts and it will be 86 degrees outside and 
I’ll put on this long-sleeve shirt and I’m just sweating.  But I wear them.” 
 Others, however, reported little to no change in their sun protection methods.   
“Probably not the right thing to do, but I very seldom use sunscreen.” 
 In addition, some reported adopting a healthier lifestyle, including losing weight, 
exercising more, and reducing work load.  A few others also reported placing higher 
value on family and that their family became closer.   
 While most followed their physician’s recommendations regarding surveillance, a 
few reported ignoring or postponing check-ups, particularly after the first year or two.   
3.3.6 Identity as Cancer Survivor 
 As our goal was not only to summarize the experience of those diagnosed with 
melanoma but also to understand how future researchers might approach them, we asked 
participants whether they considered themselves to be cancer survivors. The responses 
were approximately evenly split between yes and no, but the explanations were diverse.    
All with Stage III disease identified as cancer survivors, indicating both the literal stance 
that melanoma is cancer and also noting that it is a very serious cancer. 
“I have a close friend that has breast cancer… she was doing regular chemo 
and so I know all of that is just as grueling.  But I don’t think people realize 
sometimes that the stuff we do is just as grueling or it’s the same thing.  
Cancer is cancer.” 
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 Some with early stage disease, when asked about being a cancer survivor, said yes 
as well, though a few participants noted they felt there was a spectrum of cancer 
survivorship: 
“Knowing what I know now about melanoma, yeah, I think I am a cancer 
survivor because it would have killed me if I would have ignored it and let it 
go.” 
“I do, but I don’t consider myself like a hard core cancer survivor.  
Technically I had it, I survived it.”   
“If you took a level of cancer survivor I would consider myself a one 
compared to a ten.” 
 Participants who responded in the negative came from two different philosophies. 
Some did not consider melanoma serious enough or felt it was inappropriate because they 
did not have chemotherapy or radiation. 
“I don’t want to downplay melanoma, but when you say cancer survivor… 
that’s… I don’t want to upset anybody, but I really don’t consider melanoma 
like pancreatic cancer or breast cancer.  I’m kind of up in the air on that 
one.” 
“I feel like I didn’t pay the full due with the chemo and the radiation and 
everything.”  
 A few others, however, did not like the term because they felt they could develop 
another cancer. 
“I’ve had cancer twice.  I’ve gone through it twice, I’ve survived it twice.  I 
 26 
 
don’t consider myself a cancer survivor.  I won’t consider myself a cancer 
survivor until somebody looks me in the face and says, you know what honey, 
you’re never going to get it again.” 
“I would say no, because I look at it more like I’ve won a battle, but the war is 
still going on.” 
3.4 Discussion 
 The objective of the study was to document the experiences of persons diagnosed 
with melanoma further from their diagnosis using focus groups.  The experiences shared 
by participants in this study highlight a number of QOL issues facing melanoma 
survivors.  QOL among melanoma survivors has been an active area of research over the 
past few years and our study compliments the results of others, confirming many of the 
same themes.   
 As previously reported, most participants reported being shocked and overwhelmed 
at the time of diagnosis and having significant information needs.136-138  Our data also 
support those of others who found melanoma survivors may experience treatment-
specific symptoms such as fatigue and nausea, associated with adjuvant therapy,51,58,59 
and lingering altered sensation and pain at the surgery site.70  In addition, lymphedema 
was reported by a number of participants and resulted in notable complications, as 
reported by others with melanoma.136  As important, some participants reported no 
physical concerns.   
 A systematic review found that most issues facing melanoma survivors are 
psychological in nature.73  As noted by others, anxiety was the main concern of 
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participants in this study, though it manifested in numerous ways – general anxiety, fear 
of recurrence or of a new cancer, and fear of family members getting cancer.139  For 
most, the anxiety was worst around time of diagnosis and decreased over time.  Similar to 
other reports, participants also reported concerns about their surgical scars, including 
feelings of disfigurement and discomfort with comments about the appearance of their 
scar by others.136,137,140  We heard these concerns most notably among those with head or 
neck tumors and those with scars that were harder to disguise with clothing.  While the 
terminology might have been different, we observed no obvious differences in any of 
these emotional concerns reported by age or sex. 
 As previously reported, for some participants their melanoma diagnosis had a 
positive impact on their life because it strengthened family relationships82 whereas others 
felt socially isolated when they felt they could not join others in outdoor activities 
involving sun exposure.83  We were, however, surprised by the level of isolation and 
loneliness reported despite most participants stating that they felt generally supported by 
their families.  This high level of isolation was also recently reported by Oliveria et al. 
(2013).83  Upon probing, it appeared to be caused by the lack of public awareness about 
the seriousness of melanoma.  Compared to breast cancer survivors, for example, who 
have many opportunities to network and meet other survivors, a need exists to increase 
both awareness of melanoma and chances for melanoma survivors to interact and support 
each other.     
 It has been suggested that cancer may be a “teachable moment” for health behavior 
change.102 Unfortunately, while some survivors initiate positive health behaviors, others 
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do not.103  Among those who have already experienced melanoma, regardless of age, 
reducing sun exposure can decrease their risk of a new or recurrent melanoma 
diagnosis.101  Individuals are advised to limit time in the sun during peak hours, seek 
shade, wear protective clothing, use sunscreen, and avoid indoor tanning devices.14  
Studies to date on sun exposure and protection behaviors among melanoma survivors 
have been mixed; some have reported most survivors being conscious of sun exposure 
and protection,83,106,107,110-112  whereas others report risky sun behaviors despite their 
diagnosis.105,106,114  The participants in this study suggest that both are true – while many 
alter their behaviors to avoid sun exposure, some report not changing their behavior.   
 Finally, participants were divided on whether they considered themselves a “cancer 
survivor”.  Similar responses have been reported in other cancers, including breast, 
prostate, colorectal and hematologic cancers.141-146  While most studies found the 
majority of survivors identify as being a cancer survivor, a significant proportion do not.  
Similar to our results, previous studies in other cancers have reported that those who do 
not endorse the term stated concerns about the cancer not being severe enough or the 
future being uncertain, particularly among those with a high risk of recurrence.142,143,147  
Due to the complexity of this issue, we encourage cautious use of the term “cancer 
survivor” when working directly with those with melanoma and instead recommend 
“person diagnosed with melanoma” until further research on the preferences of this 
population can be conducted.   
 The main strength of this study is the use of qualitative methods.  Collecting data 
using focus groups allowed for a detailed and in-depth assessment of melanoma 
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survivorship issues.  These methods particularly permitted for capture of experiential 
personal information.  We also focused on survivors of early stage disease, in contrast 
with most previous research.  This study is not without limitations, however.  The 
participants were one to four years from diagnosis and were from a single institution, an 
academic medical center.  In addition, we had few participants who had undergone 
adjuvant therapy.  Therefore, the results here may not be generalizable to all melanoma 
survivors.  In addition, qualitative research can also be difficult to summarize in an 
objective way and despite efforts otherwise, our presence during data collection (i.e. 
conduct of focus groups) may affect the subjects’ responses.    
 As early detection and treatments improve, cancer survivors will continue to be a 
growing portion of the population and an understanding of their needs and concerns is 
necessary to improve their QOL. Until now, an adequate questionnaire for assessing the 
full range of QOL experiences in melanoma survivors beyond the treatment period did 
not exist.  Results from our focus group study suggested that no single survey covers all 
relevant issues, but a compilation of selected items from existing surveys can be 
constructed to cover most issues (Table 2).   
 To that end we have used these focus group data and the instruments listed in Table 
2 to create a comprehensive questionnaire, which we are now administering to 
individuals, both those with and without melanoma.  For comparison with other studies 
and populations, including those who are cancer-free, we included generic QOL 
measures such as the SF-36.148  However, cancer- and melanoma-specific measures are 
also needed.  Our selection process balanced the need to be inclusive of all QOL topics 
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identified by our focus group participants, while minimizing the number of questions.  
For particular topics of interest, such as lymphedema, we supplemented existing 
questionnaires with new questions.  Our data also point to the importance of healthcare 
costs and need for insurance, topics that were excluded from the EORTC melanoma 
module as the questionnaire was developed primarily in Europe where healthcare costs 
are not as relevant.132  Thus, we have also included questions on these issues.    
 The high risk of recurrence and progression has led to researchers recently stating 
that melanoma can be considered a chronic disease.132  With melanoma incidence on the 
rise and the unique nature of the disease both in terms of its potential early age of onset 
and severity, understanding the experiences of melanoma survivors is necessary from a 
public health perspective to promote optimal health and QOL in this growing population.  
The results of the focus groups reported here have informed a large scale survey study 
currently underway.  The ultimate goal is to take the knowledge gained to create 
interventions designed to improve the health and QOL of melanoma survivors.     
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Table 1. Focus group question guide. 
• Think back to the time of your melanoma diagnosis.   
o What ran through your mind? 
o Was there anything particularly difficult or surprising about the surgery/treatment? 
• What changes have you noticed since diagnosis? 
o Physical 
o Emotional 
o Social 
• Have you changed any behaviors since your diagnosis?  
• Was there a silver lining to this experience for you? 
• Do you consider yourself a cancer survivor? 
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Table 2. Recommended topics for comprehensive assessment of melanoma 
survivors.  
Topic Items from Existing Questionnaires 
Diagnosis Experience  
  Cancer diagnosis • American Cancer Society SCS-II149 
  Healthcare system experience • National Survey of Households Affected by Cancer150 
• Patient Satisfaction with Cancer Care151 
Physical Concerns  
  General concerns • SF-36152 
  Effects of surgery/treatment • FACT-M130 
• Impact of Cancer153 
Emotional and Social Concerns 
  General concerns • SF-36152 
  Clinical anxiety and depression • Hospital Anxiety and Depression Scale154 
  Self-image • Skin Cancer Index155 
  Emotional effects of melanoma • Quality of Life – Cancer Survivor156 
• Impact of Cancer153 
  Work and insurance issues  • National Health Interview Survey157 
• National Survey of Households Affected by Cancer150 
Health Behaviors  
  Sun exposure habits • Sun Exposure and Protection Measures158 
• Measures from Skin Health Study100,159 
  Other lifestyle behaviors • American Cancer Society SCS-II149 
• Behavioral Risk Factor Surveillance System Survey160 
• Godin Leisure Time Exercise Questionnaire161 
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4 Part I: Development a questionnaire to measure QOL in melanoma survivors 
Following completion and analysis of the focus groups, the next step was to 
design and test a questionnaire to address the specific QOL issues faced by survivors of 
melanoma.  Though briefly described in Chapter 3, more details are provided here, in 
addition to describing the pilot testing.  The study team completed the development of the 
questionnaire in two phases: 1) selection of questionnaire items and scales; and 2) pilot 
study assessment of questionnaire feasibility and reliability in a convenience sample of 
melanoma survivors.   
4.1 Phase I: Questionnaire Development 
 The data from the focus groups were reviewed to create a comprehensive 
questionnaire for assessing the QOL of melanoma survivors.  Generic QOL measures 
were considered and used appropriately for planned comparisons with population 
controls and cancer- and melanoma-specific measures were considered to encompass all 
remaining issues.  When needed, new items were created to address specific concerns not 
otherwise captured.  The following three criteria were considered when developing the 
questionnaire, in this order: 
1. Include all issues discussed during the focus groups and/or previously published 
in melanoma or other cancer survivors. 
2. Use validated, previously developed questionnaires/questions when possible. 
3. Reduce participant burden by choosing options with fewer questions. 
Both my adviser (DeAnn Lazovich) and I reviewed the focus group topic results 
and available questionnaires independently to create lists of recommended questions.  A 
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table of specific questionnaires considered is provided in Appendix A. These lists were 
compared and edited numerous times until consensus was met.  The final topics and 
question sources included for pilot testing are listed in Table 3, including whether each 
would be asked of melanoma survivors and/or population controls.  A few new items 
were added; specific questions and citations for each question are provided in Appendix 
B.   
This compilation included numerous well-studied measures along with a few new 
questions as needed, as described below. 
4.2 Questionnaire Items for Both Melanoma Survivors and Controls 
4.2.1 Medical Outcomes Study Short Form 36 (SF-36) – Version 2 
 The SF-36 version 2 includes 36 items measuring QOL, including the following 
subscales: Physical functional, Role limitations due to physical health, Role limitations 
due to emotional problems, Energy/fatigue, Emotional well-being, Social functioning, 
Pain, and General health.152 While it does not include cancer-specific items, the SF-36 
has been employed in numerous studies of participants with cancer, including melanoma 
patients (see review by Cormier et al., 2012162).  This questionnaire was included because 
it is commonly used in studies of both healthy and cancer survivor populations.  The 
psychometric properties of SF-36 have not been formally tested in melanoma survivors, 
though they have in other cancer survivors and were found to be adequate.163,164  One 
potential concern is that the SF-36 is not cancer specific; therefore, it may not be 
sensitive enough to detect changes relevant to cancer.   
4.2.2 Hospital Anxiety and Depression Scale (HADS): 
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 The Hospital Anxiety and Depression Scale (HADS) instrument includes 14 items 
designed to screen for potentially clinically relevant anxiety and depression.154 HADS is 
not cancer specific but is a short questionnaire that has been used in hundreds of health-
related studies.  It has high internal consistency and test-retest reliability in the general 
population and has been used in numerous previous studies of cancer survivors including 
those with melanoma.65,162,165-168   
4.2.3 Sun Exposure and Protection: 
Measures of sun exposure and protection behaviors include 13 self-report items 
related to sun exposure and protection practices that were developed by leading skin 
cancer prevention researchers.169  This short questionnaire is applicable to both 
melanoma survivors and the general population.  Data on the reliability and validity 
among melanoma patients have not been published.  Questions related to skin 
examination were slightly modified to ask about the past 12 months and two questions 
related to indoor tanning were added.     
4.2.4 Other Health Behaviors: 
The Godin Leisure-Time Exercise Questionnaire161 measures physical activity 
and has been previously validated and used in many studies of cancer survivors and 
healthy populations.170  Measures of the number of fruit/vegetable servings, smoking 
history, alcohol consumption, and multi-vitamin and vitamin D use were adapted from 
the American Cancer Society Study of Cancer Survivors II (ACS-SCS-II) survey,171 Skin 
Health Study,100 Iowa Women’s Health Study,172 and the Behavioral Risk Factor 
Surveillance Survey (BRFSS) questionnaires.160   
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4.2.5 Co-morbidities: 
Assessment of comorbidities included presence of heart problems, hypertension, 
chronic back pain, arthritis, stroke, severe memory or concentration problems, lung 
diseases, stomach and/or intestinal problems, diabetes, depression, anxiety, neuropathy, 
and cancer diagnoses in both melanoma survivors and population controls using 
questions from the ACS-SCS-II survey.171   
4.2.6 Work and Health Insurance: 
Measures of current employment status, days missed due to illness in the past year 
and health and life insurance coverage in both melanoma survivors and population 
controls were derived from the ACS-SCS-II 170 and National Health Interview 173 
surveys.   
4.3 Questionnaire Items for Melanoma Survivors Only 
4.3.1 Treatment for Melanoma and Physical Symptoms 
Details collected relating to melanoma diagnosis and treatment included site of 
the melanoma, stage, treatments received, and whether melanoma recurred using 
questions from the ACS-SCS-II survey.170  Measures of lymphedema (swelling) and 
treatment for lymphedema included items from the FACT-M130 and new questions 
written with assistance from a dermatologist.  The entire FACT-M subscale was not 
included because some items are relevant only near time of diagnosis or during active 
treatment.  Additional items regarding numbness at the surgical site, range of motion, and 
other physical symptoms following treatment included questions from the FACT-M,130 
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Impact of Cancer,153 and the Skin Cancer Index.174  All three measures have been used in 
studies of melanoma survivors and shown to be valid and reliable.162,175   
4.3.2 Experience with Health Care System 
 Items from the National Survey of Households Affected by Cancer176 
questionnaire were included to assess the experience of melanoma survivors with their 
health care professionals and treatment decision-making.    
4.3.3 Impact of Melanoma Diagnosis on Work and Health Insurance: 
Additional detailed measures on work and health insurance following diagnosis 
included items from the Work Concerns During and After Cancer Treatment 
questionnaire.177  The Work Concerns During and After Cancer Treatment questionnaire 
has been tested in a population of females with gynecologic cancer near the time of 
diagnosis but has not been previously tested in those with melanoma.   
4.3.4 Well-Being Associated with Melanoma Diagnosis 
Items related to the impact of a melanoma diagnosis on emotional well-being, 
relationships and social interactions, and life outlook using measures from the Quality of 
Life – Cancer Survivors156 survey (psychological and social concerns subscales) and the 
Impact of Cancer153 survey (positive outlook and negative outlook subscales) were 
included.  The Quality of Life – Cancer Survivors instrument was developed to measure 
specific concerns in long-term cancer survivors.  In a group of survivors of many cancers, 
the measure had high internal consistency and test-retest reliability.  Researchers also 
examined the validity (content, predictive, concurrent, construct, and discriminant) and 
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found all to be satisfactory.  The Impact of Cancer has been shown to have moderately 
high internal consistency among all ten domains.153   
4.4 Phase II: Assessment of questionnaire feasibility and reliability 
4.4.1 Survey Administration 
The preliminary questionnaire, as described above, was programmed as an online 
survey in Research Electronic Data Capture (REDCap).178  The survey is accessible 
anywhere with an internet connection, though it needs to be completed on a computer 
rather than phone or tablet.  REDCap allows users to exit and return to the survey at any 
time without losing data. As the participant completes the questionnaire, the data are 
entered directly into the REDCap database, which uses a MySQL database via a secure 
web interface with data checks to ensure data quality. REDCap includes features to 
support HIPAA compliance with a full audit trail, user-based privileges, and integration 
with the institutional LDAP server.  
4.4.2 Pre-Pilot test of Survey 
Five participants from the focus group study agreed to complete and assess the 
first version of the online survey. They were paid $50 as compensation for their time.  
Each completed a telephone or in-person interview about their experience with the 
questionnaire and detailed any specific technical difficulties they faced.  The two most 
frequent issues included difficulty with entering the website URL and a glitch with one of 
the built-in logic functions.  This information was used to modify and refine the 
questionnaire.   
4.4.3 Pilot Test of Survey 
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After refining the questionnaire, a pilot test was conducted among a separate 
group of melanoma survivors, recruited in the same manner as the focus groups.  The 
original plan was to obtain data on 35 participants to assess reliability using a test-retest 
method six weeks apart.  Fewer potential participants were identified than expected and 
therefore a total of 41 eligible participants were mailed a study packet.  The study packet 
included a letter describing the study, information for accessing the online questionnaire, 
and $20.   Each person who returned the questionnaire was asked to fill out the 
questionnaire a second time, six weeks later, receiving an additional $20.  Participants 
were reminded to return the questionnaire via mail and phoned two times if incomplete. 
4.4.4 Analysis  
Data were examined for coding errors, missing data or inconsistencies to identify 
potential problems with survey administration.  An analysis of test-retest reliability was 
conducted on the primary scales/items for comparisons between melanoma survivors and 
population controls (SF-36, HADS, and sun exposure and protection behaviors).  The 
interclass correlation coefficient (ICC) was used to assess questionnaire test-retest 
reliability for items with a continuous distribution.   For categorical data, agreement 
between the two measurements was calculated using Kappa coefficients.  For ordinal 
data, the weighted Kappa was calculated by giving different weights to disagreements 
according to the magnitude of the discrepancy.  Landis and Koch179 provide benchmarks 
for test-retest reliability statistics: 0.0-0.2=poor, 0.2-0.4=fair, 0.4-0.6=moderate, 0.6-
0.8=substantial, and 0.8-1.0=nearly perfect.   
4.4.5 Study Findings 
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The final recruitment was 27 (65.9%) melanoma survivors for the first 
administration; 21 (77.8%) completed both administrations.  The median time between 
questionnaire administrations was 6.0 weeks (range 4.5-9.1 weeks).  The test-retest 
reliability ICCs for the SF-36 and HADS subscales were mostly categorized as 
substantial with a few in the nearly perfect category and a few in the moderate category 
(Table 4).    
 The sun exposure and protection behavior measures had two items with fair 
agreement, some with moderate and some with substantial agreement. (Table 5).   
 The test-retest reliabilities reported here are similar to previously reported values 
for the HADS subscales,180-182 though a little low for a few of the SF-36 subscales 
(previously found to be greater than 0.70).183  Upon closer review, version 1 of the SF-36 
was programmed into the online questionnaire in error instead of the more recent version 
2.  While the questions are the same, the number of response categories were updated in 
version 2 for a number of questions to enhance reliability.152  In addition, the reliability of 
the SF-36 decreases as time between administrations increases, with the six week interval 
considered to be on the longer end.152 
 Some of the sun exposure and protection measures had lower reliability than 
anticipated.  One possible reason for this is that participants may not have fully read the 
directions for this section: “For the following questions, think about what you do when 
you are outside during the summer on a warm sunny day.”  Given that the first 
administration was conducted in August and the second in September/October, the 
differences in answers may reflect the changes in seasons.  Therefore, the questions were 
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changed to include the instruction as part of each question; for example, “How often do 
you wear sunscreen” was changed to “When you are outside during the summer on a 
warm sunny day, how often do you wear sunscreen?”  This is expected to correct the 
problem, though future summaries of these data by month of survey completion may 
need to be explored and time/season taken into account in analyses if survey 
administration covers a long period of time. 
4.5 Final Questionnaire 
 Following completion of the pilot study, one question was added for both 
melanoma survivors and controls asking whether they have life insurance.  One question 
was also added to the assessment of co-morbidities for controls to ascertain those who 
had a melanoma diagnosis following initial participation in the Skin Health Study.  The 
SF-36 version 1 was replaced with version 2 as originally intended.  Additional 
instructions were added to clarify the sun protection and exposure questions.  No other 
changes were made.   
 Finally, paper versions of each questionnaire, in the form of booklets, were 
created as an alternative to the online questionnaire.  The final online (Appendices C and 
D) and paper (Appendices E and F) questionnaires for melanoma survivors and controls 
are provided.   
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Table 3. Final Survey Topics and Measures 
Topic Melanoma 
Survivors 
Controls Description of Measures/Scales 
Health Behaviors    
Physical Activity161 X X Measure of strenuous, moderate and mild 
activity in past week. 
Diet and Supplement 
Use100,171,172 
X X Number of fruit/vegetable servings, multi-
vitamin and vitamin D use, weight and height 
UVR Exposure/Sun 
Habits158,159  
X X Number of hours outside in summer, 
sunburns, use of sun protections methods, 
amount of time spent in sun to get tan, indoor 
tanning in past year 
Alcohol Use184 X X Number of times drinking alcohol per week, 
drinks 
Smoking171 X X Current smoking and other tobacco use 
General Well-Being    
Quality of Life - SF-36148 X X General Health Quality of Life survey 
Emotional Well-Being - 
HADS154 
X X Measure of clinical depression and anxiety 
Physical Health     
Co-morbidities171 and 
Family History of 
Melanoma100 
 
X X Assessment of co-morbidities and family 
history of melanoma 
Cancer Experience    
Treatment 
Information130,171,174 
X  Treatment received, pain and numbness at 
surgical site, appearance of scars, recurrence, 
swelling (lymphedema) 
Healthcare system 
experience176 
X  Rate health professionals, frustrations with 
care, and treatment decisions 
Work and Insurance    
Work and health insurance 
status171,173,185 
X X Current employment status, days missed due 
to illness in past year, and insurance coverage 
Work status and benefits 
following 
diagnosis171,176,185 
X  Questions related to work after diagnosis, 
changes in work effort or continued work, 
healthcare and life insurance, household 
income; modified for controls 
Well-Being Associated with Melanoma Diagnosis 
Emotional effects of 
melanoma156 
X  Emotional well-being after melanoma 
diagnosis 
Social Concerns156 X  Impact of diagnosis on relationships and 
social interactions 
Silver Lining153 X  Life outlook after melanoma diagnosis 
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Table 4. ICC test-retest reliabilities for the SF-36 and HADS (N=21).   
Scale ICC 
SF-36  
   Physical functioning 0.41 
   Role – Physical 0.86 
   Role – Emotional 0.47 
   Energy 0.69 
   Emotional well-being 0.80 
   Social functioning 0.70 
   Pain 0.70 
   General Health 0.87 
HADS  
   Depression 0.63 
   Anxiety 0.89 
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Table 5.  Test-retest reliabilities for sun exposure and protection items. 
Sun Exposure and Protection Items Kappa Coefficient 
   Weekday hours of exposure 0.48 
   Weekend hours of exposure 0.42 
   Burns in past year 0.73 
   Sunscreen use 0.78 
   Shirt 0.37 
   Hat use 0.73 
   Shade 0.47 
   Avoiding exposure to the skin 0.32 
   Indoor tanning 1.00 
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5 Part II: Cross-sectional study of long-term melanoma survivors and 
population controls 
 After the final questionnaire was developed, as described in Chapter 4, a cross-
sectional study was initiated to evaluate the impact of melanoma on long-term 
survivorship, focusing on QOL and sun exposure and protection behaviors.  Studies of 
long-term melanoma survivors are lacking, and the survivorship research to date has been 
limited by the inability to compare to a population control group.  The primary data 
collection conducted in this dissertation overcomes the limitations of these previous 
studies.   
 The goals of this study were to compare QOL between melanoma survivors and 
population controls (Manuscript 2) and measures of UVR exposure and protection 
behaviors between melanoma survivors and population controls (Manuscript 3). 
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6 Part II: Detailed Methods for Primary Data Collection 
6.1 Study Design and Population  
A cross-sectional follow-up study of participants from the Skin Health Study, a 
previously completed case-control study described below, was conducted July-October 
2015.  Both melanoma survivors (cases) and controls were asked to complete the 
questionnaire developed in Part I of this dissertation.  Approval for this study was granted 
by the University of Minnesota Institutional Review Board and the Minnesota Cancer 
Surveillance System. 
The Skin Health Study served as the source of melanoma survivors and 
population controls for data collection for the remaining chapters.  The Skin Health Study 
was a population-based case-control study conducted 2004-2009 in Minnesota by DeAnn 
Lazovich of the University of Minnesota with the primary goal of assessing the 
relationship between indoor tanning and risk of melanoma.  This study was not only a 
resource for recruitment but provided a wealth of data collected at the time of diagnosis 
for both melanoma cases and age- and sex-matched controls.  
Cases in the Skin Health Study were ascertained by the Minnesota Cancer 
Surveillance System, a population-based, statewide cancer registry. Individuals with 
invasive cutaneous melanoma diagnosed between July 2004 and December 2007, 
between the ages of 25 and 59, with a state driver's license or state identification card, 
were eligible to participate. These age cutoffs were chosen to correspond with indoor 
tanning use since that was the exposure of interest in the original study.  In accordance 
with state laws, the cancer registry first obtained physician permission for research staff 
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to contact his or her patient before releasing case information to research staff; consent 
was assumed after allowing sufficient time for physician response. Controls were 
randomly selected from the Minnesota state driver's license list (which included persons 
with state identification cards) and frequency-matched to cases in a 1:1 ratio on age (in 5-
year age groups) and sex. Eligible cases and controls were required to be English-
speaking and to have a telephone number.  
Data collection began in December 2004 and was completed in March 2009. 
Eligibility was determined for 72.5% of cases and 56.3% of controls.  Among cases and 
controls for which eligibility could be confirmed, 1167 cases (84.6%) and 1101 controls 
(69.2%) completed data collection. 
Data were ascertained using both a self-administered questionnaire and detailed 
computer-assisted telephone interview.  Skin, hair and eye color, presence and pattern of 
freckles and moles, detailed indoor tanning and residential history, and 
supplement/medication intake were collected via the self-administered questionnaire.   
6.2 Identification of Eligible Skin Health Study Participants for the Follow-up Study 
 All Skin Health Study participants who were alive at the time of the survey 
administration (Summer 2015) were identified.  Deaths among cases and controls were 
identified using the Minnesota Death Index (data updated through April 2015) and 
additionally by the Minnesota Cancer Surveillance System using the National Death 
Index (data updated through July 2013).  
The Minnesota Cancer Surveillance System required updated permission from the 
physician of record in the registry before re-contacting each person with melanoma 
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(case).  They required two contact attempts.  The 1167 cases were seen by a total of 619 
different physicians.  As only the original contact information for these physicians was 
available, updated clinic contact information was obtained by purchasing the mailing list 
from the Minnesota Medical Association.  Each clinic was then called to confirm the 
physician’s status and obtain the fax number.  A form for each case seen by each 
physician was then faxed to the clinic, requesting permission or refusal to contact the 
case and signature.  Active consent was sought initially by requesting that the physician 
indicate their consent by signing the document, giving his or her permission to contact 
the patient.  If a signed fax was not returned within two weeks, a second fax was sent.  
Passive consent was assumed if the second fax was not returned within one week of 
sending.  If the physician could not be located, retired, passed away, or was no longer 
treating the case and had no further information, participants were deemed eligible to be 
re-contacted.  
The final eligibility status of all Skin Health Study participants is presented in 
Table 6 and physician contact materials are provided in Appendix G.  Overall, 73 (6.3%) 
melanoma survivors and 9 (0.8%) controls were found to be deceased at this stage and 
physician permission to contact was obtained for 1075 cases (92.1%).  A small number of 
the Skin Health Study controls (7; 0.6%) had previously requested no further contact for 
future research and were therefore ineligible for this follow-up study.  
6.3 Subject Recruitment 
 Name, date of birth, address and telephone numbers from time of last contact 
were updated by an independent contractor using national internet databases prior to 
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conducting the study.  For those for whom mail was returned and a forwarding address 
was not provided by the post office, additional methods to obtain a current address were 
used.  This included reviewing a list of participants with updated addresses who moved in 
the last four years provided by the University of Minnesota mailing services, and an 
online search using WhitePages.com. 
 Recruitment methods outlined by Dillman were used to maximize response, 
including use of adaptive design.186  A test batch of 90 each of melanoma survivors and 
population controls was mailed to assess the process.  The initial plan included three 
mailings. 
1. Initial Letter: An invitation letter explaining the study goals with the link to 
the online survey was sent to eligible Skin Health Study participants.  Letters 
were tailored to melanoma survivors and controls separately.  All mailings 
also included a consent form for their records and an online survey tip sheet. 
A study telephone number and email address was provided for participants 
who had questions or technical concerns. 
2. Thank You Card: One week after the study materials were mailed, a full-color 
thank you card with a friendly reminder to complete the online survey was 
mailed to all participants, regardless of whether they completed the survey.  
Cards had a hand written salutation and signature. 
3. Reminder: Three weeks after the initial invitation letter, the study materials 
were sent again to non-responders.  
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 Due to low initial response rates following the thank you card, a decision was 
made to add a small incentive to the first mailing ($4 in the form of two $2 bills), re-write 
the letters to have a friendlier tone, and provide the paper survey to all participants with 
the reminder mailing.  The paper survey was designed as a booklet with a full-color cover 
to ensure a professional look and return envelopes were hand stamped to encourage 
participation. In addition, a final reminder mailing was added. All changes were 
implemented prior to the reminder letter for the first batch.  These individuals received 
their incentive with the reminder letter instead of the first mailing.  
 The final process of contacting and recruiting potential participants included: 
1. Initial Letter + incentive: An invitation letter and materials were sent, as 
described above, with the addition of an incentive (two $2 bills). The final 
materials are provided in Appendix H.  
2. Thank You Card: A thank you card was mailed one week following the initial 
letter as described above. The card is provided in Appendix I. 
3. Reminder + paper survey: Three weeks after the initial invitation letter, a 
reminder letter, copy of the paper survey and a postage-paid (stamped) 
returned envelope were sent to non-responders.  A separate reminder was sent 
to those who started the online survey but had not completed it. The final 
letters are provided in Appendix J.  
4. Final Reminder: Two weeks after the reminder letter and paper survey were 
sent, a final letter was mailed to all remaining non-responders (Appendix K). 
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 The mailings were conducted initially in three batches: batch 1) 90 melanoma 
survivors and 90 controls (test group); batch 2) 510 melanoma survivors and 510 
controls; and batch 3) 475 melanoma survivors and 485 controls.  Due to a large amount 
of returned mail for participants for whom addresses were subsequently located, a final 
batch was conducted: batch 4) 96 melanoma survivors and 113 controls.   
6.4 Data Collection 
 Study participants either completed the online questionnaire or mailed back the 
paper copy of the survey provided in the reminder mailing.  A small number of 
participants reported not having a computer or having technical difficulties accessing the 
online survey and requested via telephone or email a paper copy of the survey (44 (3.8%) 
melanoma survivors and 32 (2.9%) controls). Other issues included individuals not 
remembering their original participation and wanting more information, confusion among 
controls about their purpose in a melanoma study, and those wanting to confirm 
questionnaire receipt.  Two melanoma survivors reported that subsequent testing revealed 
they did not in fact have melanoma and therefore they did not feel it was appropriate to 
participate. 
 A separate REDCap database was created for data entry of the paper survey data.  
The first 20 each of melanoma survivors and controls were double entered and compared 
to identify common errors.  Minimal differences were found, therefore due to time and 
budget constraints, the remaining surveys were not double entered. 
6.5 Survey Response 
 52 
 
 For the purposes of this dissertation, surveys completed and returned by 
November 1, 2015 are reported.  Approximately two-thirds of the surveys were 
completed online; the remaining were paper surveys (Table 7). The addition of the 
incentive increased the response.  The response in the fourth batch was lower, likely due 
to the date cutoff rather than a difference in the participants. 
 The final response rate among eligible Skin Health Study participants was 60.7%, 
with 687 (63.9%) melanoma survivors and 624 (57.5%) controls completing the survey 
(Table 8).  An additional five deaths (2 melanoma survivors and 3 controls) were 
reported by family.  Despite all efforts, 53 (4.9%) eligible melanoma survivors and 83 
(7.6%) eligible controls could not be located. 
6.6 Analysis for Bias 
 To assess for selection bias, comparisons was made between those eligible and 
ineligible for the study and between those who did and did not participate in this follow-
up survey using data from the original Skin Health Study (Table 9).  Characteristics 
including sex, age, education, risk factors for melanoma (phenotypic risk score, family 
history of melanoma, sun exposure, sunburns, and sun protection practices), and among 
melanoma survivors, disease stage and tumor location, were considered.   
 Among the 2,268 participants in the Skin Health Study, 91 (4.0%) were 
determined to have died prior to the follow-up survey and 136 (6.0%) could not be 
located.  Those who completed the survey were generally similar to those who did not 
respond, though they were older, more likely to have completed college, and less likely to 
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have ever used indoor tanning.  When examined separately by melanoma survivors and 
controls, these differences were similar.   
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Table 6. Final eligibility status of Skin Health Study Participants. 
 Cases (N=1167) Controls (N=1101) 
Ineligible     
   Known Deceased 73 6.3% 9 0.8% 
   Previous Refusal 0 0.0% 7 0.6% 
   Physician Reported Case Deceased 4 0.3%   
   Physician Refused  15 1.3%   
Eligible      
   Current Physician Not Found 225 19.3%   
   Physician Consent –Active 1st Fax 413 35.4%   
   Physician Consent – Active 2nd Fax 120 10.3%   
   Physician Consent -Passive 317 27.2%   
Total Eligible to Contact 1075 92.1% 1085 98.5% 
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Table 7. Skin Health Study follow-up survey response rates by batch and type. 
 Melanoma Survivors 
(N=1075) 
Controls 
(N=1085) 
 N % N % 
Batch 1 90  90  
   Online / no incentive 25 30.1 22 27.2 
   Paper / incentive 24 28.9 30 37.0 
   Non-Responders/Unable to Locate 34 41.0 29 35.8 
   Located additional address (Batch 4) 7  9  
     
Batch 2 510  510  
   Online / incentive 229 49.3 189 41.8 
   Paper / no incentive 96 20.7 87 19.3 
   Non-Responders/Unable to Locate 139 30.0 175 38.8 
   Located additional address (Batch 4) 46  59  
     
Batch 3 475  485  
   Online / incentive 178 41.2 167 38.0 
   Paper / no incentive 100 23.2 93 21.1 
   Non-Responders/Unable to Locate 154 35.6 180 40.9 
   Located additional address (Batch 4) 43  44  
     
Batch 4 96  113  
   Online / incentive 22 23.0 28 24.7 
   Paper / no incentive 13 13.5 8 7.0 
   Non-Responders/Unable to Locate 61 63.5 77 71.3 
     
Online 454 42.2 406 37.4 
Paper 233 21.7 218 20.1 
Total Surveys Completed 687 63.9 624 57.5 
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Table 8. Skin Health Study follow-up survey recruitment results among those 
determined to be eligible for contact. 
 Cases (N=1075) Controls (N=1085) 
 N % N % 
Unable to locate 53 4.9 83 7.6 
Deceased 2 0.2 3 0.3 
Refusal 8 0.7 17 1.6 
Non-response 325 30.2 358 33.0 
Survey Complete 687 63.9 624 57.5 
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Table 9. Characteristics of Skin Health Study Participants by Response to the 
Follow-up Survey. 
 Original Skin 
Health Study 
(N=2268) 
Died before 
2015 Survey 
(N=91) 
Unable to 
locate 
(N=136) 
Non-
respondents/ 
Refusal  
(N=730) 
Respondents 
(N=1311) 
Characteristics N % N % N % N % N % 
Case Status           
   Case  1167 51.5 79 86.8 53 39.0 348 47.7 687 52.4 
   Control 1101 48.5 12 13.2 83 61.0 382 52.3 624 47.6 
Sex           
   Male 913 40.3 47 51.7 41 30.2 290 39.7 535 40.8 
   Female 1355 59.7 44 48.4 95 69.9 440 60.3 776 59.2 
Age           
   25-29 years 144 6.4 1 1.1 23 16.9 48 6.6 72 5.5 
   30-39 years 391 17.2 8 8.8 30 22.1 159 21.8 194 14.8 
   40-49 years 800 35.3 21 23.1 47 34.6 277 38.0 455 34.7 
   50-59 years 933 41.1 61 67.0 36 26.5 246 33.7 590 45.0 
Completed college           
   No 1222 53.9 57 62.6 73 54.1 449 61.5 643 49.1 
   Yes 1044 46.1 34 37.4 62 45.9 281 38.5 667 50.9 
   Missing 2  0  1  0  1  
Phenotypic Risk 
Index 
          
   Low 712 31.7 25 28.4 41 30.8 230 31.8 416 31.9 
   Intermediate 972 43.2 33 37.5 61 45.9 317 43.8 561 43.1 
   High 564 25.1 30 34.1 31 23.3 177 24.5 326 25.0 
   Missing 20  3  3  6  8  
Family history of 
melanoma 
          
   No 1789 80.3 76 84.4 103 77.3 576 80.3 1034 80.2 
   Yes 440 19.7 14 15.6 30 22.6 141 19.7 255 19.8 
   Missing 39  1  3  13  22  
Lifetime routine 
sun exposure 
          
   Low 749 33.2 20 22.2 58 43.3 248 34.2 423 32.3 
   Medium 755 33.4 28 31.1 44 32.8 235 32.4 448 34.3 
   High 754 33.4 42 46.7 32 23.9 243 33.5 437 33.4 
   Missing 10  1  2  4  3  
Lifetime sun 
exposure from  
   outdoor 
activities 
          
   Low 754 33.3 19 21.1 47 34.6 257 35.3 431 32.9 
   Medium 755 33.4 29 32.2 49 36.0 243 33.4 434 33.1 
   High 755 33.4 42 46.7 40 29.4 228 31.3 445 34.0 
   Missing 4  1  0  2  1  
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 Original Skin 
Health Study 
(N=2268) 
Died before 
2015 Survey 
(N=91) 
Unable to 
locate 
(N=136) 
Non-
respondents/ 
Refusal  
(N=730) 
Respondents 
(N=1311) 
Characteristics N % N % N % N % N % 
Lifetime number of 
burns from sun 
          
   None 101 4.5 2 2.2 8 5.9 37 5.1 54 4.1 
   1-2 389 17.2 16 17.6 28 20.6 125 17.2 220 16.8 
   3-5 439 19.4 14 16.5 30 22.1 145 19.9 249 19.0 
   >5 1334 59.0 59 63.7 70 51.5 421 57.8 785 60.0 
   Missing 
 
5  0  0  2  3  
Ever use Indoor 
Tanning 
          
   No 971 42.8 56 61.5 46 33.8 287 39.3 582 44.4 
   Yes 1297 57.2 35 38.5 90 66.2 443 60.7 729 55.6 
Cases Only 
Disease Stage 
(MCSS) 
          
   I 823 70.5 36 45.6 40 75.5 243 69.8 504 73.4 
   II 64 5.5 11 13.9 3 5.7 15 4.3 35 5.1 
   III/IV 70 6.0 24 30.4 2 3.8 17 4.9 27 3.9 
   Unknown 210 18.0 8 10.1 8 15.1 73 21.0 121 17.6 
Tumor Location           
   Head 138 11.8 12 15.2 4 7.6 44 12.6 78 11.4 
   Upper limb 289 24.8 12 15.2 11 20.8 91 26.2 175 25.5 
   Lower limb 311 26.7 20 25.3 17 32.1 87 25.0 187 27.2 
   Trunk 398 34.1 27 34.2 19 35.9 117 33.6 235 34.2 
   Unknown 21 2.7 8 10.1 2 3.8 9 2.6 12 1.8 
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7 Part II: Manuscript 2 - A cross-sectional survey of quality of life of long-term 
melanoma survivors compared to population controls 
7.1 Introduction 
As of 2014, over one million survivors of melanoma are living in the United 
States and this number continues to climb.1  Unlike most cancer types, melanoma 
incidence has been increasing over the past 30 years, and the “melanoma epidemic”10 has 
shown little signs of trend reversal in the United States.11,12   
Change in quality of life (QOL) is a recognized major health outcome of cancer 
diagnosis and treatment, which may impact a patient’s prognosis, including survival.45-47 
QOL incorporates three overlapping domains of function: physical, psychological, and 
social, as they relate to health status.44 QOL can be significantly affected by pain, fatigue 
and other symptoms of cancer and treatment side effects.6 
Melanoma survivors are a unique population to evaluate in terms of alteration of 
QOL related to their diagnosis or treatment, as it is one of the most common cancers in 
young adults and survivors remain at significant risk for tumor recurrence or for a second 
primary tumor.  Data on QOL are available on those with advanced stage melanoma 
undergoing experimental treatments.51-67 However little is known about specific 
survivorship issues faced by those with early stage disease, which make up the majority 
of melanoma survivors, or who have survived many years.68 This is further complicated 
by the lack of control groups within studies with measured potential confounders, making 
it hard to conclude whether any changes in QOL are attributable to the melanoma 
diagnosis.  A better understanding of the long-term effects of a melanoma diagnosis is 
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needed as clinicians and researchers develop appropriate follow-up care guidelines and 
create educational and other interventions aimed to improve the QOL of melanoma 
survivors.     
7.2 Methods 
7.2.1 Study Design and Population 
 See Chapter 6, section 6.1. 
7.2.2 Identification of Eligible Participants 
See Chapter 6, section 6.2. 
7.2.3 Subject Recruitment 
 See Chapter 6, section 6.3. 
7.2.4 Data Collection and Measures 
See Chapter 6, section 6.4 for details on data collection. 
QOL was measured in both melanoma survivors and controls using the Medical 
Outcomes Study Short Form 36 (SF-36) version 2, a generic measure that includes 36 
items that can be summarized into the following subscales: Physical functional, Role 
limitations due to physical health, Role limitations due to emotional problems, 
Energy/fatigue, Emotional well-being, Social functioning, Pain, and General health.152  
Standard scoring methods were used;152  however the scores were not standardized using 
population norms in order to compare means with other studies from different countries. 
Higher scores indicate better QOL.  Reliability and validity of the instrument has been 
established for each of the eight scales with all reliability coefficients greater than 0.80.152   
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Mental health was measured using the Hospital Anxiety and Depression Survey 
(HADS), an instrument which includes 14 items designed to assess anxiety and 
depression, each scored from 0-3.154  While continuous total or subscale anxiety and 
depression scales can be calculated,154 the proportions of individuals with potentially 
clinically meaningful depression and anxiety was used rather than means due to the fact 
that many survivors likely fall within the normal range.  The maximum scores for 
depression and anxiety are 21 and an established cut-off of 8 for each scale is deemed 
potentially clinically relevant and recommended to identify persons who should be 
further screened for depression and/or anxiety.187 
Potential confounders, including demographics and comorbidities were collected.  
Assessment of co-morbidities, using questions from the ACS-SCS-II survey,171 included 
heart problems, hypertension, chronic back pain, arthritis, stroke, severe problems with 
memory or concentration, asthma/emphysema/chronic obstructive pulmonary disease, 
stomach and/or intestinal problems, diabetes, depression, anxiety, neuropathy, cancer, 
and other serious health conditions.  The total number of co-morbidities was calculated 
for each participant.  Updated information since participation in the original Skin Health 
Study was obtained, including education, income, marital status, body mass index, 
smoking status, and family history of melanoma.      
Clinical characteristics of the melanoma diagnosis, including disease stage and 
location of tumor, when available, were provided by the Minnesota Cancer Surveillance 
System and supplemented with self-report survey data as needed. 
7.2.5 Statistical Methods  
 62 
 
For the purposes of this dissertation, 1311 (687 melanoma survivor and 624 
control) surveys that were completed and returned by November 1, 2015 were included in 
the calculations of response rate.  At the time of the analysis for this dissertation, data 
entry was complete for approximately 60% of those who returned paper surveys, 
resulting in complete data for 592 (86.2%) melanoma survivors and 518 (83.0%) 
controls.  
Assessment of Bias 
To assess how death and non-response may have biased the results, comparisons 
were made between those eligible and ineligible for the study and between those who did 
and did not participate in this follow-up survey using data from the original Skin Health 
Study as described in Chapter 6.6.  Characteristics including sex, age, education, risk 
factors for melanoma (phenotype, family history of melanoma, sun exposure, sunburns, 
and sun protection practices), and among melanoma survivors, disease stage and tumor 
location, were considered.   
Identification of Potential Confounding Factors 
Demographic and general health characteristics were compared between 
melanoma survivors and population controls that completed the survey using Chi-squared 
tests.  Controls who reported a history of melanoma (n=18; 3.4%) were excluded from 
the analysis.  To confirm known confounding factors were present in this dataset, mean 
SF-36 subscale scores and depression and anxiety scores were compared across 
demographic and general health characteristics separately using univariate linear 
regression and logistic regression models, respectively.   
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Primary Analyses 
Means ± standard deviations (SD) and the effect sizes (Cohen’s d; difference in 
means divided by the standard deviation) are presented for the SF-36 subscales. It has 
been previously shown that effect sizes of 0.35-0.5 are clinically relevant for the SF-36 
subscales.188    
Comparisons of the SF-36 subscale scores between melanoma survivors and 
population controls were conducted using multivariate linear regression models.  Both 
sex and age-adjusted and fully-adjusted models were conducted and the difference in 
means and associated 95% confidence interval (CI) are presented.  Potential confounders 
included in the final models were age at survey (continuous), sex, education (high school, 
vocation/associates, some college, college graduate, graduate/professional degree), 
income (<$50,000, $50,000-$74,999, $75,000-$149,999, $150,000+, prefer not to say), 
marital status (never married, married/partnered, widowed, divorced), body mass index 
(underweight/normal, overweight, obese), current smoking status (yes, no) and number of 
co-morbidities (0, 1, 2, 3, 4, 5+).  The proportions of melanoma survivors and population 
controls with potentially clinically significant depression and/or anxiety were compared 
using multivariate logistic regression models with the same confounders listed above; 
odds ratios (OR) and 95% CI are presented. 
To explore whether QOL between melanoma survivors and controls depended on 
age or sex, stratified analyses were conducted by age group (30-39, 40-49, 50-59, and 60-
72) and by sex.  Analyses were fully adjusted for all confounders, as previously 
described, and an interaction effect was included to examine whether a statistically 
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significant interaction between melanoma status and age or sex on QOL was present.  
Age was defined as age at time of survey (as opposed to age at diagnosis) so the data 
could be directly compared to other published data.  Due to the number of statistical tests 
performed, p-values related to these primary analyses were adjusted to account for 
multiple comparisons using the Benjamini and Hochberg adjustment method;189 adjusted 
p-values <0.05 were considered statistically significant. 
Secondary Analyses 
For the purposes of this dissertation, secondary analyses were conducted to 
determine whether particular subgroups of melanoma survivors had poorer QOL relative 
to controls.  Analyses were conducted separately by melanoma stage (I, II, or III/IV), 
tumor site (head/neck, trunk, lower limb, upper limb), self-report of lymphedema, any 
report of adjuvant therapy for melanoma at time of either first diagnosis or recurrence, 
self-reported recurrence and/or metastasis, perceived seriousness of melanoma (lowest 
quartile, upper 75%), and fear of a second melanoma (below median, above median). 
Due to the exploratory nature of these analyses, p-values were not adjusted for multiple 
comparisons. 
7.3 Results 
7.3.1 Population Description and Assessment of Bias 
See Chapter 6, sections 6.5 and 6.6 for details on survey response and assessment 
of bias.   
Survey data related to QOL for 592 melanoma survivors and 518 controls were 
analyzed. Regardless of melanoma status, respondents were 55.8±9.0 years old at time of 
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the survey, primarily female, white, highly educated, married, overweight or obese and 
likely to report at least one co-morbidity.  Melanoma survivors and population controls 
were not statistically significantly different across the demographic and health 
characteristics (Table 10). 
Melanoma survivors were diagnosed an average of 9.5±1.1 years prior to 
completing the survey; the majority (86.5%) had stage I disease and received surgery 
only (Table 11).  A minority had lymph node dissection (34.6%) and some (11.4%) 
reported lymphedema.  Among the respondents, 20 (3.5%) reported a recurrence of their 
melanoma and 15 (2.6%) reported being diagnosed with metastatic disease since the 
original diagnosis. 
7.3.2 Identification of Potential Confounding Factors 
Age, sex, education, marital status, income, body mass index, smoking status, and 
each of the comorbidities were associated with the SF-36 subscales; race and family 
history of melanoma were not consistently associated, however (Tables 12a-12d). While 
these characteristics did not differ between melanoma survivors and population controls 
in this sample, they are associated with melanoma risk in the general population and were 
therefore included as potential confounders for all analyses. 
7.3.3 Primary Analyses 
Compared to population controls, melanoma survivors reported similar QOL 
measures across all SF-36 scales (Table 13).  After adjustment for potential confounders, 
melanoma survivors had statistically significant but only modestly higher general health 
(76.1±17.8 vs. 73.4±18.5, p=0.04), physical functioning (91.3±14.8 vs. 87.9±17.3, 
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p=0.0004, bodily pain (78.2±20.6 vs. 73.1±20.9, p=0.0009), and physical role functioning 
(90.7±17.0 vs. 87.6±20.1, p=0.01).  These differences, however, did not reach the 
criterion for clinical significance as no scales had effect sizes exceeding 0.35.  Further, no 
differences in the mental health, vitality, emotional role functioning or social role 
functioning subscales between melanoma survivors and controls were observed.  Finally, 
no differences were observed in the proportion of melanoma survivors compared to 
controls with anxiety (16.1% vs. 19.0%, p=0.53) or depression (5.9% vs. 8.9%, p=0.13).  
It is noteworthy that melanoma survivors were less likely to report anxiety and 
depression compared to controls, though these differences were not statistically 
significant.   
Evidence of potential differences in QOL for some of the SF-36 subscales was 
observed between melanoma survivors and controls according to their age at the time of 
the survey (Table 14a-d).  For the general health and physical functioning subscales, 
interactions of melanoma status and age were statistically significant (p=0.05 and p=0.02, 
respectively).  Specifically, melanoma survivors 50-59 years old reported statistically and 
clinically significantly better general health, physical functioning, bodily pain and 
physical role functioning QOL compared to population controls with effect sizes ranging 
from 0.35-0.44.  These and all other SF-36 subscales were similar between melanoma 
survivors and controls in the other age groups (all effect sizes <0.35). In addition, while 
not statistically significant, melanoma survivors in the youngest age group reported 
potentially clinically meaningfully better QOL as measured by the bodily pain, mental 
health, vitality, emotional role functioning and social role functioning subscales (all 
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effect sizes > 0.40) compared to population controls.   Finally, while variation in the odds 
ratios were observed for comparisons of rates of anxiety and depression between 
melanoma survivors and controls, none of the differences were statistically significant 
within the separate age groups. 
QOL also did not appear to generally differ between melanoma patients and 
controls by sex (Tables 15a-b). Interestingly, male melanoma survivors had significantly 
better social role functioning compared to controls (93.2±14.5 vs. 88.3±19.7, p=0.002) 
yet females did not (90.7±16.0 vs. 89.5±18.9, p=0.76).  While female melanoma 
survivors reported statistically significant better general health, physical functioning, 
bodily pain and physical role functioning compared to controls and the males did not, the 
effects were not clinically significant and were similar for both sexes. 
7.3.4 Secondary Analyses 
Subgroup analyses exploring the QOL of melanoma survivors according to stage, 
tumor location, lymphedema, adjuvant therapy and recurrence found most subgroups to 
have similar QOL as the population controls (Tables 16-22).  Results should be 
cautiously interpreted due to the number of comparisons conducted.   
Melanoma survivors with stage I disease were less likely to experience depression 
compared to controls (5.0% vs. 8.9%, p=0.009).  Though not statistically significant, 
those with stage III/IV were more likely to report anxiety (26.3% vs. 19.0%, p=0.26) and 
depression (13.2% vs. 8.9%, p=0.37).  In addition, while the measures of QOL were 
similar between melanoma survivors by tumor location and controls, those with 
melanoma tumors on their upper or lower limbs were less likely to report depression than 
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controls (3.3% vs. 8.9%, p=0.02 and 4.6% vs. 8.9%, p=0.04, respectively).  Those who 
reported development of lymphedema, adjuvant therapy, and having recurrent or 
metastatic disease reported comparable QOL and mental health outcomes to controls.  
Comparisons of the QOL of melanoma survivors by their perceived seriousness of 
melanoma with population controls were similar as well, though those who perceived 
melanoma to be very serious were less likely to be depressed than controls (5.6% vs. 
8.9%, p=0.03).  Finally, melanoma survivors with less fear of a second melanoma had 
statistically significantly improved QOL compared to population controls for all SF-36 
subscale measures, though none were clinically meaningful differences.  They did, 
however, have lower rates of anxiety (7.2% vs. 19.0%, p=0.0002) and depression (2.5% 
vs. 8.9%, p=0.002) compared to controls.  Survivors who reported higher fear of a second 
melanoma were, however, similar to controls for all measures.     
7.4 Discussion 
Long-term melanoma survivors participating in this cross-sectional study reported 
statistically significant but only modest differences in QOL compared to population 
controls. Melanoma survivors indicated potentially better physical QOL and no 
differences in emotional QOL compared to controls after adjustment for potential 
confounding factors.  Other than superior physical QOL reported by melanoma survivors 
50-59 years old and social role functioning in male melanoma survivors compared to 
similar controls, differences were not clinically meaningful. Our study suggests long-term 
melanoma survivors generally report similar QOL and mental health as population 
controls.   
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This is the largest study of melanoma survivors to date to compare long-term 
QOL and mental health to similarly recruited controls.  Other studies have either 1) 
included melanoma survivors only with comparisons to general population norms (age 
and sex adjusted), and therefore, were unable to adjust for other confounding factors, or 
2) were larger studies with healthy controls but included many cancer types of which 
melanoma survivors were a small minority and therefore had limited sample sizes and did 
not measure melanoma-specific potential confounding factors.   
A few large studies of QOL among melanoma survivors in Europe, measured 
using the SF-36 or European Organisation for Research and Treatment of Cancer Quality 
of Life Questionnaire (EORTC QLQ 30), found similar QOL compared to age and sex 
adjusted population normative data.89-91,190  Specifically, a study in the Netherlands of 
562 melanoma survivors, approximately five years post-diagnosis, found statistically 
significant better physical functioning, role functioning, emotional functioning, mental 
health, bodily pain, and general health compared to the population, however, the mean 
differences were not clinically significant.91  A study of 689 survivors in Germany, an 
average of eight years post-diagnosis, in contrast to our study, found evidence of poorer 
physical, emotional, cognitive and social function QOL measures in survivors compared 
to population norms.190  These studies did not recruit control participants and therefore 
were unable to adjust for confounding factors.  However, the results were generally 
similar to our study, indicating a melanoma diagnosis is not associated with poor physical 
or emotional QOL among long-term survivors.  
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A number of large studies have recruited cancer survivors, comprising numerous 
cancers including melanoma, and non-cancer controls.  A study of long-term older 
individuals with and without cancer (average age of 74 years) in the United States found 
among the subgroup of melanoma survivors (n=80), survivors reported similar physical 
and emotional QOL as non-cancer controls.191 Another large study of short- and long-
term cancer survivors and controls in the United States (including 153 with melanoma) 
also reported similar physical and emotional QOL between survivors and controls.192  An 
analysis of long-term cancer survivors in Australia, including 224 with melanoma, 
compared to 5,808 age and sex-matched respondents without a history of cancer reported 
melanoma survivors had statistically significantly better QOL outcomes than controls, 
though they were likely not clinically meaningful differences.   
In our study, male and female survivors of melanoma were no different than their 
male or female counterparts in the control group on measures of physical and emotional 
QOL. Previous studies have found that females with melanoma report higher levels of 
distress, anxiety, and emotional stress than males.81,89-93  Interestingly, a large study of 
melanoma survivors found males were more likely to believe cancer had affected their 
overall health than females.82  In addition, studies exploring the relationship between age 
and QOL among melanoma survivors found younger survivors were more likely to 
experience emotional issues and older adults were more likely to experience more 
physical issues.82,95  The general lack of association with age and sex in our study is 
likely the result of comparison with appropriately matched controls and adjustment for 
potential confounding factors.  Our data suggest previously reported differences among 
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melanoma survivors by age or sex may reflect differences in the general population rather 
than being specific to a melanoma diagnosis.   
Reviews of studies of melanoma survivors, including long-term survivors, suggest 
up to one-third are in need of psychosocial support for distress, anxiety and 
depression,73,193  however studies to date either did not include a control group or 
compared measures using population normative data only. A systematic review and meta-
analysis of depression and anxiety among long-term survivors of all cancers found rates 
of depression were similar to healthy controls but anxiety was elevated in cancer patients 
compared to healthy controls and this persisted for up to 10 years.72  While a number of 
studies have looked at depression and anxiety among patients diagnosed with melanoma, 
most have been conducted near the time of diagnosis.73  Few studies have been conducted 
specifically looking at long-term melanoma survivors, though none included a similarly 
recruited control group.96,190,193,194  One study of 689 long-term melanoma survivors 
compared their results with the general population and found melanoma survivors 
reported significantly more depression.190  These results are in contrast with our study 
findings that melanoma survivors appear to have similar rates of depression and anxiety 
as population controls.      
Taken together, our findings are consistent with the growing literature on the 
effects of cancer on QOL, signifying that survivors of cancers with generally good 
prognoses return to physical and emotional health levels similar to the general population 
over time.6,8  It has been suggested that the act of surviving a cancer may even be 
associated with improved perception of QOL,91 which may explain why some outcomes 
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were higher in melanoma survivors compared to controls. In addition, the survivors who 
participated in this study had primarily early stage melanoma and therefore few received 
adjuvant therapy, which may contribute to the lack of differences in QOL.   Further, these 
survivors were an average of 9.5 years post-diagnosis, meaning that any physical or 
emotional concerns at the time of diagnosis and treatment may have dissipated by the 
time of our study.  Numerous studies have found increased distress among melanoma 
survivors at the time of diagnosis73, however our data suggest this does not exceed rates 
of population controls once survivors are further from the diagnosis. 
7.4.1 Study Limitations 
This is largest study of both long-term melanoma survivors and similarly 
recruited controls to explore QOL to date; however, this study has limitations.  As a 
cross-sectional study, data were obtained at a single time point and therefore baseline 
QOL data were not available.  Though our data suggested participants were similar to 
those who did not participate, those diagnosed with melanoma with poorer QOL may 
have been those who died or did not respond.   
In addition, comparisons between melanoma survivors and controls used generic 
QOL measures. Cancer- and melanoma-specific measures may be needed to ascertain 
long-term negative effects and concerns among melanoma survivors, however then 
comparisons with controls would not be possible.   
While this is a population-based study, it was limited to those who lived in 
Minnesota at the time of their diagnosis and therefore may not be generalizable.  In 
addition, although melanoma is most prevalent among non-Hispanic whites, these data do 
 73 
 
not allow for an examination of possible differences in effects by race/ethnicity due to the 
fairly homogenous population.   
7.4.2 Conclusion 
In this large population-based cross-sectional study of long-term melanoma 
survivors and population controls, survivors reported similar physical and emotional 
general QOL as controls after adjustment for confounders. Consistent with data on other 
cancers, long-term melanoma survivors in this study, compared to controls, do not appear 
to have the need for an intervention focused on QOL.  Further investigation using 
specific measures of QOL, however, are needed to determine if melanoma survivors 
experience certain challenges related to their diagnosis that would not be pertinent to 
controls.  Overall, these data are encouraging for people diagnosed with melanoma, 
providers, and public health researchers alike as the number of melanoma survivors will 
continue to rise over the next few decades. 
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Table 10. Demographic and general health characteristics among melanoma 
survivors and population controls that completed the follow-up survey. 
 Melanoma Survivors 
N=592 
Population Controls 
N=518 
 
Variable N (%) N (%) p-value 
Age at survey     0.91 
   30-39 43 7.3 38 7.3  
   40-49 101 17.1 81 15.6  
   50-59 213 36.0 195 37.6  
   60-72 235 39.7 204 39.4  
Sex     0.65 
   Female 351 59.3 314 60.6  
   Male 241 40.7 204 39.4  
Race     0.007 
   White, Non-Hispanic 587 99.2 502 96.9  
   Other 5 0.8 16 3.1  
Education     0.20 
   High school                  65 11.4 55 10.9  
   Vocational/Associates        95 16.7 107 21.2  
   Some college                 102 18.0 69 13.7  
   College graduate             175 30.8 157 31.1  
   Graduate/professional degree 131 23.1 117 23.2  
   Missing 24  13   
Marital Status     0.56 
   Never married 27 4.8 27 5.3  
   Married/Partnered 481 84.8 415 82.0  
   Widowed 12 2.1 10 2.0  
   Divorced 47 8.3 54 10.7  
   Missing 24  13   
Income     0.14 
   <$50,000             65 11.5 71 14.0  
   $50,000-74,999    94 16.6 93 18.4  
   $75,000-$149,999  245 43.4 193 38.1  
   $150,000+ 115 20.4 92 18.2  
   Prefer not to say 46 8.4 57 11.3  
   Missing 25  14   
Body Mass Index (BMI)     0.97 
   Underweight (<18.5 kg/m2) 3 0.5 2 0.4  
   Normal (18.5-24.9 kg/m2) 227 38.3 204 39.4  
   Overweight (25.0-29.9 kg/m2) 202 34.1 178 34.5  
   Obese (30.0+ kg/m2) 160 27.0 134 25.9  
Current Smoker     0.06 
   No 558 94.7 468 91.9  
   Yes 31 5.3 41 8.1  
   Missing 3  9   
Family history of melanoma     0.99 
   No 406 68.6 355 68.5  
   Yes 186 31.4 163 31.5  
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 Melanoma 
Survivors 
N=592 
Population 
Controls 
N=518 
 
Variable N (%) N (%) p-
value 
Co-morbidities – Ever told you have…*      
Heart problems 68 11.8 61 12.1 0.88 
Hypertension 202 34.9 155 30.6 0.14 
Chronic Back Pain 116 20.0 123 24.3 0.09 
Arthritis 165 28.5 165 32.7 0.14 
Stroke 7 1.2 12 2.4 0.15 
Severe problems with memory or 
concentration 
8 1.4 9 1.8 0.60 
Asthma, emphysema, or COPD 56 9.7 48 9.5 0.92 
Stomach and/or intestinal problems 52 9.0 53 10.5 0.41 
Diabetes 60 10.4 56 11.1 0.69 
Depression resulting in treatment 128 22.1 116 23.0 0.73 
Anxiety resulting in treatment 99 17.1 77 15.3 0.41 
Neuropathy 35 6.0 34 6.7 0.64 
Other mental health diagnosis 2 0.3 4 0.8 0.42 
Autoimmune disease 7 1.2 7 1.4 0.77 
Other skeletal issues 29 5.0 18 3.6 0.27 
Thyroid issues 10 1.7 17 3.4 0.08 
Cancer (excluding skin cancer)** 49 8.5 39 7.7 0.66 
Non-melanoma skin cancer 29 5.0 26 5.1 0.93 
Other serious  health condition 38 6.7 30 6.0 0.65 
Number of Co-morbidities***     0.85 
   None 139 23.7 120 23.7  
   1 142 24.2 113 22.3  
   2 127 21.6 107 21.2  
   3 82 14.0 68 13.4  
   4 49 8.4 46 9.1  
   5+ 48 8.2 52 10.3  
*missing for 26 participants (14 cases and 12 controls) 
**controls with melanoma were removed from the analysis 
***sum all comorbidities except non-melanoma skin cancer 
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Table 11. Disease characteristics among melanoma survivors (N=592). 
Characteristic N % 
Disease Stage   
   I 475 86.5 
   II 35 6.4 
   III 31 5.7 
   IV 8 1.5 
   Missing 43  
Tumor Site   
   Head/neck 63 10.8 
   Trunk 204 35.0 
   Arm 159 27.3 
   Leg 157 26.9 
   Missing 9  
Treatment Received (not exclusive)   
   Surgery 569 99.1 
   Surgery including lymph nodes 193 34.6 
   Skin graft 43 7.7 
   Chemotherapy 7 1.3 
   Radiation therapy 6 1.1 
   Immunotherapy 27 4.8 
Recurrence   
   No 554 96.5 
   Yes 20 3.5 
   Missing 18  
Metastatic Disease   
   No 559 97.4 
   Yes 15 2.6 
   Missing 18  
 N Mean±SD 
Time since diagnosis (years) 592 9.5±1.1 
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Table 12a. Association between SF-36 physical subscales and demographic and 
general health characteristics among all study participants. 
 General Health 
(GH) 
Physical functioning 
(PF) 
Variable N Mean±SD p-value N Mean±SD p-value 
Age at survey   0.10   <0.0001 
   30-39 81 76.2±18.5  81 95.8±10.2  
   40-49 174 76.1±17.8  175 94.3±13.3  
   50-59 401 75.9±18.8  403 90.4±18.6  
   60-72 431 73.2±17.6  430 84.9±20.5  
Sex   0.0006   0.37 
   Female 651 76.4±18.1  654 90.1±15.5  
   Male 436 72.5±18.1  437 89.2±16.9  
Race   0.32   0.99 
   White, Non-Hispanic 1066 74.9±18.2  1070 89.7±16.1  
   Other 21 71.0±13.4  21 89.7±15.2  
Education   0.005   <0.0001 
   High school                  119 72.0±16.8  119 85.1±19.5  
   Vocational/Associates        201 73.9±18.5  201 86.6±17.6  
   Some college                 171 71.7±21.8  170 86.6±19.7  
   College graduate             331 76.5±16.4  331 92.4±12.7  
   Graduate/professional degree 248 77.1±17.5  247 83.7±10.5  
Marital Status   0.03   0.02 
   Never married 53 67.8±20.5  53 88.1±18.2  
   Married/Partnered 895 75.2±18.0  895 90.5±15.3  
   Widowed 22 75.1±17.0  21 82.6±21.9  
   Divorced 100 75.9±18.0  99 86.8±16.7  
Income   <0.0001   <0.0001 
   <$50,000             134 69.8±19.7  134 80.2±21.7  
   $50,000-74,999    187 71.0±21.3  184 87.7±16.8  
   $75,000-$149,999  437 76.1±16.6  438 91.2±14.1  
   $150,000+ 207 79.3±16.4  207 95.7±8.0  
   Prefer not to say 103 74.7±16.6  103 89.7±15.8  
Body Mass Index (BMI)   <0.0001   <0.0001 
   Normal (18.5-24.9 kg/m2)* 424 79.4±16.8  423 93.9±12.0  
   Overweight (25.0-29.9 kg/m2) 373 75.4±16.1  378 91.3±12.9  
   Obese (30.0+ kg/m2) 290 67.4±20.1  290 81.6±21.3  
Current Smoker   0.002   0.0003 
   No 1015 75.3±18.0  1017 90.2±15.3  
   Yes 70 68.5±19.4  72 83.1±23.7  
Family history of melanoma   0.50   0.17 
   No 740 75.1±18.0  745 89.3±16.9  
   Yes 347 74.3±18.6  346 90.7±14.2  
Co-morbidities – Ever told you have…       
Heart problems 129 67.7±20.4 <0.0001 128 83.3±20.8 <0.0001 
Hypertension 355 60.1±19.9 <0.0001 354 83.9±20.0 <0.0001 
Chronic Back Pain 239 66.3±20.2 <0.0001 237 80.1±21.2 <0.0001 
Arthritis 330 68.3±19.5 <0.0001 328 81.2±19.5 <0.0001 
Stroke 19 61.4±20.4 0.001 19 75.8±24.1 0.0001 
Severe problems with memory or 
concentration 
17 53.9±31.5 <0.0001 17 65.0±32.5 <0.0001 
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 General Health 
(GH) 
Physical functioning 
(PF) 
Variable N Mean±SD p-value N Mean±SD p-value 
Asthma, emphysema, or COPD 104 66.4±23.0 <0.0001 104 83.2±21.3 <0.0001 
Stomach and/or intestinal problems 105 62.2±22.1 <0.0001 104 82.5±20.7 <0.0001 
Diabetes 115 61.9±21.5 <0.0001 116 77.5±24.3 <0.0001 
Depression resulting in treatment 244 65.0±21.7 <0.0001 243 84.0±19.7 <0.0001 
Anxiety resulting in treatment 176 65.4±21.5 <0.0001 175 84.5±21.2 <0.0001 
Neuropathy 69 60.7±22.7 <0.0001 69 77.1±23.7 <0.0001 
Other mental health diagnosis 6 45.8±23.7 <0.0001 6 74.2±26.7 0.02 
Autoimmune disease 14 51.8±22.9 <0.0001 13 88.5±13.9 0.76 
Other skeletal issues 47 69.7±17.0 0.05 47 83.0±17.3 0.003 
Thyroid issues 27 70.0±20.9 0.17 27 79.8±19.2 0.0009 
Cancer (excluding skin cancer)** 87 67.8±22.0 0.0001 86 84.7±19.9 0.002 
Non-melanoma skin cancer 55 75.9±15.6 0.68 54 92.5±10.3 0.20 
Other serious  health condition 68 63.4±21.2 <0.0001 68 82.6±19.2 <0.0001 
Number of Co-morbidities***   <0.0001   <0.0001 
   None 254 84.3±12.1  256 96.7±9.5  
   1 254 79.9±13.1  255 94.0±10.4  
   2 234 77.0±15.5  233 92.1±10.5  
   3 149 68.1±18.0  149 86.2±16.1  
   4 95 63.5±18.4  94 81.3±21.2  
   5+ 100 53.4±21.7  99 68.2±23.0  
*includes 5 participants who are underweight (BMI <18.5) 
**controls with melanoma were removed from the analysis 
***sum all comorbidities except non-melanoma skin cancer 
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Table 12b. Association between SF-36 physical subscales and demographic and 
general health characteristics among all study participants. 
 Bodily pain 
(BP) 
Physical Role  
Functioning (RP) 
Variable N Mean±SD p-value N Mean±SD p-value 
Age at survey   <0.0001   <0.0001 
   30-39 81 82.4±20.6  81 95.3±13.4  
   40-49 175 80.4±18.6  176 93.5±13.8  
   50-59 403 76.7±21.3  403 91.1±14.9  
   60-72 431 72.0±20.8  431 85.9±17.6  
Sex   0.19   0.01 
   Female 654 76.5±20.6  652 90.4±17.7  
   Male 436 74.8±21.3  437 87.5±19.6  
Race   0.10   0.34 
   White, Non-Hispanic 1069 76.0±21.0  1068 89.3±18.5  
   Other 21 68.4±18.4  21 85.4±20.4  
Education   0.001   <0.0001 
   High school                  119 71.7±23.6  119 83.8±22.5  
   Vocational/Associates        202 72.9±21.4  201 88.0±18.9  
   Some college                 171 73.9±22.6  170 84.7±23.1  
   College graduate             332 78.5±19.8  331 92.1±15.7  
   Graduate/professional degree 248 78.0±18.7  247 92.5±14.3  
Marital Status   0.15   0.25 
   Never married 54 74.7±24.0  53 87.3±21.7  
   Married/Partnered 896 76.4±20.7  895 89.8±18.1  
   Widowed 22 75.6±15.8  21 88.4±18.4  
   Divorced 100 71.4±21.5  99 86.2±20.3  
Income   <0.0001   <0.0001 
   <$50,000             135 66.9±24.6  134 78.7±26.2  
   $50,000-74,999    187 72.3±21.6  184 85.7±21.2  
   $75,000-$149,999  438 77.6±19.9  438 91.3±16.0  
   $150,000+ 207 80.8±18.7  207 94.6±11.3  
   Prefer not to say 103 76.7±18.7  103 90.9±16.9  
Body Mass Index (BMI)   <0.0001   <0.0001 
   Normal (18.5-24.9 kg/m2)* 425 80.7±18.3  423 93.2±13.8  
   Overweight (25.0-29.9 kg/m2) 375 76.1±20.2  377 90.0±16.9  
   Obese (30.0+ kg/m2) 290 68.4±23.2  289 82.6±24.1  
Current Smoker   0.0006   0.05 
   No 1017 76.5±20.5  1016 89.5±18.1  
   Yes 71 67.6±24.4  71 85.0±24.0  
Family history of melanoma   0.69   0.65 
   No 743 75.7±21.2  743 89.1±19.0  
   Yes 347 76.2±20.2  346 89.6±17.7  
Co-morbidities – Ever told you have…       
Heart problems 129 70.5±21.2 0.002 128 83.0±23.3 <0.0001 
Hypertension 356 69.7±22.4 <0.0001 354 84.1±22.0 <0.0001 
Chronic Back Pain 238 61.5±22.1 <0.0001 237 77.0±25.8 <0.0001 
Arthritis 330 64.0±21.6 <0.0001 328 81.2±22.7 <0.0001 
Stroke 19 68.1±26.2 0.10 19 77.6±30.4 0.005 
Severe problems with memory or 
concentration 
17 58.2±28.6 0.0004 17 61.0±38.9 <0.0001 
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 Bodily pain 
(BP) 
Physical Role  
Functioning (RP) 
Variable N Mean±SD p-value N Mean±SD p-value 
Asthma, emphysema, or COPD 104 67.2±23.3 <0.0001 104 82.0±23.5 <0.0001 
Stomach and/or intestinal problems 105 63.1±24.4 <0.0001 104 79.6±25.7 <0.0001 
Diabetes 116 67.1±23.8 <0.0001 116 77.0±26.4 <0.0001 
Depression resulting in treatment 244 67.4±22.7 <0.0001 243 82.5±23.3 <0.0001 
Anxiety resulting in treatment 175 68.9±24.3 <0.0001 175 84.0±23.4 <0.0001 
Neuropathy 69 61.1±23.8 <0.0001 69 75.3±27.7 <0.0001 
Other mental health diagnosis 6 54.2±26.6 0.01 6 60.4±42.0 0.0001 
Autoimmune disease 14 64.1±16.5 0.03 13 86.5±22.7 0.58 
Other skeletal issues 47 63.0±20.3 <0.0001 47 82.3±22.8 0.008 
Thyroid issues 27 69.5±21.5 0.11 27 79.6±24.1 0.006 
Cancer (excluding skin cancer)** 88 72.6±22.1 0.12 86 82.8±22.2 0.0006 
Non-melanoma skin cancer 55 76.7±20.4 0.78 54 91.2±14.1 0.45 
Other serious  health condition 68 66.3±22.5 0.0001 68 75.1±25.4 <0.0001 
Number of Co-morbidities***   <0.0001   <0.0001 
   None 256 87.5±13.9  255 97.1±8.2  
   1 255 80.5±16.9  255 94.6±11.7  
   2 234 75.9±19.4  233 90.9±14.8  
   3 149 70.1±22.3  149 77.0±16.0  
   4 95 65.9±21.4  94 79.7±22.6  
   5+ 100 51.9±19.6  99 66.2±26.9  
*includes 5 participants who are underweight (BMI <18.5) 
**controls with melanoma were removed from the analysis 
***sum all comorbidities except non-melanoma skin cancer 
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Table 12c. Association between SF-36 mental subscales and demographic and 
general health characteristics among all study participants. 
 Mental Health 
(MH) 
Vitality  
(VT) 
Variable N Mean±SD p-value N Mean±SD p-value 
Age at survey   0.02   0.02 
   30-39 81 76.2±17.2  81 60.9±16.5  
   40-49 174 79.1±14.0  174 66.0±16.1  
   50-59 402 79.5±15.4  402 66.1±17.7  
   60-72 429 81.4±13.6  430 67.2±16.5  
Sex   0.13   0.34 
   Female 650 79.4±14.9  650 79.4±14.9  
   Male 436 80.7±14.4  437 66.7±16.5  
Race   0.11   0.41 
   White, Non-Hispanic 1065 80.0±14.7  1066 66.2±17.0  
   Other 21 74.8±14.6  21 63.1±14.5  
Education   0.23   0.0001 
   High school                  119 78.4±14.7  119 63.8±17.0  
   Vocational/Associates        201 79.4±15.9  201 64.6±17.9  
   Some college                 171 78.6±15.6  171 62.8±19.3  
   College graduate             330 80.6±14.1  331 66.9±16.2  
   Graduate/professional degree 248 81.2±13.5  248 69.7±14.7  
Marital Status   0.0002   0.01 
   Never married 54 74.0±16.9  54 60.2±17.3  
   Married/Partnered 893 80.7±14.0  894 66.5±17.0  
   Widowed 22 82.3±10.2  22 72.7±7.8  
   Divorced 100 75.9±17.8  100 64.5±17.3  
Income   0.0004   <0.0001 
   <$50,000             135 75.8±17.6  135 61.4±18.6  
   $50,000-74,999    187 78.6±14.9  187 62.5±16.5  
   $75,000-$149,999  436 80.2±14.3  437 66.8±16.8  
   $150,000+ 207 82.4±12.2  207 70.1±15.0  
   Prefer not to say 102 81.6±14.2  102 67.8±17.6  
Body Mass Index (BMI)   0.0005   <0.0001 
   Normal (18.5-24.9 kg/m2)* 423 80.7±13.8  424 69.2±15.4  
   Overweight (25.0-29.9 kg/m2) 373 81.2±13.5  373 67.3±15.4  
   Obese (30.0+ kg/m2) 290 77.1±16.9  290 60.0±19.2  
Current Smoker   0.0005   0.001 
   No 1014 80.3±14.4  1015 66.5±16.8  
   Yes 70 73.9±17.8  70 59.7±17.2  
Family history of melanoma   0.34   0.59 
   No 740 80.2±14.8  741 66.3±16.9  
   Yes 346 79.3±14.5  346 65.7±17.1  
Co-morbidities – Ever told you have…       
Heart problems 129 80.1±14.9 0.87 129 63.9±19.9 0.10 
Hypertension 354 78.1±15.3 0.004 354 62.1±18.2 <0.0001 
Chronic Back Pain 239 75.8±16.3 <0.0001 239 58.5±18.8 <0.0001 
Arthritis 329 78.9±15.4 0.14 329 62.2±17.9 <0.0001 
Stroke 19 71.8±24.7 0.02 19 57.6±26.0 0.02 
Severe problems with memory or 
concentration 
17 61.2±22.6 <0.0001 17 40.8±26.5 <0.0001 
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 Mental Health 
(MH) 
Vitality  
(VT) 
Variable N Mean±SD p-value N Mean±SD p-value 
Asthma, emphysema, or COPD 104 77.1±16.6 0.04 104 60.1±19.5 0.0001 
Stomach and/or intestinal problems 105 72.4±17.9 <0.0001 105 56.4±18.7 <0.0001 
Diabetes 115 74.7±17.0 <0.0001 115 58.3±20.4 <0.0001 
Depression resulting in treatment 244 69.3±18.3 <0.0001 244 55.4±19.7 <0.0001 
Anxiety resulting in treatment 176 68.8±18.4 <0.0001 176 56.2±19.3 <0.0001 
Neuropathy 69 73.0±18.6 <0.0001 69 55.7±22.2 <0.0001 
Other mental health diagnosis 6 43.3±27.9 <0.0001 6 38.5±30.0 <0.0001 
Autoimmune disease 14 74.7±13.7 0.19 14 55.8±17.2 0.02 
Other skeletal issues 47 80.8±13.3 0.67 47 64.3±17.3 0.47 
Thyroid issues 27 80.2±15.5 0.92 27 59.7±16.8 0.05 
Cancer (excluding skin cancer)** 87 83.1±12.6 0.03 87 65.3±17.0 0.61 
Non-melanoma skin cancer 55 81.5±12.6 0.43 55 67.7±14.3 0.48 
Other serious  health condition 68 75.2±17.5 0.006 68 61.4±18.2 0.02 
Number of Co-morbidities***   <0.0001   <0.0001 
   None 254 83.3±12.0  255 71.8±14.6  
   1 254 83.8±10.6  254 71.2±12.3  
   2 233 80.3±14.6  233 66.9±15.9  
   3 149 77.0±16.0  149 63.0±15.6  
   4 95 76.3±16.2  95 58.2±17.9  
   5+ 100 68.2±18.6  100 48.8±20.7  
*includes 5 participants who are underweight (BMI <18.5) 
**controls with melanoma were removed from the analysis 
***sum all comorbidities except non-melanoma skin cancer 
 83 
 
Table 12d. Association between SF-36 mental subscales and demographic and 
general health characteristics among all study participants. 
 Emotional Role  
Functioning (RE) 
Social Role  
Functioning (SF) 
Variable N Mean±SD p-value N Mean±SD p-value 
Age at survey   0.30   0.24 
   30-39 81 91.3±17.4  81 88.1±19.4  
   40-49 175 93.7±13.3  175 92.1±14.5  
   50-59 403 81.8±16.8  405 89.7±19.0  
   60-72 429 90.9±17.5  431 91.0±16.4  
Sex   0.76   0.43 
   Female 651 91.6±16.6  654 90.1±17.4  
   Male 437 91.9±16.7  438 91.0±17.2  
Race   0.10   0.87 
   White, Non-Hispanic 1067 91.8±16.5  1071 90.5±17.3  
   Other 21 85.7±22.4  21 89.9±20.4  
Education   0.03   <0.0001 
   High school                  118 88.7±18.8  120 89.6±16.9  
   Vocational/Associates        201 93.7±14.2  202 89.2±18.0  
   Some college                 170 89.5±17.8  171 85.2±22.1  
   College graduate             331 92.5±16.4  332 92.5±15.9  
   Graduate/professional degree 247 92.2±15.6  248 93.0±14.1  
Marital Status   0.05   0.0006 
   Never married 53 90.3±16.1  54 84.3±21.9  
   Married/Partnered 894 92.3±16.2  896 91.3±16.5  
   Widowed 21 89.7±17.5  22 93.2±10.7  
   Divorced 99 87.7±17.5  101 85.6±21.6  
Income   <0.0001   <0.0001 
   <$50,000             134 86.1±20.2  136 82.3±22.1  
   $50,000-74,999    184 89.9±17.9  187 88.8±19.0  
   $75,000-$149,999  438 92.5±16.1  438 91.6±16.4  
   $150,000+ 207 94.4±12.3  207 93.5±12.7  
   Prefer not to say 102 94.1±14.2  103 93.4±15.9  
Body Mass Index (BMI)   0.0003   <0.0001 
   Normal (18.5-24.9 kg/m2)* 423 93.1±14.2  425 91.6±15.6  
   Overweight (25.0-29.9 kg/m2) 376 92.7±15.3  377 92.6±14.7  
   Obese (30.0+ kg/m2) 289 88.4±20.7  290 86.1±21.7  
Current Smoker   0.002   <0.0001 
   No 1015 92.1±16.2  1019 91.0±16.9  
   Yes 71 85.8±21.8  71 82.4±21.5  
Family history of melanoma   0.46   0.59 
   No 743 92.0±16.5  745 90.7±17.3  
   Yes 345 91.2±17.0  347 90.1±17.5  
Co-morbidities – Ever told you have…       
Heart problems 128 89.8±17.3 0.15 129 88.1±19.3 0.10 
Hypertension 353 89.3±19.1 0.0007 357 88.0±20.1 0.001 
Chronic Back Pain 237 86.1±21.0 <0.0001 239 83.2±22.1 <0.0001 
Arthritis 327 90.3±18.0 0.05 330 88.0±20.0 0.002 
Stroke 19 79.4±28.6 0.0009 19 75.0±33.3 <0.0001 
Severe problems with memory or 
concentration 
17 59.3±28.8 <0.0001 17 59.6±31.1 <0.0001 
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 Emotional Role  
Functioning (RE) 
Social Role  
Functioning (SF) 
Variable N Mean±SD p-value N Mean±SD p-value 
Asthma, emphysema, or COPD 104 88.3±19.8 0.02 104 84.3±22.0 0.0001 
Stomach and/or intestinal problems 104 86.1±21.8 0.0002 105 79.8±23.8 <0.0001 
Diabetes 116 85.3±22.0 <0.0001 116 82.7±23.6 <0.0001 
Depression resulting in treatment 243 79.6±23.0 <0.0001 244 80.2±23.2 <0.0001 
Anxiety resulting in treatment 175 80.6±23.7 <0.0001 176 78.6±23.1 <0.0001 
Neuropathy 69 83.3±23.3 <0.0001 69 78.6±23.5 <0.0001 
Other mental health diagnosis 6 58.3±31.6 <0.0001 6 54.2±38.5 <0.0001 
Autoimmune disease 13 89.7±12.3 0.68 14 81.3±18.8 0.05 
Other skeletal issues 47 93.8±12.1 0.37 47 88.6±16.7 0.45 
Thyroid issues 27 92.6±15.4 0.77 27 86.6±19.3 0.24 
Cancer (excluding skin cancer)** 86 90.5±16.0 0.46 88 89.3±16.9 0.51 
Non-melanoma skin cancer 54 91.5±16.1 0.92 55 92.0±13.7 0.49 
Other serious  health condition 68 83.9±21.9 <0.0001 68 83.1±25.3 0.0004 
Number of Co-morbidities***   <0.0001   <0.0001 
   None 255 96.2±10.8  256 96.0±10.7  
   1 255 96.6±9.8  255 96.0±9.1  
   2 232 92.7±16.0  234 90.5±16.5  
   3 149 88.4±17.7  150 87.5±19.5  
   4 94 83.9±21.1  95 82.6±21.0  
   5+ 99 77.7±25.1  100 73.9±25.8  
*includes 5 participants who are underweight (BMI <18.5) 
**controls with melanoma were removed from the analysis 
***sum all comorbidities except non-melanoma skin cancer 
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Table 13. SF-36 subscale scores and HADS Anxiety and Depression categories compared between melanoma survivors and 
population controls. 
 Melanoma 
Survivors 
Population 
Controls 
Sex and age-adjusted Full model* 
SF-36 Subscale N Mean±SD N Mean±SD Diff Means  
(95% CI) 
p-value Diff Means  
(95% CI) 
p-value Adj p-value** Effect 
Size+ 
General health  580 76.1±17.8 507 73.4±18.5 2.8 (0.7, 5.0) 0.01 2.5 (0.7, 4.3) 0.008 0.04 0.17 
Physical functioning  588 91.3±14.8 503 87.9±17.3 3.5 (1.7, 5.4) 0.0002 3.5 (2.0, 5.1) <0.0001 0.0004 0.28 
Bodily pain  583 78.2±20.6 507 73.1±20.9 5.2 (2.7, 7.6) <0.0001 4.4 (2.2, 6.6) <0.0001 0.0009 0.25 
Physical Role  
   Functioning  
586 90.7±17.0 503 87.6±20.1 3.2 (1.0, 5.3) 0.004 3.0 (1.1, 4.9) 0.002 0.01 0.19 
Mental Health  580 80.6±14.5 506 79.1±14.8 1.4 (-0.3, 3.2) 0.11 1.1 (-0.6, 2.7) 0.21 0.33 0.08 
Vitality 580 67.0±17.0 507 65.1±16.8 1.8 (-0.2, 3.9) 0.07 1.4 (-0.4, 3.2) 0.12 0.21 0.10 
Emotional Role 
   Functioning  
585 92.2±16.0 503 91.1±17.4 1.1 (-0.9, 3.1) 0.26 1.0 (-0.9, 2.8) 0.29 0.44 0.07 
Social Role 
Functioning  
584 91.7±15.4 508 89.1±19.2 2.7 (0.6, 4.7) 0.01 2.3 (0.4, 4.2) 0.02 0.08 0.15 
 N % N % OR  
(95% CI) 
p-value OR  
(95% CI) 
p-value Adj p-value**  
HADS Anxiety –  
   Categories 
     0.23  0.38 0.53  
   Normal (<7) 481 83.9 410 81.0 1.00  1.00    
   Borderline/ 
      Abnormal (8+) 
92 16.1 96 19.0 0.82 (0.60, 1.13)  0.86 (0.61, 1.20)    
HADS Depression –  
   Categories 
     0.06  0.05 0.13  
   Normal 543 94.1 462 91.1 1.00  1.00    
   Borderline/ 
      Abnormal (8+) 
34 5.9 45 8.9 0.64 (0.40, 1.02)  0.59 (0.35, 1.00)    
* adjusted for sex, age, education, income, marital status, BMI category, smoking status and number of comorbidities 
** adjusted for multiple statistical tests using the Benjamini and Hochberg method189 
+ Cohen’s d; difference in means divided by the standard deviation 
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Table 14a. SF-36 subscale scores and HADS Anxiety and Depression categories compared between melanoma survivors and 
population controls among those 30-39 years at time of survey. 
AGE 30-39 Melanoma 
Survivors 
Population 
Controls 
Sex and age-adjusted Fully adjusted* 
SF-36 Subscale N Mean±SD N Mean±SD Diff Means 
(95% CI) 
p-value Diff Means  
(95% CI) 
p-value Adj p-
value** 
Effect 
Size+ 
General health  43 77.6±18.7 38 74.6±18.4 2.7 (-5.9, 11.4) 0.53 4.8 (-4.3, 14.0) 0.30 0.44 0.26 
Physical functioning  43 93.8±17.6 38 97.0±5.9 -3.7 (-9.8, 2.5) 0.24 -0.2 (-4.5, 4.0) 0.91 0.94 0.03 
Bodily pain  43 85.0±19.3 38 79.5±21.8 6.8 (-2.5, 16.1) 0.15 8.5 (-1.3, 18.2) 0.09 0.18 0.44 
Physical Role  
   Functioning  
43 95.1±11.7 38 96.5±8.2 -2.3 (-6.9, 2.3) 0.33 -1.8 (-7.3, 3.7) 0.52 0.67 0.16 
Mental Health  43 77.4±14.7 38 74.7±19.9 2.6 (-5.4, 10.5) 0.52 6.9 (-1.1, 14.8) 0.09 0.18 0.44 
Vitality 43 63.2±14.0 38 58.2±18.8 4.7 (-2.9, 12.3) 0.22 7.1 (-1.7, 15.8) 0.11 0.21 0.41 
Emotional Role 
   Functioning  
43 92.8±15.8 38 89.5±19.1 3.2 (-4.9, 11.3) 0.44 7.6 (0.0, 15.2) 0.05 0.13 0.51 
Social Role Functioning  43 89.2±17.8 38 86.8±21.1 3.2 (-5.7, 12.1) 0.48 8.5 (-0.3, 17.3) 0.06 0.14 0.49 
 N % N % OR (95% CI) p-value OR (95% CI) p-value Adj p-
value** 
 
HADS Anxiety –  
   Categories 
     0.80  0.93 0.94  
   Normal (<7) 29 67.4 25 65.8 1.00  1.00    
   Borderline/ 
      Abnormal (8+) 
14 32.6 13 34.2 0.88 (0.34, 2.30)  0.94 (0.27, 3.26)    
HADS Depression –  
   Categories 
     0.17  0.07 0.16  
   Normal 40 93.0 31 81.6 1.00  1.00    
   Borderline/ 
      Abnormal (8+) 
3 7.0 7 18.4 0.32 (0.06, 1.61)  0.11 (0.01, 1.18)    
* adjusted for sex, age, education, income, marital status (married/partnered vs. other), BMI category, smoking status and presence of any comorbidities 
** adjusted for multiple statistical tests using the Benjamini and Hochberg method189 
+ Cohen’s d; difference in means divided by the standard deviation 
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Table 14b. SF-36 subscale scores and HADS Anxiety and Depression categories compared between melanoma survivors and 
population controls among those 40-49 years at time of survey. 
AGE 40-49 Melanoma Survivors Population 
Controls 
Sex and age-adjusted Fully adjusted* 
SF-36 Subscale N Mean±SD N Mean±SD Diff Means (95% 
CI) 
p-value Diff Means 
(95% CI) 
p-value Adj p-
value** 
Effect 
Size+ 
General health  96 74.9±20.2 78 77.4±14.4 -2.2 (-7.6, 3.1) 0.41 -1.1 (-6.4, 4.1) 0.67 0.82 0.07 
Physical functioning  98 93.3±15.0 78 93.7±12.2 -0.4 (-4.5, 3.7) 0.84 0.8 (-3.2, 4.7) 0.71 0.86 0.06 
Bodily pain  97 80.9±19.8 78 79.6±17.1 1.2 (-4.4, 6.8) 0.68 2.4 (-3.4, 8.1) 0.42 0.57 0.13 
Physical Role  
   Functioning  
97 93.8±15.2 78 95.0±10.7 -0.9 (-4.9, 3.0) 0.64 0.3 (-3.7, 4.3) 0.88 0.94 0.02 
Mental Health  96 78.7±15.1 78 79.5±12.6 -0.7 (-5.0, 3.5) 0.73 -0.6 (-5.0, 3.8) 0.79 0.92 0.04 
Vitality 96 64.0±18.5 78 68.5±12.2 -4.5 (-9.3, 0.4) 0.07 -4.2 (-9.3, 0.8) 0.10 0.19 0.27 
Emotional Role 
   Functioning  
97 93.1±14.3 78 94.4±11.7 -1.2 (-5.2, 2.8) 0.55 -0.7 (-4.9, 3.5) 0.74 0.88 0.05 
Social Role Functioning  97 91.4±15.2 78 92.9±13.5 -1.5 (-5.8, 2.7) 0.48 -1.9 (-6.3, 2.6) 0.40 0.55 0.14 
 N % N % OR (95% CI) p-value OR (95% CI) p-value Adj p-
value** 
 
HADS Anxiety –  
   Categories 
     0.62  0.36 0.51  
   Normal (<7) 71 74.7 60 77.9 1.00  1.00    
   Borderline/ 
      Abnormal (8+) 
24 25.3 17 22.1 1.20 (0.59, 2.45)  1.48 (0.64, 3.43)    
HADS Depression –  
   Categories 
     0.08  0.15 0.25  
   Normal 87 90.6 76 97.4 1.00  1.00    
   Borderline/ 
      Abnormal (8+) 
9 9.4 2 2.6 4.21 (0.84, 20.96)  3.54 (0.63, 19.89)    
* adjusted for sex, age, education, income, marital status (married/partnered vs. other), BMI category, smoking status and presence of any comorbidities 
** adjusted for multiple statistical tests using the Benjamini and Hochberg method189 
+ Cohen’s d; difference in means divided by the standard deviation 
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Table 14c. SF-36 subscale scores and HADS Anxiety and Depression categories compared between melanoma survivors and 
population controls among those 50-59 years at time of survey. 
AGE 50-59 Melanoma 
Survivors 
Population 
Controls 
Sex and age-adjusted Fully adjusted* 
SF-36 Subscale N Mean±SD N Mean±SD Diff Means (95% 
CI) 
p-value Diff Means (95% 
CI) 
p-value Adj p-
value** 
Effect 
Size+ 
General health  210 79.5±16.5 191 71.9±20.3 7.5 (3.9, 11.2) <0.0001 6.9 (3.5, 10.3) <0.0001 0.0009 0.41 
Physical functioning  213 94.0±11.3 190 87.8±17.5 6.2 (3.3, 9.1) <0.0001 5.8 (3.2, 8.5) <0.0001 0.0007 0.44 
Bodily pain  212 81.0±20.0 191 72.0±21.8 8.8 (4.7, 12.9) <0.0001 8.1 (4.1, 12.0) <0.0001 0.0009 0.42 
Physical Role  
   Functioning  
213 93.5±14.2 190 87.0±22.0 6.4 (2.8, 10.0) 0.0006 5.9 (2.5, 9.4) 0.0009 0.007 0.35 
Mental Health  211 80.1±15.7 191 78.8±15.0 1.0 (-2.0, 4.1) 0.50 -0.2 (-3.2, 2.8) 0.89 0.94 0.01 
Vitality 211 68.5±17.1 191 63.4±17.9 4.8 (1.3, 8.2) 0.007 3.8 (0.5, 7.2) 0.02 0.08 0.23 
Emotional Role 
   Functioning  
213 92.3±16.8 190 91.3±16.8 0.8 (-2.5, 4.1) 0.64 -0.2 (-3.5, 3.0) 0.89 0.94 0.01 
Social Role 
Functioning  
213 91.5±16.9 192 87.7±20.9 3.6 (-0.1, 7.3) 0.06 2.8 (-0.8, 6.5) 0.12 0.21 0.16 
 N % N % OR (95% CI) p-value OR (95% CI) p-value Adj p-
value** 
 
HADS Anxiety –  
   Categories 
     0.03  0.06 0.14  
   Normal (<7) 182 87.5 150 78.5 1.00  1.00    
   Borderline/ 
      Abnormal (8+) 
26 12.5 41 21.5 0.54 (0.32, 0.93)  0.58 (0.32, 1.02)    
HADS Depression 
–  
   Categories 
     0.11  0.22 0.34  
   Normal 197 93.8 170 89.0 1.00  1.00    
   Borderline/ 
      Abnormal (8+) 
13 6.2 21 11.0 0.56 (0.27, 1.15)  0.59 (0.26, 1.37)    
* adjusted for sex, age, education, income, marital status (married/partnered vs. other), BMI category, smoking status and presence of any comorbidities 
** adjusted for multiple statistical tests using the Benjamini and Hochberg method189 
+ Cohen’s d; difference in means divided by the standard deviation 
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Table 14d. SF-36 subscale scores and HADS Anxiety and Depression categories compared between melanoma survivors and 
population controls among those 60-72 years at time of survey. 
AGE 60-72 Melanoma Survivors Population 
Controls 
Sex and age-adjusted Fully adjusted* 
SF-36 Subscale N Mean±SD N Mean±SD Diff Means 
(95% CI) 
p-value Diff Means  
(95% CI) 
p-value Adj p-
value** 
Effect 
Size+ 
General health  231 73.3±17.2 200 73.0±18.0 0.4 (-3.0, 6.7) 0.83 0.3 (-2.9, 3.5) 0.86 0.94 0.02 
Physical functioning  234 87.6±16.2 197 83.9±18.9 4.1 (0.9, 7.3) 0.01 4.5 (1.5, 7.5) 0.003 0.02 0.30 
Bodily pain  231 73.4±20.9 200 70.5±20.6 3.1 (-0.9, 7.0) 0.13 3.0 (-0.7, 6.7) 0.12 0.21 0.16 
Physical Role  
   Functioning  
233 86.0±19.6 197 83.6±21.5 2.8 (-1.1, 6.6) 0.16 3.4 (-0.2, 7.0) 0.07 0.16 0.19 
Mental Health  230 82.4±12.9 199 80.1±14.3 2.3 (-0.3, 4.8) 0.09 2.6 (0.07, 5.1) 0.04 0.12 0.20 
Vitality 230 67.6±16.6 200 66.7±16.4 0.9 (-2.2, 4.1) 0.56 0.9 (-2.2, 3.9) 0.58 0.74 0.05 
Emotional Role 
   Functioning  
232 91.7±15.9 197 89.9±19.2 2.0 (-1.3, 5.3) 0.23 2.9 (-0.4, 6.1) 0.08 0.17 0.18 
Social Role Functioning  231 92.5±13.5 200 89.3±19.0 3.4 (0.3, 6.5) 0.03 3.6 (0.6, 6.6) 0.02 0.08 0.23 
 N % N % OR (95% CI) p-value OR (95% CI) p-value Adj p-
value** 
 
HADS Anxiety –  
   Categories 
     0.97  0.94 0.94  
   Normal (<7) 199 87.7 175 87.5 1.00  1.00    
   Borderline/ 
      Abnormal (8+) 
28 12.3 25 12.5 1.01 (0.57, 1.81)  1.02 (0.56, 1.88)    
HADS Depression –  
   Categories 
     0.12  0.08 0.17  
   Normal 219 96.1 185 92.5 1.00  1.00    
   Borderline/ 
      Abnormal (8+) 
2 4.0 15 7.5 0.51 (0.22, 1.19)  0.44 (0.18, 1.09)    
* adjusted for sex, age, education, income, marital status (married/partnered vs. other), BMI category, smoking status and presence of any comorbidities 
** adjusted for multiple statistical tests using the Benjamini and Hochberg method189 
+ Cohen’s d; difference in means divided by the standard deviation 
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Table 15a. SF-36 subscale scores and HADS Anxiety and Depression categories compared between melanoma survivors and 
population controls among males. 
MALES Melanoma 
Survivors 
Population 
Controls 
Age-adjusted Fully adjusted* 
SF-36 Subscale N Mean±SD N Mean±SD Diff Means (95% 
CI) 
p-
value 
Diff Means (95% 
CI) 
p-
value 
Adj p-
value** 
Effect 
Size+ 
General health  238 73.4±18.2 198 71.6±18.0 1.8 (-1.6, 5.2) 0.31 2.1 (-1.1, 5.3) 0.21 0.33 0.13 
Physical functioning  240 90.1±16.4 197 88.1±17.5 2.0 (-1.2, 5.1) 0.22 3.2 (0.5, 5.9) 0.02 0.08 0.23 
Bodily pain  238 76.4±21.4 198 72.9±21.1 3.4 (-0.6, 7.3) 0.10 3.8 (0.1, 7.5) 0.04 0.12 0.20 
Physical Role  
   Functioning  
240 88.7±18.8 197 86.1±20.5 2.5 (-1.1, 6.1) 0.18 3.8 (0.4, 7.2) 0.03 0.11 0.22 
Mental Health  239 81.8±14.0 197 79.4±14.8 2.5 (-0.2, 5.2) 0.07 2.8 (0.2, 5.5) 0.04 0.12 0.21 
Vitality 239 67.1±17.4 198 66.2±15.5 0.9 (-2.2, 4.0) 0.57 1.2 (-1.8, 4.2) 0.44 0.58 0.08 
Emotional Role 
   Functioning  
240 92.7±15.4 197 90.9±18.1 1.8 (-1.4, 4.9) 0.27 3.0 (-0.1, 6.0) 0.06 0.14 0.19 
Social Role 
Functioning  
239 93.2±14.5 199 88.3±19.7 4.9 (1.7, 8.1) 0.003 5.9 (2.8, 9.0) 0.0002 0.002 0.37 
 N % N % OR (95% CI) p-
value 
OR (95% CI) p-
value 
Adj p-
value** 
 
HADS Anxiety –  
   Categories 
     0.08  0.05 0.13  
   Normal (<7) 208 88.5 164 82.8 1.00  1.00    
   Borderline/ 
      Abnormal (8+) 
27 11.5 34 17.2 0.62 (0.36, 1.07)  0.56 (0.31, 1.01)    
HADS Depression –  
   Categories 
     0.13  0.04 0.12  
   Normal 223 93.7 178 89.9 1.00  1.00    
   Borderline/ 
      Abnormal (8+) 
15 6.3 20 10.1 0.58 (0.28, 1.17)  0.43 (0.19, 0.97)    
* adjusted for age, education, income, marital status (married/partnered vs. other), BMI category, smoking status and presence of any comorbidities 
** adjusted for multiple statistical tests using the Benjamini and Hochberg method189 
+ Cohen’s d; difference in means divided by the standard deviation 
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Table 15b. SF-36 subscale scores and HADS Anxiety and Depression categories compared between melanoma survivors and 
population controls among females. 
FEMALES Melanoma Survivors Population 
Controls 
Age-adjusted Fully adjusted* 
SF-36 Subscale N Mean±SD N Mean±SD Diff Means 
(95% CI) 
p-value Diff Means  
(95% CI) 
p-value Adj p-
value** 
Effect Size+ 
General health  342 78.0±17.2 309 74.6±18.8 3.5 (0.7, 6.2) 0.01 3.3 (0.7, 6.0) 0.01 0.05 0.20 
Physical functioning  348 92.2±13.5 306 87.8±17.2 4.6 (2.3, 6.9) <0.0001 4.5 (2.4, 6.6) <0.0001 0.0009 0.33 
Bodily pain  345 79.5±20.0 309 73.3±20.9 6.4 (3.3, 9.5) <0.0001 5.6 (2.7, 8.6) 0.0002 0.002 0.30 
Physical Role  
   Functioning  
346 92.0±15.4 306 88.6±19.9 3.6 (1.0, 6.3) 0.007 3.5 (0.9, 6.1) 0.008 0.04 0.21 
Mental Health  341 79.7±14.8 309 78.9±14.9 0.7 (-1.5, 3.0) 0.52 0.2 (-2.0, 2.5) 0.83 0.94 0.02 
Vitality 341 66.9±16.7 309 64.4±17.6 -2.4 (-0.2, 5.1) 0.07 2.0 (-0.5, 4.6) 0.12 0.21 0.12 
Emotional Role 
   Functioning  
345 91.9±16.4 306 91.2±16.9 0.7 (-1.9, 3.3) 0.59 0.2 (-2.3, 2.7) 0.88 0.94 0.01 
Social Role Functioning  345 90.7±16.0 309 89.5±18.9 1.2 (-1.5, 3.8) 0.40 0.7 (-1.9, 3.3) 0.61 0.76 0.04 
 N % N % OR (95% CI) p-value OR (95% CI) p-value Adj p-
value** 
 
HADS Anxiety –  
   Categories 
     0.83  0.92 0.94  
   Normal (<7) 273 80.8 246 79.9 1.00  1.00    
   Borderline/ 
      Abnormal (8+) 
65 19.2 62 20.1 0.96 (0.65, 1.42)  1.02 (0.68, 1.54)    
HADS Depression –  
   Categories 
     0.21  0.30 0.44  
   Normal 320 94.4 284 91.9 1.00  1.00    
   Borderline/ 
      Abnormal (8+) 
19 5.6 25 8.1 0.68 (0.36, 1.25)  0.71 (0.37, 1.36)    
* adjusted for age, education, income, marital status (married/partnered vs. other), BMI category, smoking status and presence of any comorbidities 
** adjusted for multiple statistical tests using the Benjamini and Hochberg method189 
+ Cohen’s d; difference in means divided by the standard deviation 
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Table 16a. SF-36 subscale scores and HADS Anxiety and Depression categories compared between melanoma survivors with 
Stage I disease and population controls. 
 Stage I Population Controls Fully adjusted* 
SF-36 Subscale N Mean±SD N Mean±SD Diff Means (95% CI) p-value Effect Size+ 
General health (GH) 466 76.4±17.9 507 73.4±18.5 3.2 (1.0, 5.4) 0.004 0.19 
Physical functioning (PF) 471 91.4±15.3 503 87.9±17.3 3.9 (2.1, 5.7) <0.0001 0.28 
Bodily pain (BP) 468 79.2±20.0 507 73.1±20.9 5.9 (3.4, 8.3) <0.0001 0.31 
Physical Role Functioning (RP) 470 91.3±16.6 503 87.6±20.1 4.1 (1.9, 6.3) 0.0002 0.24 
Mental Health (MH) 466 81.2±13.8 506 79.1±14.8 1.9 (0.2, 3.7) 0.03 0.14 
Vitality (VT) 466 67.5±17.0 507 65.1±16.8 2.3 (0.2, 4.3) 0.03 0.14 
Emotional Role Functioning (RE) 469 93.2±14.3 503 91.1±17.4 2.4 (0.4, 4.4) 0.02 0.16 
Social Role Functioning (SF) 469 92.4±14.9 508 89.1±19.2 3.4 (1.2, 5.5) 0.002 0.20 
        
 N % N % OR (95% CI) p-value  
HADS Anxiety – Categories*      0.14  
   Normal (<7) 390 84.6 410 81.0 1.00   
   Borderline/Abnormal (8+) 71 15.4 96 19.0 0.77 (0.54, 1.10)   
HADS Depression – Categories*      0.009  
   Normal 441 95.0 462 91.1 1.00   
   Borderline/Abnormal (8+) 23 5.0 45 8.9 0.47 (0.27, 0.83)   
* adjusted for sex, age, education, income, marital status (married/partnered vs. other), BMI category, smoking status and presence of any comorbidities 
+ Cohen’s d; difference in means divided by the standard deviation 
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Table 16b. SF-36 subscale scores and HADS Anxiety and Depression categories compared between melanoma survivors with 
Stage II disease and population controls. 
 Stage II Population Controls Fully adjusted* 
SF-36 Subscale N Mean±SD N Mean±SD Diff Means (95% CI) p-value Effect Size+ 
General health (GH) 35 76.2±16.9 507 73.4±18.5 2.5 (-3.4, 8.5) 0.41 0.07 
Physical functioning (PF) 35 93.0±10.1 503 87.9±17.3 4.5 (-0.7, 9.7) 0.09 0.15 
Bodily pain (BP) 35 76.2±22.4 507 73.1±20.9 2.9 (-3.9, 9.6) 0.40 0.07 
Physical Role Functioning (RP) 35 88.6±19.1 503 87.6±20.1 0.6 (-5.8, 7.0) 0.85 0.02 
Mental Health (MH) 35 80.7±13.4 506 79.1±14.8 2.5 (-3.9, 5.9) 0.68 0.04 
Vitality (VT) 35 67.0±14.3 507 65.1±16.8 1.1 (-4.4, 6.5) 0.70 0.03 
Emotional Role Functioning (RE) 35 90.2±17.6 503 91.1±17.4 -1.1 (-6.9, 4.7) 0.71 0.03 
Social Role Functioning (SF) 35 92.5±13.3 508 89.1±19.2 3.1 (-3.2, 9.3) 0.33 0.08 
        
 N % N % OR (95% CI) p-value  
HADS Anxiety – Categories*      0.41  
   Normal (<7) 30 88.2 410 81.0 1.00   
   Borderline/Abnormal (8+) 4 11.8 96 19.0 0.63 (0.21, 1.91)   
HADS Depression – Categories*      0.25  
   Normal 34 97.1 462 91.1 1.00   
   Borderline/Abnormal (8+) 1 2.9 45 8.9 0.30 (0.04, 2.36)   
* adjusted for sex, age, education, income, marital status (married/partnered vs. other), BMI category, smoking status and presence of any comorbidities 
+ Cohen’s d; difference in means divided by the standard deviation 
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Table 16c. SF-36 subscale scores and HADS Anxiety and Depression categories compared between melanoma survivors with 
Stage III/IV disease and population controls. 
 Stage III/IV Population Controls Fully adjusted* 
SF-36 Subscale N Mean±SD N Mean±SD Diff Means (95% CI) p-value Effect Size+ 
General health (GH) 38 73.4±14.1 507 73.4±18.5 0.0 (-5.9, 5.8) 0.99 0.00 
Physical functioning (PF) 39 91.4±10.6 503 87.9±17.3 4.7 (-0.3, 9.7) 0.07 0.16 
Bodily pain (BP) 39 69.9±24.4 507 73.1±20.9 -2.9 (-9.6, 3.7) 0.38 0.08 
Physical Role Functioning (RP) 39 86.9±17.9 503 87.6±20.1 0.1 (-6.1, 6.3) 0.98 0.00 
Mental Health (MH) 38 78.3±18.2 506 79.1±14.8 -1.0 (-6.0, 4.0) 0.69 0.04 
Vitality (VT) 38 63.7±17.4 507 65.1±16.8 -0.5 (-6.0, 4.9) 0.85 0.02 
Emotional Role Functioning (RE) 39 85.3±24.1 503 91.1±17.4 -4.8 (-10.7, 1.0) 0.11 0.14 
Social Role Functioning (SF) 39 87.2±19.3 508 89.1±19.2 -1.5 (-7.7, 4.8) 0.65 0.04 
        
 N % N % OR (95% CI) p-value  
HADS Anxiety – Categories*      0.26  
   Normal (<7) 28 73.7 410 81.0 1.00   
   Borderline/Abnormal (8+) 10 26.3 96 19.0 1.59 (0.71, 3.59)   
HADS Depression – Categories*      0.37  
   Normal 33 86.8 462 91.1 1.00   
   Borderline/Abnormal (8+) 5 13.2 45 8.9 1.63 (0.56, 4.75)   
* adjusted for sex, age, education, income, marital status (married/partnered vs. other), BMI category, smoking status and presence of any comorbidities 
+ Cohen’s d; difference in means divided by the standard deviation 
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Table 17a. SF-36 subscale scores and HADS Anxiety and Depression categories compared between melanoma survivors with 
melanoma on head/neck and population controls. 
 Head/Neck Population Controls Fully adjusted* 
SF-36 Subscale N Mean±SD N Mean±SD Diff Means (95% CI) p-value Effect Size+ 
General health (GH) 62 78.0±17.5 507 73.4±18.5 5.3 (0.7, 9.8) 0.02 0.19 
Physical functioning (PF) 63 90.9±13.9 503 87.9±17.3 4.5 (0.5, 8.5) 0.03 0.19 
Bodily pain (BP) 62 77.0±21.3 507 73.1±20.9 5.3 (0.1, 10.5) 0.04 0.17 
Physical Role Functioning (RP) 63 89.4±17.8 503 87.6±20.1 4.2 (-0.6, 9.1) 0.09 0.15 
Mental Health (MH) 62 81.0±13.7 506 79.1±14.8 1.7 (-2.1, 5.5) 0.38 0.08 
Vitality (VT) 62 69.0±14.5 507 65.1±16.8 4.4 (0.2, 8.6) 0.04 0.18 
Emotional Role Functioning (RE) 63 94.0±11.7 503 91.1±17.4 4.1 (-0.3, 8.4) 0.07 0.16 
Social Role Functioning (SF) 62 93.1±13.9 508 89.1±19.2 5.2 (0.4, 10.0) 0.03 0.18 
        
 N % N % OR (95% CI) p-value  
HADS Anxiety – Categories*      0.23  
   Normal (<7) 54 87.1 410 81.0 1.00   
   Borderline/Abnormal (8+) 8 12.9 96 19.0 0.61 (0.27, 1.38)   
HADS Depression – Categories*      0.19  
   Normal 59 95.2 462 91.1 1.00   
   Borderline/Abnormal (8+) 3 4.8 45 8.9 0.43 (0.12, 1.53)   
* adjusted for sex, age, education, income, marital status (married/partnered vs. other), BMI category, smoking status and presence of any comorbidities 
+ Cohen’s d; difference in means divided by the standard deviation 
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Table 17b. SF-36 subscale scores and HADS Anxiety and Depression categories compared between melanoma survivors with 
melanoma on trunk and population controls. 
 Trunk Population Controls Fully adjusted* 
SF-36 Subscale N Mean±SD N Mean±SD Diff Means (95% CI) p-value Effect Size+ 
General health (GH) 200 74.3±19.2 507 73.4±18.5 1.6 (-1.3, 4.5) 0.28 0.08 
Physical functioning (PF) 203 89.9±17.2 503 87.9±17.3 3.2 (0.8, 5.7) 0.01 0.20 
Bodily pain (BP) 200 77.0±21.9 507 73.1±20.9 3.6 (0.3, 6.9) 0.03 0.17 
Physical Role Functioning (RP) 202 89.7±18.1 503 87.6±20.1 2.5 (-0.5, 5.6) 0.10 0.13 
Mental Health (MH) 200 79.7±16.2 506 79.1±14.8 0.8 (-1.7, 3.2) 0.53 0.05 
Vitality (VT) 200 64.9±18.6 507 65.1±16.8 0.1 (-2.6, 2.8) 0.94 0.01 
Emotional Role Functioning (RE) 202 91.0±19.4 503 91.1±17.4 0.6 (-2.3, 3.4) 0.71 0.03 
Social Role Functioning (SF) 201 90.3±18.1 508 89.1±19.2 1.2 (-1.9, 4.2) 0.45 0.06 
        
 N % N % OR (95% CI) p-value  
HADS Anxiety – Categories*      0.72  
   Normal (<7) 159 81.5 410 81.0 1.00   
   Borderline/Abnormal (8+) 36 18.5 96 19.0 0.92 (0.58, 1.46)   
HADS Depression – Categories*      0.87  
   Normal 180 90.5 462 91.1 1.00   
   Borderline/Abnormal (8+) 19 9.6 45 8.9 1.05 (0.57, 1.93)   
* adjusted for sex, age, education, income, marital status (married/partnered vs. other), BMI category, smoking status and presence of any comorbidities 
+ Cohen’s d; difference in means divided by the standard deviation 
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Table 17c. SF-36 subscale scores and HADS Anxiety and Depression categories compared between melanoma survivors with 
melanoma on upper limbs and population controls. 
 Upper limbs Population Controls Fully adjusted* 
SF-36 Subscale N Mean±SD N Mean±SD Diff Means (95% CI) p-value Effect Size+ 
General health (GH) 156 76.0±15.9 507 73.4±18.5 2.9 (-0.2, 6.0) 0.07 0.14 
Physical functioning (PF) 159 91.7±13.3 503 87.9±17.3 5.1 (2.5, 7.7) 0.0001 0.31 
Bodily pain (BP) 158 77.6±19.3 507 73.1±20.9 5.5 (2.1, 9.0) 0.002 0.25 
Physical Role Functioning (RP) 158 91.9±15.5 503 87.6±20.1 5.5 (2.3, 8.7) 0.0007 0.27 
Mental Health (MH) 156 81.1±14.0 506 79.1±14.8 1.7 (-0.9, 4.3) 0.19 0.10 
Vitality (VT) 156 67.4±16.8 507 65.1±16.8 1.9 (-1.0, 4.9) 0.20 0.10 
Emotional Role Functioning (RE) 157 92.3±14.3 503 91.1±17.4 1.4 (-1.5, 4.3) 0.35 0.07 
Social Role Functioning (SF) 158 93.8±12.8 508 89.1±19.2 5.1 (1.9, 8.2) 0.002 0.25 
        
 N % N % OR (95% CI) p-value  
HADS Anxiety – Categories*      0.08  
   Normal (<7) 136 88.3 410 81.0 1.00   
   Borderline/Abnormal (8+) 18 11.7 96 19.0 0.61 (0.35, 1.06)   
HADS Depression – Categories*      0.02  
   Normal 149 96.8 462 91.1 1.00   
   Borderline/Abnormal (8+) 5 3.3 45 8.9 0.27 (0.09, 0.79)   
* adjusted for sex, age, education, income, marital status (married/partnered vs. other), BMI category, smoking status and presence of any comorbidities 
+ Cohen’s d; difference in means divided by the standard deviation 
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Table 17d. SF-36 subscale scores and HADS Anxiety and Depression categories compared between melanoma survivors with 
melanoma on lower limbs and population controls. 
 Lower limbs Population Controls Fully adjusted* 
SF-36 Subscale N Mean±SD N Mean±SD Diff Means (95% CI) p-value Effect Size+ 
General health (GH) 153 77.5±17.8 507 73.4±18.5 4.0 (0.7, 7.2) 0.02 0.19 
Physical functioning (PF) 154 92.7±13.3 503 87.9±17.3 4.0 (1.2, 6.7) 0.005 0.23 
Bodily pain (BP) 154 80.6±20.3 507 73.1±20.9 6.3 (2.7, 9.9) 0.0007 0.27 
Physical Role Functioning (RP) 154 90.9±16.9 503 87.6±20.1 2.9 (-0.5, 6.3) 0.09 0.14 
Mental Health (MH) 153 80.6±13.2 506 79.1±14.8 1.3 (-1.4, 3.9) 0.35 0.07 
Vitality (VT) 153 67.9±16.0 507 65.1±16.8 2.8 (-0.1, 5.8) 0.06 0.15 
Emotional Role Functioning (RE) 154 92.5±14.5 503 91.1±17.4 1.2 (-1.8, 4.3) 0.42 0.06 
Social Role Functioning (SF) 154 90.7±14.8 508 89.1±19.2 1.4 (-1.8, 4.7) 0.38 0.07 
        
 N % N % OR (95% CI) p-value  
HADS Anxiety – Categories*      1.00  
   Normal (<7) 124 81.1 410 81.0 1.00   
   Borderline/Abnormal (8+) 29 19.0 96 19.0 1.00 (0.61, 1.63)   
HADS Depression – Categories*      0.04  
   Normal 146 95.4 462 91.1 1.00   
   Borderline/Abnormal (8+) 7 4.6 45 8.9 0.39 (0.17, 0.94)   
* adjusted for sex, age, education, income, marital status (married/partnered vs. other), BMI category, smoking status and presence of any comorbidities 
+ Cohen’s d; difference in means divided by the standard deviation 
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Table 18. SF-36 subscale scores and HADS Anxiety and Depression categories compared between melanoma survivors with 
lymphedema and population controls. 
 Lymphedema Population Controls Fully adjusted* 
SF-36 Subscale N Mean±SD N Mean±SD Diff Means (95% CI) p-value Effect Size+ 
General health (GH) 22 72.0±15.8 507 73.4±18.5 -2.6 (-10.0, 4.8) 0.48 0.06 
Physical functioning (PF) 22 92.0±11.3 503 87.9±17.3 3.0 (-3.5, 9.5) 0.36 0.08 
Bodily pain (BP) 22 71.2±26.8 507 73.1±20.9 -3.1 (-11.6, 5.4) 0.47 0.06 
Physical Role Functioning (RP) 22 88.4±15.2 503 87.6±20.1 -0.7 (-8.7, 7.2) 0.85 0.02 
Mental Health (MH) 22 77.3±16.3 506 79.1±14.8 -2.6 (-8.8, 3.6) 0.41 0.07 
Vitality (VT) 22 64.0±16.9 507 65.1±16.8 -2.4 (-9.2, 4.5) 0.49 0.06 
Emotional Role Functioning (RE) 22 86.4±18.6 503 91.1±17.4 -5.1 (-12.4, 2.1) 0.17 0.12 
Social Role Functioning (SF) 22 89.2±15.1 508 89.1±19.2 -1.1 (-9.0, 6.8) 0.78 0.02 
        
 N % N % OR (95% CI) p-value  
HADS Anxiety – Categories*      0.47  
   Normal (<7) 17 77.3 410 81.0 1.00   
   Borderline/Abnormal (8+) 5 22.7 96 19.0 1.48 (0.51, 4.33)   
HADS Depression – Categories*      0.62  
   Normal 20 91.9 462 91.1 1.00   
   Borderline/Abnormal (8+) 2 9.1 45 8.9 1.48 (0.31, 7.01)   
* adjusted for sex, age, education, income, marital status (married/partnered vs. other), BMI category, smoking status and presence of any comorbidities 
+ Cohen’s d; difference in means divided by the standard deviation 
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Table 19. SF-36 subscale scores and HADS Anxiety and Depression categories compared between melanoma survivors who 
had any adjuvant therapy (chemotherapy, radiation or immunotherapy at time of initial or recurrent disease) and population 
controls. 
 Any Adjuvant Therapy Population Controls Fully adjusted* 
SF-36 Subscale N Mean±SD N Mean±SD Diff Means (95% CI) p-value Effect Size+ 
General health (GH) 34 76.0±14.1 507 73.4±18.5 -2.6 (-3.4, 8.6) 0.40 0.07 
Physical functioning (PF) 35 93.0±9.8 503 87.9±17.3 6.4 (1.2, 11.7) 0.02 0.21 
Bodily pain (BP) 35 76.5±21.4 507 73.1±20.9 4.0 (-2.6, 10.8) 0.24 0.10 
Physical Role Functioning (RP) 35 88.8±16.4 503 87.6±20.1 2.4 (-4.1, 8.8) 0.47 0.06 
Mental Health (MH) 35 79.6±14.8 506 79.1±14.8 0.3 (-4.7, 5.3) 0.90 0.01 
Vitality (VT) 35 67.0±13.7 507 65.1±16.8 2.4 (-3.1, 7.9) 0.39 0.08 
Emotional Role Functioning (RE) 35 90.0±16.5 503 91.1±17.4 -0.6 (-6.4, 5.3) 0.85 0.02 
Social Role Functioning (SF) 35 93.2±13.0 508 89.1±19.2 3.2 (-1.9, 10.7) 0.17 0.12 
        
 N % N % OR (95% CI) p-value  
HADS Anxiety – Categories*      0.87  
   Normal (<7) 28 80.0 410 81.0 1.00   
   Borderline/Abnormal (8+) 7 20.0 96 19.0 1.08 (0.43, 2.70)   
HADS Depression – Categories*      0.22  
   Normal 34 97.1 462 91.1 1.00   
   Borderline/Abnormal (8+) 1 2.9 45 8.9 0.27 (0.03, 2.19)   
* adjusted for sex, age, education, income, marital status (married/partnered vs. other), BMI category, smoking status and presence of any comorbidities 
+ Cohen’s d; difference in means divided by the standard deviation 
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Table 20. SF-36 subscale scores and HADS Anxiety and Depression categories compared between melanoma survivors with 
recurrence or metastases and population controls. 
 Recurrence or Metastases Population Controls Fully adjusted* 
SF-36 Subscale N Mean±SD N Mean±SD Diff Means (95% CI) p-value Effect Size+ 
General health (GH) 27 73.6±15.8 507 73.4±18.5 0.4 (-6.5, 7.2) 0.91 0.01 
Physical functioning (PF) 28 91.6±11.5 503 87.9±17.3 4.1 (-1.8, 10.0) 0.18 0.12 
Bodily pain (BP) 28 76.5±26.6 507 73.1±20.9 3.5 (-4.2, 11.3) 0.37 0.08 
Physical Role Functioning (RP) 28 88.8±16.0 503 87.6±20.1 2.0 (-5.2, 9.2) 0.59 0.05 
Mental Health (MH) 27 78.7±17.2 506 79.1±14.8 -0.4 (-6.1, 5.4) 0.91 0.01 
Vitality (VT) 27 64.1±18.1 507 65.1±16.8 -0.8 (-5.5, 7.2) 0.80 0.02 
Emotional Role Functioning (RE) 27 91.4±15.8 503 91.1±17.4 3.4 (-6.2, 7.2) 0.89 0.01 
Social Role Functioning (SF) 28 88.4±18.0 508 89.1±19.2 -0.2 (-7.4, 7.0) 0.96 0.00 
        
 N % N % OR (95% CI) p-value  
HADS Anxiety – Categories*      0.96  
   Normal (<7) 21 77.8 410 81.0 1.00   
   Borderline/Abnormal (8+) 6 22.2 96 19.0 1.03 (0.38, 2.79)   
HADS Depression – Categories*      0.21  
   Normal 26 96.3 462 91.1 1.00   
   Borderline/Abnormal (8+) 1 3.7 45 8.9 0.26 (0.03, 2.14)   
* adjusted for sex, age, education, income, marital status (married/partnered vs. other), BMI category, smoking status and presence of any comorbidities 
+ Cohen’s d; difference in means divided by the standard deviation 
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Table 21a. SF-36 subscale scores and HADS Anxiety and Depression categories compared between melanoma survivors who 
report melanoma to be not very serious (lowest quartile) and population controls. 
 Survivor - Perceive 
Melanoma as Less Serious 
Population Controls Fully adjusted* 
SF-36 Subscale N Mean±SD N Mean±SD Diff Means (95% CI) p-value Effect Size+ 
General health (GH) 139 76.8±17.3 507 73.4±18.5 2.8 (-0.5, 6.0) 0.10 0.13 
Physical functioning (PF) 141 91.6±14.5 503 87.9±17.3 3.7 (1.0, 6.5) 0.008 0.21 
Bodily pain (BP) 141 77.2±20.4 507 73.1±20.9 3.4 (-0.2, 7.1) 0.07 0.15 
Physical Role Functioning (RP) 141 91.0±16.6 503 87.6±20.1 3.0 (-0.4, 6.5) 0.09 0.14 
Mental Health (MH) 139 79.2±16.1 506 79.1±14.8 0.1 (-2.6, 2.9) 0.92 0.01 
Vitality (VT) 139 66.5±17.2 507 65.1±16.8 1.1 (-1.9, 4.2) 0.47 0.06 
Emotional Role Functioning (RE) 141 90.8±18.0 503 91.1±17.4 -0.2 (-3.4, 3.0) 0.90 0.01 
Social Role Functioning (SF) 141 91.3±16.4 508 89.1±19.2 2.5 (-0.9, 5.9) 0.14 0.12 
        
 N % N % OR (95% CI) p-value  
HADS Anxiety – Categories*      0.80  
   Normal (<7) 113 81.3 410 81.0 1.00   
   Borderline/Abnormal (8+) 26 18.7 96 19.0 0.94 (0.56, 1.57)   
HADS Depression – Categories*      0.30  
   Normal 129 92.8 462 91.1 1.00   
   Borderline/Abnormal (8+) 10 7.2 45 8.9 0.66 (0.30, 1.45)   
* adjusted for sex, age, education, income, marital status (married/partnered vs. other), BMI category, smoking status and presence of any comorbidities 
+ Cohen’s d; difference in means divided by the standard deviation 
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Table 21b. SF-36 subscale scores and HADS Anxiety and Depression categories compared between melanoma survivors who 
report melanoma to be very serious (upper 75%) and population controls. 
 Survivor - Perceive 
Melanoma as Very Serious 
Population Controls Fully adjusted* 
SF-36 Subscale N Mean±SD N Mean±SD Diff Means (95% CI) p-value Effect Size+ 
General health (GH) 429 76.2±17.6 507 73.4±18.5 2.9 (0.7, 5.1) 0.009 0.17 
Physical functioning (PF) 430 91.4±14.8 503 87.9±17.3 4.0 (2.2, 5.9) <0.0001 0.28 
Bodily pain (BP) 429 78.6±20.8 507 73.1±20.9 5.4 (2.9, 7.9) <0.0001 0.28 
Physical Role Functioning (RP) 430 90.8±16.8 503 87.6±20.1 3.7 (1.5, 6.0) 0.001 0.22 
Mental Health (MH) 429 81.1±14.0 506 79.1±14.8 1.8 (0.0, 3.6) 0.05 0.13 
Vitality (VT) 429 67.2±17.0 507 65.1±16.8 2.1 (0.1, 4.2) 0.04 0.13 
Emotional Role Functioning (RE) 429 92.6±15.4 503 91.1±17.4 1.9 (-0.2, 3.9) 0.07 0.12 
Social Role Functioning (SF) 430 91.8±15.2 508 89.1±19.2 2.7 (0.6, 4.9) 0.01 0.16 
        
 N % N % OR (95% CI) p-value  
HADS Anxiety – Categories*      0.19  
   Normal (<7) 359 84.7 410 81.0 1.00   
   Borderline/Abnormal (8+) 65 15.3 96 19.0 0.79 (0.55, 1.13)   
HADS Depression – Categories*      0.03  
   Normal 404 94.4 462 91.1 1.00   
   Borderline/Abnormal (8+) 24 5.6 45 8.9 0.55 (0.32, 0.96)   
* adjusted for sex, age, education, income, marital status (married/partnered vs. other), BMI category, smoking status and presence of any comorbidities 
+ Cohen’s d; difference in means divided by the standard deviation 
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Table 22a. SF-36 subscale scores and HADS Anxiety and Depression categories compared between melanoma survivors who 
report being less fearful of a second melanoma (below median) and population controls. 
 Survivor – Less Fearful 
of 2nd Melanoma 
Population Controls Fully adjusted* 
SF-36 Subscale N Mean±SD N Mean±SD Diff Means (95% CI) p-value Effect Size+ 
General health (GH) 279 78.5±16.8 507 73.4±18.5 4.2 (1.8, 6.7) 0.0009 0.24 
Physical functioning (PF) 281 91.6±14.4 503 87.9±17.3 4.0 (1.9, 6.1) 0.0002 0.27 
Bodily pain (BP) 281 80.4±19.1 507 73.1±20.9 6.7 (3.9, 9.5) <0.0001 0.34 
Physical Role Functioning (RP) 281 91.8±15.4 503 87.6±20.1 4.6 (2.0, 7.1) 0.0005 0.25 
Mental Health (MH) 279 83.6±12.4 506 79.1±14.8 3.8 (1.8, 5.9) 0.0002 0.27 
Vitality (VT) 279 69.7±16.2 507 65.1±16.8 3.7 (1.3, 6.0) 0.002 0.22 
Emotional Role Functioning (RE) 280 94.2±13.9 503 91.1±17.4 3.3 (1.0, 5.6) 0.005 0.20 
Social Role Functioning (SF) 281 93.6±12.9 508 89.1±19.2 3.9 (1.5, 6.4) 0.002 0.23 
        
 N % N % OR (95% CI) p-value  
HADS Anxiety – Categories*      0.0002  
   Normal (<7) 257 92.8 410 81.0 1.00   
   Borderline/Abnormal (8+) 20 7.2 96 19.0 0.37 (0.22, 0.62)   
HADS Depression – Categories*      0.002  
   Normal 271 97.5 462 91.1 1.00   
   Borderline/Abnormal (8+) 7 2.5 45 8.9 0.24 (0.10, 0.58)   
* adjusted for sex, age, education, income, marital status (married/partnered vs. other), BMI category, smoking status and presence of any comorbidities 
+ Cohen’s d; difference in means divided by the standard deviation 
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Table 22b. SF-36 subscale scores and HADS Anxiety and Depression categories compared between melanoma survivors who 
report being more fearful of a second melanoma (above median) and population controls. 
 Survivor – More Fearful 
of 2nd Melanoma 
Population Controls Fully adjusted* 
SF-36 Subscale N Mean±SD N Mean±SD Diff Means (95% CI) p-value Effect Size+ 
General health (GH) 289 74.3±18.0 507 73.4±18.5 1.4 (-1.1, 4.0) 0.27 0.08 
Physical functioning (PF) 290 91.7±14.0 503 87.9±17.3 3.9 (1.8, 6.0) 0.0003 0.26 
Bodily pain (BP) 289 76.2±21.9 507 73.1±20.9 3.2 (0.4, 6.1) 0.03 0.23 
Physical Role Functioning (RP) 290 90.0±17.9 503 87.6±20.1 2.5 (-0.2, 5.1) 0.07 0.13 
Mental Health (MH) 289 77.9±15.4 506 79.1±14.8 -1.0 (-3.2, 1.1) 0.36 0.07 
Vitality (VT) 289 64.5±17.4 507 65.1±16.8 0.1 (-2.3, 2.5) 0.96 0.00 
Emotional Role Functioning (RE) 290 90.5±17.2 503 91.1±17.4 -0.5 (-3.0, 2.0) 0.68 0.03 
Social Role Functioning (SF) 290 90.0±17.2 508 89.1±19.2 1.5 (-1.1, 4.1) 0.25 0.08 
        
 N % N % OR (95% CI) p-value  
HADS Anxiety – Categories*      0.17  
   Normal (<7) 214 75.4 410 81.0 1.00   
   Borderline/Abnormal (8+) 70 24.7 96 19.0 1.30 (0.89, 1.88)   
HADS Depression – Categories*      0.68  
   Normal 261 90.9 462 91.1 1.00   
   Borderline/Abnormal (8+) 26 9.1 45 8.9 0.89 (0.52, 1.53)   
* adjusted for sex, age, education, income, marital status (married/partnered vs. other), BMI category, smoking status and presence of any comorbidities 
+ Cohen’s d; difference in means divided by the standard deviation 
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8 Part II: Manuscript 3 - A cross-sectional survey of the sun exposure and 
protection behaviors of long-term melanoma survivors compared to population 
controls 
8.1 Introduction 
Melanoma is considered a generally preventable cancer, with excessive UVR 
exposure being one of the strongest risk factors for the diasese.16,17  Additional risk 
factors include a large number of moles and/or freckles, fair skin, family history of 
melanoma, and immune suppression.18  Even when diagnosed at an early stage, 
melanoma can be aggressive and treatment resistant, having the ability to metastasize at 
the earliest stages.19  Patients diagnosed with melanoma experience high rates of 
recurrence, with excess risk of recurrence remaining 20 years after the initial 
diagnosis20,21 and have an approximately 9-fold increased risk of developing another 
melanoma.21 
For melanomas that develop as a consequence of UVR exposure, the damage 
done to the skin prior to the first melanoma cannot be ameliorated and this damage may 
increase risk of a subsequent melanoma.  Importantly, however, UVR exposure following 
a melanoma diagnosis can be modified to reduce risk of a new melanoma diagnosis.101   
It has been suggested that cancer may be a “teachable moment” for health 
behavior change.102 Unfortunately, while some cancer survivors initiate positive health 
behaviors, others do not.103  In the case of melanoma, reduction of sun exposure is 
paramount.  Individuals are advised to limit time in the sun during peak hours, seek 
shade, wear protecting clothing, use sunscreen, and avoid indoor tanning devices.14   
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The young age at diagnosis of melanoma for some suggests ample opportunity to 
engage in improved sun protection behaviors following diagnosis. Surprisingly little 
research has documented UVR exposure among melanoma survivors.  Studies to date on 
sun protection behaviors among melanoma survivors have been mixed, though most 
suggest that if an improvement in sun behaviors among melanoma survivors is present, it 
is moderate.195  Further clarification of these behaviors in long-term melanoma survivors 
is needed.  In particular, data are lacking on sun exposure patterns and specific sun 
protection behaviors compared to an appropriately matched control group with measured 
potential confounders.   
The objective of this study was to compare measures of UVR exposure and 
protection behaviors between melanoma survivors and population controls and explore 
relationships between these measures and melanoma survivor characteristics.   
8.2 Methods 
8.2.1 Study Design and Population 
 See Chapter 6, section 6.1. 
8.2.2 Identification of Eligible Participants 
See Chapter 6, section 6.2. 
8.2.3 Subject recruitment 
 See Chapter 6, section 6.3. 
8.2.4 Data collection and Measures 
See Chapter 6, section 6.3 for details on data collection. 
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The primary outcomes for this study were self-reported sun exposure and 
protection measures. The questionnaire included nine self-report items related to sun 
exposure and protection practices developed by leading skin cancer prevention 
researchers and have been validated.169,196  All items had categorical responses.  Two 
questions asked about number of hours outside per day during peak hours (10am-4pm) in 
the summer separately for weekdays and weekend days using the following categories: 0-
30 minutes, 31 minutes-1 hour, 2 hours, 3 hours, 4 hours, 5 hours or 6 hours. Participants 
were also asked to report the number of red or painful sunburns that lasted a day or more 
in the past year: 0, 1, 2, 3, 4, or 5 or more.  Sun protection methods utilized during the 
summer on a warm sunny day, including wearing sunscreen, a shirt with sleeves, a hat 
with a wide brim, staying in the shade, and spending time in the sun in order to get a tan 
(intentional tanning) were collected using the following categories: Never, Rarely, 
Sometimes, Often, or Always. The final question asked whether the participant had used 
a tanning bed or booth in the past 12 months (yes, no).  For the purposes of this analysis 
and ease of interpretation, all of these measures were dichotomized into “optimal” and 
“suboptimal” categories; the following were considered optimal: weekday sun exposure 
in the summer of less than two hours, weekend day sun exposure in the summer of less 
than two hours, no sunburns in the past year, no indoor tanning in the past year, and 
reporting often or always using sunscreen, often or always wearing a shirt with sleeves, 
often or always wearing a hat, often or always staying in the shade, and rarely or never 
intentionally tanning.    
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Secondary outcomes included three additional items for melanoma survivors only 
asking whether they avoided sun exposure, wore sun-protective clothing, or used 
sunscreen more, the same, or less than before their diagnosis or if it was never their 
habit.149   
Potential confounders, including demographics and comorbidities, were also 
collected as described in Chapter 7.2.4.  In addition, data collected as part of the original 
Skin Health Study, described elsewhere, were considered.100,197 Briefly, data were 
ascertained using both a self-administered questionnaire and detailed computer-assisted 
telephone interview.  Skin, hair and eye color, presence and pattern of freckles and moles, 
detailed indoor tanning and residential history, and supplement/medication intake were 
collected via the self-administered questionnaire. Indoor tanning and sun exposure, 
history and number of painful sunburns before and after age 18, and sun protection 
behaviors, including sunscreen use, were collected during the telephone interview.  A 
phenotypic risk score was calculated based on hair and eye color, and tanning ability.  
The score ranges from 1 for lowest to 5 for highest melanoma risk.  For hair color, a 
score of 1 was assigned for dark brown or black, 2 for blond or light brown, and 3 for 
red; having eye colors of grey, blue, green or hazel contributed 1 additional point to the 
phenotype score, as did having no ability to tan.198 
Clinical characteristics of the melanoma diagnosis, including disease stage and 
location of tumor, when available, were provided by the Minnesota Cancer Surveillance 
System and supplemented with self-report follow-up survey data as needed. 
8.2.5 Statistical Methods 
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For the purposes of this dissertation, 1311 (687 melanoma survivor and 624 
control) surveys that were completed and returned by November 1, 2015 were included in 
the calculations of response rate.  At the time of the analysis for this dissertation, data 
entry was complete for approximately 60% of those who returned paper surveys, 
resulting in complete data for 592 (86.2%) melanoma survivors and 518 (83.0%) control 
surveys.   
Assessment of Bias 
To assess how death and non-response may have biased the results, comparisons 
were made between those eligible and ineligible for the study and between those who did 
and did not participate in this follow-up survey using data from the original Skin Health 
Study as described in Chapter 6.6.  Characteristics including sex, age, education, risk 
factors for melanoma (phenotype, family history of melanoma, sun exposure, sunburns, 
and sun protection practices), and among melanoma survivors, disease stage and tumor 
location, were considered.   
Identification of Potential Confounding Factors 
Demographic, general health characteristics, and pre-diagnosis sun exposure and 
protection behaviors were compared between melanoma survivors and population 
controls that completed the survey using Chi-squared tests, t-tests, and Wilcoxon Rank 
Sum tests as appropriate. To identify potential confounders, each sun exposure and 
protection outcome was compared across demographic, general health characteristics and 
risk factors for melanoma separately using Chi-squared tests, t-tests and Wilcoxon Rank 
Sum tests as appropriate.  
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Primary Analyses 
Primary analyses compared optimal UVR exposure and protection behaviors 
between melanoma survivors and population controls. Initial comparisons between 
melanoma survivors and population controls for all categories were conducted using Chi-
squared tests. Multivariate logistic regression models, both sex and age-adjusted, and 
fully-adjusted, were conducted and odds ratios (OR) and 95% confidence intervals (CI) 
for each outcome are presented.  Potential confounders included in the final models were 
age (continuous), sex, education (high school, vocation/associates, some college, college 
graduate, graduate/professional degree), income (<$50,000, $50,000-$74,999, $75,000-
$149,999, $150,000+, prefer not to say), current smoking status (yes, no), phenotypic risk 
score (low, intermediate, high), personal history of other skin cancer, family history of 
melanoma, and sun exposure data reported prior to diagnosis (lifetime sun exposure, 
outdoor activity sun exposure, mean sunscreen use, and number of sunburns).    
To explore whether differences in optimal UVR exposure and sun protection 
behaviors between melanoma survivors and controls differed according to age or sex, 
stratified analyses were compared to controls by age group at survey (30-49, 50-59, 60-
72) and sex.  Analyses were fully adjusted for all confounders, as previously described, 
and an interaction effect was included to examine whether a statistically significant 
interaction between melanoma status and age or sex was present.  Due to the number of 
statistical tests performed, p-values related to these primary analyses were adjusted for 
multiple comparisons using the Benjamini and Hochberg method;189 adjusted p-values 
<0.05 were considered statistically significant. 
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Secondary Analyses 
To determine whether particular subgroups of survivors had poorer sun exposure 
and protection behaviors, analyses of these outcomes among subgroups of melanoma 
survivors compared to all controls were conducted.  Analyses were done separately by 
melanoma stage (I vs. II/III/IV) and tumor site (head/neck, trunk, lower limb, upper 
limb). Due to the exploratory nature of these analyses, p-values were not adjusted for 
multiple comparisons.   
Finally, melanoma survivors’ report of changes in sun protection behaviors since 
diagnosis were summarized and compared by sex, age, melanoma stage, and tumor site 
using Chi-squared and Fisher’s Exact tests.  
8.3 Results 
Population Description and Assessment of Bias 
See Chapter 7, Section 7.3.1 for a detailed description of the population and 
potential for bias due to non-response.  Briefly, those who completed the survey were 
generally similar to those who did not respond, though they were slightly older, more 
likely to have completed college, and less likely to have ever used indoor tanning.   
This analysis included 592 melanoma survivors and 518 control surveys. Among 
those who completed the survey, melanoma survivors and population controls were not 
statistically significantly different across most demographic and health characteristics, 
though melanoma survivors were more likely to have a high phenotypic risk score 
(p<0.0001), more likely to use indoor tanning before their diagnosis (p=0.003), and 
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reported more lifetime sunburns prior to their diagnosis compared to the reference date of 
the controls (p<0.0001; Table 23).    
Identification of Potential Confounding Factors 
Age, sex, education, income, smoking status, phenotypic risk score, personal 
history of population skin cancer and pre-diagnosis measures of sun exposure and 
protection behaviors were generally associated with the sun exposure and protection 
measures, though these were not uniform across all behaviors (Tables 24a-24i).  
In particular, older individuals were more likely to report greater weekday sun 
exposure and less sunscreen use compared to younger individuals.  Older participants 
also reported, however, less weekend sun exposure and intentional tanning, fewer 
sunburns, and were more likely to wear a shirt and hat compared to younger participants. 
Males were more likely than females to report greater weekday sun exposure, weekend 
sun exposure and sunburns.  Males were also less likely to use sunscreen and stay in the 
shade compared to females, though they were more likely to wear a shirt and less likely 
to intentionally tan.  
Participants who were more educated reported less weekday sun exposure and 
intentional tanning and more sunscreen use and wearing of a hat than those who were less 
educated.  Respondents with higher income reported less weekday sun exposure and 
more sunscreen use, however they also reported greater weekend sun exposure than those 
with lower income. Participants who were current smokers reported greater weekday sun 
exposure, more sunburns, less sunscreen use, and were less likely to stay in the shade 
than those who were not current smokers.  Individuals with a low phenotypic risk score 
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reported more weekday sun exposure, less sunscreen use, were less likely to stay in the 
shade and were more likely to intentionally tan than those with higher risk scores.   
Participants who reported pre-diagnosis indoor tanning, compared to those who 
did not, reported more sunburns, were more likely to currently tan indoors and 
intentionally tan outdoors, and were less likely to wear a shirt or hat, though they did also 
report being more likely to wear sunscreen.  Individuals with higher pre-diagnosis sun 
exposure and outdoor activity exposure were more likely to have greater weekday and 
weekend sun exposure, more sunburns, and were less likely to use sunscreen and stay in 
the shade compared to those who reported lower pre-diagnosis sun exposure.  These 
individuals also reported being more likely to wear a shirt and hat and were less likely to 
intentionally tan than those with lower pre-diagnosis sun exposure.  Participants who 
reported higher pre-diagnosis sunscreen use reported less weekday sun exposure, were 
less likely to intentionally tan, and reported more sunscreen use, hat use, and staying in 
the shade than participants with lower pre-diagnosis sunscreen use.  Finally, individuals 
who reported a greater number of lifetime sunburns pre-diagnosis reported more 
sunburns in the past year, though they were more likely to wear a shirt and hat and less 
likely to intentionally tan than those with fewer sunburns pre-diagnosis. 
Primary Analyses 
Detailed survey responses to each sun exposure and protection behavior outcome 
compared between melanoma survivors and population controls are presented in Table 
25.  Very few individuals, whether a melanoma survivor or control, reported indoor 
tanning (n=7 and n=31, respectively).  When comparing melanoma survivors with 
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optimal behavior to that of controls, melanoma survivors were statistically significantly 
more likely to report optimal behaviors than population controls with the exception of 
sun exposure on weekend days in the summer (Table 26).  Specifically, melanoma 
survivors, compared to controls, were less likely to spend two or more hours outside on 
weekdays during the summer (31.1% vs. 43.0%, p=0.003), were less likely to report a 
sunburn in the past year (20.1% vs. 37.0%, p<0.0001), were less likely to have indoor 
tanned in the past year (1.2% vs. 6.1%, p=0.0004), were less likely to intentionally tan 
(10.0% vs. 24.4%, p<0.0001).  In addition, melanoma survivors were more likely to 
report often or always engaging in sun protection behaviors, including wearing sunscreen 
(62.2% vs. 39.7%, p<0.0001), a shirt with sleeves (46.7% vs. 65.8%, p=0.0006), hat 
(32.2% vs. 22.9%, p=0.0004), and stay in the shade in the summer (48.6% vs. 27.8%, 
p<0.0001).  Of note, however, 74.5% of melanoma survivors reported spending two or 
more hours in the sun on a typical day weekend day in the summer, compared to 78.9% 
(p=0.23) in the control group.     
A comparison of optimal UVR exposure and sun protection behaviors between 
melanoma survivors and controls by age was similar to the overall comparison with the 
exception of hours spent in the sun on weekend days (p=0.007; Table 27a-d). While none 
of the comparisons within age group were statistically significant, the youngest and 
oldest melanoma survivors were more likely to avoid sun exposure on weekend days 
compared to controls whereas those 50-59 years old reported more sun exposure on 
weekend days compared to controls.  While males and females differed in their sun 
exposure and protection behaviors, whether they were a survivor or not, sex-specific 
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comparisons between melanoma survivors and controls revealed no differences (Tables 
28a-28b).        
Secondary Analyses 
Secondary analyses exploring the sun exposure and protection behaviors of 
subgroups of melanoma survivors compared to controls found they did not appear to 
differ by stage (Tables 29a-29b) or tumor site (Tables 30a-30d). 
When looking at self-reported change in key behaviors, most melanoma survivors 
reported engaging in each behavior more, namely 79.6% reported more effort to avoid 
exposure to the sun, 62.5% wore more sun-protective clothing, and 78.2% used more 
sunscreen (Tables 31-33).  Sex and age differences were observed.  Females were more 
likely to report than males changing their exposure (85.0% vs. 71.6%, p=0.001) and 
sunscreen behaviors (84.5% vs. 68.9%, p<0.0001) and males were more likely to use and 
change their use of protective clothing compared to females (64.6% vs. 61.0%, p=0.004).  
Younger individuals were more likely to use sunscreen (p<0.0001) and less likely to use 
protective clothing (p=0.02).  Finally, those with tumors on their head or neck were less 
likely to change their sun exposure habits compared to other tumor sites (p=0.02).  No 
other statistically significant differences in self-reported changes in behaviors by 
melanoma stage or tumor site were observed. 
8.4 Discussion 
This population-based cross-sectional study is the largest to date to report UVR 
exposure and protection behaviors of long-term melanoma survivors compared with an 
appropriate population control group.  Exposure to UVR is a significant and modifiable 
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risk factor for melanoma, with intermittent exposure and sunburns identified as the main 
culprits.199  Like all cancer survivors, melanoma survivors are at risk for subsequent 
cancer,200 however, UVR exposure following a melanoma diagnosis can be modified to 
reduce risk of a new melanoma diagnosis.101  Consistent with other health behaviors 
reported by cancer survivors201 and a recent meta-analysis of the limited available 
literature among melanoma survivors,195 our study indicates long-term melanoma 
survivors report healthier UVR exposure and protection behaviors compared to 
population controls and self-report changes since diagnosis.  Despite this, opportunities 
remain to reduce future melanoma risk among melanoma survivors as a significant 
proportion still report elevated sun exposure, sunburns and suboptimal sun protection 
behaviors.    
8.4.1 Ultraviolet Radiation Exposure 
While debate continues about the best sun protection methods for skin cancer 
prevention,202 UVR avoidance, including from sun and artificial sources, is crucial.  Few 
studies report UVR exposure among melanoma survivors, with most focusing on 
frequency of sunbathing or indoor tanning as opposed to time spent in the sun.    
Consistent with our results, a recent qualitative study reported many melanoma survivors 
are more conscious of sun exposure and protection.83   Surprisingly, however, melanoma 
survivors in our study reported being outside two or more hours on weekend days during 
peak hours in the summer at similar rates as controls.  This is concerning because it 
implies a sun exposure pattern that is intermittent in nature, which has been associated 
with increased melanoma risk.203  Our finding may be due, in part, to the long period of 
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time since melanoma diagnosis.  A small prospective study of melanoma survivors and 
controls (N=40) found that UVR exposure was initially lower among survivors compared 
to controls but then converged over the three-year study.108,109   
We found that few melanoma survivors and controls reported indoor tanning in 
the past year.  This may be explained by the fact that this population is likely aging out of 
this habit and awareness of the negative effects of indoor tanning has been increasing.  
While long-term melanoma survivors were less likely to report indoor tanning in the past 
year than controls, a small number of survivors reported still engaging in this behavior.  
This phenomenon has been reported elsewhere107,138 and indicates a small proportion of 
individuals will continue this high-risk behavior despite a melanoma diagnosis.   
8.4.2 Sunburns 
Sunburn is a critical measure of excessive sun exposure.  A meta-analysis found 
increased risk of melanoma with increasing sunburns throughout the lifetime, not just 
childhood,204 emphasizing the importance of continued and improved sunburn prevention 
among melanoma survivors.  Few studies have reported sunburn occurrence among 
melanoma survivors, however. A large international online survey had a subgroup of 
participants who reported a previous melanoma diagnosis and 27% of them reported at 
least one severe sunburn in the past year,106 similar our result of 20%.  While our study 
indicates melanoma survivors are about half as likely to report a sunburn as population 
controls, a significant minority engage in behaviors that result in sunburns. 
Studies of the general United States population have reported that the percent of 
females with sunburns in the past year is lower than that of than males117 and the percent 
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of adults with sunburns in past year decreases with age.205  Our results were similar and 
suggest that while differences were found among melanoma survivors by age and sex, 
they follow the sunburn trends of the general population.    
8.4.3 Sunscreen 
The use of sunscreen as a form of UVR protection has been debated, though the 
general conclusion is that broad-spectrum sunscreen is a part of skin cancer prevention.206  
Other methods of sun protection are encouraged first, including wearing protective 
clothing and staying in the shade. This is due, in part, to research showing that 
individuals who apply sunscreen stay in the sun longer.207 In addition, numerous barriers 
to proper sunscreen use have been reported, including difficulty of use if engaging in 
physical activity, planning to be in the sun for only a short period of time, or the time 
needed to apply prior to exposure.208  A randomized controlled trial in Australia, 
however, found participants randomized to daily sunscreen use had fewer new primary 
melanomas ten years later compared to those assigned to discretionary sunscreen.209   
A number of studies have reported sunscreen use among melanoma survivors 
alone,110,111,114,116,138,210,211 however, a review found that general population estimates of 
regular sunscreen use vary greatly in the literature (7-90%),73 therefore it is critical to 
simultaneously collect data on population controls for comparison.  Few studies have 
included a control group104,107-109; the largest to date compared 156 melanoma survivors 
to 11408 respondents without cancer who participated in 2005 and 2007 National Cancer 
Institute Health Information National Trends Surveys (HINTS).107 The results were 
similar to our study, though HINTS respondents reported slightly lower frequencies of 
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sunscreen use with 51% of melanoma survivors and 35% of cancer-free controls 
reporting sunscreen use in the past year.  Our study also found that females and younger 
individuals, regardless of melanoma diagnosis status, were more likely to use sunscreen, 
which has been previously reported in the general population212 and among melanoma 
survivors.116      
8.4.4 Other Ultraviolet Radiation Protection Behaviors 
Wearing UVR protective clothing and staying in the shade during peak hours are 
recommended as important components of proper sun protection.  A few studies have 
reported increases in sun-protection behaviors among melanoma patients following 
diagnosis.110-112 Studies of melanoma survivors alone, one of which included longer-term 
survivors, found modest sun protection behaviors similar to our results.114,116  In 
comparison to non-cancer controls, two studies found that melanoma survivors use 
sunscreen and seek shade more frequently than controls,107,108 whereas another study 
found sun protection behaviors were comparable but not greater than general population 
estimates.114  Our study is the largest to date and after adjustment for potential 
confounding factors, found melanoma survivors are more likely to report optimal sun 
protection behaviors.  As found previously, these differences were modest, however, with 
more than half reporting they do not wear a hat or stay in the shade during peak hours.  
The differences in these behaviors observed by sex in our study have been 
previously reported among melanoma survivors, with males being more likely to wear 
protective clothing and females being more likely to stay in the shade.114,116,117  These 
differences have also been reported in the United States general population,115 suggesting 
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any observed differences reflect the habits of the general population rather than being 
specific to a melanoma diagnosis.  
8.4.5 Limitations 
Our study provides a more complete picture of the UVR exposure and protection 
habits of melanoma survivors as compared to a similarly recruited population control 
group than previous research.  While this study has many strengths, including the large 
sample size, population-based sample, and inclusion of a control group with measured 
confounding factors, we note important limitations. As with other self-reported measures, 
participants may have over-reported behaviors due to social desirability, particularly 
among melanoma survivors, resulting in an overestimate of sun protection behaviors 
leading to potential bias. The self-report measures used have been previously shown to 
compare well with direct observation measures, however,196 and the anonymity of the 
questionnaire makes this less likely.   
Another limitation is that survivors who responded to our survey may be more 
likely to practice health behaviors, or those who are still alive may be those who 
frequently use optimal sun protection behaviors.  
Finally, while melanoma is most prevalent among non-Hispanic whites, these data 
do not allow for an examination of possible differences in effects by race/ethnicity due to 
the fairly homogenous population in Minnesota. It is noteworthy, however, that the 
proportion of respondents reporting sunburn in the past year among the controls is similar 
to those reported in national United States survey studies.115,205 
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8.4.6 Conclusion 
Despite limitations, this study contributes to the field as the largest to date to 
examine the UVR exposure and protection behaviors of long-term melanoma survivors as 
compared to similarly recruited controls.  While a melanoma diagnosis appears to serve 
as a trigger for behavior change for many, resulting in better sun protection behaviors 
among survivors compared to controls, one-fifth of survivors experienced sunburn in the 
past year and many reported engaging in suboptimal sun protection behaviors.  Barriers 
to sun protection in the general population have been identified as “inconvenience, 
forgetting to use sun safety measures, desire to be tanned, and protective clothing being 
too hot to wear.”113  Additional research is needed to determine barriers to sun protection 
in melanoma survivors in order to guide development of interventions to further improve 
sun behaviors and reduce risk of skin cancer in the future.  
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Table 23. Demographic and general health characteristics among melanoma 
survivors and population controls that completed the follow-up survey. 
 Melanoma 
Survivors 
N=592 
Population 
Controls 
N=518 
 
Variable N % N % p-value 
Phenotypic Risk Index     <0.0001 
   Low 159 27.1 194 37.5  
   Intermediate 252 42.9 227 43.8  
   High 176 30.0 97 18.7  
Personal History of Non-Melanoma Skin 
Cancer 
    0.93 
   No 549 95.0 480 94.9  
   Yes 29 5.0 26 5.1  
Family history of melanoma     0.99 
   No 406 68.6 355 68.5  
   Yes 186 31.4 163 31.5  
MEASURES FROM ORIGINAL STUDY      
Indoor tanning use prior to 
diagnosis/reference 
    0.003 
   No 235 39.7 251 48.5  
   Yes 357 60.3 267 51.5  
Sun Exposure – Before Diagnosis, mean±SD 591 2542±1667 518 2660±1659 0.15 
Outdoor Activity Exposure – Before 
Diagnosis, mean±SD 
591 2004±1653 518 2054±1664 0.47 
Mean sunscreen use –Before Diagnosis, 
mean±SD 
592 1.37±1.00 518 1.31±1.02 0.24 
Lifetime sunburns – Before Diagnosis, median 
(min, max) 
590 10 (0-400) 516 6 (0-250) <0.0001 
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Table 24a. Associations between demographic and previous sun characteristics by 
hours of weekday sun exposure in the summer. 
 Weekday Sun 
1 hour or less 
Weekday Sun 
2 hours or more 
 
Variable N % N % p-value 
Age at survey     <0.0001 
   30-39 63 9.1 18 4.5  
   40-49 123 17.8 56 13.9  
   50-59 273 39.4 131 32.5  
   60-72 234 33.8 198 49.1  
Sex     <0.0001 
   Male 232 34.3 190 48.8  
   Female 444 65.7 199 51.2  
Race     0.56 
   White, Non-Hispanic 681 98.3 394 97.8  
   Other 12 1.7 9 2.2  
Education     <0.0001 
   High school                  51 7.5 68 17.4  
   Vocational/Associates        125 18.5 76 19.4  
   Some college                 100 14.8 71 18.2  
   College graduate             232 34.3 99 25.3  
   Graduate/professional degree 169 25.0 77 19.7  
Marital Status     0.85 
   Never married 35 5.2 19 4.9  
   Married/Partnered 565 83.6 327 83.4  
   Widowed 12 1.8 10 2.6  
   Divorced 64 9.5 36 9.2  
Income     <0.0001 
   <$50,000             68 10.1 65 16.6  
   $50,000-74,999    103 15.3 84 21.5  
   $75,000-$149,999  294 43.6 144 36.8  
   $150,000+ 149 22.1 56 14.3  
   Prefer not to say 61 9.0 42 10.7  
Body Mass Index (BMI)     0.25 
   Underweight (<18.5 kg/m2) 1 0.1 4 1.0  
   Normal (18.5-24.9 kg/m2) 268 38.7 153 38.0  
   Overweight (25.0-29.9 kg/m2) 241 34.8 137 34.0  
   Obese (30.0+ kg/m2) 183 26.4 109 27.1  
Current Smoker     0.02 
   No 656 94.8 365 91.0  
   Yes 36 5.2 36 9.0  
Phenotypic Risk Index     0.004 
   Low 199 28.9 149 37.1  
   Intermediate 301 43.7 172 42.8  
   High 189 27.4 81 20.2  
Personal History of Non-Melanoma Skin Cancer     0.84 
   No 647 95.0 377 94.7  
   Yes 34 5.0 21 5.3  
Family history of melanoma     0.65 
   No 469 67.7 278 69.0  
   Yes 224 32.3 125 31.0  
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 Weekday Sun 
1 hour or less 
Weekday Sun 
2 hours or more 
 
 N % N % p-value 
MEASURES FROM ORIGINAL STUDY      
Indoor tanning use prior to diagnosis/reference     0.26 
   No 294 42.4 185 45.9  
   Yes 399 57.6 218 54.1  
Sun Exposure – Before Diagnosis, mean±SD 692 2113±1156 403 3411±2010 <0.0001 
Outdoor Activity Exposure – Before Diagnosis, 
mean±SD 
693 1727±1346 402 2545±1978 <0.0001 
Mean sunscreen use –Before Diagnosis, mean±SD 693 1.45±1.02 403 1.16±0.96 <0.0001 
Lifetime sunburns – Before Diagnosis, median 
(min, max) 
691 7 (0, 400) 401 9 (0, 250) 0.22 
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Table 24b. Associations between demographic and previous sun characteristics by 
hours of weekday sun exposure in the summer. 
 Weekend Sun 
1 hour or less 
Weekend Sun 
2 hours or more 
 
Variable N % N % p-value 
Age at survey     0.02 
   30-39 15 5.8 66 7.9  
   40-49 31 12.1 148 17.7  
   50-59 90 35.0 314 37.5  
   60-72 121 47.1 310 37.0  
Sex     <0.0001 
   Male 67 26.9 355 43.6  
   Female 182 73.1 460 56.4  
Race     0.80 
   White, Non-Hispanic 4 1.6 17 2.0  
   Other 253 98.4 821 98.0  
Education     0.42 
   High school                  22 8.8 97 11.9  
   Vocational/Associates        44 17.7 157 19.2  
   Some college                 37 14.9 134 16.4  
   College graduate             80 32.1 250 30.6  
   Graduate/professional degree 66 26.5 180 22.0  
Marital Status     0.68 
   Never married 16 6.4 38 4.7  
   Married/Partnered 204 81.9 687 84.0  
   Widowed 6 2.4 16 2.0  
   Divorced 23 9.2 77 9.4  
Income     0.03 
   <$50,000             41 16.5 92 11.3  
   $50,000-74,999    44 17.7 143 17.5  
   $75,000-$149,999  88 35.5 349 42.7  
   $150,000+ 43 17.3 162 19.8  
   Prefer not to say 32 12.9 71 8.7  
Body Mass Index (BMI)     0.61 
   Underweight (<18.5 kg/m2) 1 0.4 4 0.5  
   Normal (18.5-24.9 kg/m2) 90 35.0 331 39.5  
   Overweight (25.0-29.9 kg/m2) 95 37.0 282 33.7  
   Obese (30.0+ kg/m2) 71 27.6 221 26.4  
Current Smoker     0.26 
   No 243 94.9 777 92.9  
   Yes 13 5.1 59 7.1  
Phenotypic Risk Index     0.07 
   Low 75 29.5 273 32.7  
   Intermediate 102 40.2 370 44.3  
   High 77 30.3 193 23.1  
Personal History of Non-Melanoma Skin Cancer     0.46 
   No 235 94.0 788 95.2  
   Yes 15 6.0 40 4.8  
Family history of melanoma     0.17 
   No 184 71.6 562 67.1  
   Yes 73 28.4 276 32.9  
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 Weekend Sun 
1 hour or less 
Weekend Sun 
2 hours or more 
 
 N % N % p-value 
MEASURES FROM ORIGINAL STUDY      
Indoor tanning use prior to diagnosis/reference     0.22 
   No 121 47.1 358 42.7  
   Yes 136 52.9 480 57.3  
Sun Exposure – Before Diagnosis, mean±SD 257 2082±1160 837 2748±1744 <0.0001 
Outdoor Activity Exposure – Before Diagnosis, 
mean±SD 
257 1756±1532 837 2110±1683 0.0002 
Mean sunscreen use –Before Diagnosis, mean±SD 257 1.35±1.01 838 1.34±1.01 0.85 
Lifetime sunburns – Before Diagnosis, median 
(min, max) 
257 8 (0, 115) 834 8 (0, 400) 0.85 
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Table 24c. Associations between demographic and previous sun characteristics by 
sunburns in past year. 
 No sunburns  
in past year 
1 or more sunburns  
in past year 
 
Variable N % N % p-value 
Age at survey     <0.0001 
   30-39 42 5.3 39 12.7  
   40-49 99 12.5 80 26.1  
   50-59 296 37.4 109 35.5  
   60-72 355 44.8 79 25.7  
Sex     0.05 
   Male 291 37.9 133 44.3  
   Female 477 62.1 167 55.7  
Race     0.58 
   White, Non-Hispanic 778 98.2 300 97.7  
   Other 14 1.8 7 2.3  
Education     0.17 
   High school                  90 11.7 30 10.0  
   Vocational/Associates        131 17.0 70 23.3  
   Some college                 122 15.8 49 16.3  
   College graduate             247 32.0 85 28.3  
   Graduate/professional degree 181 23.5 66 22.0  
Marital Status     0.46 
   Never married 34 4.4 20 6.6  
   Married/Partnered 645 83.8 249 82.7  
   Widowed 17 2.2 5 1.7  
   Divorced 74 9.6 27 9.0  
Income     0.73 
   <$50,000             97 12.6 38 12.6  
   $50,000-74,999    133 17.3 54 17.9  
   $75,000-$149,999  313 40.8 125 41.5  
   $150,000+ 145 18.9 61 20.3  
   Prefer not to say 80 10.4 23 7.6  
Body Mass Index (BMI)     0.31 
   Underweight (<18.5 kg/m2) 5 0.6 0 0.0  
   Normal (18.5-24.9 kg/m2) 312 39.4 109 35.5  
   Overweight (25.0-29.9 kg/m2) 268 33.8 112 36.5  
   Obese (30.0+ kg/m2) 207 26.1 86 28.0  
Current Smoker     0.007 
   No 748 94.7 276 90.2  
   Yes 42 5.3 30 9.8  
Phenotypic Risk Index     0.65 
   Low 254 32.2 95 31.2  
   Intermediate 336 42.6 139 45.6  
   High 199 25.2 71 23.3  
Personal History of Non-Melanoma Skin Cancer     0.29 
   No 735 94.5 292 96.1  
   Yes 43 5.5 12 4.0  
Family history of melanoma     0.13 
   No 551 69.6 199 64.8  
   Yes 241 30.4 108 35.2  
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 No sunburns  
in past year 
1 or more 
sunburns  
in past year 
 
 N % N % p-
value 
MEASURES FROM ORIGINAL STUDY      
Indoor tanning use prior to diagnosis/reference     0.01 
   No 364 46.0 116 37.8  
   Yes 428 54.0 191 62.2  
Sun Exposure – Before Diagnosis, mean±SD 791 2599±1611 307 2608±1805 0.37 
Outdoor Activity Exposure – Before Diagnosis, 
mean±SD 
792 2100±1696 306 1860±1553 0.01 
Mean sunscreen use –Before Diagnosis, mean±SD 792 1.37±1.04 307 1.27±0.92 0.25 
Lifetime sunburns – Before Diagnosis, median 
(min, max) 
791 7 (0, 350) 304 10 (0, 400) 0.0006 
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Table 24d. Associations between demographic and previous sun characteristics by 
report of indoor tanning in past year. 
 No indoor 
tanning  
Indoor tanning  
Variable N % N % p-value 
Age at survey     0.05 
   30-39 76 7.2 5 13.2  
   40-49 168 15.8 11 29.0  
   50-59 394 37.1 12 31.6  
   60-72 423 39.9 10 26.3  
Sex     0.02 
   Male 416 40.4 8 21.1  
   Female 615 59.7 30 79.0  
Race     0.53 
   White, Non-Hispanic 1041 98.1 37 97.4  
   Other 20 1.9 1 2.6  
Education     0.61 
   High school                  114 11.0 6 15.8  
   Vocational/Associates        194 18.8 8 21.1  
   Some college                 162 15.7 8 21.1  
   College graduate             322 31.1 10 26.3  
   Graduate/professional degree 242 23.4 6 15.8  
Marital Status     0.22 
   Never married 52 5.0 2 5.3  
   Married/Partnered 866 83.8 29 76.3  
   Widowed 22 2.1 0 0.0  
   Divorced 94 9.1 7 18.4  
Income     0.84 
   <$50,000             132 12.8 4 10.5  
   $50,000-74,999    178 17.3 9 23.7  
   $75,000-$149,999  421 40.8 16 42.1  
   $150,000+ 201 19.5 6 15.8  
   Prefer not to say 100 9.7 3 7.9  
Body Mass Index (BMI)     0.73 
   Underweight (<18.5 kg/m2) 5 0.5 0 0.0  
   Normal (18.5-24.9 kg/m2) 409 38.6 14 36.8  
   Overweight (25.0-29.9 kg/m2) 364 34.3 16 42.1  
   Obese (30.0+ kg/m2) 283 26.7 8 21.1  
Current Smoker     0.51 
   No 988 93.3 37 97.4  
   Yes 71 6.7 1 2.6  
Phenotypic Risk Index     0.95 
   Low 336 31.8 13 34.2  
   Intermediate 459 43.5 16 42.1  
   High 261 24.7 9 23.7  
Personal History of Non-Melanoma Skin Cancer     0.72 
   No 991 94.8 37 97.4  
   Yes 54 5.2 1 2.6  
Family history of melanoma     0.49 
   No 726 68.4 24 63.2  
   Yes 335 31.6 14 36.8  
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 No indoor 
tanning  
Indoor tanning  
 N % N % p-value 
MEASURES FROM ORIGINAL STUDY      
Indoor tanning use prior to diagnosis/reference     <0.0001 
   No 479 45.2 2 5.3  
   Yes 582 54.9 36 94.7  
Sun Exposure – Before Diagnosis, mean±SD 1060 2604±1671 38 2483±1438 0.63 
Outdoor Activity Exposure – Before Diagnosis, 
mean±SD 
1060 2028±1665 38 2265±1518 0.20 
Mean sunscreen use –Before Diagnosis, mean±SD 1061 1.35±1.02 38 1.05±0.72 0.11 
Lifetime sunburns – Before Diagnosis, median 
(min, max) 
1058 8 (0, 400) 37 5 (0, 80) 0.20 
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Table 24e. Associations between demographic and previous sun characteristics by 
current sunscreen use. 
 Often/Always 
Use Sunscreen 
Never/Rarely/Sometimes 
Use Sunscreen 
 
Variable N % N % p-value 
Age at survey     <0.0001 
   30-39 51 9.0 30 5.7  
   40-49 110 19.3 69 13.0  
   50-59 226 39.7 180 34.0  
   60-72 182 32.0 251 47.4  
Sex     <0.0001 
   Male 161 29.0 263 51.2  
   Female 394 71.0 251 48.8  
Race     0.03 
   White, Non-Hispanic 563 99.0 515 97.2  
   Other 6 1.1 15 2.8  
Education     <0.0001 
   High school                  38 6.8 82 15.9  
   Vocational/Associates        90 16.2 112 21.7  
   Some college                 80 14.4 90 17.4  
   College graduate             197 35.4 135 26.2  
   Graduate/professional degree 151 27.2 97 18.8  
Marital Status     0.23 
   Never married 25 4.5 29 5.6  
   Married/Partnered 472 54.9 423 82.0  
   Widowed 14 2.5 8 1.6  
   Divorced 45 8.1 56 10.9  
Income     <0.0001 
   <$50,000             49 8.8 87 16.9  
   $50,000-74,999    86 15.5 101 19.6  
   $75,000-$149,999  234 42.2 203 39.3  
   $150,000+ 137 24.7 70 3.6  
   Prefer not to say 48 8.7 55 10.7  
Body Mass Index (BMI)     0.0003 
   Underweight (<18.5 kg/m2) 2 0.4 3 0.6  
   Normal (18.5-24.9 kg/m2) 253 44.5 170 32.1  
   Overweight (25.0-29.9 kg/m2) 183 32.2 197 37.2  
   Obese (30.0+ kg/m2) 131 23.0 160 30.2  
Current Smoker     0.0005 
   No 545 96.0 480 90.7  
   Yes 23 4.1 49 9.3  
Phenotypic Risk Index     <0.0001 
   Low 144 25.4 205 38.9  
   Intermediate 253 44.6 222 42.1  
   High 170 30.0 100 19.0  
Personal History of Non-Melanoma 
Skin Cancer 
    0.12 
   No 526 93.9 502 96.0  
   Yes 
 
 
34 6.1 21 4.0  
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 Often/Always 
Use Sunscreen 
Never/Rarely/Sometimes 
Use Sunscreen 
 
 N % N % p-value 
Family history of melanoma     0.63 
   No 392 68.9 358 67.6  
   Yes 177 31.1 172 32.5  
MEASURES FROM ORIGINAL 
STUDY 
     
Indoor tanning use prior to 
diagnosis/reference 
    <0.0001 
   No 212 37.3 269 50.8  
   Yes 357 62.7 261 49.3  
Sun Exposure – Before Diagnosis, 
mean±SD 
569 2211±1279 529 3018±1910 <0.0001 
Outdoor Activity Exposure – Before 
Diagnosis, mean±SD 
569 1803±1388 529 2287±1880 <0.0001 
Mean sunscreen use –Before 
Diagnosis, mean±SD 
569 1.74±1.01 530 0.92±0.83 <0.0001 
Lifetime sunburns – Before 
Diagnosis, median (min, max) 
568 8 (0, 400) 527 8 (0, 350) 0.26 
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Table 24f. Associations between demographic and previous sun characteristics by 
use of shirt with sleeves. 
 Often/Always 
Wear Shirt w/ Sleeves 
Never/Rarely/Sometimes 
Wear Shirt w/ Sleeves 
 
Variable N % N % p-value 
Age at survey     <0.0001 
   30-39 38 4.8 43 13.8  
   40-49 110 14.0 69 22.2  
   50-59 287 36.6 117 37.6  
   60-72 350 44.6 82 26.4  
Sex     <0.0001 
   Male 376 49.0 48 16.1  
   Female 391 51.0 251 84.0  
Race     0.98 
   White, Non-Hispanic 770 98.1 305 98.1  
   Other 15 1.9 6 1.9  
Education     0.18 
   High school                  78 10.1 41 13.7  
   Vocational/Associates        151 19.6 51 17.0  
   Some college                 113 14.7 56 18.7  
   College graduate             243 31.6 88 29.3  
   Graduate/professional 
degree 
184 23.9 64 21.3  
Marital Status     0.69 
   Never married 38 4.9 15 5.0  
   Married/Partnered 646 84.0 247 82.3  
   Widowed 17 2.2 5 1.7  
   Divorced 68 8.8 33 11.0  
Income     0.54 
   <$50,000             95 12.4 41 13.7  
   $50,000-74,999    138 18.0 49 16.4  
   $75,000-$149,999  304 39.6 131 43.8  
   $150,000+ 157 20.4 50 16.7  
   Prefer not to say 74 9.6 28 9.4  
Body Mass Index (BMI)     <0.0001 
   Underweight (<18.5 kg/m2) 3 0.4 2 0.6  
   Normal (18.5-24.9 kg/m2) 267 34.0 153 49.2  
   Overweight (25.0-29.9 
kg/m2) 
291 37.1 89 28.6  
   Obese (30.0+ kg/m2) 224 28.5 67 21.5  
Current Smoker     0.13 
   No 737 94.1 285 91.6  
   Yes 46 5.9 26 8.4  
Phenotypic Risk Index     0.49 
   Low 252 32.3 96 30.9  
   Intermediate 331 42.4 144 46.3  
   High 197 25.3 71 22.8  
Personal History of Non-
Melanoma Skin Cancer 
    0.11 
   No 732 94.3 294 96.7  
   Yes 44 5.7 10 3.3  
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 Often/Always 
Wear Shirt w/ Sleeves 
Never/Rarely/Sometimes 
Wear Shirt w/ Sleeves 
 
 N % N % p-value 
Family history of melanoma     0.14 
   No 546 69.6 202 65.0  
   Yes 239 30.5 109 35.1  
MEASURES FROM 
ORIGINAL STUDY 
     
Indoor tanning use prior to 
diagnosis/reference 
    <0.0001 
   No 397 50.6 83 26.7  
   Yes 388 49.4 228 73.3  
Sun Exposure – Before 
Diagnosis, mean±SD 
784 2707±1703 311 2336±1533 <0.0001 
Outdoor Activity Exposure 
– Before Diagnosis, 
mean±SD 
784 2048±1637 311 2008±1725 0.37 
Mean sunscreen use –
Before Diagnosis, mean±SD 
785 1.38±1.04 311 1.25±0.93 0.16 
Lifetime sunburns – Before 
Diagnosis, median (min, 
max) 
783 8 (0, 250) 309 7 (0, 400) 0.01 
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Table 24g. Associations between demographic and previous sun characteristics by 
use of hat. 
 Often/Always 
Wear Hat 
Never/Rarely/ 
Sometimes Wear Hat 
 
Variable N % N % p-value 
Age at survey     <0.0001 
   30-39 9 2.9 72 9.1  
   40-49 33 10.8 146 18.5  
   50-59 116 37.9 289 36.6  
   60-72 148 48.4 282 35.7  
Sex     <0.0001 
   Male 160 53.5 263 34.3  
   Female 139 46.5 503 65.7  
Race     0.67 
   White, Non-Hispanic 301 98.4 773 98.0  
   Other 5 1.6 16 2.0  
Education     0.001 
   High school                  24 8.0 93 12.1  
   Vocational/Associates        44 14.7 157 20.4  
   Some college                 42 14.1 128 16.6  
   College graduate             97 32.4 235 30.6  
   Graduate/professional degree 92 30.8 156 20.3  
Marital Status     0.42 
   Never married 10 3.3 44 5.7  
   Married/Partnered 255 85.3 636 82.7  
   Widowed 7 2.3 15 2.0  
   Divorced 27 9.0 74 9.6  
Income     0.29 
   <$50,000             28 9.4 106 13.8  
   $50,000-74,999    50 16.8 137 17.8  
   $75,000-$149,999  124 41.6 312 40.6  
   $150,000+ 64 21.5 143 18.6  
   Prefer not to say 32 10.7 70 9.1  
Body Mass Index (BMI)     0.23 
   Underweight (<18.5 kg/m2) 1 0.3 4 0.5  
   Normal (18.5-24.9 kg/m2) 117 38.2 305 38.7  
   Overweight (25.0-29.9 kg/m2) 118 38.6 260 33.0  
   Obese (30.0+ kg/m2) 70 22.9 220 27.9  
Current Smoker     0.44 
   No 288 94.4 734 93.2  
   Yes 17 5.6 54 6.9  
Phenotypic Risk Index     0.15 
   Low 90 29.6 257 32.7  
   Intermediate 127 41.8 348 44.3  
   High 87 28.6 181 23.0  
Personal History of Non-Melanoma Skin 
Cancer 
    0.42 
   No 284 94.0 740 95.2  
   Yes 
 
 
18 6.0 37 4.8  
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 Often/Always 
Wear Hat 
Never/Rarely/Sometimes 
Wear Hat 
 
 N % N % p-value 
Family history of melanoma     0.38 
   No 203 66.3 545 69.1  
   Yes 103 33.7 244 30.9  
MEASURES FROM ORIGINAL STUDY      
Indoor tanning use prior to 
diagnosis/reference 
    <0.0001 
   No 182 59.5 296 37.5  
   Yes 124 40.5 493 62.5  
Sun Exposure – Before Diagnosis, 
mean±SD 
305 2838±1619 789 2506±1671 <0.0001 
Outdoor Activity Exposure – Before 
Diagnosis, mean±SD 
306 2242±1650 789 1957±1661 0.0003 
Mean sunscreen use –Before Diagnosis, 
mean±SD 
306 1.48±1.05 789 1.29±0.99 0.01 
Lifetime sunburns – Before Diagnosis, 
median (min, max) 
306 9 (0, 250) 785 7 (0, 400) 0.02 
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Table 24h. Associations between demographic and previous sun characteristics by 
staying in the shade. 
 Often/Always 
Stay in the Shade 
Never/Rarely/Sometimes 
Stay in the Shade 
 
Variable N % N % p-value 
Age at survey     0.18 
   30-39 27 6.3 54 8.1  
   40-49 59 13.9 120 17.9  
   50-59 164 38.5 241 36.0  
   60-72 176 41.3 254 38.0  
Sex     0.0009 
   Male 139 33.5 284 43.7  
   Female 276 66.5 366 56.3  
Race     0.60 
   White, Non-Hispanic 419 98.4 655 97.9  
   Other 7 1.6 14 2.1  
Education     0.29 
   High school                  48 11.5 70 10.7  
   Vocational/Associates        72 17.3 129 19.8  
   Some college                 57 13.7 112 17.2  
   College graduate             142 34.1 190 29.1  
   Graduate/professional degree 97 23.3 151 23.2  
Marital Status     0.43 
   Never married 23 5.5 31 4.8  
   Married/Partnered 344 52.7 548 84.1  
   Widowed 12 2.9 10 1.5  
   Divorced 37 8.9 63 9.7  
Income     0.57 
   <$50,000             56 13.6 79 12.1  
   $50,000-74,999    71 17.2 115 17.6  
   $75,000-$149,999  176 42.6 260 39.8  
   $150,000+ 77 18.6 130 19.9  
   Prefer not to say 33 8.0 69 10.6  
Body Mass Index (BMI)     0.54 
   Underweight (<18.5 kg/m2) 1 0.2 4 0.6  
   Normal (18.5-24.9 kg/m2) 157 36.9 265 39.6  
   Overweight (25.0-29.9 kg/m2) 147 34.5 230 34.4  
   Obese (30.0+ kg/m2) 121 28.4 170 25.4  
Current Smoker     0.03 
   No 405 95.5 617 92.2  
   Yes 19 4.5 52 7.8  
Phenotypic Risk Index     0.0002 
   Low 113 26.8 234 35.0  
   Intermediate 178 42.2 297 44.5  
   High 131 31.0 137 20.5  
Personal History of Non-
Melanoma Skin Cancer 
    0.002 
   No 385 92.3 639 96.5  
   Yes 32 7.7 23 3.5  
 139 
 
 
 Often/Always 
Stay in the Shade 
Never/Rarely/Sometimes 
Stay in the Shade 
 
 N % N % p-value 
Family history of melanoma     0.35 
   No 298 7.0 450 67.3  
   Yes 128 30.1 219 32.7  
MEASURES FROM ORIGINAL 
STUDY 
     
Indoor tanning use prior to 
diagnosis/reference 
    0.90 
   No 187 43.9 291 43.5  
   Yes 239 56.1 378 56.5  
Sun Exposure – Before 
Diagnosis, mean±SD 
425 2304±1335 669 2787±1817 0.0004 
Outdoor Activity Exposure – 
Before Diagnosis, mean±SD 
426 1898±1443 668 2125±1783 0.09 
Mean sunscreen use –Before 
Diagnosis, mean±SD 
426 1.48±1.00 669 1.25±1.00 <0.0001 
Lifetime sunburns – Before 
Diagnosis, median (min, max) 
425 7 (0, 350) 666 8 (0, 400) 0.92 
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Table 24i. Associations between demographic and previous sun characteristics by 
whether they intentionally tan. 
 Rarely/Never 
Intentionally Tan 
Sometimes/Often/Always 
Intentionally Tan 
 
Variable N % N % p-value 
Age at survey     <0.0001 
   30-39 56 6.1 25 13.7  
   40-49 132 14.4 47 25.7  
   50-59 343 37.5 62 33.9  
   60-72 382 41.9 49 26.8  
Sex     <0.0001 
   Male 379 42.6 45 25.4  
   Female 511 57.4 132 74.6  
Race     0.77 
   White, Non-Hispanic 896 98.0 180 98.4  
   Other 18 2.0 3 1.6  
Education     0.006 
   High school                  97 10.9 22 12.4  
   Vocational/Associates        160 17.9 42 23.7  
   Some college                 130 14.6 39 22.0  
   College graduate             288 32.3 44 24.9  
   Graduate/professional degree 218 24.4 30 17.0  
Marital Status     0.36 
   Never married 42 4.7 12 6.8  
   Married/Partnered 751 84.1 143 80.8  
   Widowed 20 2.2 2 1.1  
   Divorced 80 9.0 20 11.3  
Income     0.37 
   <$50,000             113 12.7 23 13.0  
   $50,000-74,999    151 17.0 35 19./8  
   $75,000-$149,999  372 41.8 65 36.7  
   $150,000+ 166 18.6 41 23.2  
   Prefer not to say 89 10.0 13 7.3  
Body Mass Index (BMI)     0.24 
   Underweight (<18.5 kg/m2) 4 0.4 1 0.55  
   Normal (18.5-24.9 kg/m2) 341 37.3 81 44.3  
   Overweight (25.0-29.9 kg/m2) 317 34.7 62 33.9  
   Obese (30.0+ kg/m2) 252 27.6 39 21.3  
Current Smoker     0.19 
   No 856 93.9 167 91.3  
   Yes 56 6.1 16 8.7  
Phenotypic Risk Index     0.03 
   Low 286 31.4 62 34.1  
   Intermediate 386 42.4 89 48.9  
   High 238 26.2 31 17.0  
Personal History of Non-Melanoma 
Skin Cancer 
    0.42 
   No 853 94.7 173 96.1  
   Yes 48 5.3 7 3.9  
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 Rarely/Never 
Intentionally Tan 
Sometimes/Often/Always 
Intentionally Tan 
 
 N % N % p-value 
Family history of melanoma     0.58 
   No 620 67.8 128 70.0  
   Yes 294 32.2 55 30.1  
      
MEASURES FROM ORIGINAL 
STUDY 
     
Indoor tanning use prior to 
diagnosis/reference 
    <0.0001 
   No 441 48.3 38 20.8  
   Yes 473 51.8 145 79.2  
Sun Exposure – Before Diagnosis, 
mean±SD 
913 2626±1644 183 2486±1753 0.04 
Outdoor Activity Exposure – Before 
Diagnosis, mean±SD 
913 2040±1657 183 2022±1688 0.49 
Mean sunscreen use –Before 
Diagnosis, mean±SD 
914 1.38±1.02 183 1.18±0.90 0.03 
Lifetime sunburns – Before Diagnosis, 
median (min, max) 
912 8 (0, 350) 181 6 (0, 400) 0.02 
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Table 25. Sun exposure and protection habits by melanoma survivors and 
population controls. 
 Melanoma Survivors Population Controls  
 N % N % p-value 
Hours outside in summer on Weekdays     0.0009 
   0-30 minutes 200 34.0 145 28.6  
   31 minutes to 1 hour 204 34.6 144 28.4  
   2 hours 100 17.0 94 18.5  
   3 hours 33 5.6 53 10.5  
   4 hours 23 3.9 40 7.9  
   5 hours 13 2.2 12 2.4  
   6 hours 16 2.7 19 3.8  
Hours outside in summer on Weekend days     0.11 
   0-30 minutes 49 8.3 27 5.3  
   31 minutes to 1 hour 101 17.2 80 15.8  
   2 hours 168 28.6 132 26.0  
   3 hours 84 14.3 78 15.4  
   4 hours 106 18.0 92 18.2  
   5 hours 35 6.0 45 8.9  
   6 hours 45 7.7 53 10.5  
Number of sunburns in past 12 months     <0.0001 
   0 472 79.9 320 63.0  
   1  92 15.6 121 23.8  
   2 19 3.2 47 9.3  
   3 6 1.0 11 2.2  
   4 0 0.0 3 0.6  
   5 or more 2 0.3 6 1.2  
Use of tanning bed in past 12 months     <0.0001 
   No 583 98.8 478 93.9  
   Yes 7 1.2 31 6.1  
Wear sunscreen     <0.0001 
   Never 33 5.6 75 14.7  
   Rarely 62 10.5 109 21.4  
   Sometimes 128 21.7 123 24.2  
   Often 180 30.5 138 27.1  
   Always 187 31.7 64 12.6  
Wear shirt with sleeves     <0.0001 
   Never 17 2.9 27 5.3  
   Rarely 30 5.1 55 10.8  
   Sometimes 90 15.3 92 18.1  
   Often 177 30.1 167 32.9  
   Always 274 46.6 167 32.9  
Wear a hat with brim     0.0004 
   Never 145 24.7 180 35.5  
   Rarely 116 19.7 101 19.9  
   Sometimes 137 23.3 110 21.7  
   Often 127 21.6 84 16.6  
   Always 63 10.7 32 6.3  
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 Melanoma Survivors Population Controls  
 N % N % p-value 
Stay in the shade     <0.0001 
   Never 33 5.6 54 10.6  
   Rarely 59 10.1 115 22.6  
   Sometimes 210 35.8 198 39.0  
   Often 257 43.8 129 25.4  
   Always 28 4.8 12 2.4  
Spend time in the sun to get a tan     <0.0001 
   Never 410 69.6 256 50.4  
   Rarely 120 20.4 128 25.2  
   Sometimes 49 8.3 86 16.9  
   Often 7 1.2 29 5.7  
   Always 3 0.5 9 1.8  
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Table 26. Sun exposure and protection behaviors compared between melanoma survivors and population controls.  
 Melanoma Survivors Controls Sex and age-adjusted Fully adjusted* 
 N % N % OR (95% CI) p-value OR (95% CI) p-value Adj p-
value** 
Hours outside in summer  - weekdays      <0.0001  0.002 0.003 
   1 hour or less 404 68.6 289 57.0 1.00  1.00   
   2 hours or more 185 31.4 218 43.0 0.59 (0.45, 0.76)  0.63 (0.48, 0.84)   
Hours outside in summer - weekend       0.08  0.21 0.23 
   1 hour or less 150 25.5 107 21.1 1.00  1.00   
   2 hours or more 438 74.5 400 78.9 0.77 (0.58, 1.03)  0.82 (0.60, 1.12)   
Sunburns in past 12 months      <0.0001  <0.0001 <0.0001 
   None 472 79.9 320 63.0 1.00  1.00   
   1 or more 119 20.1 188 37.0 0.39 (0.30, 0.52)  0.37 (0.28, 0.50)   
Tanning bed use in past 12 months      0.0001  0.0001 0.0004 
   No 583 98.8 478 93.9 1.00  1.00   
   Yes 7 1.2 31 6.1 0.19 (0.08, 0.45)  0.18 (0.08, 0.44)   
Wear sunscreen      <0.0001  <0.0001 <0.0001 
   Never/Rarely/Sometimes 223 37.8 307 60.3 1.00  1.00   
   Often/Always 367 62.2 202 39.7 2.75 (2.13, 3.56)  3.06 (2.27, 4.13)   
Wear shirt with sleeves      0.01  0.0002 0.0006 
   Never/Rarely/Sometimes 137 23.3 174 34.3 1.00  1.00   
   Often/Always 451 76.7 334 65.8 1.81 (1.36, 2.41)  1.79 (1.32, 2.43)   
Wear a hat with brim      <0.0001  0.002 0.004 
   Never/Rarely/Sometimes 398 67.7 391 77.1 1.00  1.00   
   Often/Always 190 32.3 116 22.9 1.62 (1.23, 2.10)  1.57 (1.17, 2.11)   
Stay in the shade      <0.0001  <0.0001 <0.0001 
   Never/Rarely/Sometimes 302 51.5 367 72.2 1.00  1.00   
   Often/Always 285 48.6 141 27.8 2.52 (1.95, 3.27)  2.37 (1.80, 3.11)   
Spend time in the sun to get a tan      <0.0001  <0.0001 <0.0001 
   Sometimes/Often/Always 59 10.0 124 24.4 1.00  1.00   
   Rarely/Never 530 90.0 384 75.6 3.13 (2.20, 4.46)  3.30 (2.26, 4.82)   
*adjusted for sex, age, education, income, smoking status, phenotypic risk group, personal history of other skin cancer, family history of melanoma, and lifetime sun exposure, outdoor activities, mean 
sunscreen and sunburns reported prior to diagnosis or reference date. 
** adjusted for multiple statistical tests using the Benjamini and Hochberg method189
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Table 27a. Sun exposure and protection behaviors compared between /survivors and /controls - 30-49 years at time of survey.  
 Melanoma Survivors Controls Sex and age-adjusted Fully adjusted* 
 N % N % OR (95% CI) p-value OR (95% CI) p-value Adj p-value** 
Hours outside in summer  - weekdays      0.07  0.15 0.17 
   1 hour or less 110 76.4 76 65.5 1.00  1.00   
   2 hours or more 34 23.6 40 34.5 0.59 (0.34, 1.04)  0.63 (0.34, 1.17)   
Hours outside in summer - weekend       0.28  0.47 0.49 
   1 hour or less 29 20.1 17 14.7 1.00  1.00   
   2 hours or more 115 79.9 99 85.3 0.69 (0.35, 1.35)  0.75 (0.35, 1.63)   
Sunburns in past 12 months      0.004  0.004 0.007 
   None 90 62.5 51 44.0 1.00  1.00   
   1 or more 54 37.5 65 53.0 0.47 (0.28, 0.79)  0.44 (0.25, 0.77)   
Tanning bed use in past 12 months      -  - - 
   No 142 98.6 102 87.9 1.00  1.00   
   Yes 2 1.4 14 12.1 NE  NE   
Wear sunscreen      <0.0001  <0.0001 <0.0001 
   Never/Rarely/Sometimes 38 26.4 61 52.6 1.00  1.00   
   Often/Always 106 73.6 55 47.4 3.32 (1.93, 5.71)  5.39 (2.70, 10.76)   
Wear shirt with sleeves      0.005  0.009 0.01 
   Never/Rarely/Sometimes 51 35.4 61 52.6 1.00  1.00   
   Often/Always 93 64.6 5 47.4 2.20 (1.27, 3.85)  2.40 (1.24, 4.63)   
Wear a hat with brim      0.02  0.03 0.04 
   Never/Rarely/Sometimes 114 79.2 104 89.7 1.00  1.00   
   Often/Always 30 20.8 12 10.3 2.39 (1.15, 4.97)  2.51 (1.11, 5.69)   
Stay in the shade      0.001  0.002 0.004 
   Never/Rarely/Sometimes 84 58.3 90 77.6 1.00  1.00   
   Often/Always 60 41.7 26 22.4 2.57 (1.47, 4.50)  2.75 (1.46, 5.19)   
Spend time in the sun to get a tan      0.002  0.002 0.004 
   Sometimes/Often/Always 29 20.1 43 37.1 1.00  1.00   
   Rarely/Never 115 79.9 73 62.9 2.58 (1.43, 4.67)  3.03 (1.49, 6.15)   
*adjusted for sex, age, education, income, smoking status, phenotypic risk group, personal history of other skin cancer, family history of melanoma, and lifetime 
sun exposure, outdoor activities, mean sunscreen and sunburns reported prior to diagnosis or reference date. 
** adjusted for multiple statistical tests using the Benjamini and Hochberg method189 
 146 
 
Table 27b. Sun exposure and protection behaviors compared between survivors and controls - 50-59 years at time of survey.  
 Melanoma Survivors Controls Sex and age-adjusted Fully adjusted* 
 N % N % OR (95% CI) p-value OR (95% CI) p-value Adj p-value** 
Hours outside in summer  - weekdays      0.003  0.03 0.04 
   1 hour or less 157 74.1 116 60.4 1.00  1.00   
   2 hours or more 55 25.9 76 39.6 0.52 (0.34, 0.80)  0.55 (0.33, 0.94)   
Hours outside in summer - weekend       0.73  0.56 0.57 
   1 hour or less 46 21.7 44 22.9 1.00  1.00   
   2 hours or more 166 78.3 148 77.1 1.09 (0.67, 1.78)  1.17 (0.69, 1.99)   
Sunburns in past 12 months      <0.0001  <0.0001 <0.0001 
   None 181 85.0 115 59.9 1.00  1.00   
   1 or more 32 15.0 77 40.1 0.26 (0.16, 0.41)  0.22 (0.13, 0.37)   
Tanning bed use in past 12 months      0.08  - - 
   No 210 98.6 184 95.3 1.00  1.00   
   Yes 3 1.4 9 4.7 0.31 (0.08, 1.16)  NE   
Wear sunscreen      <0.0001  0.0003 0.0008 
   Never/Rarely/Sometimes 73 34.3 107 55.4 1.00  1.00   
   Often/Always 140 65.7 86 44.6 2.51 (1.65, 3.81)  2.50 (1.52, 4.12)   
Wear shirt with sleeves      0.01  0.0008 0.002 
   Never/Rarely/Sometimes 49 23.1 68 35.4 1.00  1.00   
   Often/Always 163 76.9 124 64.6 1.78 (1.13, 2.82)  1.97 (1.19, 3.25)   
Wear a hat with brim      0.07  0.15 0.17 
   Never/Rarely/Sometimes 143 67.1 146 76.0 1.00  1.00   
   Often/Always 70 32.9 46 24.0 1.51 (0.97, 2.37)  1.44 (0.88, 2.36)   
Stay in the shade      0.002  <0.0001 <0.0001 
   Never/Rarely/Sometimes 104 48.8 137 71.4 1.00  1.00   
   Often/Always 109 51.2 55 28.7 2.73 (1.79, 4.16)  2.78 (1.75, 4.39)   
Spend time in the sun to get a tan      <0.0001  <0.0001 <0.0001 
   Sometimes/Often/Always 16 7.5 46 24.0 1.00  1.00   
   Rarely/Never 197 92.5 146 76.0 3.92 (2.10, 7.31)  4.48 (2.25, 8.91)   
*adjusted for sex, age, education, income, smoking status, phenotypic risk group, personal history of other skin cancer, family history of melanoma, and lifetime sun exposure, outdoor activities, mean 
sunscreen and sunburns reported prior to diagnosis or reference date. 
** adjusted for multiple statistical tests using the Benjamini and Hochberg method189 
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Table 27c. Sun exposure and protection behaviors compared between survivors and controls - 60-72 years at time of survey.  
 Melanoma Survivors Controls Sex and age-adjusted Fully adjusted* 
 N % N % OR (95% CI) p-value OR (95% CI) p-value Adj p-value** 
Hours outside in summer  - weekdays      0.02  0.08 0.10 
   1 hour or less 137 58.8 97 48.7 1.00  1.00   
   2 hours or more 96 41.2 102 51.3 0.64 (0.43, 0.94)  0.67 (0.43, 1.05)   
Hours outside in summer - weekend       0.02  0.07 0.09 
   1 hour or less 75 32.3 46 23.1 1.00  1.00   
   2 hours or more 157 67.7 153 76.9 0.60 (0.38, 0.93)  0.64 (0.39, 1.04)   
Sunburns in past 12 months      0.01  0.01 0.01 
   None 201 85.9 154 77.0 1.00  1.00   
   1 or more 33 14.1 46 23.00 0.52 (0.31, 0.87)  0.50 (0.29, 0.86)   
Tanning bed use in past 12 months      0.06  - - 
   No 231 99.1 192 96.0 1.00  1.00   
   Yes 2 0.9 8 4.0 0.22 (0.05, 1.06)  NE   
Wear sunscreen      <0.0001  <0.0001 <0.0001 
   Never/Rarely/Sometimes 112 48.1 139 59.5 1.00  1.00   
   Often/Always 121 51.9 61 30.5 2.69 (1.77, 4.07)  3.00 (1.82, 4.94)   
Wear shirt with sleeves      0.08  0.22 0.23 
   Never/Rarely/Sometimes 37 16.0 45 22.5 1.00  1.00   
   Often/Always 195 84.1 155 77.5 1.59 (0.95, 2.65)  1.43 (0.81, 2.50)   
Wear a hat with brim      0.06  0.07 0.09 
   Never/Rarely/Sometimes 141 61.0 141 70.9 1.00  1.00   
   Often/Always 90 39.0 58 29.2 1.50 (0.99, 2.27)  1.52 (0.97, 2.38)   
Stay in the shade      <0.0001  0.0003 0.0008 
   Never/Rarely/Sometimes 114 49.6 140 70.0 1.00  1.00   
   Often/Always 116 50.4 60 30.0 2.40 (1.60, 3.60)  2.26 (1.45, 3.51)   
Spend time in the sun to get a tan      0.0004  0.009 0.01 
   Sometimes/Often/Always 14 6.0 35 17.5 1.00  1.00   
   Rarely/Never 218 94.0 165 82.5 3.36 (1.71, 6.59)  3.28 (1.56, 6.92)   
*adjusted for sex, age, education, income, smoking status, phenotypic risk group, personal history of other skin cancer, family history of melanoma, and lifetime sun exposure, outdoor activities, mean 
sunscreen and sunburns reported prior to diagnosis or reference date. 
** adjusted for multiple statistical tests using the Benjamini and Hochberg method189 
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Table 28a. Sun exposure and protection behaviors compared between survivors and controls - males.  
 Melanoma Survivors Controls Sex and age-adjusted Fully adjusted* 
 N % N % OR (95% CI) p-value OR (95% CI) p-value Adj p-value** 
Hours outside in summer  - weekdays      0.04  0.14 0.16 
   1 hour or less 136 59.7 96 49.5 1.00  1.00   
   2 hours or more 92 40.4 98 50.5 0.66 (0.45, 0.98)  0.71 (0.44, 1.12)   
Hours outside in summer - weekend       0.04  0.08 0.10 
   1 hour or less 44 19.3 23 11.9 1.00  1.00   
   2 hours or more 184 80.7 171 88.1 0.56 (0.32, 0.96)  0.59 (0.33, 1.07)   
Sunburns in past 12 months      <0.0001  <0.0001 0.0001 
   None 177 77.0 114 58.8 1.00  1.00   
   1 or more 53 23.0 80 41.2 0.40 (0.26, 0.62)  0.38 (0.24, 0.60)   
Tanning bed use in past 12 months      0.12  - - 
   No 227 99.1 189 96.9 1.00  1.00   
   Yes 2 0.9 6 3.1 0.28 (0.06, 1.40)  NE   
Wear sunscreen      <0.0001  <0.0001 <0.0001 
   Never/Rarely/Sometimes 115 50.2 148 75.9 1.00  1.00   
   Often/Always 114 49.8 47 24.1 3.18 (2.08, 4.86)  3.65 (2.18, 6.11)   
Wear shirt with sleeves      0.007  0.007 0.01 
   Never/Rarely/Sometimes 17 7.4 31 15.9 1.00  1.00   
   Often/Always 212 92.6 164 84.1 2.35 (1.26, 4.40)  2.52 (1.28, 4.95)   
Wear a hat with brim      0.001  0.005 0.008 
   Never/Rarely/Sometimes 126 55.3 137 70.3 1.00  1.00   
   Often/Always 102 44.7 58 29.7 1.94 (1.29, 2.90)  1.86 (1.21, 2.88)   
Stay in the shade      0.0004  0.005 0.008 
   Never/Rarely/Sometimes 136 59.7 148 75.9 1.00  1.00   
   Often/Always 92 40.4 47 24.1 2.14 (1.40, 3.27)  1.90 (1.21, 2.98)   
Spend time in the sun to get a tan      0.0002  0.0006 0.001 
   Sometimes/Often/Always 12 5.2 33 16.9 1.00  1.00   
   Rarely/Never 217 94.8 162 83.1 3.69 (1.85, 7.37)  3.67 (1.75, 7.70)   
*adjusted for sex, age, education, income, smoking status, phenotypic risk group, personal history of other skin cancer, family history of melanoma, and lifetime sun exposure, outdoor activities, mean 
sunscreen and sunburns reported prior to diagnosis or reference date. 
** adjusted for multiple statistical tests using the Benjamini and Hochberg method189 
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Table 28b. Sun exposure and protection behaviors compared between survivors and controls - females.  
 Melanoma Survivors Controls Sex and age-adjusted Fully adjusted* 
 N % N % OR (95% CI) p-value OR (95% CI) p-value Adj p-value** 
Hours outside in summer  - weekdays      0.0003  0.005 0.008 
   1 hour or less 252 75.2 192 62.3 1.00  1.00   
   2 hours or more 83 24.8 116 37.7 0.54 (0.38, 0.75)  0.60 (0.41, 0.86)   
Hours outside in summer - weekend       0.49  0.80 0.80 
   1 hour or less 99 29.6 83 27.0 1.00  1.00   
   2 hours or more 235 70.4 225 73.1 0.88 (0.62, 1.25)  0.95 (0.66, 1.38)   
Sunburns in past 12 months      <0.0001  <0.0001 <0.0001 
   None 275 82.1 202 65.4 1.00  1.00   
   1 or more 60 17.9 107 34.6 0.39 (0.26, 0.57)  0.35 (0.23, 0.52)   
Tanning bed use in past 12 months      0.0004  0.0002 0.0006 
   No 330 98.5 285 91.9 1.00  1.00   
   Yes 5 1.5 25 8.1 0.17 (0.07, 0.46)  0.14 (0.05, 0.39)   
Wear sunscreen      <0.0001  <0.0001 <0.0001 
   Never/Rarely/Sometimes 96 28.7 155 50.0 1.00  1.00   
   Often/Always 239 71.3 155 50.0 2.52 (1.82, 3.49)  2.97 (2.03, 4.34)   
Wear shirt with sleeves      0.002  0.004 0.007 
   Never/Rarely/Sometimes 111 33.3 140 45.3 1.00  1.00   
   Often/Always 222 66.7 169 54.7 1.69 (1.22, 2.35)  1.68 (1.18, 2.39)   
Wear a hat with brim      0.11  0.13 0.15 
   Never/Rarely/Sometimes 253 75.8 250 81.2 1.00  1.00   
   Often/Always 81 24.3 58 18.8 1.37 (0.94, 2.02)  1.38 (0.91, 2.09)   
Stay in the shade      <0.0001  <0.0001 <0.0001 
   Never/Rarely/Sometimes 151 45.4 215 69.6 1.00  1.00   
   Often/Always 182 54.7 94 30.4 2.78 (2.00, 3.85)  2.69 (1.90, 3.81)   
Spend time in the sun to get a tan      <0.0001  0.0002 0.0006 
   Sometimes/Often/Always 42 15.6 90 29.1 1.00  1.00   
   Rarely/Never 292 87.4 219 70.9 2.97 (1.96, 4.51)  3.48 (2.19, 5.54)   
*adjusted for sex, age, education, income, smoking status, phenotypic risk group, personal history of other skin cancer, family history of melanoma, and lifetime sun exposure, outdoor activities, mean 
sunscreen and sunburns reported prior to diagnosis or reference date. 
** adjusted for multiple statistical tests using the Benjamini and Hochberg method189 
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Table 29a. Sun exposure and protection behaviors compared between survivors with Stage I disease and controls.  
 Stage I Population Controls Fully adjusted* 
 N % N % OR (95% CI) p-value 
Hours outside in summer  - weekdays      0.02 
   1 hour or less 324 68.5 289 57.0 1.00  
   2 hours or more 149 31.5 218 43.0 0.69 (0.51, 0.93)  
Hours outside in summer - weekend       0.29 
   1 hour or less 123 26.1 107 21.1 1.00  
   2 hours or more 349 73.9 400 78.9 0.84 (0.61, 1.16)  
Sunburns in past 12 months      <0.0001 
   None 380 80.2 320 63.0 1.00  
   1 or more 94 19.8 188 37.0 0.37 (0.27, 0.52)  
Tanning bed use in past 12 months      0.0004 
   No 467 98.7 478 93.9 1.00  
   Yes 6 1.3 31 6.1 0.19 (0.08, 0.48)  
Wear sunscreen      <0.0001 
   Never/Rarely/Sometimes 171 36.2 307 60.3 1.00  
   Often/Always 302 63.9 202 39.7 3.32 (2.41, 4.58)  
Wear shirt with sleeves      0.0007 
   Never/Rarely/Sometimes 113 24.0 174 34.3 1.00  
   Often/Always 358 76.0 334 65.8 1.75 (1.27, 2.41)  
Wear a hat with brim      0.01 
   Never/Rarely/Sometimes 325 68.9 391 77.1 1.00  
   Often/Always 147 31.1 116 22.9 1.49 (1.09, 2.04)  
Stay in the shade      <0.0001 
   Never/Rarely/Sometimes 242 51.4 367 72.2 1.00  
   Often/Always 229 48.6 141 27.8 2.33 (1.75, 3.12)  
Spend time in the sun to get a tan      <0.0001 
   Sometimes/Often/Always 49 10.4 124 24.4 1.00  
   Rarely/Never 423 89.6 384 75.6 3.28 (2.18, 4.93)  
*adjusted for age, education, income, smoking status, phenotypic risk group, personal history of other skin cancer, family history of melanoma, and lifetime sun 
exposure, outdoor activities, mean sunscreen and sunburns reported prior to diagnosis or reference date. 
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Table 29b. Sun exposure and protection behaviors compared between survivors with Stage II/III/IV disease and controls.  
 Stages II/III/IV Population Controls Fully adjusted* 
 N % N % OR (95% CI) p-value 
Hours outside in summer  - weekdays      0.02 
   1 hour or less 51 69.9 289 57.0 1.00  
   2 hours or more 22 30.1 218 43.0 0.46 (0.24, 0.86)  
Hours outside in summer - weekend       0.70 
   1 hour or less 15 20.6 107 21.1 1.00  
   2 hours or more 58 79.5 400 78.9 0.88 (0.45, 1.70)  
Sunburns in past 12 months      0.0002 
   None 60 81.1 320 63.0 1.00  
   1 or more 14 18.9 188 37.0 0.26 (0.13, 0.52)  
Tanning bed use in past 12 months      - 
   No 74 100.0 478 93.9 1.00  
   Yes 0 0.0 31 6.1 NE  
Wear sunscreen      0.0004 
   Never/Rarely/Sometimes 29 39.2 307 60.3 1.00  
   Often/Always 45 60.8 202 39.7 3.28 (1.71, 6.32)  
Wear shirt with sleeves      0.02 
   Never/Rarely/Sometimes 13 17.6 174 34.3 1.00  
   Often/Always 61 82.4 334 65.8 2.42 (1.18, 4.95)  
Wear a hat with brim      0.02 
   Never/Rarely/Sometimes 44 60.3 391 77.1 1.00  
   Often/Always 29 39.7 116 22.9 1.99 (1.11, 3.58)  
Stay in the shade      0.0006 
   Never/Rarely/Sometimes 37 50.7 367 72.2 1.00  
   Often/Always 36 49.3 141 27.8 2.62 (1.51, 4.55)  
Spend time in the sun to get a tan      0.002 
   Sometimes/Often/Always 5 6.7 124 24.4 1.00  
   Rarely/Never 69 93.2 384 75.6 5.66 (1.93, 16.64)  
*adjusted for age, sex, education, income, smoking status, phenotypic risk group, personal history of other skin cancer, family history of melanoma, and lifetime 
sun exposure, outdoor activities, mean sunscreen and sunburns reported prior to diagnosis or reference date. 
 152 
 
Table 30a. Sun exposure and protection behaviors compared between survivors with head/neck tumors and controls.  
 Head/Neck Melanoma Population Controls Adjusted* 
 N % N % OR (95% CI) p-value 
Hours outside in summer  - weekdays      0.12 
   1 hour or less 41 65.1 289 57.0 1.00  
   2 hours or more 22 34.9 218 43.0 0.59 (0.30, 1.16)  
Hours outside in summer - weekend       0.59 
   1 hour or less 10 15.9 107 21.1 1.00  
   2 hours or more 53 84.1 400 78.9 1.24 (0.57, 2.71)  
Sunburns in past 12 months      0.02 
   None 48 76.2 320 63.0 1.00  
   1 or more 15 23.8 188 37.0 0.45 (0.23, 0.89)  
Tanning bed use in past 12 months      - 
   No 62 98.4 478 93.9 1.00  
   Yes 1 1.6 31 6.1 NE  
Wear sunscreen      <0.0001 
   Never/Rarely/Sometimes 26 41.3 307 60.3 1.00  
   Often/Always 37 58.7 202 39.7 4.17 (2.06, 8.46)  
Wear shirt with sleeves      0.64 
   Never/Rarely/Sometimes 14 22.2 174 34.3 1.00  
   Often/Always 49 77.8 334 65.8 1.19 (0.57, 2.52)  
Wear a hat with brim      0.43 
   Never/Rarely/Sometimes 40 63.5 391 77.1 1.00  
   Often/Always 23 36.5 116 22.9 1.30 (0.68, 2.50)  
Stay in the shade      0.001 
   Never/Rarely/Sometimes 31 49.2 367 72.2 1.00  
   Often/Always 32 50.8 141 27.8 2.75 (1.49, 5.07)  
Spend time in the sun to get a tan      0.14 
   Sometimes/Often/Always 8 12.7 124 24.4 1.00  
   Rarely/Never 55 87.3 384 75.6 1.91 (0.81, 4.50)  
*adjusted for age, sex, education, income, smoking status, phenotypic risk group, personal history of other skin cancer, family history of melanoma, and lifetime 
sun exposure, outdoor activities, mean sunscreen and sunburns reported prior to diagnosis or reference date. 
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Table 30b. Sun exposure and protection behaviors compared between survivors with trunk tumors and controls.  
 Trunk Melanoma Population Controls Adjusted* 
 N % N % OR (95% CI) p-value 
Hours outside in summer  - weekdays      0.07 
   1 hour or less 131 65.2 289 57.0 1.00  
   2 hours or more 70 34.8 218 43.0 0.69 (0.47, 1.03)  
Hours outside in summer - weekend       0.40 
   1 hour or less 48 24.0 107 21.1 1.00  
   2 hours or more 152 76.0 400 78.9 0.83 (0.53, 1.29)  
Sunburns in past 12 months      <0.0001 
   None 159 78.3 320 63.0 1.00  
   1 or more 44 21.7 188 37.0 0.37 (0.24, 0.57)  
Tanning bed use in past 12 months      - 
   No 202 99.5 478 93.9 1.00  
   Yes 1 0.5 31 6.1 NE  
Wear sunscreen      <0.0001 
   Never/Rarely/Sometimes 79 38.9 307 60.3 1.00  
   Often/Always 124 61.1 202 39.7 4.06 (2.60, 6.35)  
Wear shirt with sleeves      0.04 
   Never/Rarely/Sometimes 48 23.8 174 34.3 1.00  
   Often/Always 154 76.2 334 65.8 1.57 (1.02, 2.43)  
Wear a hat with brim      0.008 
   Never/Rarely/Sometimes 133 65.5 391 77.1 1.00  
   Often/Always 70 34.5 116 22.9 1.71 (1.15, 2.54)  
Stay in the shade      0.0008 
   Never/Rarely/Sometimes 118 58.1 367 72.2 1.00  
   Often/Always 85 41.9 141 27.8 1.91 (1.31, 2.78)  
Spend time in the sun to get a tan      <0.0001 
   Sometimes/Often/Always 16 7.9 124 24.4 1.00  
   Rarely/Never 187 92.1 384 75.6 4.99 (2.59, 9.59)  
*adjusted for age, sex, education, income, smoking status, phenotypic risk group, personal history of other skin cancer, family history of melanoma, and lifetime 
sun exposure, outdoor activities, mean sunscreen and sunburns reported prior to diagnosis or reference date. 
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Table 30c. Sun exposure and protection behaviors compared between survivors with upper limb tumors and controls.  
 Upper limb Melanoma Population Controls Adjusted* 
 N % N % OR (95% CI) p-value 
Hours outside in summer  - weekdays      0.01 
   1 hour or less 109 68.6 289 57.0 1.00  
   2 hours or more 50 31.5 218 43.0 0.58 (0.37, 0.90)  
Hours outside in summer - weekend       0.18 
   1 hour or less 44 27.7 107 21.1 1.00  
   2 hours or more 115 72.3 400 78.9 0.73 (0.47, 1.15)  
Sunburns in past 12 months      <0.0001 
   None 130 81.8 320 63.0 1.00  
   1 or more 29 18.2 188 37.0 0.31 (0.19, 0.51)  
Tanning bed use in past 12 months      - 
   No 157 98.7 478 93.9 1.00  
   Yes 2 1.3 31 6.1 NE  
Wear sunscreen      <0.0001 
   Never/Rarely/Sometimes 63 39.6 307 60.3 1.00  
   Often/Always 96 60.4 202 39.7 3.47 (2.20, 5.48)  
Wear shirt with sleeves      0.002 
   Never/Rarely/Sometimes 31 19.5 174 34.3 1.00  
   Often/Always 128 80.5 334 65.8 2.18 (1.33, 3.57)  
Wear a hat with brim      0.02 
   Never/Rarely/Sometimes 102 64.6 391 77.1 1.00  
   Often/Always 56 35.4 116 22.9 1.72 (1.11, 2.66)  
Stay in the shade      <0.0001 
   Never/Rarely/Sometimes 79 50.0 367 72.2 1.00  
   Often/Always 79 50.0 141 27.8 2.61 (1.73, 3.93)  
Spend time in the sun to get a tan      <0.0001 
   Sometimes/Often/Always 15 9.4 124 24.4 1.00  
   Rarely/Never 144 90.6 384 75.6 3.62 (1.90, 6.91)  
*adjusted for age, sex, education, income, smoking status, phenotypic risk group, personal history of other skin cancer, family history of melanoma, and lifetime 
sun exposure, outdoor activities, mean sunscreen and sunburns reported prior to diagnosis or reference date. 
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Table 30d. Sun exposure and protection behaviors compared between survivors with lower limb tumors and controls.  
 Lower limb Melanoma Population Controls Adjusted* 
 N % N % OR (95% CI) p-value 
Hours outside in summer  - weekdays      0.05 
   1 hour or less 117 74.5 289 57.0 1.00  
   2 hours or more 40 25.5 218 43.0 0.63 (0.40, 0.99)  
Hours outside in summer - weekend       0.56 
   1 hour or less 45 28.7 107 21.1 1.00  
   2 hours or more 112 71.3 400 78.9 0.88 (0.56, 1.38)  
Sunburns in past 12 months      <0.0001 
   None 128 81.5 320 63.0 1.00  
   1 or more 29 18.5 188 37.0 0.35 (0.21, 0.58)  
Tanning bed use in past 12 months      - 
   No 153 98.1 478 93.9 1.00  
   Yes 3 1.9 31 6.1 NE  
Wear sunscreen      0.0003 
   Never/Rarely/Sometimes 52 33.3 307 60.3 1.00  
   Often/Always 104 66.7 202 39.7 2.35 (1.48, 3.74)  
Wear shirt with sleeves      0.02 
   Never/Rarely/Sometimes 40 25.8 174 34.3 1.00  
   Often/Always 115 74.2 334 65.8 1.71 (1.09, 2.71)  
Wear a hat with brim      0.25 
   Never/Rarely/Sometimes 114 73.6 391 77.1 1.00  
   Often/Always 41 26.5 116 22.9 1.32 (0.82, 2.11)  
Stay in the shade      <0.0001 
   Never/Rarely/Sometimes 70 45.5 367 72.2 1.00  
   Often/Always 84 54.6 141 27.8 2.52 (1.67, 3.80)  
Spend time in the sun to get a tan      0.001 
   Sometimes/Often/Always 19 12.3 124 24.4 1.00  
   Rarely/Never 136 87.7 384 75.6 2.55 (1.44, 4.52)  
*adjusted for age, sex, education, income, smoking status, phenotypic risk group, personal history of other skin cancer, family history of melanoma, and lifetime 
sun exposure, outdoor activities, mean sunscreen and sunburns reported prior to diagnosis or reference date. 
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Table 31. Self-reported changes in avoidance of sun exposure since diagnosis among 
melanoma survivors. 
 More Same Less Never my habit  
 N % N % N % N % p-value 
All melanoma survivors 448 79.6 84 14.9 19 3.4 12 2.1  
Sex         0.001 
   Male 164 71.6 48 21.0 10 4.4 7 3.1  
   Female 284 85.0 36 10.8 9 2.7 5 1.5  
Age at survey         0.27 
   30-39 34 79.1 9 20.9 0 0.0 0 0.0  
   40-49 79 78.2 17 16.8 3 3.0 2 2.0  
   50-59 177 83.1 22 10.3 7 3.3 7 3.3  
   60-72 176 75.9 41 17.7 11 4.7 4 1.7  
Melanoma Stage         0.55 
   I 373 78.8 72 15.3 15 3.2 13 2.8  
   II 29 82.9 4 11.4 2 5.7 0 0.0  
   III/IV 35 89.7 3 7.7 1 2.6 0 0.0  
Tumor Site         0.02 
   Head/neck 43 68.3 10 15.9 5 7.9 5 7.9  
   Trunk 162 79.8 33 16.3 5 2.5 3 1.5  
   Upper limb 123 77.4 25 15.7 7 4.4 4 2.5  
   Lower limb 130 83.9 21 13.6 3 1.9 1 0.7  
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Table 32. Self-reported changes in wearing of sun protective clothing since diagnosis 
among melanoma survivors. 
 More Same Less Never my habit  
 N % N % N % N % p-value 
All melanoma survivors 351 62.5 132 23.5 4 0.7 75 13.4  
Sex         0.004 
   Male 148 64.6 63 27.5 1 0.4 17 7.4  
   Female 203 61.0 69 20.7 3 0.9 58 17.4  
Age at survey         0.02 
   30-39 21 48.8 10 23.3 0 0.0 12 27.9  
   40-49 60 59.4 26 25.7 0 0.0 15 14.9  
   50-59 129 60.9 49 23.1 0 0.0 34 16.0  
   60-72 153 66.0 55 23.7 4 1.7 20 8.6  
Melanoma Stage         0.75 
   I 292 62.0 102 21.7 4 0.9 73 15.5  
   II 21 60.0 10 28.6 0 0.0 4 11.4  
   III/IV 27 69.2 9 23.1 0 0.0 3 7.7  
Tumor Site         0.75 
   Head/neck 33 52.4 20 31.8 0 0.0 4 15.9  
   Trunk 131 64.9 40 19.8 2 1.0 29 14.4  
   Upper limb 97 61.0 39 24.5 1 0.6 22 13.8  
   Lower limb 99 63.9 37 23.9 1 0.7 18 11.6  
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Table 33. Self-reported changes in sunscreen use since diagnosis among melanoma 
survivors. 
 More Same Less Never my habit  
 N % N % N % N % p-value 
All melanoma survivors 440 78.2 95 16.9 3 0.5 25 4.4  
Sex         <0.0001 
   Male 157 68.9 52 22.8 1 0.4 18 7.9  
   Female 282 84.5 43 12.8 2 0.6 7 2.1  
Age at survey         <0.0001 
   30-39 41 95.4 2 4.7 0 0.0 0 0.0  
   40-49 90 89.1 11 10.9 0 0.0 0 0.0  
   50-59 166 77.9 38 17.8 2 0.9 7 3.3  
   60-72 159 68.5 50 21.6 2 0.9 21 9.1  
Melanoma Stage         0.54 
   I 372 78.7 75 15.9 4 0.9 22 4.7  
   II 23 65.7 10 28.6 0 0.0 2 5.7  
   III/IV 32 82.1 5 12.8 0 0.0 2 5.1  
Tumor Site         0.08 
   Head/neck 42 66.7 16 25.4 0 0.0 5 7.9  
   Trunk 150 73.9 39 19.2 3 1.5 11 5.4  
   Upper limb 126 79.8 26 16.5 0 0.0 6 3.8  
   Lower limb 133 85.3 17 10.9 1 0.6 5 3.2  
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9 Conclusion 
As early detection and treatments improve, cancer survivors will continue to be a 
growing portion of the population and an understanding of their needs and concerns is 
necessary to improve their QOL. The overarching goal of this dissertation was to 
document the long-term effects of a melanoma diagnosis and treatment on survivors and 
compare their QOL and health behaviors with population controls.   
The experiences shared by participants in the focus groups highlighted a number 
of QOL issues facing melanoma survivors, including a level of isolation and loneliness 
that underscores the need to increase both awareness of melanoma and chances for 
survivors to interact and support each other.  In the subsequent cross-sectional study of 
longer-term melanoma survivors compared to population controls, however, melanoma 
survivors reported similar QOL and mental health measures as controls.  This suggests 
that melanoma survivors are doing well in general, though future investigation into the 
disease-specific QOL data collected in the study that was not analyzed as part of this 
dissertation will help elucidate whether identification of potential risk factors of long-
term poor QOL outcomes are needed.    
Melanoma survivors reported greater use of sun protection behaviors than 
controls, however they had similar weekend sun exposure and while less than controls, a 
significant subgroup experienced sunburns in the past year.  The next step is to 
understand what barriers exist which prevent melanoma survivors from discontinuing 
risky sun exposure, with the ultimate goal of developing an easily disseminated 
intervention to address these barriers and promote behavior change.   
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The studies conducted as part of this dissertation fill gaps in the literature 
regarding descriptions of the physical, emotional and social health and behaviors of long-
term melanoma survivors and specifically the differences between long-term melanoma 
survivors and population controls.  The knowledge gained here serves as the platform 
from which interventions can be designed to improve the experience of melanoma 
survivors.      
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Appendix A. List of questionnaires considered for inclusion in Melanoma-specific 
QOL questionnaire 
Instrument Cancer 
Type(s) 
# Items Topics Covered Ref. 
ACS SCS-II Breast, 
prostate, 
colorectal, 
urinary bladder, 
skin melanoma 
and uterine 
cancers 
56 + 4 
open 
Basic demographics, co-morbid 
conditions, cancer diagnosis and 
treatment, health insurance, 
Satisfaction with Life Domains 
Scale-Cancer, Cancer Problems in 
Living Scale, Modified Rotterdam 
Symptom Checklist, Functional 
Assessment of Chronic Illness Therapy-
Spiritual Well-being, Medial Outcomes 
Study Short Form-36, 
Multidimensional Scale of Perceived 
Social Support, POMS-37, 
employment, lifestyle behavior scale 
1
State-Trait 
Anger 
Expression 
Inventory 
General 
population 
44 Contains Anger Expression Scale 
(AXS), Anger-expression in, anger- 
expression out, anger-control in, anger-
control out, state anger, trait anger  
2,3
Assessment of 
Survivor 
Concerns 
Cancer 
survivors 
5 Cancer worry, Health worry 4
Beck’s 
Depression 
Inventory 
General 
population 
21 Measures depression – focuses on 
uncovering severe depression requiring 
medication/hospitalization 
5
Body Image 
and 
Relationships 
Scale (BIRS) 
Breast cancer 
survivors 
32 Strength and health, social barriers, 
appearance and sexuality 
6
Brief Fatigue 
Inventory 
Psychiatric 
patients, cancer 
patients, normal 
volunteers 
4 Fatigue 7
Brief Pain 
Inventory 
Breast, 
prostate, 
colorectal and 
gynecologic 
cancer and 
arthritis 
9 Pain 8
Brief Symptom 
Inventory 
General 
population 
53 Psychological Problems – Subscales: 
Somatization, Obsessive-Compulsive, 
Interpersonal Sensitivity, Depression, 
Anxiety, Hostility, Phobic Anxiety, 
Paranoid Ideation, Psychoticism.  
Developed as shorter version of SCL-
90R 
9
Cancer 
Problems in 
Living Scale 
(CPILS) 
BMT 29 Quality of life – wide range of questions 10 
191
Instrument Cancer 
Type(s) 
# Items Topics Covered Ref. 
Cancer 
Rehabilitation 
Evaluation 
Scale (CARES) 
– Short form
Lung, prostate, 
colorectal, 
breast 
59 + 
Open 
Physical, Psychosocial, Medical 
interaction, martial, sexual, other 
cancer-related items 
11
Cancer 
Survivor’s 
Unmet Needs 
(CaSUN) 
Breast, 
gynecologic, 
prostate, 
colorectal, other 
42 + 1 
open 
Information needs and medical care, 
quality of life, emotional and 
relationship issues, life perspective, 
positive changes 
12
Cassileth Scar 
questionnaire 
Melanoma 12 + 
body 
drawing 
for 
location 
of scar 
Patient opinions regarding size and 
cosmetic implications of their excisions 
13
CES-D General 
population, 
psychiatric 
patients 
20 Depression – six scales: depressed 
mood, feelings of guilt and 
worthlessness, feelings of helplessness 
and hopelessness, psychomotor 
retardation, loss of appetite, sleep 
disturbance 
14
Chronic Strains 
Survey 
Breast cancer 
and melanoma 
survivors 
13 Subjective burden of many strains, from 
1 (mildly burdensome) to 3 (extremely 
burdensome) 
15
Cognitive 
Appraisal of 
Health 
Breast cancer 28 Threat, Challenge, Harm/Loss, 
Benign/Irrelevant 
16
Daily Fatigue 
Impact Scale 
(D-FIS) 
Patients with 
hypertension, 
MS or Chronic 
Fatigue 
Syndrome, flu 
8 Fatigue 17
Dealing with 
Illness Coping 
Inventory 
AIDS, used in 
cancer as well 
48 Cognitive and behavioral responses to 
cope with illness.  Eight coping 
strategies: active-positive, active-
expressive, active-reliance, cognitive-
positive, cognitive-passive, avoidance-
solitary, distraction, and passive-
resignation 
18
Depression 
scale (DEPS) 
10 Developed to screen for depression in 
Finnish primary health-care settings 
19
Dermatology 
Life Quality 
Index 
Atopic eczema, 
psoriasis, 
generalized 
pruritus, acne, 
basal cell 
carcinomas, 
viral warts 
10 Impairment of skin-related quality of life 20 
192
Instrument Cancer Type(s)  # Items Topics Covered Ref. 
Dermatology 
Quality of 
Life Scale 
Psoriasis, 
eczema, acne, 
disorder of 
keratinization, 
benign and 
malignant tumors, 
pigmentation, 
alopecia, other 
conditions 
41 Dermatologic symptoms, physical 
activities, psychosocial state  
21
Dermatology 
Specific 
Quality of 
Life 
Contact 
dermatitis, acne 
36 + 8 
global 
Symptoms, daily activities, social 
functioning, work/school performance, 
personal perceptions 
22
DS14 – Type 
D personality 
Coronary heart 
disease, 
hypertension 
14 Negative Affectivity (dysphoria, worry, 
irritability), Social Inhibition (discomfort 
in social situations, reticence, lack of 
social poise), Type D personality 
23
EORTC QLQ-
C30 
Cancer specific, 
not specified 
30 Physical, role , cognitive, emotional, 
social, fatigue, pain, nausea/vomiting 
24
FACT-M All types / 
Melanoma-
specific 
27  / 24 Physical, social/family, emotional, 
functional, melanoma-specific (pain, 
skin, physical, fatigue), swelling/issues 
at surgery site 
25
F-COPES General 
population? 
30 Measures internal and external family 
coping mechanisms: acquiring social 
support, reframing, seeking spiritual 
support, mobilizing the family to acquire 
and accept help, passive appraisal 
26
Fear of 
Cancer 
Recurrence 
Inventory 
Prostate, breast, 
lung, colorectal 
42 Fear of cancer recurrence – triggers, 
severity, psychological distress, coping 
strategies, functioning impairments, 
insight, reassurance 
27
Functional 
Living Index 
– Cancer
Cancer-specific, 
not specified 
22 Physical well-being and ability, 
emotional state factor 
28
General 
Coping 
Strategies 
Scale (COPE) 
60 Positive reinterpretation and growth, 
mental disengagement, focus on and 
venting of emotions, use of instrumental 
social support, active coping, denial, 
religious coping, humor, behavioral 
disengagement, restraint, use of 
emotional social support, substance 
use, acceptance, suppression of 
competing activities, planning 
29
GHQ-28 28 Four subscales: Anxiety, depression, 
somatic complaints, social dysfunction 
30
Global 
Assessment 
of Recent 
Stress Scale 
31
193
Instrument Cancer Type(s)  # Items Topics Covered Ref. 
GLQ-8 Cancer and 
chemotherapy 
8 32
Groningen 
Activity 
Restriction 
scale 
Rheumatoid 
arthritis 
18 Measures physical disability (level of 
independence) 
33
Hardiness 
Scale 
34
Hornheide 
questionnaire 
Cancer-specific 9 Psychosocial issues of cancer patients 35
Hospital 
Anxiety and 
Depression 
Scale (HADS) 
Not cancer-
specific, 
originally 
developed for 
use with 
outpatients 
attending 
medical clinics 
14 Depression, Anxiety 36
Impact of 
Cancer 
Breast, 
Colorectal, 
Lymphoma, 
Prostate 
41 Employment, Life Outlook, Body and 
Health, Feelings about Cancer, 
Meaning of Cancer, Social Activities 
and Relationships 
37
Impact of 
Event Scale 
(IES) 
Not cancer-
specific 
(stressful  life 
events) 
15 Intrusion, Avoidance 38
Interpersonal 
Support 
Evaluation List 
(ISEL) 
40 Belonging or companionship support, 
Appraisal, Self-esteem maintenance, 
Instrumental support 
39
Inventory to 
Diagnose 
Depression 
General 
population 
22 Diagnoses major depression 40
Life 
Experience 
survey 
General 
population 
50 Self-report of positive and negative 
events experienced over the previous 
year and perceived 
 stress associated with those events 
41
Locus of 
Control 
questionnaire 
29 Sense of control over self and life 
events 
42
Long-term 
Quality of Life 
(LTQL) 
Breast, uterine, 
cervical, other 
34 Somatic concerns, 
philosophical/spiritual view of life, 
fitness, social support 
43
McGill Pain 
questionnaire 
Many events, 
including cancer 
48 What does pain feel like, how does pain 
change over time, how strong is pain 
44
Measure of 
Body 
Apperception 
Breast cancer 10 Investment in appearance, investment 
in body integrity – reliance on physical 
appearance for self-worth 
45
Medical 
Coping Modes 
Questionnaire 
Lymphoma, 
colon, lung 
cancer 
32 3 coping modes: Confrontation, 
avoidance, acceptance-resignation 
46
Mental Health 
Inventory 
38 Well-being, distress 47
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Instrument Cancer 
Type(s)  
# Items Topics Covered Ref. 
Millon Behavioral 
Medical 
Diagnostic 
Cancer, 
chronic pain, 
diabetes, 
HIV/AIDS, 
heart 
disease 
165 Response patterns, negative health 
habits, psychiatric indications, coping 
styles, stress moderators 
48 
Minnesota 
Multiphasic 
Personality 
Inventory (MMPI)  
General 
population 
567 Clinical scales: Hypochondriasis, 
Depression, Hysteria, Psychopathic 
Deviate, Masculinity-Feminity, 
Paranoia, Psychastenia, Schizophrenia, 
Hypomania, Social Introversion 
49 
MOS – 20 item Chronic 
illnesses 
20 Physical functioning, role functioning, 
social functioning, mental health, 
current health perceptions, pain 
50 
Multidimensional 
Support Scale 
General 
population 
16 Measures availability and adequacy of 
social support from various sources 
51 
Multi-item 
Measure of Adult 
Attachment 
 36 Measures attachment on two 
dimensions: anxiety and avoidance 
52 
National Survey of 
Households 
Affected by 
Cancer 
Cancer in 
past 5 years 
(excluding 
non-
melanoma 
skin cancer) 
 Included questions regarding both self 
and family member living in house 
cancer diagnoses; interactions with 
doctors, side effects, self-help and 
alternative therapies, impact on family 
members, health insurance and health 
care costs, impact on work, post-cancer 
life 
53 
Nonsolar Tanning 
Items 
Non-cancer 8 Ever use, times and duration of indoor 
tanning and sunless tanning items 
54 
Patient Health 
Questionnaire 
(PHQ-9) 
OB-GYN 
patients, 
younger 
population, 
not cancer 
specific 
9 + 1 Depression 55 
Patient 
Satisfaction with 
Cancer Care 
Breast, 
cervical, 
colorectal, 
prostate 
18 Satisfaction with cancer care  56 
Perceived Aim of 
Treatment 
Metastatic 
melanoma 
1 Single item: patient perception of aim of 
their treatment: complete cure, 
increased long-term survival, increased 
short-term survival or reduction of 
symptoms 
57 
Perceived Stress 
Scale 
General 
population 
4/10/14 Measures perceived stress in past 
month 
58 
Posttraumatic 
Growth Inventory 
Not cancer-
specific 
21 Relating to others, new possibilities, 
personal strength, spiritual change 
appreciation of life; SF also available 
(10 items) 
59,60 
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Instrument Cancer Type(s)  # Items Topics Covered Ref. 
Profile of Mood 
States (POMS) 
 65 (58 
used in 
scoring) 
Related to today/this week/right now; 
tension/anxiety, depression, anger-
hostility, vigor-activity, fatigue, 
confusion 
61 
Psychological 
Adjustment to 
Cancer 
Any cancer, >19 
years old, in 
active treatment 
46 Health-care orientation (perception of 
services), vocational environment, 
domestic environment, sexual 
relationships, extended family 
relationships, social support, 
psychological distress 
62 
Quality of Life 
in Adult 
Cancer 
Survivors 
(QLACS) 
Breast, Bladder, 
Head and Neck, 
Gynecologic, 
Prostate, 
Colorectal 
47 Negative feelings [depression], positive 
feelings,  cognitive problems, pain, 
sexual interest/function, energy/fatigue, 
social avoidance, financial problems, 
benefits, distress-family, appearance, 
distress-recurrence 
63 
Quality of Life-
Cancer 
Survivors 
(QOL-CS) 
Breast, 
lymphoma, 
ovarian, 
Hodgkin’s, 
cervical, 
leukemia, colon, 
other 
41 Physical well-being, psychological well-
being, social well-being spiritual well-
being, fear distress, spiritual 
64 
Quality of Well-
Being 
Adults at 
primary clinic 
80 Acute and chronic physical symptoms, 
mental health symptoms, self care, 
mobility, physical functioning, 
performance 
65 
Recent Life 
Changes 
Questionnaire 
(RLCQ) 
 73 Tracks life changes as a source of 
stress (usually ask about events in past 
6 months or year)  Questions resolve 
around Health, Work, Home and 
Family, Personal and Social, Financial 
66 
Rotterdam 
symptom 
checklist 
Female cancers 30+ 8 
activities 
Cancer-specific tool to measure 
psychological and physical distress in 
cancer patients.  Physical symptoms, 
physiological symptoms, activities of 
daily living 
67 
Satisfaction 
with Life 
Domain Scales 
for Cancer 
SLDS-C 
BMT 17 Relationships, health, appearance, 
leisure time, ability to eat, physical 
strength 
68 
SCL-90R 
symptom 
checklist 
Participants in 
psychotherapy 
drug trials 
90 9 primary symptom dimensions 
(somatization, obsessive compulsive, 
depression, anxiety, hostility, phobic 
anxiety, paranoid ideation, 
psychoticism) and 3 global indices 
(global severity index, positive symptom 
distress index, positive symptom total) 
69 
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Instrument Cancer 
Type(s)  
# Items Topics Covered Ref. 
SF-36 General health 
(not cancer 
specific) 
36 Limitations in physical activities 
because of health problems, limitations 
in social activities because of physical 
or emotional problems, limitations in 
usual role activities because of physical 
health problems, bodily pain, general 
mental health, limitations in usual role 
activities because of emotional 
problems, vitality (energy and fatigue), 
and general health perceptions 
70 
Skin Cancer 
Index 
Non-melanoma 
skin cancer 
15 Emotional, appearance, work/financial, 
lifestyle/recreation, social/family, 
physical/functioning 
71,72 
Skindex-29 Adults with 
appointments 
at private 
dermatology 
clinics 
30 Emotions, symptoms, functioning 73 
Social 
Difficulties 
Inventory 
Oncology clinic 21 Social difficulties – physical ability, 
providing for family, contact with others 
74 
Social 
Provisions 
Scale (SPS) 
Not cancer-
specific 
24 Attachment, Social integration, 
Reassurance of worth, Reliable 
alliance, guidance, and opportunity for 
nurturance 
75 
Social Support 
Survey 
Not cancer 
specific 
(designed for ill 
patients) 
19 Physical functioning, role limitations – 
physical and emotional, pain, mental 
health, current health, social activity, 
energy/fatigue, physical symptoms, 
loneliness, family functioning, family 
happiness, marital functioning 
 
76 
State-Trait 
Anxiety 
Inventory 
 20 Assesses state and trait anxiety 77 
Stress 
Questionnaire 
(cognitive 
appraisal sub-
scale) 
  Confrontive coping, distancing, self-
controlling, seeking social support, 
accepting responsibility, escape-
avoidance, planful problem-solving, 
positive reappraisal 
78 
Structural-
Functional 
Social Support 
Scale (SFSS) 
Cancer-
specific; breast, 
melanoma 
10/10 Number of sources of social support, 
amount of support from those sources 
79 
Sun Exposure 
and Sun 
Protection 
Measures 
Skin cancer 
and general 
population 
14 Sun habits (exposure and protection) 
and skin examination 
80 
Survivors 
Module 
Early stage 
Breast cancer  
46  
 
 
81 
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Instrument Cancer Type(s)  # Items Topics Covered Ref. 
Systems of 
Beliefs 
Inventory 
Cancer, 
malignant 
melanoma 
15 Measure religious and spiritual beliefs 
and practices and the social support 
derived from a community sharing 
those beliefs 
82 
Ways of 
Coping 
Questionnaire 
Used in study of 
melanoma and 
breast cancer 
survivors 
50 Identify thoughts/actions used to cope 
with a specific stressor; 8 coping 
factors: confrontive coping, distancing, 
self-controlling, seeking social support, 
accepting responsibility, escape-
avoidance, planful problem solving, 
positive reappraisal  
83 
Work Concerns 
During/After 
Cancer 
Tested in 
gynecological 
cancer 
survivors 
81 + 8 
open 
In depth questions regarding 
employment both at time of cancer 
diagnosis and after treatment; health 
insurance/benefits 
84 
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Appendix B. Pilot Questionnaire and Data Sources. 
 
I. Your Health Habits 
 
Question Source Melanoma 
Survivors 
Controls 
 
Physical Activity Habits 
Consider a typical 7-day period (a week) in the 
past month.  How many times on average do you 
do the following kinds of exercise for more than 
15 minutes during your free time and for how long 
per exercise session? 
   Strenuous (Times, Average time) 
   Moderate (Times, Average time) 
   Mild (Times, Average time) 
Godin Leisure 
Time Exercise 
questionnaire1 
X X 
 
Diet Habits 
How many days per week to you eat at least five 
(5) servings of vegetables and fruits a day? 
American Cancer 
Society – SCS II2 
X X 
Do you currently take a multi-vitamin? Iowa Women’s 
Health Study3 
X X 
Do you currently take vitamin D on a regular 
basis, either as part of a multi-vitamin, calcium 
supplement, or as its own pill? 
Skin Health Study4 X X 
On average, how many days per week do you 
take vitamin D? 
Skin Health Study4 X X 
What is the usual amount you take each day? Skin Health Study4 X X 
 
Body Size 
How tall are you? 
   Feet 
   Inches 
Skin Health Study4 X X 
What is your current weight in pounds? Skin Health Study4 X X 
 
Sun Habits 
In the summer, on average, how many hours are 
outside per day between 10am and 4pm? 
   ON WEEKDAYS 
   ON WEEKEND DAYS 
Glanz, Lazovich5 X X 
In the past 12 months, how many times did you 
have a red OR painful sunburn that lasted a day 
or more? 
Glanz, Lazovich5 X X 
Think about what you do when you are outside 
during the summer on a warm sunny day. 
   How often do you… 
   Wear sunscreen? 
   Wear a shirt with sleeves that cover your  
     shoulders? 
   Wear a hat with a wide brim? 
   Stay in the shade or under an umbrella? 
   Spend time in the sun in order to get a tan? 
Glanz, Lazovich5 X X 
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Question Source Melanoma 
Survivors 
Controls 
In the last 12 months, have you used a tanning bed 
or booth with tanning lamps? 
   If yes, how many times? 
Glanz, Lazovich5 X X 
In the last 12 months have you or your partner 
examined your entire body, including your back, for 
skin cancer? 
   If yes, how many times? 
Glanz, Lazovich5 X X 
What is the color or your untanned skin? Glanz, Lazovich5 X X 
Since your melanoma diagnosis have you been… 
   Avoiding exposure to the sun? 
   Wearing sun-protective clothing? 
   Using sunscreen? 
American Cancer 
Society – SCS II2 
X  
 
Alcohol Habits 
During the past 30 days, how many days per 
month did you have at least one drink of any 
alcoholic beverage, such as beer, wine, a malt 
beverage or liquor? One drink is equivalent to a 
12-ounce beer, a 5-ounce glass of wine or a drink 
with one shot of liquor. 
BRFSS 20126, 
modified from 
days per week or 
days per month 
X X 
During the past 30 days, on the days when you 
drank, about how many did you drink on the 
average? 
BRFSS 20126 X X 
Considering all types of alcoholic beverages, how 
many times during the past 30 days did you 
have… 
   5 or more drinks on one occasion if you  
   are man? 
   4 or more drinks on one occasion if you  
   are a woman? 
BRFSS 20126 X X 
 
Smoking Habits 
Do you currently smoke cigarettes on a regular 
basis? 
American Cancer 
Society – SCS II2 
X X 
On average, how many packs of cigarettes do you 
smoke per day now (1 pack=20 cigarettes)? 
American Cancer 
Society – SCS II2 
X X 
Do you currently use any of the following tobacco 
products on a regular basis? 
American Cancer 
Society – SCS II2 
X X 
 
 
II. Your Health Habits 
 
Question Source Melanoma 
Survivors 
Controls 
 
Quality of Life 
SF-36-Version 2 (36 questions) SF-367 X X 
 
Emotional Well-Being 
Hospital Anxiety and Depression Scale (HADS; 14 
questions) 
HADS8 X X 
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III. Health Conditions 
 
Question Source Melanoma 
Survivors 
Controls 
Has a medical doctor or healthcare professional ever 
told you that you have any of the following? 
o Heart Problems, such as a heart attack, coronary 
artery disease, congestive heart failure, irregular 
heartbeat, etc. 
o Hypertension (high blood pressure) 
o Chronic back pain, including sciatica (pain or 
numbness that travels down your leg to below 
your knees) 
o Arthritis 
o Stroke, including mini-stroke or blood clots in the 
brain 
o Severe problems with memory or concentration 
o Asthma, emphysema, or COPD (Chronic 
Obstructive Pulmonary Disease) 
o Stomach and/or intestinal problems, such as 
Chron’s disease, ulcers, or inflammatory bowel 
disease 
o Diabetes, high blood sugar, or sugar in urine 
o Depression (feeling sad or blue) that required 
treatment 
o Anxiety or “nervousness” that required treatment 
o Neuropathy (numbness in both hands or both feet) 
o Melanoma (controls only) 
o Cancer other than melanoma 
o Other: _______________________ 
 
American 
Cancer 
Society – SCS 
II2 
X X 
Have any of the following members of your family 
been diagnosed with melanoma? 
   Parents 
   Grandparents 
   Brothers 
   Sisters 
   Children 
   Grandchildren 
Skin Health 
Study4 
X X 
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IV. Cancer Experience 
 
Question Source Melanoma 
Survivors 
Controls 
What year were you first diagnosed with 
melanoma? 
American Cancer 
Society – SCS II2 
X  
Where on your body was your melanoma found? American Cancer 
Society – SCS II2 
X  
What stage was your melanoma? American Cancer 
Society – SCS II2 
X  
Please mark all treatment you received when 
your melanoma was first diagnosed? 
   Surgery to remove melanoma 
   Surgery to remove lymph nodes 
   A skin graft 
   Chemotherapy 
   Radiation treatment 
   Immunotherapy (such as Interferon, vaccines) 
American Cancer 
Society – SCS II2 
X  
Has your doctor ever told you that your 
melanoma has come back to the same part of 
your body (recurrence)? 
American Cancer 
Society – SCS II2 
X  
What year was the recurrence? American Cancer 
Society – SCS II2 - 
modified 
X  
Has your doctor ever told you that your 
melanoma has spread to another part of your 
body (metastasized)? 
American Cancer 
Society – SCS II2 
X  
What year did the melanoma spread? American Cancer 
Society – SCS II2 
X  
If your first melanoma returned or spread to 
another part of your body, which additional 
treatments have you received? 
   Surgery to remove melanoma 
   Surgery to remove lymph nodes 
   A skin graft 
   Chemotherapy 
   Radiation treatment 
   Immunotherapy (such as Interferon, vaccines) 
American Cancer 
Society – SCS II2 
X  
When you had surgery to remove lymph nodes, 
how many were removed? 
American Cancer 
Society – SCS II2 - 
modified 
X  
Did you experience swelling or lymphedema 
lasting greater than 1 month at any point after 
surgery or radiation treatment? 
NEW X  
When did your swelling or lymphedema first 
occur? 
NEW X  
How long did the swelling last? 
   Years 
   Months 
NEW X  
Where was your swelling? NEW X  
Do you still have swelling? NEW X  
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Question Source Melanoma 
Survivors 
Controls 
These questions are about the swelling that you 
have: 
   I am bothered by the amount of swelling. 
   Movement of my swollen area is painful. 
   Swelling keeps me from doing the things I want 
to do. 
   Swelling keeps me from wearing clothes or 
shoes I want to wear. 
FACT-M9 
 
X  
Have you ever received or are you currently 
receiving treatment for your swelling or 
lymphedema? 
NEW X  
What types of treatment for swelling or 
lymphedema have you received (check all that 
apply)? 
   Manual lymphatic drainage 
   Compression 
   Pump 
   Exercise 
   Other: __________________ 
 
NEW X  
How helpful have the treatments for your swelling 
or lymphedema been? 
NEW X  
Please describe how much these concerns affect 
you. 
I feel numbness at my surgical site. 
I have good range of movement in my arms and 
legs. 
 
I am more aware of physical problems or 
changes in my body since having had 
melanoma. 
New symptoms (aches, pains, getting sick) make 
me worry about the melanoma coming back.    
 
I am worried that family members may also 
develop skin cancer/melanoma. 
I feel bothered by people’s questions related to 
my melanoma. 
I am worried about the size of the scar. 
I think about how my melanoma scar affects my 
attractiveness. 
I think about how noticeable the scar is to others. 
 
I sometimes wear clothing to cover up my scar. 
 
FACT-M9 
 
 
 
Impact of 
Cancer10 
 
 
 
 
Skin Cancer 
Index11 - modified 
 
 
 
 
 
 
 
Impact of 
Cancer10 - 
modified 
 
X  
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V. Experience with Health Care System 
 
Question Source Melanoma 
Survivors 
Controls 
When you were diagnosed with melanoma, did 
the doctor tell you what the likely outcome of 
having melanoma would be? 
National Survey of 
Households Affected 
by Cancer12 
X  
Did the doctor say the melanoma could be 
cured or go into long-term remission, or didn’t 
the doctor say that? 
National Survey of 
Households Affected 
by Cancer12 
X  
Did the doctor say the melanoma was likely to 
be fatal or lead to death? 
 
National Survey of 
Households Affected 
by Cancer12 
X  
When you first found out you had melanoma, 
were you mostly optimistic or mostly 
pessimistic about surviving melanoma? 
National Survey of 
Households Affected 
by Cancer12 
X  
Please rate the doctors and other health 
professionals seen during the course of your 
melanoma surgery/treatment: 
• Knowledge and expertise in handling your 
medical issues 
• Level of compassion 
• Attention to factors outside of direct 
medical care, such as support network for 
dealing with cancer 
National Survey of 
Households Affected 
by Cancer12 
X  
When getting care for your melanoma, was 
there ever a time when 
• Your medical records or test results did not 
reach your doctor’s office in time for your 
appointment 
• You were sent for duplicate test or 
diagnostic procedures by different doctors, 
nurses or health care workers 
• You left a doctor’s office without getting 
important questions answered about your 
care or treatment? 
• You were confused about the medication 
the doctor prescribed? 
• You had to wait longer than you thought to 
find out results of medical tests? 
National Survey of 
Households Affected 
by Cancer12 
X  
Did waiting for test results produce stress and 
anxiety? 
National Survey of 
Households Affected 
by Cancer12 
X  
Did you ever have to make a decision about 
whether to undergo a treatment that would 
increase your chances of survival by only a 
small amount but could potentially lead to 
severe side effects?  
National Survey of 
Households Affected 
by Cancer12 
X  
Did you decide to undergo the treatment? National Survey of 
Households Affected 
by Cancer12 
X  
How satisfied are you with your decision? NEW X  
Before your diagnosis, how much did you know 
about melanoma? 
NEW X  
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VI. Work and Insurance 
 
Question Source Melanoma 
Survivors 
Controls 
Please indicate the one category that best 
describes your CURRENT employment 
situation. 
American Cancer 
Society – SCS II2 
X X 
During the past 12 months, about how many 
days did you miss work at a job or business 
because of illness (do not include maternity 
leave)? 
National Health 
Interview Survey13 
X X 
During the past 12 months, about how many 
days did illness keep you in bed more than half 
of the day (include days while an overnight 
patient in a hospital)? 
National Health 
Interview Survey13 
X X 
At the time you were FIRST DIAGNOSED with 
melanoma, what was your employment status? 
National Survey of 
Households Affected 
by Cancer12 
X  
At the time you were diagnosed with melanoma, 
were you offered the following benefits from 
your main employer? 
   Paid sick time 
   Paid vacation 
   Unpaid time off 
   Short-term disability coverage 
   Long-term disability coverage 
Nancy Nachreiner14 X  
Since being diagnosed with melanoma, did you 
miss any days from work because of your 
melanoma (either for treatment, rest, side-
effects of treatment)? 
Nancy Nachreiner14 X  
Approximately how many days did you miss? Nancy Nachreiner14 X  
How well did your employer treat you during 
your experience with melanoma? 
National Survey of 
Households Affected 
by Cancer12 
X  
Have any of the following happened to you 
since you were diagnosed with melanoma? 
   You were laid off or fired? 
   Your responsibilities on the job were cut? 
   You were passed over for a raise? 
   You were passed over for a promotion? 
   Your salary was reduced? 
   You were demoted? 
   You were given an easier assignment? 
   You were treated differently by people at 
work? 
   You felt supported by your employer? 
   You felt supported by your co-workers? 
   You were transferred or moved? 
   You were forced into retirement? 
   You chose retirement earlier than you had 
planned? 
American Cancer 
Society – SCS II2 
 
 
 
 
 
 
 
 
 
 
 
 
NEW 
X  
Do you currently have health insurance 
coverage? 
   Indicate the source of your health insurance 
(check all that apply). 
Nancy Nachreiner14 X X 
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During the time you were treated for melanoma, 
were you covered by health insurance for all or 
part of the time? 
   Indicate the source of your health insurance 
at the time you were treated for melanoma 
(check all that apply). 
National Survey of 
Households Affected 
by Cancer12 
X  
Do you currently have life insurance? NEW X X 
After your melanoma diagnosis, did you 
experience any of the following problems with a 
health insurance plan related to your melanoma 
treatment? 
   Plan would not pay anything for care that you 
thought was covered 
   Plan paid less than you expected for a bill 
received from a doctor, hospital, or lab 
   Reached a limit of what the insurance 
company would pay for cancer treatment 
   Turned away or unable to get specific type of 
treatment because of insurance issues 
National Survey of 
Households Affected 
by Cancer12 
X  
How much of a burden on your family were the 
costs of overall medical care related to your 
melanoma treatment? 
National Survey of 
Households Affected 
by Cancer12 
X  
Did any of the following things happen to you as 
a result of the financial cost of dealing with 
melanoma? 
   Used up all or most of your savings 
   Unable to pay for basic necessities like food, 
heat, or housing 
   Borrowed money from relatives or friends 
   Borrowed money from other sources (such as 
bank loan, mortgage on your home, against a 
retirement account) 
   Contacted by a collection agency 
   Declared bankruptcy 
   Sought the aid of a charity or public 
assistance 
   Lost your health insurance 
   Couldn’t buy health insurance because of 
having melanoma 
   Couldn’t buy life insurance because of having 
melanoma 
National Survey of 
Households Affected 
by Cancer12 
X  
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VII. Well-Being Associated with Melanoma Diagnosis 
 
Question Source Melanoma 
Survivors 
Controls 
How difficult is it for you to cope today as a 
result of melanoma diagnosis and treatment? 
Quality of Life – 
Cancer Survivors15 
X  
How good is your quality of life? Quality of Life – 
Cancer Survivors15 
X  
How much happiness do you feel? Quality of Life – 
Cancer Survivors15 
X  
Do you feel like you are in control of things in 
your life? 
Quality of Life – 
Cancer Survivors15 
X  
How satisfying is your life? Quality of Life – 
Cancer Survivors15 
X  
How is your present ability to concentrate or to 
remember things? 
Quality of Life – 
Cancer Survivors15 
X  
How useful do you feel? Quality of Life – 
Cancer Survivors15 
X  
Has your melanoma diagnosis or treatment 
caused changes in your appearance? 
Quality of Life – 
Cancer Survivors15 
X  
Has your illness or treatment caused changes in 
your self-concept (the way you see yourself)? 
Quality of Life – 
Cancer Survivors15 
X  
How serious do you consider melanoma to be? NEW X  
How distressing were the following aspects of 
your illness and treatment…  
   Initial Diagnosis 
   Melanoma treatments 
   Time since your treatment was completed 
   How much anxiety do you have? 
   How much depression do you have? 
Quality of Life – 
Cancer Survivors15 
X  
To what extent are you fearful of… 
   Future diagnostic tests 
   A second melanoma 
   Recurrence of your melanoma 
   Spreading (metastasis) of your melanoma 
 
   Children/Other Family Members getting  
   melanoma 
   Dying from melanoma 
Quality of Life – 
Cancer Survivors15 
 
 
 
 
NEW 
X  
How distressing has melanoma been for your 
family? 
Quality of Life – 
Cancer Survivors15 
X  
Is the amount of support you receive from others 
sufficient to meet your needs? 
Quality of Life – 
Cancer Survivors15 
X  
Is your continuing health care interfering with 
your personal relationships? 
Quality of Life – 
Cancer Survivors15 
X  
Is your sexuality impacted by your melanoma? Quality of Life – 
Cancer Survivors15 
X  
To what degree has your melanoma and 
treatment interfered with your employment? 
Quality of Life – 
Cancer Survivors15 
X  
To what degree has your melanoma and 
treatment interfered with your activities at 
home? 
Quality of Life – 
Cancer Survivors15 
X  
How much isolation do you feel is caused by 
your melanoma or treatment? 
Quality of Life – 
Cancer Survivors15 
X  
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Question Source Melanoma 
Survivors 
Controls 
How much financial burden have you incurred as 
a result of your melanoma and treatment? 
Quality of Life – 
Cancer Survivors15 
X  
How frustrated are you that some people do not 
understand the seriousness of a melanoma 
diagnosis? 
NEW X  
Because of melanoma, I live each day one at a 
time. 
Impact of Cancer10 X  
I feel grateful to be alive. Impact of Cancer10 X  
I feel like time in my life is limited. Impact of Cancer10 X  
I learned something about life because of having 
had melanoma. 
Impact of Cancer10 X  
Having had melanoma makes me feel unsure 
about my future. 
Impact of Cancer10 X  
I worry about my future. Impact of Cancer10 X  
I am afraid to die. Impact of Cancer10 X  
I can accept my mortality, that I am going to die 
someday. 
Impact of Cancer10 X  
I feel like time in my life is running out. Impact of Cancer10 X  
Having had melanoma has made me realize that 
time is precious. 
Impact of Cancer10 X  
Having had melanoma has strengthened my 
religious faith or my sense of spirituality. 
Impact of Cancer10 X  
I consider myself to be a cancer survivor. Impact of Cancer10 X  
I spend more time with loved ones since my 
diagnosis. 
NEW X  
 
 
VIII. Your Background 
 
Question Source Melanoma 
Survivors 
Controls 
What is your current age? Skin Health Study4 X X 
Sex Skin Health Study4 X X 
Race (select all that apply) US Census Bureau16 X X 
Ethnicity US Census Bureau16 X X 
Education Skin Health Study4 X X 
Marital Status Skin Health Study4 X X 
Annual Household Income Skin Health Study4 X X 
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Skin Health Study - Follow-up Survey
Thank you for being willing to share your experience after a melanoma diagnosis by completing our online survey. 
For a better online experience, please use a computer rather than a tablet or smart phone. 
Please use the Previous and Next buttons found at the bottom of each page instead of the back and forward arrows
on your browser. 
For each question, please give the answer that seems to best describe how you feel or what your experience has
been like. Some of the survey questions may seem the same, but they are all important to answer.
The reset button can be used to clear your answer(s) if you want to start a question over. 
If you do not finish in one sitting, you can close your browser window and come back later to where you left off. To do
this:
• Click on Save and Return Later
• You will be given a code, or password, to use upon re-entry
• Use the same web link that was included in your letter for re-entry, click on Returning in the top right corner, then
enter the code given
Study ID  This number can be found on your letter. __________________________________
Please Re-Enter Study ID __________________________________
The Study ID's did not match.  Please correct.
Date __________________________________
((Please click on the 'Now' button))
Appendix C. Online Melanoma Survivor Survey
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CONSENT FORM
INTRODUCTION
You are invited to be in a scientific research study that is being conducted by Dr. DeAnn Lazovich at the University of
Minnesota School of Public Health.  The purpose of this study is to learn more about the experiences of people with
melanoma after diagnosis compared to people without a melanoma diagnosis.  The study is funded by the University
of Minnesota.   You were selected because you previously participated in the Skin Health Study between 2004 and
2009. 
STUDY PROCEDURES
If you choose to be in the study, we will ask you to take a one-time online survey.  The survey asks about your
diagnosis and treatment, current health, health habits such as physical activity and sun protection, physical,
emotional and social well-being, employment and insurance. The survey will take between 20 and 40 minutes,
depending on your medical history.  
CONFIDENTIALITY
The records of this study will be kept private and confidential.  In any report we might publish, we will not include any
information that will make it possible to identify a participant.  Every precaution is taken to make sure that all data
are kept safe and secure.  The online survey uses a secure web interface to protect the data that you enter.  Only
researchers involved in this project will have access to these data files.  
RISKS AND BENEFITS
There are no known risks, except for possible breach of confidentiality.  However we will take every precaution to
keep your study information confidential.  Although there are no direct benefits to you from participating in this
study, the information you provide may help us learn about ways to assist persons who have been diagnosed with
melanoma.
VOLUNTARY NATURE
Your decision whether or not to participate will not affect your current or future relations with the University of
Minnesota.  If you decide to participate, you are free to withdraw at any time without affecting those relationships.
WHOM TO CONTACT
If you have any questions about the study, you may contact Dr. Lazovich or her research staff by email
(shs@umn.edu) or by phone (612 624-3056).  If you have questions or concerns regarding this study and would like
to talk to someone other than the researcher (s), you are encouraged to contact the Fairview Research Helpline at
telephone number 612-672-7692  or toll free at 866-508-6961.  You may also contact this office in writing or in
person at Fairview Research Administration, 2433 Energy Park Drive, St. Paul, MN, 55108.
Statement of consent: Check the appropriate box below 
I have read the above information.  I agree to participate in this study.
I do not agree to participate in the study.
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I. Your Health Habits
The first questions are about your physical activity, diet, body size, sun protection, alcohol and smoking habits. 
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Physical Activity Habits
Consider a typical 7-day period (a week) in the past month.
How many times on average do you do the following kinds of exercise for more than 15 minutes during your free
time and for how long per exercise session?
Strenuous activity (heart beats rapidly, heaving sweating)
Examples: running, jogging, hockey, soccer, squash, cross country skiing, judo, roller skating, vigorous swimming,
vigorous long distance bicycling, vigorous aerobic dance classes, heavy weight training.
Times per week __________________________________
(Enter times per week)
Average amount of time per session __________________________________
(Enter minutes)
Moderate activity (not exhausting, light sweating)
Examples: fast walking, baseball, tennis, easy bicycling, volleyball, badminton, easy swimming, alpine skiing, popular
and folk dancing.
Times per week __________________________________
(Enter times per week)
Average amount of time per session __________________________________
(Enter minutes)
Mild activity (minimal effort, no sweating)
 
Examples: easy walking, yoga, archery, fishing, bowling, lawn bowling, shuffleboard, horseshoes, golf, snowmobiling
Times per week __________________________________
(Enter times per week)
Average amount of time per session __________________________________
(Enter minutes)
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Diet Habits
How many days per week do you eat at least five (5) 0 days
servings of fruits and vegetables a day?   One 1 day
serving = 1 piece of fruit, half a cup of cooked 2 days
vegetables, or one cup of raw leafy vegetables. 3 days
4 days
5 days
6 days
7 days
Do you currently take a multi-vitamin? Yes No
On average, how many days per week do you take a multivitamin?
1-2 days 3-4 days 5-6 days 7 days
Do you currently take vitamin D on a regular basis,
either as part of a multi-vitamin, calcium
supplement, or as its own pill?
Yes No Don't know
On average, how many days per week do you take vitamin D?
1-2 days 3-4 days 5-6 days 7 days
What is the usual amount you take each day? Less than 400 IU
400 IU
600 IU
800 IU
1000 IU
2000 IU
Greater than 2000 IU
Other
Unknown
Usual Amount __________________________________
224
projectredcap.org
Confidential
Page 6 of 55
Body Size
How tall are you?
Feet __________________________________
(Feet)
Inches __________________________________
(Inches)
What is your current weight in pounds? __________________________________
(Pounds)
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Sun Habits
In the summer, on average, how many hours are you outside per day between 10 am and 4 pm...
on WEEKDAYS (Monday - Friday)? 0 to 30 minutes
31 minutes to 1 hour
2 hours
3 hours
4 hours
5 hours
6 hours
on WEEKEND DAYS (Saturday & Sunday)? 0 to 30 minutes
31 minutes to 1 hour
2 hours
3 hours
4 hours
5 hours
6 hours
In the past 12 months, how many times did you have a red OR painful sunburn that lasted a day or more?
0 1 2 3 4 5 or more
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Sun Habits continued
For the following questions, think about what you typically do when you are outside during the summer on a warm
sunny day.
When you are outside during the summer on a warm sunny day, how often do you wear sunscreen ?
Never Rarely Sometimes Often Always
When you are outside during the summer on a warm sunny day, how often do you wear a shirt with sleeves that
cover your shoulders?
Never Rarely Sometimes Often Always
When you are outside during the summer on a warm sunny day, how often do you wear a hat with a wide brim?
Never Rarely Sometimes Often Always
When you are outside during the summer on a warm sunny day, how often do you stay in the shade or under an
umbrella?
Never Rarely Sometimes Often Always
When you are outside during the summer on a warm sunny day, how often do you spend time in the sun in order to
get a tan?
Never Rarely Sometimes Often Always
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Sun Habits continued
In the last 12 months, have you used a tanning bed or
booth with tanning lamps?
Yes No
How many times in the last 12 months have you used a __________________________________
tanning bed or booth with tanning lamps?
In the last 12 months, have you had your skin checked
from head to toe by a health professional?
Yes No
In the last 12 months have you or a partner examined
your entire body, including your back for skin cancer?
Yes No
How many times? __________________________________
What is the color of your untanned skin? Very fair Fair Olive
Light brown Dark brown
Very dark
Since your melanoma diagnosis, have you been...
Avoiding exposure to the sun? More Same Less
Never my habit
Wearing sun-protective clothing? More
Same
Less
Never my habit
Using sunscreen? More
Same
Less
Never my habit
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Alcohol Habits
During the past 30 days, how many days per month did none
you have at least one drink of any alcoholic 1
beverage, such as beer, wine, a malt beverage or 2
liquor?  One drink is equivalent to a 12-ounce beer, 3
a 5-ounce glass of wine or a drink with one shot of 4
liquor. 5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
(days per month)
During the past 30 days, on the days when you drank, 1 drink
about how may drinks did you drink on the average? 2 drinks
3 drinks
4 drinks
5 drinks
6 drinks
7 drinks
8 drinks
9 drinks
10 drinks
11 drinks
12 drinks
more than 12
Considering all types of alcoholic beverages, how __________________________________
many times during the past 30 days did you have...  5 (times)
or more drinks on one occasion if you are a man?  4
or more drinks on one occasion if you are a woman?
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Smoking Habits
Do you currently smoke cigarettes on a regular basis? Yes No
On average, how many packs of cigarettes do you smoke Less than ½ pack
per day now? (1 pack = 20 cigarettes) ½ pack
1 pack
1 ½ packs
2 packs
more than 2 packs
Do you currently use any of the following tobacco None
products on a regular basis?   Mark all that apply. Cigars
Mark "none" if you do not use any on a regular basis. Pipe tobacco
Chewing tobacco
Dip or snuff
Other (please specify)
If Other, please describe __________________________________
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 II. Your Health and Well-Being 
The next questions ask about your general physical, emotional and social well-being. 
In general, would you say your health is:
Excellent Very good Good Fair Poor
Compared to one year ago, how would your rate your Much better now than one year ago
health in general now? Somewhat better now than one year ago
About the same as one year ago
Somewhat worse now than one year ago
Much worse now than one year ago
231
projectredcap.org
Confidential
Page 13 of 55
Your Health and Well-Being continued
The following questions are about activities that you might do during a typical day.  Does your
health now limit in these activities? If so, how much?
Yes, limited a lot Yes, limited a little Not limited at all
Vigorous activities, such as
running, lifting heavy objects,
participating in strenuous sports
Moderate activities, such as
moving a table, pushing a
vacuum cleaner, bowling, or
playing golf
Lifting or carrying groceries
Climbing several flights of stairs
Climbing one flight of stairs
Bending, kneeling, or stooping
Walking more than a mile
Walking several blocks
Walking one block
Bathing or dressing yourself
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Your Health and Well-Being continued
During the past 4 weeks, how much of the time have you had any of the following problems
with your work or other regular daily activities as a result of your physical health?
All of the time Most of the time Some of the time A little of the
time
None of the time
Cut down on the amount of time
you spent on work or other
activities
Accomplished less than you
would like
Were limited in the kind of work
or other activities
Had difficulty performing the
work or other activities (for
example, it took extra effort)
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Your Health and Well-Being continued
During the past 4 weeks, how much of the time have you had any of the following problems
with your work or other regular daily activities as a result of any emotional problems (such as
feeling depressed or anxious)?
All of the time Most of the time Some of the time A little of the
time
None of the time
Cut down on the amount of time
you spent on work or other
activities
Accomplished less than you
would like
Did work or other activities less
carefully than usual
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Your Health and Well-Being continued
During the past 4 weeks, to what extent has your physical health or emotional problems interfered with your normal
social activities with family, friends, neighbors, or groups?
Not at all Slightly Moderately Quite a bit Extremely
How much bodily pain have you had during the past 4 weeks?
None Very mild Mild Moderate Severe Very severe
During the past 4 weeks, how much did pain interfere with your normal work (including both work outside the home
and housework)?
Not at all A little bit Moderately Quite a bit Extremely
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Your Health and Well-Being continued These next few questions are about how you feel and
how things have been with you during the past 4 weeks. For each question, please give the
one answer that comes closest to the way you have been feeling. How much of the time during
the past 4 weeks...
All of the time Most of the time Some of the time A little of the
time
None of the time
Did you feel full of life?
Have you been very nervous?
Have you felt so down in the
dumps that nothing could cheer
you up?
Have you felt calm and
peaceful?Did you have a lot of energy?
Have you felt downhearted and
depressed?
Did you feel worn out?
Have you been happy?
Did you feel tired?
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Your Health and Well-Being continued
During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your
social activities (like visiting with friends, relatives, etc.)?
All of the time Most of the time Some of the time A little of the time None of the time
237
projectredcap.org
Confidential
Page 19 of 55
Your Health and Well-Being continued
How TRUE or FALSE is each of the following statements for you?
Definitely true Mostly true Don't know Mostly false Definitely false
I seem to get sick a little easier
than other people
I am as healthy as anybody I
know
I expect my health to get worse
My health is excellent
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Emotional Well-Being 
The next set of questions will ask you about your emotional well-being.
I feel tense or 'wound up':
Most of the time A lot of the time From time to time, occasionally Not at all
I still enjoy the things I used to enjoy:
Definitely as much Not quite as much Only a little Hardly at all
I get a sort of frightened feeling as if something awful is about to happen:
Very definitely and quite badly Yes, but not too badly A little, but it doesn't worry me
Not at all
I can laugh and see the funny side of things:
As much as I always could Not quite so much now Definitely not so much now
Not at all
Worry thoughts go through my mind:
A great deal of the time A lot of the time From time to time, but not too often
Only occasionally
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 Emotional Well-Being continued
I feel cheerful:
Not at all Not often Sometimes Most of the time
I can sit at ease and feel relaxed:
Definitely Usually Not often Not at all
I feel restless as if I have to be on the move:
Very much indeed Quite a lot Not very much Not at all
I look forward with enjoyment to things:
As much as I ever did Rather less than I used to Definitely less than I used to
Hardly at all
I get sudden feelings of panic:
Very often indeed Quite often Not very often Not at all
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 Emotional Well-Being continued
I can enjoy a good book or radio or TV program:
Often Sometimes Not often Very seldom
I feel as if I am slowed down:
Nearly all the time Very often Sometimes Not at all
I get a sort of frightened feeling like 'butterflies' in the stomach:
Not at all Occasionally Quite often Very often
I have lost interest in my appearance: Definitely
I don't take as much care as I should
I may not take quite as much care
I take just as much care as ever
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III. Health Conditions
Has a medical doctor or healthcare professional ever told you that you have any of the following?
Heart Problems, such as a heart attack, coronary
artery disease, congestive heart failure, irregular
heartbeat, etc.
Yes No
Hypertension (high blood pressure) Yes No
Chronic back pain, including sciatica (pain or
numbness that travels down your leg to below your
knees)
Yes No
Arthritis Yes No
Stroke, including mini-stroke or blood clots in the
brain
Yes No
Severe problems with memory or concentration Yes No
Asthma, emphysema, or COPD (Chronic Obstructive
Pulmonary Disease)
Yes No
Stomach and/or intestinal problems, such as Crohn's
disease, ulcers, or inflammatory bowel disease
Yes No
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 Health Conditions continued
Has a medical doctor or healthcare professional ever told you that you have any of the following?
Diabetes, high blood sugar, or sugar in urine Yes No
Depression (feeling sad or blue) that resulted in
treatment with medication and/or counseling
Yes No
Anxiety or "nervousness" that resulted in treatment
with medication and/or counseling
Yes No
Neuropathy (numbness in both hands or both feet) Yes No
Cancer other than melanoma Yes No
Please describe __________________________________
Other health condition(s) Yes No
Please describe __________________________________
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 Health Conditions continued
Have any of the following members of your family been diagnosed with melanoma?
Parents Yes No Not applicable
Grandparents Yes No Not applicable
Brothers Yes No Not applicable
Sisters Yes No Not applicable
Children Yes No Not applicable
Grandchildren Yes No Not applicable
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IV. Cancer Experience
The next questions are about your experience after diagnosis with your FIRST (or only) melanoma. 
What year were you first diagnosed with melanoma? __________________________________
(Enter year)
Where on your body was your melanoma found?
Head or neck Trunk Arms Legs
What stage was your melanoma? I II III IV
Don't know
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Cancer Experience continued
Please mark all treatments you received when your melanoma was first diagnosed:
Surgery to remove melanoma Yes No Don't know
Surgery to remove lymph nodes Yes No Don't know
A skin graft Yes No Don't know
Chemotherapy Yes No Don't know
Radiation treatment Yes No Don't know
Immunotherapy (such as Interferon, vaccines) Yes No Don't know
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Cancer Experience continued
Has your doctor ever told you that your melanoma has
come back to the same part of your body (recurrence)?
Yes No
What year was the recurrence? __________________________________
(Enter year)
Has your doctor ever told you that your melanoma has
spread to another part of your body (metastasized)?
Yes No
What year did the melanoma spread? __________________________________
(Enter year)
If your first melanoma returned or spread to another part of your body, please mark all additional treatments you
have received.
Surgery to remove melanoma Yes No
Surgery to remove lymph nodes Yes No
A skin graft Yes No
Chemotherapy Yes No
Radiation treatment Yes No
Immunotherapy (such as Interferon, vaccines) Yes No
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Cancer Experience continued
When you had surgery to remove lymph nodes, how many
were removed?
1-4 5-9 10-14
15+ Don't Know
Did you experience swelling or lymphedema lasting
greater than 1 month at any point after surgery or
radiation treatment?
Yes No Don't Know
When did your swelling or lymphedema FIRST occur? Following treatment of your first melanoma
Following treatment of melanoma that
returned to same part of your body
Following treatment of melanoma that
spread to other parts of your body
How long did the swelling last?
Years __________________________________
(Enter number of years or 0 if less than 1 year)
Months __________________________________
(Enter number of months)
Where on your body was your swelling? __________________________________
(Write in body location)
Have you received or are currently receiving
treatment to PREVENT swelling or lymphedema following
your surgery or radiation treatment?
Yes No Don't know
When did you first begin treatment to prevent Following treatment of your first melanoma
swelling or lymphedema? Following treatment of melanoma that returned to
same part of your body
Following treatment of melanoma that spread to
other parts of your body
How long did or have the treatments lasted? 
Years __________________________________
(Enter number of years or 0 if less than 1 year)
Months __________________________________
(Enter number of months)
What part of your body was treated? __________________________________
(Write in body location)
248
projectredcap.org
Confidential
Page 30 of 55
Cancer Experience continued
Do you still have swelling? Yes No
These questions are about the swelling that you have.
I am bothered by the amount of swelling.
Not at all A little bit Somewhat Quite a bit Very Much
Movement of my swollen area is painful.
Not at all A little bit Somewhat Quite a bit Very Much
Swelling keeps me from doing the things I want to do.
Not at all A little bit Somewhat Quite a bit Very Much
Swelling keeps me from wearing clothes or shoes I want to wear.
Not at all A little bit Somewhat Quite a bit Very Much
Have you received or are you currently receiving
treatment for your swelling or lymphedema?
Yes No
What types of treatment for swelling or lymphedema Manual lymphatic drainage
have you received? (mark all that apply) Compression
Pump
Exercise
Other
Please describe other treatment __________________________________
How helpful have the treatments for your swelling or lymphedema been?
Very helpful Somewhat helpful A little helpful Not at all helpful
What types of treatment for prevention of swelling or Manual lymphatic drainage
lymphedema have you received? (mark all that apply) Compression
Pump
Exercise
Other
Please describe other treatment __________________________________
How helpful have the treatments been for preventing swelling or lymphedema?
Very helpful Somewhat helpful A little helpful Not at all helpful
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Cancer Experience continued
Please describe how much these concerns affect you.
Not at all A little bit Somewhat Quite a bit Very Much
I feel numbness at my surgical
site.
I have good range of movement
in my arms and legs.
I am more aware of physical
problems or changes in my body
since having had melanoma.
New symptoms (aches, pains,
getting sick) make me worry
about the melanoma coming
back.
I am worried that family
members may also develop skin
cancer/melanoma.
I feel bothered by people's
questions related to my
melanoma.
I am worried about the size of
the scar.
I think about how my melanoma
scar affects my attractiveness.
I think about how noticeable the
scar is to others.
I sometimes wear clothing to
cover up my scar.
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V. Experience with Health Care System
These questions ask about your experience with the health care professionals who took care of you at the time you
were first diagnosed with melanoma. 
When you were first diagnosed with melanoma, did the
doctor tell you what the likely outcome of having
melanoma would be?
Yes No Don't know
Did the doctor say the melanoma could be cured or go
into long-term remission?
Yes No Don't know
Did the doctor say the melanoma was likely to be
fatal or lead to death?
Yes No Don't know
When you first found out you had melanoma, were you mostly optimistic or mostly pessimistic about surviving
melanoma?
Mostly optimistic Mostly pessimistic Don't know
Before your diagnosis, how much did you know about melanoma?
Nothing Very little Some Quite a bit A lot
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Experience with Health Care System continued
Please rate the doctors and other health professionals seen during the course of your treatment:
Knowledge and expertise in handling your medical
issues
Excellent Good Fair
Poor
Level of compassion Excellent Good Fair
Poor
Attention to factors outside of direct medical care,
such as support network for dealing with melanoma
Excellent Good Fair
Poor
During the course of your first melanoma treatment,
did you receive conflicting information about
melanoma from different doctors or health care
professionals?
Yes No Don't know
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Experience with Health Care System continued
When getting care for your melanoma, was there ever a time when...
Your medical records or test results did not reach
your doctor's office in time for your appointment?
Yes No Not applicable
You were sent for duplicate test or diagnostic
procedures by different doctors, nurses or health
care workers?
Yes No
You left a doctor's office without getting important
questions answered about your care or treatment?
Yes No
You were confused about the medication the doctor
prescribed?
Yes No Not applicable
You had to wait longer than you thought you should to
find out results of medical tests?
Yes No
Did waiting for test results produce stress and
anxiety?
Yes, a lot Just some
No
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Experience with Health Care System continued
Did you ever have to make a decision about whether to
undergo a treatment that would increase your chances
of survival by only a small amount but could
potentially lead to severe side effects?
Yes No Don't know
Did you decide to undergo the treatment? Yes No Don't know
How satisfied are you with your decision?
Not at all A little bit Somewhat Quite a bit Very Much
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VI. Work and Insurance
The next questions are about work and insurance. 
What is your CURRENT employment status?   If more Paid full-time employment
than one category applies, please choose the one that Paid part-time employment
best describes your current employment status. Self-employed
Volunteer
Homemaker
Unemployed, looking for work
Unemployed, not looking for work
Not employed - disabled
Retired, not working
Student, not working
During the past 12 months, about how many days did __________________________________
you miss work at your job or business because of (days)
illness (do not include maternity leave)?
During the past 12 months, about how many days did __________________________________
illness keep you in bed more than half of the day (days)
(include days while an overnight patient in a
hospital)?
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Work and Insurance continued
At the time you were FIRST DIAGNOSED with melanoma, Paid full-time employment
what was your employment status?  If more than one Paid part-time employment
category applies, please choose the one that best Self-employed
describes your employment status when you were first Volunteer
diagnosed. Homemaker
Unemployed, looking for work
Unemployed, not looking for work
Not employed - disabled
Retired, not working
Student, not working
At the time you were diagnosed with melanoma, were you offered the following benefits from your main employer?
(or yourself if self-employed)
Paid sick time Yes No Not Applicable
Paid vacation Yes No Not Applicable
Unpaid time off Yes No Not Applicable
Short-term disability coverage Yes No Not Applicable
Long-term disability coverage Yes No Not Applicable
Since being diagnosed with melanoma, did you miss any
days from work because of your melanoma (either for
treatment, rest, side-effects of treatment)?
Yes No
Approximately how many days did you miss? __________________________________
(days)
How well did your employer treat you during your experience with melanoma?
Very well Somewhat well Not too well Not well at all
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Work and Insurance continued
Have any of the following things happened to you since you were diagnosed with melanoma?
You were laid off or fired? Yes No Not Applicable
Your responsibilities on the job were cut? Yes No Not Applicable
You were passed over for a raise? Yes No Not Applicable
You were passed over for a promotion? Yes No Not Applicable
Your salary was reduced? Yes No Not Applicable
You were demoted? Yes No Not Applicable
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Work and Insurance continued
Have any of the following things happened to you since you were diagnosed with melanoma?
You were given an easier assignment? Yes No Not Applicable
You were treated differently by people at work? Yes No Not Applicable
You felt supported by your employer? Yes No Not Applicable
You felt supported by your co-workers? Yes No Not Applicable
You were transferred or moved? Yes No Not Applicable
You were forced into retirement? Yes No Not Applicable
You chose to retire earlier than you had planned? Yes No Not Applicable
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Work and Insurance continued
Do you currently have health insurance coverage? Yes No
Indicate the source of your health insurance (check Your current or former employer
all that apply). A policy you purchased directly (not through your
employer or union)
Your union
Military (Tricare, Tristar, Champus)
Spouse/Partner's employer
Another family member's health plan (not
spouse/partner)
Medicare
Medicaid
Other (specify)
Other Insurance: Please describe __________________________________
Do you have a life insurance policy? Yes No Unsure
During the time you were treated for melanoma, were
you covered by health insurance for all or part of
the time?
Yes No
Indicate the source of your health insurance at the Your current or former employer
time you were treated for melanoma (check all that A policy you purchased directly (not through your
apply). employer or union)
Your union
Military (Tricare, Tristar, Champus)
Spouse/Partner's employer
Another family member's health plan (not
spouse/partner)
Medicare
Medicaid
Other (specify)
Other Insurance: Please describe __________________________________
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Work and Insurance continued
After your melanoma diagnosis, did you experience any of the following problems with a health insurance plan
related to your melanoma treatment?
Plan would not pay anything for care that you thought
was covered
Yes No
Plan paid less than you expected for a bill received
from a doctor, hospital or lab
Yes No
Reached a limit of what the insurance company would
pay for cancer treatment
Yes No
Turned away or unable to get specific type of
treatment because of insurance issues
Yes No
How much of a burden on your family were the costs of overall medical care related to your melanoma treatment?
A major burden A minor burden Not a burden at all
How much distress did you experience from dealing
with insurance and/or billing for your melanoma care?
A lot Some Very little
None
Did any of the following things happen to you as a result of the financial cost of dealing with melanoma?
Used up all or most of your savings Yes No Not Applicable
Unable to pay for basic necessities like food, heat,
or housing
Yes No
Borrowed money from relatives or friends Yes No
Borrowed money from other sources (such as bank loan,
mortgage on your home, a retirement account)
Yes No
Contacted by a collection agency Yes No
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Work and Insurance continued
Did any of the following things happen to you as a result of the financial cost of dealing with melanoma?
Declared bankruptcy Yes No
Sought the aid of a charity or public assistance Yes No
Lost your health insurance Yes No Not Applicable
Couldn't buy health insurance because of having
melanoma
Yes No Not Applicable
Couldn't buy life insurance because of having melanoma Yes No Not Applicable
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VII. Well-Being Associated with Melanoma Diagnosis
These next questions are about your emotional well-being after a melanoma diagnosis. 
How difficult is it for you to cope today as a result Not at all
of your melanoma diagnosis and treatment? difficult Very difficult
(Place a mark on the scale above)           
How good is your quality of life? Extremely poor Excellent
(Place a mark on the scale above)           
How much happiness do you feel? None at all A great deal
(Place a mark on the scale above)           
Do you feel like you are in control of things in your
life? Not at all Completely
(Place a mark on the scale above)           
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Well-Being after Melanoma continued
How satisfying is your life? Not at all Completely
(Place a mark on the scale above)           
How is your present ability to concentrate or to
remember things? Extremely poor Excellent
(Place a mark on the scale above)           
How useful do you feel? Not at all Extremely
(Place a mark on the scale above)           
Has your melanoma diagnosis or treatment caused
changes in your appearance? Not at all Extremely
(Place a mark on the scale above)           
Has your illness or treatment caused changes in your
self-concept (the way you see yourself)? Not at all Extremely
(Place a mark on the scale above)           
How serious do you consider melanoma to be? Not at all Extremely
(Place a mark on the scale above)           
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Well-Being after Melanoma continued
How distressing were the following aspects of your melanoma diagnosis and treatment?
Initial diagnosis Not at all Very
(Place a mark on the scale above)           
Melanoma treatments Not at all Very
(Place a mark on the scale above)           
Time since your treatment was completed Not at all Very
(Place a mark on the scale above)           
How much anxiety do you have? Not at all A great deal
(Place a mark on the scale above)           
How much depression do you have? Not at all A great deal
(Place a mark on the scale above)           
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Well-Being after Melanoma continued
To what extent are you fearful of:
Future diagnostic tests No fear Extreme fear
(Place a mark on the scale above)           
A second melanoma No fear Extreme fear
(Place a mark on the scale above)           
Recurrence of your melanoma No fear Extreme fear
(Place a mark on the scale above)           
Spreading (metastasis) of your melanoma No fear Extreme fear
(Place a mark on the scale above)           
Dying from melanoma No fear Extreme fear
(Place a mark on the scale above)           
Children/Other Family Members getting melanoma No fear Extreme fear
(Place a mark on the scale above)           
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Well-Being after Melanoma continued
How much has your melanoma diagnosis affected your Not at all
consideration of having children or having more A little bit
children? Somewhat
Quite a bit
Very Much
Not Applicable
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Well-Being after Melanoma continued
These next questions are about your social well-being.
How distressing has melanoma been for your family? Not at all A great deal
(Place a mark on the scale above)           
Is the amount of support you receive from others
sufficient to meet your needs? Not at all A great deal
(Place a mark on the scale above)           
Is your continuing health care interfering with your
personal relationships? Not at all A great deal
(Place a mark on the scale above)           
Is your sexuality impacted by your melanoma? Not at all A great deal
(Place a mark on the scale above)           
How comfortable are you talking with others about Not at all
your melanoma? comfortable Very comfortable
(Place a mark on the scale above)           
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Well-Being after Melanoma continued
To what degree has your melanoma and treatment
interfered with your employment? No problem Severe problem
(Place a mark on the scale above)           
To what degree has your melanoma and treatment
interfered with your activities at home? No problem Severe problem
(Place a mark on the scale above)           
How much isolation do you feel is caused by your
melanoma or treatment? Not at all A great deal
(Place a mark on the scale above)           
How much financial burden have you incurred as a
result of your melanoma and treatment? Not at all A great deal
(Place a mark on the scale above)           
How frustrated are you that some people do not
understand the seriousness of a melanoma diagnosis? Not at all A great deal
(Place a mark on the scale above)           
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Well-Being after Melanoma continued
Please tell us about the impact of a melanoma diagnosis on your life. 
Strongly
Disagree
Disagree Neutral Agree Strongly Agree
Because of melanoma, I live
each day one at a time.
I feel grateful to be alive.
I feel like time in my life is
limited.I learned something about life
because of having had
melanoma.
Having had melanoma makes
me feel unsure about my future.
I worry about my future.
I am afraid to die.
269
projectredcap.org
Confidential
Page 51 of 55
Well-Being after Melanoma contiued
Strongly
Disagree
Disagree Neutral Agree Strongly Agree
I can accept my mortality, that I
am going to die someday.
I feel like time in my life is
running out.
Having had melanoma has made
me realize that time is precious.
Having had melanoma has
strengthened my religious faith
or my sense of spirituality.
I consider myself to be a cancer
survivor.
I spend more time with loved
ones since my diagnosis.
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VIII. Your Background
Please tell us about yourself. 
What is your current age? __________________________________
What is your sex? Male Female
What is your race? (1 or more categories may be White
selected) Black or African American
American Indian or Alaska Native
Asian Indian
Chinese
Filipino
Japanese
Korean
Vietnamese
Other Asian
Native Hawaiian
Guamanian or Chamorro
Samoan
Other Pacific Islander
((check all that apply))
Are you Hispanic, Latino/a, or of Spanish origin? (1 No, not of Hispanic, Latino/a, Spanish origin
or more categories may be selected) Yes, Mexican, Mexican American, Chicano/a
Yes, Puerto Rican
Yes, Cuban origin
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Your Background continued
What is the highest level of schooling you have Less than high school
completed? High school graduate
Vocational or business school or AA degree
Some college
College or university graduate (bachelors degree)
Graduate or professional training (graduate degree)
What is your marital status? Never married
Married / Partnered
Widowed
Divorced
What is your annual household income? Less than $20,000
$20,000 to $49,999
$50,000 to $74,999
$75,000 to $99,999
$100,000 to $149,999
$150,000 to $199,999
$200,000 or more
Prefer not to say
If you have any other comments for us about your
experience with melanoma, please share them in the
box provided. __________________________________
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Future Research
We are interested in conducting new research about melanoma that builds on the information that you have so
generously shared with us.   Below, we ask for your permission to continue to work with us on melanoma research. 
You may agree to none, one, two or all three of our requests.  Thank you for your consideration!
1.  Request to allow us to send you information on a new research project:   We are asking for your permission to
send you information on a new research project that involves collection of records related to your melanoma
treatment and a sample of your melanoma tumor.  If you agree, we will mail you additional information about the
project and you can make a final decision at that time.   If you mark 'yes', we will mail you additional information. 
You can make a final decision at that time.
Yes, I would consider this, please send me the additional information.
No.  Please do not contact me in the future.
2.  Request your permission to collect information from the State Cancer Registry:  To learn more about the effect of
melanoma on your current or future health, would you be willing to give us permission to get information about your
cancer diagnosis (or diagnoses) that is contained in the state cancer registry?
Yes, I give my permission.
No, I prefer not to participate.
3.  Request permission to contact you in the future:  Would you give us permission to contact you in the future for
new research projects?  And if yes, could you provide the name of a contact person who will know of your
whereabouts in the event that you move? 
Yes, I give my permission.
No.  Please do not contact me in the future.
My contact information:
E-Mail Address __________________________________
Telephone Number __________________________________
Alternative person you may contact:
Name __________________________________
Relationship __________________________________
Street Adress __________________________________
City __________________________________
Zip Code __________________________________
E-Mail Address __________________________________
Telephone Number __________________________________
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You have completed the survey.  Thank you very much for participating in our study.
Please click "submit" as the final step.
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Skin Health Study - Follow-up Survey
Thank you for being willing to share your experience by completing our online survey. 
For a better online experience, please use a computer rather than a tablet or smart phone. 
Please use the Previous and Next buttons found at the bottom of each page instead of the back and forward arrows
on your browser. 
For each question, please give the answer that seems to best describe how you feel or what your experience has
been like. Some of the survey questions may seem the same, but they are all important to answer.
The reset button can be used to clear your answer(s) if you want to start a question over. 
If you do not finish in one sitting, you can close your browser window and come back later to where you left off. To do
this:
• Click on Save and Return Later
• You will be given a code, or password, to use upon re-entry
• Use the same web link that was included in your letter for re-entry, click on Returning in the top right corner, then
enter the code given
Study ID  This number can be found on your letter. __________________________________
Please Re-Enter Study ID __________________________________
The Study ID's did not match.  Please correct.
Date __________________________________
((Please click on the 'Now' button))
Appendix D. Online Control Survey
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CONSENT FORM
INTRODUCTION
You are invited to be in a scientific research study that is being conducted by Dr. DeAnn Lazovich at the University of
Minnesota School of Public Health.  The purpose of this study is to learn more about the experiences of people with
melanoma after diagnosis compared to people without a melanoma diagnosis.  The study is funded by the University
of Minnesota.   You were selected because you previously participated in the Skin Health Study between 2004 and
2009. 
STUDY PROCEDURES
If you choose to be in the study, we will ask you to take a one-time online survey.  The survey asks about your
current health, health habits such as physical activity and sun protection, physical, emotional and social well-being,
employment and insurance. The survey will take between 15 and 25 minutes.
CONFIDENTIALITY
The records of this study will be kept private and confidential.  In any report we might publish, we will not include any
information that will make it possible to identify a participant.  Every precaution is taken to make sure that all data
are kept safe and secure.  The online survey uses a secure web interface to protect the data that you enter.  Only
researchers involved in this project will have access to these data files.  
RISKS AND BENEFITS
There are no known risks, except for possible breach of confidentiality.  However we will take every precaution to
keep your study information confidential.  Although there are no direct benefits to you from participating in this
study, the information you provide may help us learn about ways to assist persons who have been diagnosed with
melanoma.
VOLUNTARY NATURE
Your decision whether or not to participate will not affect your current or future relations with the University of
Minnesota.  If you decide to participate, you are free to withdraw at any time without affecting those relationships.
WHOM TO CONTACT
If you have any questions about the study, you may contact Dr. Lazovich or her research staff by email
(shs@umn.edu) or by phone (612 624-3056).  If you have questions or concerns regarding this study and would like
to talk to someone other than the researcher (s), you are encouraged to contact the Fairview Research Helpline at
telephone number 612-672-7692  or toll free at 866-508-6961.  You may also contact this office in writing or in
person at Fairview Research Administration, 2433 Energy Park Drive, St. Paul, MN, 55108. 
Statement of consent: Check the appropriate box below 
I have read and understood the above information.  I agree to participate in this study.
I do not agree to participate in the study.
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I. Your Health Habits
The first questions are about your physical activity, diet, body size, sun protection, alcohol and smoking habits. 
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Physical Activity Habits
Consider a typical 7-day period (a week) in the past month.
How many times on average do you do the following kinds of exercise for more than 15 minutes during your free
time and for how long per exercise session?
Strenuous activity (heart beats rapidly, heaving sweating)
Examples: running, jogging, hockey, soccer, squash, cross country skiing, judo, roller skating, vigorous swimming,
vigorous long distance bicycling, vigorous aerobic dance classes, heavy weight training.
Times per week __________________________________
(Enter times per week)
Average amount of time per session __________________________________
(Enter minutes)
Moderate activity (not exhausting, light sweating)
Examples: fast walking, baseball, tennis, easy bicycling, volleyball, badminton, easy swimming, alpine skiing, popular
and folk dancing.
Times per week __________________________________
(Enter times per week)
Average amount of time per session __________________________________
(Enter minutes)
Mild activity (minimal effort, no sweating)
 
Examples: easy walking, yoga, archery, fishing, bowling, lawn bowling, shuffleboard, horseshoes, golf, snowmobiling
Times per week __________________________________
(Enter times per week)
Average amount of time per session __________________________________
(Enter minutes)
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Diet Habits
How many days per week do you eat at least five (5) 0 days
servings of fruits and vegetables a day?   One 1 day
serving = 1 piece of fruit, half a cup of cooked 2 days
vegetables, or one cup of raw leafy vegetables. 3 days
4 days
5 days
6 days
7 days
Do you currently take a multi-vitamin? Yes No
On average, how many days per week do you take a multi-vitamin?
1-2 days 3-4 days 5-6 days 7 days
Do you currently take vitamin D on a regular basis,
either as part of a multi-vitamin, calcium
supplement, or as its own pill?
Yes No Don't know
On average, how many days per week do you take vitamin D?
1-2 days 3-4 days 5-6 days 7 days
What is the usual amount you take each day? Less than 400 IU
400 IU
600 IU
800 IU
1000 IU
2000 IU
Greater than 2000 IU
Other
Unknown
Usual Amount __________________________________
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Body Size
How tall are you?
Feet __________________________________
(Feet)
Inches __________________________________
(Inches)
What is your current weight in pounds? __________________________________
(Pounds)
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Sun Habits
In the summer, on average, how many hours are you outside per day between 10 am and 4 pm...
on WEEKDAYS (Monday - Friday)? 0 to 30 minutes
31 minutes to 1 hour
2 hours
3 hours
4 hours
5 hours
6 hours
on WEEKEND DAYS (Saturday & Sunday)? 0 to 30 minutes
31 minutes to 1 hour
2 hours
3 hours
4 hours
5 hours
6 hours
In the past 12 months, how many times did you have a red OR painful sunburn that lasted a day or more?
0 1 2 3 4 5 or more
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Sun Habits continued
For the following questions, think about what you typically do when you are outside during the summer on a warm
sunny day.
When you are outside during the summer on a warm sunny day, how often do you wear sunscreen ?
Never Rarely Sometimes Often Always
When you are outside during the summer on a warm sunny day, how often do you wear a shirt with sleeves that
cover your shoulders?
Never Rarely Sometimes Often Always
When you are outside during the summer on a warm sunny day, how often do you wear a hat with a wide brim?
Never Rarely Sometimes Often Always
When you are outside during the summer on a warm sunny day, how often do you stay in the shade or under an
umbrella?
Never Rarely Sometimes Often Always
When you are outside during the summer on a warm sunny day, how often do you spend time in the sun in order to
get a tan?
Never Rarely Sometimes Often Always
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Sun Habits continued
In the last 12 months, have you used a tanning bed or
booth with tanning lamps?
Yes No
How many times in the last 12 months have you used a __________________________________
tanning bed or booth with tanning lamps?
In the last 12 months, have you had your skin checked
from head to toe by a health professional?
Yes No
In the last 12 months have you or a partner examined
your entire body, including your back for skin cancer?
Yes No
How many times? __________________________________
What is the color of your untanned skin? Very fair Fair Olive
Light brown Dark brown
Very dark
283
projectredcap.org
Confidential
Page 10 of 31
Alcohol Habits
During the past 30 days, how many days per month did none
you have at least one drink of any alcoholic 1
beverage, such as beer, wine, a malt beverage or 2
liquor?  One drink is equivalent to a 12-ounce beer, 3
a 5-ounce glass of wine or a drink with one shot of 4
liquor. 5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
(days per month)
During the past 30 days, on the days when you drank, 1 drink
about how may drinks did you drink on the average? 2 drinks
3 drinks
4 drinks
5 drinks
6 drinks
7 drinks
8 drinks
9 drinks
10 drinks
11 drinks
12 drinks
more than 12
Considering all types of alcoholic beverages, how __________________________________
many times during the past 30 days did you have...  5 (times)
or more drinks on one occasion if you are a man?  4
or more drinks on one occasion if you are a woman?
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Smoking Habits
Do you currently smoke cigarettes on a regular basis? Yes No
On average, how many packs of cigarettes do you smoke Less than ½ pack
per day now? (1 pack = 20 cigarettes) ½ pack
1 pack
1 ½ packs
2 packs
more than 2 packs
Do you currently use any of the following tobacco None
products on a regular basis?   Mark all that apply. Cigars
Mark "none" if you do not use any on a regular basis. Pipe tobacco
Chewing tobacco
Dip or snuff
Other (please specify)
If Other, please describe __________________________________
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II. Your Health and Well-Being
The next questions ask about your general physical, emotional and social well-being. 
In general, would you say your health is:
Excellent Very good Good Fair Poor
Compared to one year ago, how would your rate your Much better now than one year ago
health in general now? Somewhat better now than one year ago
About the same as one year ago
Somewhat worse now than one year ago
Much worse now than one year ago
286
projectredcap.org
Confidential
Page 13 of 31
Your Health and Well-Being continued
The following questions are about activities that you might do during a typical day.  Does your
health now limit in these activities? If so, how much?
Yes, limited a lot Yes, limited a little Not limited at all
Vigorous activities, such as
running, lifting heavy objects,
participating in strenuous sports
Moderate activities, such as
moving a table, pushing a
vacuum cleaner, bowling, or
playing golf
Lifting or carrying groceries
Climbing several flights of stairs
Climbing one flight of stairs
Bending, kneeling, or stooping
Walking more than a mile
Walking several blocks
Walking one block
Bathing or dressing yourself
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Your Health and Well-Being continued
During the past 4 weeks, how much of the time have you had any of the following problems
with your work or other regular daily activities as a result of your physical health?
All of the time Most of the time Some of the time A little of the
time
None of the time
Cut down on the amount of time
you spent on work or other
activities
Accomplished less than you
would like
Were limited in the kind of work
or other activities
Had difficulty performing the
work or other activities (for
example, it took extra effort)
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Your Health and Well-Being continued
During the past 4 weeks, how much of the time have you had any of the following problems
with your work or other regular daily activities as a result of any emotional problems (such as
feeling depressed or anxious)?
All of the time Most of the time Some of the time A little of the
time
None of the time
Cut down on the amount of time
you spent on work or other
activities
Accomplished less than you
would like
Did work or other activities less
carefully than usual
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Your Health and Well-Being continued
During the past 4 weeks, to what extent has your physical health or emotional problems interfered with your normal
social activities with family, friends, neighbors, or groups?
Not at all Slightly Moderately Quite a bit Extremely
How much bodily pain have you had during the past 4 weeks?
None Very mild Mild Moderate Severe Very severe
During the past 4 weeks, how much did pain interfere with your normal work (including both work outside the home
and housework)?
Not at all A little bit Moderately Quite a bit Extremely
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Your Health and Well-Being continued These next few questions are about how you feel and
how things have been with you during the past 4 weeks. For each question, please give the
one answer that comes closest to the way you have been feeling. How much of the time during
the past 4 weeks...
All of the time Most of the time Some of the time A little of the
time
None of the time
Did you feel full of life?
Have you been very nervous?
Have you felt so down in the
dumps that nothing could cheer
you up?
Have you felt calm and
peaceful?Did you have a lot of energy?
Have you felt downhearted and
depressed?
Did you feel worn out?
Have you been happy?
Did you feel tired?
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Your Health and Well-Being continued
During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your
social activities (like visiting with friends, relatives, etc.)?
All of the time Most of the time Some of the time A little of the time None of the time
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Your Health and Well-Being continued
How TRUE or FALSE is each of the following statements for you?
Definitely true Mostly true Don't know Mostly false Definitely false
I seem to get sick a little easier
than other people
I am as healthy as anybody I
know
I expect my health to get worse
My health is excellent
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Emotional Well-Being 
The next set of questions will ask you about your emotional well-being.
I feel tense or 'wound up':
Most of the time A lot of the time From time to time, occasionally Not at all
I still enjoy the things I used to enjoy:
Definitely as much Not quite as much Only a little Hardly at all
I get a sort of frightened feeling as if something awful is about to happen:
Very definitely and quite badly Yes, but not too badly A little, but it doesn't worry me
Not at all
I can laugh and see the funny side of things:
As much as I always could Not quite so much now Definitely not so much now
Not at all
Worry thoughts go through my mind:
A great deal of the time A lot of the time From time to time, but not too often
Only occasionally
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 Emotional Well-Being continued
I feel cheerful:
Not at all Not often Sometimes Most of the time
I can sit at ease and feel relaxed:
Definitely Usually Not often Not at all
I feel restless as if I have to be on the move:
Very much indeed Quite a lot Not very much Not at all
I look forward with enjoyment to things:
As much as I ever did Rather less than I used to Definitely less than I used to
Hardly at all
I get sudden feelings of panic:
Very often indeed Quite often Not very often Not at all
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 Emotional Well-Being continued
I can enjoy a good book or radio or TV program:
Often Sometimes Not often Very seldom
I feel as if I am slowed down:
Nearly all the time Very often Sometimes Not at all
I get a sort of frightened feeling like 'butterflies' in the stomach:
Not at all Occasionally Quite often Very often
I have lost interest in my appearance: Definitely
I don't take as much care as I should
I may not take quite as much care
I take just as much care as ever
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III. Health Conditions
Has a medical doctor or healthcare professional ever told you that you have any of the following?
Heart Problems, such as a heart attack, coronary
artery disease, congestive heart failure, irregular
heartbeat, etc.
Yes No
Hypertension (high blood pressure) Yes No
Chronic back pain, including sciatica (pain or
numbness that travels down your leg to below your
knees)
Yes No
Arthritis Yes No
Stroke, including mini-stroke or blood clots in the
brain
Yes No
Severe problems with memory or concentration Yes No
Asthma, emphysema, or COPD (Chronic Obstructive
Pulmonary Disease)
Yes No
Stomach and/or intestinal problems, such as Crohn's
disease, ulcers, or inflammatory bowel disease
Yes No
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 Health Conditions continued
Has a medical doctor or healthcare professional ever told you that you have any of the following?
Diabetes, high blood sugar, or sugar in urine Yes No
Depression (feeling sad or blue) that resulted in
treatment with medication and/or counseling
Yes No
Anxiety or "nervousness" that resulted in treatment
with medication and/or counseling
Yes No
Neuropathy (numbness in both hands or both feet) Yes No
Melanoma Yes No
Cancer other than melanoma Yes No
Please describe __________________________________
Other health condition(s) Yes No
Please describe __________________________________
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 Health Conditions continued
Have any of the following members of your family been diagnosed with melanoma?
Parents Yes No Not applicable
Grandparents Yes No Not applicable
Brothers Yes No Not applicable
Sisters Yes No Not applicable
Children Yes No Not applicable
Grandchildren Yes No Not applicable
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VI. Work and Insurance
The next questions are about work and insurance. 
What is your CURRENT employment status?   If more Paid full-time employment
than one category applies, please choose the one that Paid part-time employment
best describes your current employment status. Self-employed
Volunteer
Homemaker
Unemployed, looking for work
Unemployed, not looking for work
Not employed - disabled
Retired, not working
Student, not working
During the past 12 months, about how many days did __________________________________
you miss work at your job or business because of (days)
illness (do not include maternity leave)?
During the past 12 months, about how many days did __________________________________
illness keep you in bed more than half of the day (days)
(include days while an overnight patient in a
hospital)?
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Work and Insurance continued
Do you currently have health insurance coverage? Yes No
Indicate the source of your health insurance (check Your current or former employer
all that apply). A policy you purchased directly (not through your
employer or union)
Your union
Military (Tricare, Tristar, Champus)
Spouse/Partner's employer
Another family member's health plan (not
spouse/partner)
Medicare
Medicaid
Other (specify)
Other Insurance: Please describe __________________________________
Do you have a life insurance policy? Yes No Unsure
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VIII. Your Background
Please tell us about yourself. 
What is your current age? __________________________________
What is your sex? Male Female
What is your race? (1 or more categories may be White
selected) Black or African American
American Indian or Alaska Native
Asian Indian
Chinese
Filipino
Japanese
Korean
Vietnamese
Other Asian
Native Hawaiian
Guamanian or Chamorro
Samoan
Other Pacific Islander
((check all that apply))
Are you Hispanic, Latino/a, or of Spanish origin? (1 No, not of Hispanic, Latino/a, Spanish origin
or more categories may be selected) Yes, Mexican, Mexican American, Chicano/a
Yes, Puerto Rican
Yes, Cuban origin
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Your Background continued
What is the highest level of schooling you have Less than high school
completed? High school graduate
Vocational or business school or AA degree
Some college
College or university graduate (bachelors degree)
Graduate or professional training (graduate degree)
What is your marital status? Never married
Married / Partnered
Widowed
Divorced
What is your annual household income? Less than $20,000
$20,000 to $49,999
$50,000 to $74,999
$75,000 to $99,999
$100,000 to $149,999
$150,000 to $199,999
$200,000 or more
Prefer not to say
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Future Research
Request permission to contact you in the future:  Would you give us permission to contact you in the future for new
research projects?  And if yes, could you provide the name of a contact person who will know of your whereabouts in
the event that you move? 
Yes, I give my permission.
No.  Please do not contact me in the future.
My contact information:
E-Mail Address __________________________________
Telephone Number __________________________________
Alternative person you may contact:
Name __________________________________
Relationship __________________________________
Street Address __________________________________
City __________________________________
Zip Code __________________________________
E-Mail Address __________________________________
Telephone Number __________________________________
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You have completed the survey.  Thank you very much for participating in our study.
Please click "submit" as the final step.
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Skin Health Study: Follow-up Survey
Instructions
For each question, please give the 
answer that seems to best describe how 
you feel or what your experience has 
been like. Some of the survey questions 
may seem the same, but they are all 
important to answer. 
There are questions on both the front 
and back of each page. Please answer 
all questions.
Survey available online: http://z.umn.edu/shs1
Appendix E. Paper Melanoma Survivor Survey
306
1I. Your Health Habits
The first questions are about your physical activity, diet, body size, sun protection, and 
alcohol and smoking habits.
1. Consider a typical 7-day period (a week) in the past month. How many times on average do 
you do the following kinds of exercise for more than 15 minutes during your free time and 
for how long per exercise session?
a. Strenuous activity (heart beats rapidly, heaving sweating)
Examples: running, jogging, hockey, soccer, squash, cross country, skiing, judo, roller 
skating, vigorous swimming, vigorous long distance bicycling, vigorous aerobic dance 
classes, heavy weight training
Times per week:  ______________
Average amount of time per session (minutes): ____________
b. Moderate activity (not exhausting, light sweating)
Examples: fast walking, baseball, tennis, easy bicycling, volleyball, badminton, easy 
swimming, alpine skiing, popular and folk dancing
Times per week:  ______________
Average amount of time per session (minutes): ____________
c. Mild activity (minimal effort, no sweating)
Examples: easy walking, yoga, archery, fishing, bowling, lawn bowling, shuffleboard, 
horseshoes, golf, snowmobiling
Times per week:  ______________
Average amount of time per session (minutes): ____________
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2Diet Habits
2. How many days per week do you eat at least five (5) servings of fruit and vegetables a day?
One serving = 1 piece of fruit, half a cup of cooked vegetables or one cup of raw leafy vegetables.
□ 0 days
□ 1 day
□ 2 days
□ 3 days
□ 4 days
□ 5 days
□ 6 days
□ 7 days
3. Do you currently take a multi-vitamin?
□ No
□ Yes  → 3a. On average, how many days per week do you take a multi-vitamin?
□ 1-2 days
□ 3-4 days
□ 5-6 days
□ 7 days
4. Do you currently take vitamin D on a regular basis, either as part of a multi-vitamin, calcium
supplement, or as its own pill?
□ No
□ Yes  → 4a. On average, how many days per week do you take vitamin D?
□ 1-2 days
□ 3-4 days
□ 5-6 days
□ 7 days
4b. What is the usual amount you take each day?
□ Less than 400 IU
□ 400 IU
□ 600 IU
□ 800 IU
□ 1000 IU
□ 2000 IU
□ More than 2000 IU
□ Other: ___________
□ Unknown
5. How tall are you?
_________  Feet   _____________ Inches
6. What is your current weight in pounds?  ______________
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3Sun Habits
7. In the summer, on average, how many hours are you outside per day between 10am and 
4pm…
a. On WEEKDAYS (Monday – Friday)?
□ 0-30 minutes
□ 31-minutes to 1 hour
□ 2 hours
□ 3 hours
□ 4 hours
□ 5 hours
□ 6 hours
b. On WEEKEND DAYS (Saturday & Sunday)?
□ 0-30 minutes
□ 31-minutes to 1 hour
□ 2 hours
□ 3 hours
□ 4 hours
□ 5 hours
□ 6 hours
8. In the past 12 months, how many times did you have a red OR painful sunburn that lasted a 
day or more?
□ 0
□ 1
□ 2
□ 3
□ 4
□ 5 or more
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49. For the following questions, think about what you typically do when you are outside during 
the summer on a warm sunny day:
When you are outside during the summer on a 
warm sunny day, how often do… Never Rarely Sometimes Often Always
a. Wear sunscreen? □ □ □ □ □
b. Wear a shirt with sleeves that cover your 
shoulders?
□ □ □ □ □
c. Wear a hat with a wide brim? □ □ □ □ □
d. Stay in the shade or under an umbrella? □ □ □ □ □
e. Spend time in the sun in order to get a tan? □ □ □ □ □
10. In the last 12 months, have you used a tanning bed or booth with tanning lamps?
□ No
□ Yes  → 10a. How many times in the last 12 months have you used a tanning bed or 
booth with tanning lamps? ___________
11. In the last 12 months, have you had your skin checked from head to toe by a health 
professional?
□ No
□ Yes  
12. In the last 12 months have you or your partner examined your entire body, including your 
back, for skin cancer?
□ No
□ Yes  → 12a. How many times in the past 12 months?  _____________
13. What is the color of your untanned skin?
□ Very fair
□ Fair
□ Olive
□ Light brown
□ Dark brown
□ Very dark
14. Since your melanoma diagnosis, have you been…
More Same Less Never my habit
a. Avoiding exposure to the sun? □ □ □ □
b. Wearing sun-protective clothing? □ □ □ □
c. Using sunscreen? □ □ □ □
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15. During the past 30 days, how many days per month did you have at least one drink of any 
alcoholic beverage, such as beer, wine, a malt beverage or liquor?  One drink is equivalent 
to a 12-ounce beer, a 5-ounce glass of wine or a drink with one shot of liquor.
__________  (number of days in past month: 0-30)
16. During the past 30 days, on the days when you drank, about how many drinks did you 
drink on average?
__________  (number of drinks)
17. Considering all types of alcoholic beverages, how many times during the past 30 days did 
you have…
… 5 or more drinks on one occasion if you are a man?
… 4 or more drinks on one occasion if you are a woman?
__________ (times in past 30 days)
Smoking Habits
18. Do you currently smoke cigarettes on a regular basis?
□ No
□ Yes  → 18a. On average, how many packs of cigarettes do you smoke per day? 
(1 pack = 20 cigarettes)
□ Less than ½ pack
□ ½ pack
□ 1 pack
□ 1½ packs
□ 2 packs
□ More than 2 packs
19. Do you currently use any of the following tobacco products on a regular basis?  Mark all 
that apply.  Mark “none” if you do not use any on a regular basis.
□ None
□ Cigars
□ Pipe tobacco
□ Chewing tobacco
□ Dip or snuff
□ Other →  Specify: ____________________
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6II. Your Health Habits and Well-Being
The next questions ask about your general physical, emotional, and social well-being.
20. In general, would you say your health is:  
□ Excellent
□ Very good
□ Good
□ Fair
□ Poor
21. Compared to 1 year ago, how would you rate your health in general now?
□ Much better now than one year ago
□ Somewhat better now than one year ago
□ About the same as one year ago
□ Somewhat worse now than one year ago
□ Much worse now than one year ago
22. The following items are about activities you might do during a typical day.  Does your health 
now limit you in these activities?  If so, how much? 
                        
Yes, limited 
a lot
Yes, limited 
a little
Not limited 
at all
a. Vigorous activities, such as running, lifting 
heavy objects, participating in strenuous sports
□ □ □
b. Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling or playing 
golf
□ □ □
c. Lifting or carrying groceries □ □ □
d. Climbing several flights of stairs □ □ □
e. Climbing one flight of stairs □ □ □
f. Bending, kneeling, or stooping □ □ □
g. Walking more than a mile □ □ □
h. Walking several blocks □ □ □
i. Walking one block □ □ □
j. Bathing or dressing yourself □ □ □
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723. During the past 4 weeks, how much of the time have you had any of the following problems 
with your work or other regular daily activities as a result of your physical health?
All of 
the time
Most of 
the time
Some of 
the time
A little of 
the time
None of 
the time
a. Cut down on the amount of time you 
spent on work or other activities
□ □ □ □ □
b. Accomplished less than you would 
like
□ □ □ □ □
c. Were limited in the kind of work or 
other activities
□ □ □ □ □
d. Had difficulty performing the work or 
other activities (for example, it took 
extra effort)
□ □ □ □ □
24. During the past 4 weeks, how much of the time have you had any of the following problems 
with your work or other regular daily activities as a result of any emotional problems (such as 
feeling depressed or anxious)?
All of 
the time
Most of 
the time
Some of 
the time
A little of 
the time
None of 
the time
a. Cut down on the amount of time you 
spent on work or other activities
□ □ □ □ □
b. Accomplished less than you would 
like
□ □ □ □ □
c. Did work or other activities less 
carefully than usual
□ □ □ □ □
25. During the past 4 weeks, to what extent has your physical health or emotional problems 
interfered with your normal social activities with family, friends, neighbors or groups? 
□ Not at all
□ Slightly
□ Moderately
□ Quite a bit
□ Extremely
26. How much bodily pain have you had in the past 4 weeks?
□ None
□ Very mild
□ Mild
□ Moderate
□ Severe
□ Very severe
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827. During the past 4 weeks, how much did pain interfere with your normal work (Including work 
outside the house and housework)?
□ Not at all
□ Slightly
□ Moderately
□ Quite a bit
□ Extremely
28. For each question, please give the one answer that comes closest to the way you have been 
feeling. How much of the time during the past 4 weeks...
All of 
the time
Most of 
the time
Some of 
the time
A little of 
the time
None of 
the time
a. Did you feel full of life? □ □ □ □ □
b. Have you been very nervous? □ □ □ □ □
c. Have you felt so down in the dumps 
that nothing could cheer you up?
□ □ □ □ □
d. Have you felt calm and peaceful? □ □ □ □ □
e. Did you have a lot of energy? □ □ □ □ □
f. Have you felt downhearted and 
depressed?
□ □ □ □ □
g. Did you feel worn out? □ □ □ □ □
h. Have you been happy? □ □ □ □ □
i. Did you feel tired? □ □ □ □ □
29. During the past 4 weeks, how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting with friends, relatives, etc.)?
□ All of the time
□ Most of the time
□ Some of the time
□ A little of the time
□ None of the time
314
930. How TRUE or FALSE is each of the following statements for you?
Definitely 
true
Mostly 
true
Don’t 
know
Mostly 
false
Definitely 
false
a. I seem to get sick a little easier than other 
people
□ □ □ □ □
b. I am as healthy as anybody I know □ □ □ □ □
c. I expect my health to get worse □ □ □ □ □
d. My health is excellent □ □ □ □ □
Emotional Well-Being
The next set of questions will ask you about your emotional well-being.
31. I feel tense or ‘wound up’:
□ Most of the time
□ A lot of the time
□ From time to time, occasionally
□ Not at all
32. I still enjoy the things I used to enjoy:
□ Definitely as much
□ Not quite as much
□ Only a little
□ Hardly at all
33. I get a sort of frightened feeling as if something awful is about to happen:
□ Very definitely and quite badly
□ Yes, but not too badly
□ A little, but it doesn’t worry me
□ Not at all
34. I can laugh and see the funny side of things:
□ As much as I always could
□ Not quite so much now
□ Definitely not so much now
□ Not at all
35. Worry thoughts go through my mind:
□ A great deal of the time
□ A lot of the time
□ From time to time, but not too often
□ Only occasionally
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36. I feel cheerful:
□ Not at all
□ Not often
□ Sometimes
□ Most of the time
37. I can sit at ease and feel relaxed:
□ Definitely
□ Usually
□ Not often
□ Not at all
38. I feel restless as if I have to be on the move:
□ Very much indeed
□ Quite a lot
□ Not very much
□ Not at all
39. I look forward with enjoyment to things:
□ As much as I ever did
□ Rather less than I used to
□ Definitely less than I used to
□ Hardly at all
40. I get sudden feelings of panic:
□ Very often indeed
□ Quite often
□ Not very often
□ Not at all
41. I can enjoy a good book or radio or TV program:
□ Often
□ Sometimes
□ Not often
□ Very seldom
42. I feel as if I am slowed down:
□ Nearly all the time
□ Very often
□ Sometimes
□ Not at all
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43. I get a sort of frightened feeling like ‘butterflies’ in the stomach:
□ Not at all
□ Occasionally
□ Quite often
□ Very often
44. I have lost interest in my appearance:
□ Definitely
□ I don’t take as much care as I should
□ I may not take quite as much care
□ I take just as much care as ever
III. Health Conditions
45. Has a medical doctor or healthcare professional ever told you that you have any of the 
following?
Yes No
a. Heart problems, such as a heart attack, coronary artery disease, 
congestive heart failure, irregular heartbeat, etc.
□ □
b. Hypertension (high blood pressure) □ □
c. Chronic back pain, including sciatica (pain or numbness that 
travels down your leg to below your knees)
□ □
d. Arthritis □ □
e. Stroke, including mini-stroke or blood clots in the brain □ □
f. Severe problems with memory or concentration   □ □
g. Asthma, emphysema, or COPD (Chronic Obstructive Pulmonary 
Disease)
□ □
h. Stomach and/or intestinal problems, such as Crohn’s disease, 
ulcers, or inflammatory bowel disease
□ □
i. Diabetes, high blood sugar, or sugar in urine □ □
j. Depression (feeling sad or blue) that resulted in treatment with 
medication and/or counseling
□ □
k. Anxiety or “nervousness” that resulted in treatment with 
medication and/or counseling
□ □
l. Neuropathy (numbness in both hands or both feet) □ □
m. Cancer other than melanoma
If yes, provide details:
_____________________________________________________
□ □
n. Other health conditions
If yes, provide details:
____________________________________________________
□ □
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46. Have any of the following members of your family been diagnosed with melanoma?
Yes No Not Applicable
a. Parents □ □ □
b. Grandparents □ □ □
c. Brother □ □ □
d. Sisters □ □ □
e. Children □ □ □
f. Grandchildren □ □ □
IV. Cancer Experience
The next questions are about your experience after diagnosis with your FIRST (or only) 
melanoma.
47. What year were you first diagnosed with melanoma? ____________
48. Where on your body was your melanoma found?
□ Head or neck
□ Trunk
□ Arms
□ Legs
49. What stage was your melanoma?
□ Stage I
□ Stage II
□ Stage III
□ Stage IV
□ Don’t know
50. Please mark all treatments you received when your melanoma was first diagnosed:
Yes No Don’t Know
a. Surgery to remove melanoma □ □ □
b. Surgery to remove lymph nodes □ □ □
c. A skin graft □ □ □
d. Chemotherapy □ □ □
e. Radiation treatment □ □ □
f. Immunotherapy (such as Interferon, vaccines) □ □ □
318
13
51. Has your doctor ever told you that your melanoma has come back to the same part of your 
body (recurrence)?
□ No  
□ Yes → 51a. What year was the recurrence? __________
52. Has your doctor ever told you that your melanoma has spread to another part of your body 
(metastasized)?
□ No  
□ Yes →  52a. What year did the melanoma spread? __________
If you answered “No” to both questions 51 & 52 above, skip to question 54 on 
page 14. Otherwise continue below.
53. If your first melanoma returned or spread to another part of your body, please mark all 
additional treatments you have received:
Yes No Don’t Know
a. Surgery to remove melanoma □ □ □
b. Surgery to remove lymph nodes □ □ □
c. A skin graft □ □ □
d. Chemotherapy □ □ □
e. Radiation treatment □ □ □
f. Immunotherapy (such as Interferon, vaccines) □ □ □
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If you had surgery to remove lymph nodes, continue below with question 54.
Otherwise Skip to question 59 on page 16.
54. When you had surgery to remove lymph nodes, how many were removed?
□ 1-4
□ 5-9
□ 10-14
□ 15+
□ Don’t Know
55. Did you experience swelling or lymphedema lasting greater than 1 month at any point 
after surgery or radiation treatment?
□ No → Skip to question 59 on page 16
□ Yes → Continue below
55a. When did your swelling or lymphedema FIRST occur?
□ Following treatment of your first melanoma
□ Following treatment of melanoma that returned to same part of your body
□ Following treatment of melanoma that spread to other parts of your body
55b. How long did the swelling last? (years/months) ____________
55c. Where on your body was the swelling? ___________________________
55d. Have you received or are you currently receiving treatment to PREVENT swelling 
or lymphedema following your surgery or radiation treatment?
□ No → Skip to question 56 on page 16
□ Yes → Continue below
55e. When did you first begin treatment to prevent swelling or lymphedema?
□ Following treatment of your first melanoma
□ Following treatment of melanoma that returned to same part of your body
□ Following treatment of melanoma that spread to other parts of your body
55f. How long did you or have the treatments lasted? (years/months) _________
55g. What part of your body was treated? _______________________
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If you have ever experienced swelling following surgery or radiation, continue 
below.  Otherwise Skip to question 59 on page 16.
56. Do you still have swelling?
□ No → Skip to question 59 on page 16
□ Yes → Continue below
57. These questions are about the swelling that you have:
Not at 
all
A little 
bit
Somewhat Quite a 
bit
Very 
much
a. I am bothered by the amount of 
swelling.
□ □ □ □ □
b. Movement of my swollen area is 
painful.
□ □ □ □ □
c. Swelling keeps me from doing the 
things I want to do.
□ □ □ □ □
d. Swelling keeps me from wearing 
clothes or shoes I want to wear.
□ □ □ □ □
58. Have you received or are you currently receiving treatment for your swelling or
lymphedema?
□ No → Skip to question 59 on page 16
□ Yes → Continue below
58a. What types of treatment for swelling or lymphedema have you received? 
Check all that apply.
□ Manual lymphatic drainage
□ Compression
□ Pump
□ Exercise
□ Other: __________________________
58b. How helpful have the treatments been for preventing swelling or lymphedema?
□ Very helpful
□ Somewhat helpful
□ A little helpful
□ Not at all helpful
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59. Please describe how much these concerns affect you.
Not at 
all
A little 
bit
Some
what
Quite 
a bit
Very 
much
a. I feel numbness at my surgical site. □ □ □ □ □
b. I have good range of movement in my arms and 
legs.
□ □ □ □ □
c. I am more aware of physical problems or changes 
in my body since having had melanoma.
□ □ □ □ □
d. New symptoms, aches, pains, getting sick, make me 
worry about the melanoma coming back.
□ □ □ □ □
e. I am worried that family members may also develop 
skin cancer/melanoma.
□ □ □ □ □
f. I feel bothered by people’s questions related to my 
melanoma.
□ □ □ □ □
g. I am worried about the size of the scar. □ □ □ □ □
h. I think about how my melanoma scar affects my 
attractiveness.
□ □ □ □ □
i. I think about how noticeable the scar is to others. □ □ □ □ □
j. I sometimes wear clothing to cover up my scar. □ □ □ □ □
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V. Experience with Health Care System
These questions ask about your experience with the health care professionals who took care of 
you at the time you were first diagnosed with melanoma.
60. When you were first diagnosed with melanoma…
Yes No Don’t 
Know
Did the doctor tell you what the likely outcome of having 
melanoma would be?
□ □ □
Did the doctor say the melanoma could be cured or go into long-
term remission?
□ □ □
Did the doctor say the melanoma was likely to be fatal or lead to 
death?
□ □ □
61. When you first found out you had melanoma, were you mostly optimistic or mostly 
pessimistic about surviving melanoma?
□ Mostly optimistic
□ Mostly pessimistic
□ Don’t know
62. Before your diagnosis, how much did you know about melanoma?
□ Nothing
□ Very little
□ Some
□ Quite a bit
□ A lot
63. Please rate the doctors and health professionals seen during the course of your treatment.
Excellent Good Fair Poor
a. Knowledge and expertise in handling your medical 
issues
□ □ □ □
b. Level of compassion □ □ □ □
c. Attention to factors outside of direct medical care, such 
as support network for dealing melanoma
□ □ □ □
64. During the course of your first melanoma treatment, did you receive conflicting information 
about melanoma from different doctors or health care professionals?
□ Yes
□ No
□ Don’t know
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65. When getting care for your melanoma, was there ever a time when…
Yes No Not Applicable
a. Your medical records or test results did not reach your 
doctor’s office in time for your appointment?
□ □ □
b. You were sent for duplicate tests or diagnostic procedures 
by different doctors, nurses, or health care workers?
□ □ □
c. You left a doctor’s office without getting important questions 
answered about your care of treatment?
□ □ □
d. You were confused about the medication the doctor 
prescribed?
□ □ □
e. You had to wait longer that you thought you should to find 
out results of medical tests?
□ □ □
66. Did waiting for test results produce stress and anxiety?
□ Yes, a lot
□ Just some
□ No
67. Did you ever have to make a decision about whether to undergo a treatment that would 
increase your chances of survival by only a small amount but could potentially lead to severe 
side effects?
□ No → Skip to question 68 on page 19
□ Yes → Continue below
67a. Did you decide to undergo the treatment?
□ No
□ Yes
67b. How satisfied are you with your decision?
□ Not at all
□ A little bit
□ Somewhat
□ Quite a bit
□ Very much
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VI. Work and Insurance
The next questions are about work and insurance.
68. What is your CURRENT employment status?  If more than one category applies, please 
choose the one that best describes your current employment status.
□ Paid full-time employment
□ Paid part-time employment
□ Self-employed
□ Volunteer
□ Homemaker
□ Unemployed, looking for work
□ Unemployed, not looking for work
□ Not employed – disabled
□ Retired, not working
□ Student, not working
69. During the past 12 months, about how many days did you miss work at your job or business 
because of illness (do not include maternity leave)? _____________ days
70. During the past 12 months, about how many days did illness keep you in bed more than half 
of the day (include days while an overnight patient in a hospital)? _____________ days
71. At the time you were FIRST DIAGNOSED with melanoma, what was your employment status?  
If more than one category applies, please choose the one that best describes employment 
status when you were first diagnosed.
□ Paid full-time employment
□ Paid part-time employment
□ Self-employed
□ Volunteer
□ Homemaker
□ Unemployed, looking for work
□ Unemployed, not looking for work
□ Not employed – disabled
□ Retired, not working
□ Student, not working
72. At the time you were diagnosed with melanoma, were you offered the following benefits from 
your main employer? (or yourself if self-employed)
Yes No Not Applicable
a. Paid sick time □ □ □
b. Paid vacation □ □ □
c. Unpaid time off □ □ □
d. Short-term disability coverage □ □ □
e. Long-term disability coverage □ □ □
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73. Since being diagnosed with melanoma, did you miss any days from work because of your 
melanoma (either for treatment, rest, side effect of treatment)?
□ No → Go to question 74
□ Yes → Continue below
73a. Approximately how many days did you miss? ___________ days
74. How well did your employer treat you during your experience with melanoma?
□ Very well
□ Somewhat well
□ Not too well
□ Not well at all
□ Not Applicable
75. Have any of the following things happened to you since you were diagnosed with melanoma?
Yes No Not Applicable
a. You were laid off or fired? □ □ □
b. Your responsibilities on the job were cut? □ □ □
c. You were passed over for a raise? □ □ □
d. You were passed over for a promotion? □ □ □
e. Your salary was reduced? □ □ □
f. You were demoted? □ □ □
g. You were given an easier assignment? □ □ □
h. You were treated differently by people at work? □ □ □
i. You felt supported by your employer? □ □ □
j. You felt supported by your co-workers? □ □ □
k. You were transferred or moved? □ □ □
l. You were forced into retirement? □ □ □
m. You chose to retire earlier than you had planned? □ □ □
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76. Do you currently have health insurance coverage?
□ No → Go to question 77
□ Yes → Continue below
76a. Indicate the source of your health insurance (check all that apply)
□ Your current or former employer
□ A policy you purchased directly (not through your employer or union)
□ Your union
□ Military (Tricare, Tristar, Champus)
□ Spouse/Partner’s employer
□ Another family member’s health plan (not spouse/partner)
□ Medicare
□ Medicaid
□ Other: ___________________________
77. Do you have a life insurance policy?
□ Yes
□ No
□ Unsure
78. During the time you were treated for melanoma, were you covered by health insurance for all 
or part of the time?
□ No → Go to question 80 on page 22
□ Yes → Continue below
78a. Indicate the source of your health insurance at the time you were treated for 
melanoma (check all that apply)
□ Your current or former employer
□ A policy you purchased directly (not through your employer or union)
□ Your union
□ Military (Tricare, Tristar, Champus)
□ Spouse/Partner’s employer
□ Another family member’s health plan (not spouse/partner)
□ Medicare
□ Medicaid
□ Other: ___________________________
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79. After your melanoma diagnosis, did you experience any of the following problems with a 
health insurance plan related to your melanoma treatment?
Yes No
a. Plan would not pay anything for care that 
you thought was covered
□ □
b. Plan paid less than you expected for a bill 
received from a doctor, hospital or lab
□ □
c. Reached a limit of what the insurance 
company would pay for cancer treatment
□ □
d. Turned away or unable to get specific type 
of treatment because of insurance issues
□ □
80. How much of a burden on your family were the costs of overall medical care related to your 
melanoma treatment?
□ A major burden
□ A minor burden
□ Not a burden at all
81. How much distress did you experience from dealing with insurance and/or billing for your 
melanoma care?
□ A lot
□ Some
□ Very little
□ None
82. Did any of the following things happen to you as a result of the financial cost of dealing with 
melanoma?
Yes No Not Applicable
a. Used up all or most of your savings □ □ □
b. Unable to pay for basic necessities like food, heat or 
housing
□ □
c. Borrowed money from relatives or friends □ □
d. Borrowed money from other sources (such as a bank loan, 
mortgage on your home, a retirement account)
□ □
e. Contacted by a collection agency □ □
f. Declared bankruptcy □ □
g. Sought the aid of a charity or public assistance □ □
h. Lost your health insurance □ □ □
i. Couldn’t buy health insurance because of having melanoma □ □ □
j. Couldn’t buy life insurance because of having melanoma □ □ □
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VII. Well-Being Associated with Melanoma Diagnosis
Circle the number that best describes you for each question.
EXAMPLE: How good is your quality of life?  
Extremely poor 0 10 20 30 40 50 60 70 80 90 100 Excellent
83. How difficult is it for you to cope today as a result of your melanoma diagnosis and 
treatment?
Not at all difficult 0 10 20 30 40 50 60 70 80 90 100 Very Difficult
84. How good is your quality of life?
Extremely poor 0 10 20 30 40 50 60 70 80 90 100 Excellent
85. How much happiness do you feel?
None at all 0 10 20 30 40 50 60 70 80 90 100 A great deal
86. Do you feel like you are in control of things in your life?
Not at all 0 10 20 30 40 50 60 70 80 90 100 Completely
87. How satisfying is your life?
Not at all 0 10 20 30 40 50 60 70 80 90 100 Completely
88. How is your present ability to concentrate or to remember things?
Extremely poor 0 10 20 30 40 50 60 70 80 90 100 Excellent
89. How useful do you feel?
Not at all 0 10 20 30 40 50 60 70 80 90 100 Extremely
90. Has your melanoma diagnosis or treatment caused changes in your appearance?
Not at all 0 10 20 30 40 50 60 70 80 90 100 Extremely
91. Has your illness or treatment caused changes in your self-concept (the way you see 
yourself)?
Not at all 0 10 20 30 40 50 60 70 80 90 100 Extremely
92. How serious do you consider melanoma to be?
Not at all 0 10 20 30 40 50 60 70 80 90 100 Extremely
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93. How distressing were the following aspects of your melanoma diagnosis and treatment?
a. Initial diagnosis
Not at all 0 10 20 30 40 50 60 70 80 90 100 Very
b. Melanoma treatments
Not at all 0 10 20 30 40 50 60 70 80 90 100 Very
c. Time since your treatment was completed
Not at all 0 10 20 30 40 50 60 70 80 90 100 Very
d. How much anxiety do you have?
Not at all 0 10 20 30 40 50 60 70 80 90 100 Very
e. How much depression do you have?
Not at all 0 10 20 30 40 50 60 70 80 90 100 Very
94. To what extent are you fearful of:
a. Future diagnostic tests
No fear 0 10 20 30 40 50 60 70 80 90 100 Extreme fear
b. A second melanoma
No fear 0 10 20 30 40 50 60 70 80 90 100 Extreme fear
c. Recurrence of your melanoma
No fear 0 10 20 30 40 50 60 70 80 90 100 Extreme fear
d. Spreading (metastasis) of your melanoma
No fear 0 10 20 30 40 50 60 70 80 90 100 Extreme fear
e. Dying from melanoma
No fear 0 10 20 30 40 50 60 70 80 90 100 Extreme fear
f. Children/Other family members getting melanoma
No fear 0 10 20 30 40 50 60 70 80 90 100 Extreme fear
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95. How much has your melanoma diagnosis affected your consideration of having children or 
having more children?
□ Not at all
□ A little bit
□ Somewhat
□ Quite a bit
□ Very much
□ Not Applicable
These next questions are about your social well-being.
96. How distressing has melanoma been for your family?
Not at all 0 10 20 30 40 50 60 70 80 90 100 A great deal
97. Is the amount of support you receive from others sufficient to meet your needs?
Not at all 0 10 20 30 40 50 60 70 80 90 100 A great deal
98. Is your continuing health care interfering with your personal relationships?
Not at all 0 10 20 30 40 50 60 70 80 90 100 A great deal
99. Is your sexuality impacted by your melanoma?
Not at all 0 10 20 30 40 50 60 70 80 90 100 A great deal
100. How comfortable are you talking with others about your melanoma?
Not at all 
comfortable
0 10 20 30 40 50 60 70 80 90 100 Very 
comfortable
101. To what degree has your melanoma and treatment interfered with your employment?
No problem 0 10 20 30 40 50 60 70 80 90 100 Severe problem
102. To what degree has your melanoma and treatment interfered with your activities at home?
No problem 0 10 20 30 40 50 60 70 80 90 100 Severe problem
103. How much isolation do you feel is caused by your melanoma or treatment?
Not at all 0 10 20 30 40 50 60 70 80 90 100 A great deal
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104. How much financial burden have you incurred as a result of your melanoma and treatment?
Not at all 0 10 20 30 40 50 60 70 80 90 100 A great deal
105. How frustrated are you that some people do not understand the seriousness of a melanoma 
diagnosis?
Not at all 0 10 20 30 40 50 60 70 80 90 100 A great deal
106. Please tell us about the impact of a melanoma diagnosis on your life.
Strongly 
Disagree
Disagree Neutral Agree Strongly 
Agree
a. Because of melanoma, I live each 
day one at a time.
□ □ □ □ □
b. I feel grateful to be alive. □ □ □ □ □
c. I feel like time in my life is limited. □ □ □ □ □
d. I learned something about life 
because of having had melanoma.
□ □ □ □ □
e. Having had melanoma makes me 
feel unsure about my future.
□ □ □ □ □
f. I worry about my future. □ □ □ □ □
g. I am afraid to die. □ □ □ □ □
h. I can accept my mortality, that I am 
going to die someday.
□ □ □ □ □
i. I feel like time in my life is running 
out.
□ □ □ □ □
j. Having had melanoma has made 
me realize that time is precious.
□ □ □ □ □
k. Having had melanoma has 
strengthened my religious faith or 
my sense of spirituality.
□ □ □ □ □
l. I consider myself to be a cancer 
survivor.
□ □ □ □ □
m. I spend more time with loved ones 
since my diagnosis.
□ □ □ □ □
VIII. Your Background
107. What is your current age? __________
108. What is your sex?
□ Male
□ Female
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109. What is your race? (1 or more categories may be selected)
□ White 
□ Black or African American
□ American Indian or Alaska Native
□ Asian Indian
□ Chinese
□ Filipino
□ Japanese
□ Korean
□ Vietnamese
□ Other Asian
□ Native Hawaiian
□ Guamanian or Chamorro
□ Samoan
□ Other Pacific Islander
110. Are you Hispanic, Latino/a, or of Spanish origin? (1 or more categories may be selected)
□ No, not of Hispanic, Latino/a, Spanish origin
□ Yes, Mexican, Mexican American, Chicano/a
□ Yes, Puerto Rican
□ Yes, Cuban origin
111. What is the highest level of schooling you have completed?
□ Less than high school
□ High school graduate
□ Vocational or business school or AA degree
□ Some college
□ College or university graduate (bachelor’s degree)
□ Graduate or professional training (graduate degree)
112. What is your marital status?
□ Never married
□ Married / Partnered
□ Widowed
□ Divorced
113. What is your annual household income?
□ Less than $20,000
□ $20,000 to $49,999
□ $50,000 to $74,999
□ $75,000 to $99,999
□ $100,000 to $149,999
□ $150,000 to $199,999
□ $200,00 or more
□ Prefer not to say
*** CONTINUE TO BACK PAGE ***
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Future research
We are interested in conducting new research about melanoma that builds on the information that 
you have so generously shared with us.   Below, we ask for your permission to continue to work with 
us on melanoma research.  You may agree to none, one, two or all three of our requests.  Thank you
for your consideration!
1.  Request to allow us to send you information on a new research project: 
We are asking for your permission to send you information on a new research project that involves 
collection of records related to your melanoma treatment and a sample of your melanoma tumor.  If 
you agree, we will mail you additional information about the project and you can make a final decision 
at that time.
□ Yes, I would consider this, please send me the additional information.
□ No, I prefer not to participate.
2.  Request your permission to collect information from the State Cancer Registry:
To learn more about the effect of melanoma on your current or future health, would you be willing to 
give us permission to get information about your cancer diagnosis (or diagnoses) that is contained in 
the state cancer registry?
□ Yes, I give my permission.
□ No, I prefer not to participate.
3.  Request permission to contact you in the future:
Would you give us permission to contact you in the future for new research projects? If yes, could you 
provide the name of a contact person who will know of your whereabouts in the event that you move?
□ Yes, I give my permission.
My contact Information:
Email address: ____________________________ Telephone Number: __________________
Alternative Person you may contact:    
____________________________________________       _______________________
Name Relationship
___________________________________________________________________________
Street Address                                  City                      State                 Zip Code
___________________________________________________________________________
E-mail address                                                 Telephone Number
□ No.  Please do not contact me in the future.
Thank you! Please return the completed survey using the stamped envelope provided.
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Thank you!
Please return the survey to:
Skin Health Study (Lazovich)
Division of Epidemiology and Community Health
School of Public Health
WBOB
1300 South Second St., Suite 300
Minneapolis, MN 55454-1015
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Skin Health Study: Follow-up Survey
Instructions
For each question, please give the 
answer that seems to best describe how 
you feel or what your experience has 
been like. Some of the survey questions 
may seem the same, but they are all 
important to answer. 
There are questions on both the front 
and back of each page. Please answer 
all questions.
Survey available online: http://z.umn.edu/shs2
Appendix F. Paper Control Survey
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1I. Your Health Habits
The first questions are about your physical activity, diet, body size, sun protection, and 
alcohol and smoking habits.
1. Consider a typical 7-day period (a week) in the past month. How many times on average do 
you do the following kinds of exercise for more than 15 minutes during your free time and 
for how long per exercise session?
a. Strenuous activity (heart beats rapidly, heaving sweating)
Examples: running, jogging, hockey, soccer, squash, cross country, skiing, judo, roller 
skating, vigorous swimming, vigorous long distance bicycling, vigorous aerobic dance 
classes, heavy weight training
Times per week:  ______________
Average amount of time per session (minutes): ____________
b. Moderate activity (not exhausting, light sweating)
Examples: fast walking, baseball, tennis, easy bicycling, volleyball, badminton, easy 
swimming, alpine skiing, popular and folk dancing
Times per week:  ______________
Average amount of time per session (minutes): ____________
c. Mild activity (minimal effort, no sweating)
Examples: easy walking, yoga, archery, fishing, bowling, lawn bowling, shuffleboard, 
horseshoes, golf, snowmobiling
Times per week:  ______________
Average amount of time per session (minutes): ____________
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2Diet Habits
2. How many days per week do you eat at least five (5) servings of fruit and vegetables a day?
One serving = 1 piece of fruit, half a cup of cooked vegetables or one cup of raw leafy vegetables.
□ 0 days
□ 1 day
□ 2 days
□ 3 days
□ 4 days
□ 5 days
□ 6 days
□ 7 days
3. Do you currently take a multi-vitamin?
□ No
□ Yes  → 3a. On average, how many days per week do you take a multi-vitamin?
□ 1-2 days
□ 3-4 days
□ 5-6 days
□ 7 days
4. Do you currently take vitamin D on a regular basis, either as part of a multi-vitamin, calcium
supplement, or as its own pill?
□ No
□ Yes  → 4a. On average, how many days per week do you take vitamin D?
□ 1-2 days
□ 3-4 days
□ 5-6 days
□ 7 days
4b. What is the usual amount you take each day?
□ Less than 400 IU
□ 400 IU
□ 600 IU
□ 800 IU
□ 1000 IU
□ 2000 IU
□ More than 2000 IU
□ Other: ___________
□ Unknown
5. How tall are you?
_________  Feet   _____________ Inches
6. What is your current weight in pounds?  ______________
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3Sun Habits
7. In the summer, on average, how many hours are you outside per day between 10am and 
4pm…
a. On WEEKDAYS (Monday – Friday)?
□ 0-30 minutes
□ 31-minutes to 1 hour
□ 2 hours
□ 3 hours
□ 4 hours
□ 5 hours
□ 6 hours
b. On WEEKEND DAYS (Saturday & Sunday)?
□ 0-30 minutes
□ 31-minutes to 1 hour
□ 2 hours
□ 3 hours
□ 4 hours
□ 5 hours
□ 6 hours
8. In the past 12 months, how many times did you have a red OR painful sunburn that lasted a 
day or more?
□ 0
□ 1
□ 2
□ 3
□ 4
□ 5 or more
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49. For the following questions, think about what you typically do when you are outside during 
the summer on a warm sunny day:
When you are outside during the summer on a 
warm sunny day, how often do… Never Rarely Sometimes Often Always
a. Wear sunscreen? □ □ □ □ □
b. Wear a shirt with sleeves that cover your 
shoulders?
□ □ □ □ □
c. Wear a hat with a wide brim? □ □ □ □ □
d. Stay in the shade or under an umbrella? □ □ □ □ □
e. Spend time in the sun in order to get a tan? □ □ □ □ □
10. In the last 12 months, have you used a tanning bed or booth with tanning lamps?
□ No
□ Yes  → 10a. How many times in the last 12 months have you used a tanning bed or 
booth with tanning lamps? ___________
11. In the last 12 months, have you had your skin checked from head to toe by a health 
professional?
□ No
□ Yes  
12. In the last 12 months have you or your partner examined your entire body, including your 
back, for skin cancer?
□ No
□ Yes  → 12a. How many times in the past 12 months?  _____________
13. What is the color of your untanned skin?
□ Very fair
□ Fair
□ Olive
□ Light brown
□ Dark brown
□ Very dark
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5Alcohol Habits
14. During the past 30 days, how many days per month did you have at least one drink of any 
alcoholic beverage, such as beer, wine, a malt beverage or liquor?  One drink is equivalent 
to a 12-ounce beer, a 5-ounce glass of wine or a drink with one shot of liquor.
__________  (number of days in past month: 0-30)
15. During the past 30 days, on the days when you drank, about how many drinks did you 
drink on average?
__________  (number of drinks)
16. Considering all types of alcoholic beverages, how many times during the past 30 days did 
you have…
… 5 or more drinks on one occasion if you are a man?
… 4 or more drinks on one occasion if you are a woman?
__________ (times in past 30 days)
Smoking Habits
17. Do you currently smoke cigarettes on a regular basis?
□ No
□ Yes  → 17a. On average, how many packs of cigarettes do you smoke per day? 
(1 pack = 20 cigarettes)
□ Less than ½ pack
□ ½ pack
□ 1 pack
□ 1½ packs
□ 2 packs
□ More than 2 packs
18. Do you currently use any of the following tobacco products on a regular basis?  Mark all 
that apply.  Mark “none” if you do not use any on a regular basis.
□ None
□ Cigars
□ Pipe tobacco
□ Chewing tobacco
□ Dip or snuff
□ Other →  Specify: ____________________
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6II. Your Health Habits and Well-Being
The next questions ask about your general physical, emotional, and social well-being.
19. In general, would you say your health is:  
□ Excellent
□ Very good
□ Good
□ Fair
□ Poor
20. Compared to 1 year ago, how would you rate your health in general now?
□ Much better now than one year ago
□ Somewhat better now than one year ago
□ About the same as one year ago
□ Somewhat worse now than one year ago
□ Much worse now than one year ago
21. The following items are about activities you might do during a typical day.  Does your health 
now limit you in these activities?  If so, how much?  
                       
Yes, limited 
a lot
Yes, limited 
a little
Not limited 
at all
a. Vigorous activities, such as running, lifting 
heavy objects, participating in strenuous sports
□ □ □
b. Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling or playing 
golf
□ □ □
c. Lifting or carrying groceries □ □ □
d. Climbing several flights of stairs □ □ □
e. Climbing one flight of stairs □ □ □
f. Bending, kneeling, or stooping □ □ □
g. Walking more than a mile □ □ □
h. Walking several blocks □ □ □
i. Walking one block □ □ □
j. Bathing or dressing yourself □ □ □
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722. During the past 4 weeks, how much of the time have you had any of the following problems 
with your work or other regular daily activities as a result of your physical health?
All of 
the time
Most of 
the time
Some of 
the time
A little of 
the time
None of 
the time
a. Cut down on the amount of time you 
spent on work or other activities
□ □ □ □ □
b. Accomplished less than you would 
like
□ □ □ □ □
c. Were limited in the kind of work or 
other activities
□ □ □ □ □
d. Had difficulty performing the work or 
other activities (for example, it took 
extra effort)
□ □ □ □ □
23. During the past 4 weeks, how much of the time have you had any of the following problems 
with your work or other regular daily activities as a result of any emotional problems (such as 
feeling depressed or anxious)?
All of 
the time
Most of 
the time
Some of 
the time
A little of 
the time
None of 
the time
a. Cut down on the amount of time you 
spent on work or other activities
□ □ □ □ □
b. Accomplished less than you would 
like
□ □ □ □ □
c. Did work or other activities less 
carefully than usual
□ □ □ □ □
24. During the past 4 weeks, to what extent has your physical health or emotional problems 
interfered with your normal social activities with family, friends, neighbors or groups? 
□ Not at all
□ Slightly
□ Moderately
□ Quite a bit
□ Extremely
25. How much bodily pain have you had in the past 4 weeks?
□ None
□ Very mild
□ Mild
□ Moderate
□ Severe
□ Very severe
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826. During the past 4 weeks, how much did pain interfere with your normal work (Including work 
outside the house and housework)?
□ Not at all
□ Slightly
□ Moderately
□ Quite a bit
□ Extremely
27. For each question, please give the one answer that comes closest to the way you have been 
feeling. How much of the time during the past 4 weeks...
All of 
the time
Most of 
the time
Some of 
the time
A little of 
the time
None of 
the time
a. Did you feel full of life? □ □ □ □ □
b. Have you been very nervous? □ □ □ □ □
c. Have you felt so down in the dumps 
that nothing could cheer you up?
□ □ □ □ □
d. Have you felt calm and peaceful? □ □ □ □ □
e. Did you have a lot of energy? □ □ □ □ □
f. Have you felt downhearted and 
depressed?
□ □ □ □ □
g. Did you feel worn out? □ □ □ □ □
h. Have you been happy? □ □ □ □ □
i. Did you feel tired? □ □ □ □ □
28. During the past 4 weeks, how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting with friends, relatives, etc.)?
□ All of the time
□ Most of the time
□ Some of the time
□ A little of the time
□ None of the time
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929. How TRUE or FALSE is each of the following statements for you?
Definitely 
true
Mostly 
true
Don’t 
know
Mostly 
false
Definitely 
false
a. I seem to get sick a little easier than other 
people
□ □ □ □ □
b. I am as healthy as anybody I know □ □ □ □ □
c. I expect my health to get worse □ □ □ □ □
d. My health is excellent □ □ □ □ □
Emotional Well-Being
The next set of questions will ask you about your emotional well-being.
30. I feel tense or ‘wound up’:
□ Most of the time
□ A lot of the time
□ From time to time, occasionally
□ Not at all
31. I still enjoy the things I used to enjoy:
□ Definitely as much
□ Not quite as much
□ Only a little
□ Hardly at all
32. I get a sort of frightened feeling as if something awful is about to happen:
□ Very definitely and quite badly
□ Yes, but not too badly
□ A little, but it doesn’t worry me
□ Not at all
33. I can laugh and see the funny side of things:
□ As much as I always could
□ Not quite so much now
□ Definitely not so much now
□ Not at all
34. Worry thoughts go through my mind:
□ A great deal of the time
□ A lot of the time
□ From time to time, but not too often
□ Only occasionally
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35. I feel cheerful:
□ Not at all
□ Not often
□ Sometimes
□ Most of the time
36. I can sit at ease and feel relaxed:
□ Definitely
□ Usually
□ Not often
□ Not at all
37. I feel restless as if I have to be on the move:
□ Very much indeed
□ Quite a lot
□ Not very much
□ Not at all
38. I look forward with enjoyment to things:
□ As much as I ever did
□ Rather less than I used to
□ Definitely less than I used to
□ Hardly at all
39. I get sudden feelings of panic:
□ Very often indeed
□ Quite often
□ Not very often
□ Not at all
40. I can enjoy a good book or radio or TV program:
□ Often
□ Sometimes
□ Not often
□ Very seldom
41. I feel as if I am slowed down:
□ Nearly all the time
□ Very often
□ Sometimes
□ Not at all
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42. I get a sort of frightened feeling like ‘butterflies’ in the stomach:
□ Not at all
□ Occasionally
□ Quite often
□ Very often
43. I have lost interest in my appearance:
□ Definitely
□ I don’t take as much care as I should
□ I may not take quite as much care
□ I take just as much care as ever
III. Health Conditions
44. Has a medical doctor or healthcare professional ever told you that you have any of the 
following?
Yes No
a. Heart problems, such as a heart attack, coronary artery disease, 
congestive heart failure, irregular heartbeat, etc.
□ □
b. Hypertension (high blood pressure) □ □
c. Chronic back pain, including sciatica (pain or numbness that 
travels down your leg to below your knees)
□ □
d. Arthritis □ □
e. Stroke, including mini-stroke or blood clots in the brain □ □
f. Severe problems with memory or concentration   □ □
g. Asthma, emphysema, or COPD (Chronic Obstructive Pulmonary 
Disease)
□ □
h. Stomach and/or intestinal problems, such as Crohn’s disease, 
ulcers, or inflammatory bowel disease
□ □
i. Diabetes, high blood sugar, or sugar in urine □ □
j. Depression (feeling sad or blue) that resulted in treatment with 
medication and/or counseling
□ □
k. Anxiety or “nervousness” that resulted in treatment with 
medication and/or counseling
□ □
l. Neuropathy (numbness in both hands or both feet) □ □
m. Melanoma □ □
n. Cancer other than melanoma
If yes, provide details:___________________________________
□ □
o. Other health conditions
If yes, provide details:___________________________________
□ □
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45. Have any of the following members of your family been diagnosed with melanoma?
Yes No Not Applicable
a. Parents □ □ □
b. Grandparents □ □ □
c. Brother □ □ □
d. Sisters □ □ □
e. Children □ □ □
f. Grandchildren □ □ □
IV. Work and Insurance
The next questions are about work and insurance.
46. What is your CURRENT employment status?  If more than one category applies, please 
choose the one that best describes your current employment status.
□ Paid full-time employment
□ Paid part-time employment
□ Self-employed
□ Volunteer
□ Homemaker
□ Unemployed, looking for work
□ Unemployed, not looking for work
□ Not employed – disabled
□ Retired, not working
□ Student, not working
47. During the past 12 months, about how many days did you miss work at your job or business 
because of illness (do not include maternity leave)? _____________ days
48. During the past 12 months, about how many days did illness keep you in bed more than half 
of the day (include days while an overnight patient in a hospital)? _____________ days
49. Do you currently have health insurance coverage?
□ No 
□ Yes → Continue below
49a. Indicate the source of your health insurance (check all that apply)
□ Your current or former employer
□ A policy you purchased directly (not through your employer or union)
□ Your union
□ Military (Tricare, Tristar, Champus)
□ Spouse/Partner’s employer
□ Another family member’s health plan (not spouse/partner)
□ Medicare
□ Medicaid
□ Other: ___________________________
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50. Do you have a life insurance policy?
□ Yes
□ No
□ Unsure
V. Your Background
51. What is your current age? __________
52. What is your sex?
□ Male
□ Female
53. What is your race? (1 or more categories may be selected)
□ White 
□ Black or African American
□ American Indian or Alaska Native
□ Asian Indian
□ Chinese
□ Filipino
□ Japanese
□ Korean
□ Vietnamese
□ Other Asian
□ Native Hawaiian
□ Guamanian or Chamorro
□ Samoan
□ Other Pacific Islander
54. Are you Hispanic, Latino/a, or of Spanish origin? (1 or more categories may be selected)
□ No, not of Hispanic, Latino/a, Spanish origin
□ Yes, Mexican, Mexican American, Chicano/a
□ Yes, Puerto Rican
□ Yes, Cuban origin
55. What is the highest level of schooling you have completed?
□ Less than high school
□ High school graduate
□ Vocational or business school or AA degree
□ Some college
□ College or university graduate (bachelor’s degree)
□ Graduate or professional training (graduate degree)
*** CONTINUE TO NEXT PAGE ***
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56. What is your marital status?
□ Never married
□ Married / Partnered
□ Widowed
□ Divorced
57. What is your annual household income?
□ Less than $20,000
□ $20,000 to $49,999
□ $50,000 to $74,999
□ $75,000 to $99,999
□ $100,000 to $149,999
□ $150,000 to $199,999
□ $200,00 or more
□ Prefer not to say
Future research
We are interested in conducting new research about melanoma that builds on the information that 
you have so generously shared with us.   Below, we ask for your permission to continue to work with 
us on related research.  Thank you for your consideration!
Request permission to contact you in the future:
Would you give us permission to contact you in the future for new research projects? If yes, could you 
provide the name of a contact person who will know of your whereabouts in the event that you move?
□ Yes, I give my permission.
My contact Information:
Email address: ____________________________ Telephone Number: __________________
Alternative Person you may contact:    
____________________________________________       _______________________
Name Relationship
___________________________________________________________________________
Street Address                                  City                      State                 Zip Code
___________________________________________________________________________
E-mail address                                                 Telephone Number
□ No.  Please do not contact me in the future.
Thank You.  Please return the completed survey using the stamped envelope provided.
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Thank you!
Please return the survey to:
Skin Health Study (Lazovich)
Division of Epidemiology and Community Health
School of Public Health
WBOB
1300 South Second St., Suite 300
Minneapolis, MN 55454-1015
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UNIVERSITY OF MINNESOTA
Twin Cities Campus Division of Epidemiology 1300 S. 2nd Street, Suite 300 
& Community Health Minneapolis, MN 55454-1025
School of Public Health Fax:  612-624-0315
October 3, 2015
Dr. «Doc_CURRENT_fname» «Doc_CURRENT_lname»
«Clinic_Name»
«Clinic_address»
«Clinic_city», MN, «Clinic_zip»
Dear Dr. «Doc_CURRENT_lname»:
With your permission, one or more of your patients diagnosed with melanoma participated in the Skin 
Health Study conducted between December 2004 and March 2009.  This research study, funded by the 
National Institutes of Health, was designed to identify new risk factors for melanoma, e.g., indoor tanning.  
We found that use of indoor tanning increased risk of melanoma by 74%, the risk increased with greater 
frequency of indoor tanning, and that no type of tanning device was safe.  These results have informed 
policies that limit indoor tanning use, especially for minors, here and abroad.  Your patient’s participation 
was critical to the success of our research and contributed to improving the public's health.
With funding from the Masonic Cancer Center at the University of Minnesota, we have now launched a 
new study to follow patients who were previously in the Skin Health Study.  In the new study, Skin Health 
Study participants will be asked to:
• Complete an online survey about quality of life and experience living with a melanoma diagnosis 
to inform new strategies to improve survivorship; 
• Provide permission to obtain medical records related to their diagnosis and treatment to 
understand the effect of treatment (if any) on melanoma survivorship;  
• Provide permission to obtain a sample of their original tumor specimen to support studies for the 
molecular characterization of tumors and prognosis in a large population-based sample.
The University of Minnesota's Human Subjects Committee approved this proposed expansion of our 
original study.  The Minnesota Commissioner of Health, upon recommendation from the scientific review 
committee of the Minnesota Cancer Surveillance System, has also approved the study.  
The Minnesota Cancer Surveillance System at the Minnesota Department of Health has determined that 
we are required by law to ask your permission before re-contacting your patients who participated in the 
Skin Health Study.  Enclosed is a separate consent form for each of your patients.  Please note that it is 
not required that you contact your patients.  Your consent does not obligate your patient(s) to participate; 
it only allows us to contact patients to invite their participation.  If you have no objection, we will send 
your patients a letter with details about the study.  Their participation is completely voluntary.  
Please indicate your decision regarding patient contact by checking a box and signing each consent form 
and returning it to us via fax (612 624-0315).  
If you have any questions or you would like more information, please feel free to contact me (612 626-
9099 or lazov001@umn.edu).  Thank you for your time and attention.
Sincerely, 
DeAnn Lazovich, Ph.D.
Associate Professor and Principal Investigator
Division of Epidemiology and Community Health
University of Minnesota
«Doc_ID»
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Version 1, 02/20/2015
Skin Health Study Expansion Research Project
Physician Consent Form
INSTRUCTIONS: Please complete this form and fax to DeAnn Lazovich, Ph.D. at 
(612) 624-0315. Thank you!
Name: «Pt_fname» «Pt_mname» «Pt_lname» Study ID: Pt.(«IDBase») Dr.(«Doc_ID»)
Date of Birth: «Pt_DOB» Sex: «Pt_Sex»
Last known address: «Pt_Addr»
City: «Pt_city» State: «Pt_State» Zip Code: «Pt_Zip»
I GIVE MY CONSENT to allow Dr. Lazovich, as a representative of the Commissioner of 
Health, to contact this patient.
I DO NOT GIVE MY CONSENT to allow this patient to be contacted.
Patient is under the care of another physician who is better able to make a decision about the 
appropriateness of contacting this patient.
Name of Physician:  ______________________________________________________
Address: ______________________________________________________________
City:  _____________________________   State: _______________  Zip:  ______________
Patient is deceased.  
We would like to contact next of kin for permission to obtain a sample of the patient's tumor, if 
available.  Please provide name and contact information for next of kin, if known.
Name of next of kin: ______________________________________________________
Address: ______________________________________________________________
City:  _____________________________   State: _______________  Zip:  ______________
I am no longer caring for this patient and have no knowledge of this patient's status or current 
provider.
 
Physician Signature: _____________________________________  Date: ________________
Patient Information
If Patient is STILL under your care, please check one of the following:
If Patient is NO LONGER under your care, please complete this section
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UNIVERSITY OF MINNESOTA
Twin Cities Campus Division of Epidemiology 1300 S. 2nd Street, Suite 300 
& Community Health Minneapolis, MN 55454-1025
School of Public Health Fax:  612-624-0315
October 3, 2015
Dr. «Doc_CURRENT_fname» «Doc_CURRENT_lname»
«Clinic_Name»
«Clinic_address»
«Clinic_city», MN, «Clinic_zip»
Dear Dr. «Doc_CURRENT_lname»:
With your permission, one or more of your patients diagnosed with melanoma participated in the Skin 
Health Study conducted between December 2004 and March 2009. This research study, funded by the 
National Institutes of Health, was designed to identify new risk factors for melanoma, e.g., indoor tanning.  
We found that use of indoor tanning increased risk of melanoma by 74%, the risk increased with greater 
frequency of indoor tanning, and that no type of tanning device was safe.  These results have informed 
policies that limit indoor tanning use, especially for minors, here and abroad.  Your patient’s participation 
was critical to the success of our research and contributed to improving the public's health.
With funding from the Masonic Cancer Center at the University of Minnesota, we have now launched a 
new study to follow patients who were previously in the Skin Health Study.  In the new study, Skin Health 
Study participants will be asked to:
• Complete an online survey about quality of life and experience living with a melanoma diagnosis 
to inform new strategies to improve survivorship; 
• Provide permission to obtain medical records related to their diagnosis and treatment to 
understand the effect of treatment (if any) on melanoma survivorship;  
• Provide permission to obtain a sample of their original tumor specimen to support studies for the 
molecular characterization of tumors and prognosis in a large population-based sample.
The University of Minnesota's Human Subjects Committee approved this proposed expansion of our 
original study.  The Minnesota Commissioner of Health, upon recommendation from the scientific review 
committee of the Minnesota Cancer Surveillance System, has also approved the study.  
The Minnesota Cancer Surveillance System at the Minnesota Department of Health has determined that 
we are required by law to ask your permission before re-contacting your patients who participated in the 
Skin Health Study.  Enclosed is a separate consent form for each of your patients.  Please note that it is 
not required that you contact your patients.  Your consent does not obligate your patient(s) to participate; 
it only allows us to contact patients to invite their participation.  If you have no objection, we will send 
your patients a letter with details about the study.  Their participation is completely voluntary.  
Please indicate your decision regarding patient contact by checking a box and signing each consent form 
and returning it to us via fax (612 624-0315).  If we do not hear from you by
«Deadline_for_2nd_Return», we will assume that we have your consent to contact these patients.
If you have any questions or you would like more information, please feel free to contact me (612 626-
9099 or lazov001@umn.edu).  Thank you for your time and attention.
Sincerely, 
DeAnn Lazovich, Ph.D.
Associate Professor and Principal Investigator
Division of Epidemiology and Community Health
University of Minnesota «Doc_ID»
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TYPE DATE HERE
«First_Name» «Last_Name»
«Address»
«City», «State» «Zip_Code»
Dear «First_Name», 
Between 2004 and 2009, you participated in our Skin Health Study to help us learn more about the 
causes of melanoma.  Thanks to your time and willingness to share details about yourself, we 
learned new information about melanoma that is now making a difference in the lives of others.   
I am writing now to ask for your help in improving our understanding of life after a melanoma 
diagnosis. The best way we know to do this is by asking you to complete a one-time survey that we 
have made available to you online. The survey asks about your melanoma diagnosis and treatment, 
current health, health habits such as physical activity and sun protection, physical, emotional and 
social well-being, employment and insurance. We are inviting everyone in the Skin Health Study to 
take part in this new research study, which is funded by the University of Minnesota.
To take our online survey, first enter this address into your Internet browser's address bar:
http://z.umn.edu/shs1
When prompted, enter your study ID: «ID»
If taking the survey on a computer is hard for you, we can send you a paper copy if you let us know 
by email (shs@umn.edu) or telephone (612-624-3056). 
Your participation is completely voluntary and the information you provide is strictly confidential. The 
online survey uses a secure web interface to protect the data that you enter.  If you have any 
questions or concerns, or if you are sure you do not wish to participate, please feel free to contact us
at any time.
By sharing your experiences with us, you will be adding to our understanding of this cancer to help 
others better cope with a melanoma diagnosis.  Your participation has already and will continue to 
make a difference!  
Many thanks, 
DeAnn Lazovich, Ph.D., Associate Professor
Principal Investigator, Skin Health Study
University of Minnesota
School of Public Health
P.S. We have enclosed a small token of appreciation as a way of saying thanks for taking the 
time to complete the survey!
Appendix H. Initial Mailing Materials
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Ver_1_CA_052014
CONSENT FORM
SKIN HEALTH FOLLOW-UP STUDY
Online Survey
INTRODUCTION
You are invited to be in a scientific research study that is being conducted by Dr. DeAnn Lazovich at 
the University of Minnesota School of Public Health.  The purpose of this study is to learn more about 
the experiences of people with melanoma after diagnosis compared to people without a melanoma 
diagnosis.  The study is funded by the University of Minnesota.   You were selected because you 
previously participated in the Skin Health Study between 2004 and 2009. 
STUDY PROCEDURES
If you choose to be in the study, we will ask you to take a one-time online survey.  The survey asks 
about your diagnosis and treatment, current health, health habits such as physical activity and sun 
protection, physical, emotional and social well-being, employment and insurance. The survey will take 
between 20 and 40 minutes, depending on your medical history.  
CONFIDENTIALITY
The records of this study will be kept private and confidential.  In any report we might publish, we will 
not include any information that will make it possible to identify a participant.  Every precaution is 
taken to make sure that all data are kept safe and secure.  The online survey uses a secure web 
interface to protect the data that you enter.  Only researchers involved in this project will have access 
to these data files.  
RISKS AND BENEFITS
There are no known risks, except for possible breach of confidentiality.  However we will take every 
precaution to keep your study information confidential.  Although there are no direct benefits to you 
from participating in this study, the information you provide may help us learn about ways to assist 
persons who have been diagnosed with melanoma.
VOLUNTARY NATURE
Your decision whether or not to participate will not affect your current or future relations with the 
University of Minnesota.  If you decide to participate, you are free to withdraw at any time without 
affecting those relationships.
WHOM TO CONTACT
If you have any questions about the study, you may contact Dr. Lazovich or her research staff by 
email (melanoma@umn.edu) or by phone (612 624-3056).  If you have questions or concerns 
regarding this study and would like to talk to someone other than the researcher (s), you are 
encouraged to contact the Fairview Research Helpline at telephone number 612-672-7692  or toll free 
at 866-508-6961.  You may also contact this office in writing or in person at Fairview Research 
Administration, 2433 Energy Park Drive, St. Paul, MN, 55108.
_________________________________________________________________________________
Please See Reverse Side of Page
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2STATEMENT OF CONSENT:
I have read the above information.  I have had the opportunity to ask questions and receive answers.  
I agree to participate in the study.
When you start the online survey you will be asked at that time if you agree to 
participate in this study.  Please keep this Consent Form for your records.  
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TYPE DATE HERE
«First_Name» «Last_Name»
«Address»
«City», «State» «Zip_Code»
Dear «First_Name»,
Between 2004 and 2009, you participated in our Skin Health Study to help us learn more about the 
causes of melanoma, a serious form of skin cancer.  Thanks to your time and willingness to share 
details about yourself, we learned new information about melanoma that is now making a difference in 
the lives of others. 
I am writing now to ask your help in improving our understanding of life after a melanoma diagnosis.  
The best way we know to do this is by asking you to complete a one-time survey that we have made 
available to you online. The survey asks about your current health, health habits such as physical 
activity and sun protection, physical, emotional and social well-being, employment and insurance. We 
are inviting everyone in the Skin Health Study to take part in this new research study, which is funded 
by the University of Minnesota.  
For scientific reasons, it is very important that we include you in this study even if you have never been 
diagnosed with melanoma.
To take our online survey, first enter this address into your Internet browser's address bar:
http://z.umn.edu/shs2
When prompted, enter your study ID: «ID»
If taking the survey on a computer is hard for you, we can send you a paper copy, if you let us know by 
email (shs@umn.edu) or telephone (612-624-3056). 
Your participation is completely voluntary and the information you provide is strictly confidential. The 
online survey uses a secure web interface to protect the data that you enter.  If you have any questions 
or concerns, or if you are sure you do not wish to participate, please feel free to contact us at any time. 
By sharing your experiences with us as someone who does not have melanoma, you will be adding to 
our understanding of this cancer to help others better cope with a melanoma diagnosis.  Your 
participation has already and will continue to make a difference!
Many thanks, 
DeAnn Lazovich, Ph.D., Associate Professor
Principal Investigator, Skin Health Study
University of Minnesota
School of Public Health
P.S.  We have enclosed a small token of appreciation as a way of saying thanks for taking the time 
to complete the survey!
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Ver_2_CO_061114
CONSENT FORM
SKIN HEALTH FOLLOW-UP STUDY
Online Survey
INTRODUCTION
You are invited to be in a scientific research study that is being conducted by Dr. DeAnn Lazovich at 
the University of Minnesota School of Public Health.  The purpose of this study is to learn more about 
the experiences of people with melanoma after diagnosis compared to people without a melanoma 
diagnosis.  The study is funded by the University of Minnesota.   You were selected because you 
previously participated in the Skin Health Study between 2004 and 2009. 
STUDY PROCEDURES
If you choose to be in the study, we will ask you to take a one-time online survey.  The survey asks 
about your current health, health habits such as physical activity and sun protection, physical, 
emotional and social well-being, employment and insurance. The survey will take between 15 and 25 
minutes.
CONFIDENTIALITY
The records of this study will be kept private and confidential.  In any report we might publish, we will 
not include any information that will make it possible to identify a participant.  Every precaution is 
taken to make sure that all data are kept safe and secure.  The online survey uses a secure web 
interface to protect the data that you enter.  Only researchers involved in this project will have access 
to these data files.  
RISKS AND BENEFITS
There are no known risks, except for possible breach of confidentiality.  However we will take every 
precaution to keep your study information confidential.  Although there are no direct benefits to you
from participating in this study, the information you provide may help us learn about ways to assist 
persons who have been diagnosed with melanoma.
VOLUNTARY NATURE
Your decision whether or not to participate will not affect your current or future relations with the 
University of Minnesota.  If you decide to participate, you are free to withdraw at any time without 
affecting those relationships.
WHOM TO CONTACT
If you have any questions about the study, you may contact Dr. Lazovich or her research staff by 
email (melanoma@umn.edu) or by phone (612 624-3056).  If you have questions or concerns 
regarding this study and would like to talk to someone other than the researcher (s), you are 
encouraged to contact the Fairview Research Helpline at telephone number 612-672-7692  or toll free 
at 866-508-6961.  You may also contact this office in writing or in person at Fairview Research 
Administration, 2433 Energy Park Drive, St. Paul, MN, 55108.
_________________________________________________________________________________
Please See Reverse Side of Page
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2STATEMENT OF CONSENT:
I have read the above information.  I have had the opportunity to ask questions and receive answers. 
I agree to participate in the study.
When you start the online survey you will be asked at that time if you agree to 
participate in this study.  Please keep this Consent Form for your records.  
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Helpful Tips for Taking the Online Survey 
Before linking to the online survey 
• Please use a computer, NOT a smartphone or tablet
• The best browsers to use are Mozilla Firefox, Safari, and Google Chrome.
While taking the survey online 
• To make the survey easier to read, you can change the font size.  In the upper
right hand corner of the screen, click on ‘resize fonts’ to increase or decrease
font size.  However, changing the font size may change the survey format.
• At the bottom of each survey page, you have the option to go back to the ‘previous
page’, go to the ‘next page’ or ‘save & return later’.  Most of the time, these
instructions can be seen on your screen along with the questions on that page.
Occasionally, you may need to scroll down to answer all questions and go to the
next page.
• Use the ‘reset’ button on the right hand side of each question to clear your answer.
• If you skip a question by mistake, the computer will remind you before it allows
you to go to the next page.  Questions that show in red print “must provide value”
will need to be answered before you are able to move on.
If you want to stop and finish the survey at a later time  
• The survey will give you a validation code and instructions for returning to the
survey at a later time.
• Write down validation code here:
To continue and finish the survey 
• Click on Returning in upper right had corner and enter your validation code:
Questions or problems?  Contact us at 
shs@umn. edu or 61 2- 624- 3056 
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Thank you!
Appendix I. Thank You Card
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Thank you for completing the 
Skin Health Study follow-up survey online.
If you have not yet completed the survey, 
we hope you will do it today.
If you have any questions, email us at 
shs@umn.edu or call 612-624-3056. 
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TYPE DATE HERE
«First_Name» «Last_Name»
«Address»
«City», «State» «Zip_Code»
Dear «First_Name», 
About three weeks ago, we sent you a survey request asking for your help in improving our 
understanding of life after a melanoma diagnosis.  To the best of our knowledge, we have not 
yet received your responses.  Our hope is to learn how to help others cope with a melanoma 
diagnosis if ever faced with that diagnosis.
We are writing again because of the importance that your responses have for helping us get 
accurate results.  It is only by hearing from nearly everyone who was part of the Skin Health 
Study that we can be sure that the results truly represent the experience of persons who have 
had melanoma.  Thus, we hope that you will fill out the survey soon.  
You have two options for taking the survey.  You can complete the enclosed survey and return 
to us in the postage-paid envelope provided.  Or you can take the survey online. If you took the 
survey online since the date of this letter, we thank you and please disregard this mailing.
If you choose to take our online survey, first enter this address into your Internet browser's 
address bar:
http://z.umn.edu/shs1
When prompted, enter your study ID: «ID»
Your participation is completely voluntary and the information you provide is strictly confidential. 
The online survey uses a secure web interface to protect the data that you enter.  If you have 
any questions, concerns, or further issues, please contact us by email (shs@umn.edu) or 
telephone (612-624-3056). 
Thank you so much for your help with this important health concern.
Many thanks, 
DeAnn Lazovich, Ph.D., Associate Professor
Principal Investigator, Skin Health Study
University of Minnesota
School of Public Health
Appendix J. Reminder Mailing Letters
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TYPE DATE HERE
«First_Name» «Last_Name»
«Address»
«City», «State» «Zip_Code»
Dear «First_Name»,
Our records show that you started the online Skin Health Study follow-up survey but did not 
have a chance to finish it. 
If you were unable to finish due to technical or computer problems with the online survey, 
please email or call us and we will be happy to help you. If you did not finish for other 
reasons and wish to do so, the information you need is provided below.
To return to your online survey, first enter this address into your Internet browser's address 
bar:
http://z.umn.edu/shs1
Then enter your validation code.  Your validation Code is:  .
You will be directed to where you left off.
Your participation is completely voluntary and the information you provide is strictly 
confidential. The online survey uses a secure web interface to protect the data that you 
enter.  
If you have any questions, concerns, or further issues or would prefer a paper survey, 
please contact us by email (shs@umn.edu) or by telephone (612-624-3056).
We hope you will choose to complete the survey. Your contributions will help researchers 
understand the unique experience of persons who have had melanoma.  
Many thanks,
DeAnn Lazovich, Ph.D., Associate Professor
Principal Investigator, Skin Health Study
University of Minnesota
School of Public Health
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TYPE DATE HERE
«First_Name» «Last_Name»
«Address»
«City», «State» «Zip_Code»
Dear «First_Name»,
About three weeks ago, we sent you a survey request asking for your help in improving our 
understanding of life after a melanoma diagnosis.  To the best of our knowledge, we have not 
yet received your responses.  Our hope is to learn from both persons with and without 
melanoma how to help others cope with a melanoma diagnosis if ever faced with that diagnosis.
We are writing again because of the importance that your responses have for helping us get 
accurate results.  It is only by hearing from nearly everyone who was part of the Skin Health 
Study that we can be sure that the results truly represent the experience of persons who have 
and have not had melanoma.  Thus, we hope that you will fill out the survey soon.  
You have two options for taking the survey.  You can complete the enclosed survey and return 
to us in the postage-paid envelope provided.  Or you can take the survey online. If you took the 
survey online since the date of this letter, we thank you and please disregard this mailing.
If you choose to take our online survey, first enter this address into your Internet browser's 
address bar:
http://z.umn.edu/shs2
When prompted, enter your study ID: «ID»
Your participation is completely voluntary and the information you provide is strictly confidential. 
The online survey uses a secure web interface to protect the data that you enter.  If you have 
any questions, concerns, or further issues, please contact us by email (shs@umn.edu) or 
telephone (612-624-3056). 
Thank you so much for your help with this important health concern.
Many thanks,
DeAnn Lazovich, Ph.D., Associate Professor
Principal Investigator, Skin Health Study
University of Minnesota
School of Public Health
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TYPE DATE HERE
«First_Name» «Last_Name»
«Address»
«City», «State» «Zip_Code»
Dear «First_Name»,
Our records show that you started the online Skin Health Study follow-up survey but did not have a chance to 
finish it. 
If you were unable to finish due to technical or computer problems with the online survey, please email or call 
us and we will be happy to help you. If you did not finish for other reasons and wish to do so, the information 
you need is provided below.
To return to your online survey, first enter this address into your Internet browser's address bar:
http://z.umn.edu/shs2
Then enter your validation code.  Your validation Code is:  ___________________.
You will be directed to where you left off.
Your participation is completely voluntary and the information you provide is strictly confidential. The online 
survey uses a secure web interface to protect the data that you enter.  
If you have any questions, concerns, or further issues or would prefer a paper survey, please contact us by 
email (shs@umn.edu) or by telephone (612-624-3056).
We hope you will choose to complete the survey. Your contributions will help researchers understand the 
unique experience of persons who have had melanoma.  
Many thanks,
DeAnn Lazovich, Ph.D., Associate Professor
Principal Investigator, Skin Health Study
University of Minnesota
School of Public Health
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TYPE DATE HERE
«First_Name» «Last_Name»
«Address»
«City», «State» «Zip_Code»
Dear «First_Name», 
In recent weeks, our research team has asked you, as a previous participant in the Skin 
Health Study, to help us improve our understanding of life after a melanoma diagnosis.  
We plan to start summarizing results soon, so we hope that all questionnaires will be 
completed by the middle of October. 
You can help us by EITHER 1) filling out the questionnaire we mailed to your household 
about 1-2 weeks ago and returning it in the stamped envelope, OR 2) by completing the 
questionnaire online.  
To complete the questionnaire online, first enter this address into your Internet 
browser's address bar: 
http://z.umn.edu/shs1
Next enter your study ID: «ID»
Our hope from this research is to learn how to help others cope with melanoma if ever 
faced with that diagnosis.  
This is the last contact we will be sending you about this survey, as we are bringing this 
phase of the project to a close.  If you need another paper copy of the survey, or have 
any questions about the study, please contact us by email at shs@umn.edu or by 
phone at 612-624-3056.
Many thanks for considering our request.
Respectfully and with appreciation,
DeAnn Lazovich, Ph.D.
Associate Professor
Appendix K. Final Reminder Letters
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TYPE DATE HERE
«First_Name» «Last_Name»
«Address»
«City», «State» «Zip_Code»
Dear «First_Name»,
In recent weeks, our research team has asked you, as a previous participant in the Skin 
Health Study, to help us learn how to help others cope with melanoma if ever faced with 
that diagnosis.  For scientific reasons, it is very important that we include you in this 
study even if you have never been diagnosed with melanoma. We plan to start 
summarizing results soon, so we hope that all questionnaires will be completed by the 
middle of October.
You can help us by EITHER 1) filling out the questionnaire we mailed to your household 
about 1-2 weeks ago and returning it in the stamped envelope, OR 2) by completing the 
questionnaire online.  
To complete the questionnaire online, first enter this address into your Internet 
browser's address bar:
http://z.umn.edu/shs2
Next enter your study ID: «ID»
This is the last contact we will be sending you about this survey, as we are bringing this 
phase of the project to a close.  If you need another paper copy of the survey or have 
any questions about the study, please contact us by email at shs@umn.edu or by 
phone at 612-624-3056.
Many thanks for considering our request.
Respectfully and with appreciation,
DeAnn Lazovich, Ph.D.
Associate Professor
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